[
  {
    "section": "Content",
    "content": "OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF NEPHROLOGY",
    "page": 1,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "KDIGO Clinical Practice Guideline for Acute Kidney Injury",
    "content": "||\nVOLUME 2  ISSUE 1  MARCH 2012\nhttp://www.kidney-international.org\nKI_SuppCover_2.1.indd   1KI_SuppCover_2.1.indd   12/7/12   12:32 PM2/7/12   12:32 PM",
    "page": 1,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "KDIGOClinicalPracticeGuidelineforAcuteKidneyInjury",
    "content": "TablesandFiguresiv\nNotice1\nWorkGroupMembership2\nKDIGOBoardMembers3\nReferenceKeys4\nAbbreviationsandAcronyms5\nAbstract6\nForeword7\nSummaryofRecommendationStatements8\nSection1:IntroductionandMethodology13\nChapter1.1:Introduction13\nChapter1.2:Methodology17\nSection2:AKIDefinition19\nChapter2.1:DefinitionandclassificationofAKI19\nChapter2.2:Riskassessment23\nChapter2.3:EvaluationandgeneralmanagementofpatientswithandatriskforAKI25\nChapter2.4:Clinicalapplications28\nChapter2.5:Diagnosticapproachtoalterationsinkidneyfunctionandstructure33\nSection3:PreventionandTreatmentofAKI37\nChapter3.1:HemodynamicmonitoringandsupportforpreventionandmanagementofAKI37\nChapter3.2:GeneralsupportivemanagementofpatientswithAKI,includingmanagementof42\ncomplications\nChapter3.3:Glycemiccontrolandnutritionalsupport43\nChapter3.4:TheuseofdiureticsinAKI47\nChapter3.5:Vasodilatortherapy:dopamine,fenoldopam,andnatriureticpeptides50\nChapter3.6:Growthfactorintervention57\nChapter3.7:Adenosinereceptorantagonists59\nChapter3.8:Preventionofaminoglycoside-andamphotericin-relatedAKI61\nChapter3.9:OthermethodsofpreventionofAKIinthecriticallyill66\nSection4:Contrast-inducedAKI69\nChapter4.1:Contrast-inducedAKI:definition,epidemiology,andprognosis69\nChapter4.2:AssessmentofthepopulationatriskforCI-AKI72\nChapter4.3:NonpharmacologicalpreventionstrategiesofCI-AKI76\nChapter4.4:PharmacologicalpreventionstrategiesofCI-AKI80\nChapter4.5:Effectsofhemodialysisorhemofiltration87\nSection5:DialysisInterventionsforTreatmentofAKI89\nChapter5.1:TimingofrenalreplacementtherapyinAKI89\nChapter5.2:CriteriaforstoppingrenalreplacementtherapyinAKI93\nChapter5.3:Anticoagulation95\nChapter5.4:VascularaccessforrenalreplacementtherapyinAKI101\nChapter5.5:DialyzermembranesforrenalreplacementtherapyinAKI105\nChapter5.6:ModalityofrenalreplacementtherapyforpatientswithAKI107\nChapter5.7:BuffersolutionsforrenalreplacementtherapyinpatientswithAKI111\nChapter5.8:DoseofrenalreplacementtherapyinAKI113\nBiographicandDisclosureInformation116\nAcknowledgments122\nReferences124",
    "page": 2,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "TABLES",
    "content": "Table1.Implicationsofthestrengthofarecommendation18\nTable2.StagingofAKI19\nTable3.ComparisonofRIFLEandAKINcriteriafordiagnosisandclassificationofAKI21\nTable4.Cross-tabulationofpatientsclassifiedbyRIFLEvs.AKIN21\nTable5.CausesofAKIanddiagnostictests22\nTable6.CausesofAKI:exposuresandsusceptibilitiesfornon-specificAKI23\nTable7.AKIdiagnosis28\nTable8.OverviewoftheapproachestodeterminebaselineSCrintheapplicationofRIFLEclassificationinprevious29\nstudies\nTable9.EstimatedbaselineSCr29\nTable10.AKIstaging30\nTable11.DefinitionsofAKI,CKD,andAKD33\nTable12.ExamplesofAKI,CKD,andAKDbasedonGFRandincreasesinSCr33\nTable13.MarkersofkidneydamageinAKDandCKD35\nTable14.IntegratedapproachtointerpretmeasuresofkidneyfunctionandstructurefordiagnosisofAKI,AKD,andCKD35\nTable15.CI-AKIrisk-scoringmodelforpercutaneouscoronaryintervention73\nTable16.AdditionalradiologicalmeasurestoreduceCI-AKI77\nTable17.PotentialapplicationsforRRT91\nTable18.FluidoverloadandoutcomeincriticallyillchildrenwithAKI91\nTable19.OverviewoftheadvantagesanddisadvantagesofdifferentanticoagulantsinAKIpatients97\nTable20.Catheterandpatientsizes104\nTable21.TypicalsettingofdifferentRRTmodalitiesforAKI(for70-kgpatient)107\nTable22.TheoreticaladvantagesanddisadvantagesofCRRT,IHD,SLED,andPD108\nTable23.Microbiologicalqualitystandardsofdifferentregulatoryagencies112",
    "page": 3,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "FIGURES",
    "content": "Figure1.TheRIFLEcriteriaforAKI14\nFigure2.OverviewofAKI,CKD,andAKD20\nFigure3.ConceptualmodelforAKI20\nFigure4.Stage-basedmanagementofAKI25\nFigure5.EvaluationofAKIaccordingtothestageandcause26\nFigure6.ChronicKidneyDiseaseEpidemiologyCollaborationcohortchangesineGFRandfinaleGFRcorrespondingto34\nKDIGOdefinitionandstagesofAKI\nFigure7.GFR/SCralgorithm34\nFigure8.ConceptualmodelfordevelopmentandclinicalcourseofAKI38\nFigure9.Effectoffurosemidevs.controlonall-causemortality48\nFigure10.Effectoffurosemidevs.controlonneedforRRT48\nFigure11.Effectoflow-dosedopamineonmortality51\nFigure12.Effectoflow-dosedopamineonneedforRRT52\nFigure13.Samplequestionnaire73\nFigure14.Riskforcontrast-inducednephropathy78\nFigure15.Bicarbonatevs.salineandriskofCI-AKI81\nFigure16.NACandbicarbonatevs.NACforriskofCI-AKI85\nFigure17.Flow-chartsummaryofrecommendations96\nAdditionalinformationintheformofsupplementarymaterialscanbefoundonlineathttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\niv\nKidneyInternationalSupplements(2012)2,iv\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 3,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Notice",
    "content": "KidneyInternationalSupplements(2012)2,1;doi:10.1038/kisup.2012.1\nSECTIONI:USEOFTHECLINICALPRACTICEGUIDELINE\nThisClinicalPracticeGuidelinedocumentisbaseduponthebestinformationavailableasof\nFebruary2011.Itisdesignedtoprovideinformationandassistdecision-making.Itisnot\nintendedtodeﬁneastandardofcare,andshouldnotbeconstruedasone,norshoulditbe\ninterpretedasprescribinganexclusivecourseofmanagement.Variationsinpracticewill\ninevitablyandappropriatelyoccurwhenclinicianstakeintoaccounttheneedsofindividual\npatients,availableresources,andlimitationsuniquetoaninstitutionortypeofpractice.Every\nhealth-careprofessionalmakinguseoftheserecommendationsisresponsibleforevaluatingthe\nappropriatenessofapplyingtheminthesettingofanyparticularclinicalsituation.The\nrecommendationsforresearchcontainedwithinthisdocumentaregeneralanddonotimplya\nspeciﬁcprotocol.\nSECTIONII:DISCLOSURE\nKidneyDisease:ImprovingGlobalOutcomes(KDIGO)makeseveryefforttoavoidanyactualor\nreasonablyperceivedconﬂictsofinterestthatmayariseasaresultofanoutsiderelationshipora\npersonal,professional,orbusinessinterestofamemberoftheWorkGroup.Allmembersofthe\nWorkGrouparerequiredtocomplete,sign,andsubmitadisclosureandattestationform\nshowingallsuchrelationshipsthatmightbeperceivedoractualconﬂictsofinterest.This\ndocumentisupdatedannuallyandinformationisadjustedaccordingly.Allreportedinformation\nispublishedinitsentiretyattheendofthisdocumentintheWorkGroupmembers’\nBiographicalandDisclosureInformationsection,andiskeptonﬁleattheNationalKidney\nFoundation(NKF),ManagingAgentforKDIGO.\nKidneyInternationalSupplements(2012)2,1\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 4,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "WorkGroupMembership",
    "content": "KidneyInternationalSupplements(2012)2,2;doi:10.1038/kisup.2012.2\nWORKGROUPCO-CHAIRS\nJohnAKellum,MD,FCCM,FACPNorbertLameire,MD,PhD\nUniversityofPittsburghSchoolofMedicineGhentUniversityHospital\nPittsburgh,PAGhent,Belgium\nWORKGROUP\nPeterAspelin,MD,PhD\nAlisonMMacLeod,MBChB,MD,FRCP\nKarolinskaUniversityHospitalUniversityofAberdeen\nStockholm,Sweden\nAberdeen,UnitedKingdom\nRavindraLMehta,MD,FACP,FASN,FRCP\nRashadSBarsoum,MD,FRCP,FRCPE\nUCSDMedicalCenter\nCairoUniversity\nSanDiego,CA\nCairo,Egypt\nPatrickTMurray,MD,FASN,FRCPI,FJFICMI\nEmmanuelABurdmann,MD,PhD\nUCDSchoolofMedicineandMedicalScience\nUniversityofSaoPauloMedicalSchool\nDublin,Ireland\nSaoPaulo,Brazil\nSaraladeviNaicker,MBChB,MRCP,FRCP,\nStuartLGoldstein,MD\nFCP(SA),PhD\nCincinnatiChildren’sHospital&MedicalCenter\nUniversityoftheWitwatersrand\nCincinnati,OH\nJohannesburg,SouthAfrica\nCharlesAHerzog,MD\nStevenMOpal,MD\nHennepinCountyMedicalCenter\nAlpertMedicalSchoolofBrownUniversity\nMinneapolis,MN\nPawtucket,RI\nMichaelJoannidis,MD\nFranzSchaefer,MD\nMedicalUniversityofInnsbruck\nHeidelbergUniversityHospital\nInnsbruck,Austria\nHeidelberg,Germany\nAndreasKribben,MD\nMietSchetz,MD,PhD\nUniversityDuisburg-Essen\nUniversityofLeuven\nEssen,Germany\nLeuven,Belgium\nAndrewSLevey,MD\nShigehikoUchino,MD,PhD\nTuftsMedicalCenter\nJikeiUniversitySchoolofMedicine\nBoston,MA\nTokyo,Japan\nEVIDENCEREVIEWTEAM\nTuftsCenterforKidneyDiseaseGuidelineDevelopmentandImplementation,\nTuftsMedicalCenter,Boston,MA,USA:\nKatrinUhlig,MD,MS,ProjectDirector;Director,GuidelineDevelopment\nJoseCalvo-Broce,MD,MS,NephrologyFellow\nAneetDeo,MD,MS,NephrologyFellow\nAmyEarley,BS,ProjectCoordinator\nInaddition,supportandsupervisionwereprovidedby:\nEthanMBalk,MD,MPH,ProgramDirector,EvidenceBasedMedicine\nKidneyInternationalSupplements(2012)2,2\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 5,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "KDIGOBoardMembers",
    "content": "KidneyInternationalSupplements(2012)2,3;doi:10.1038/kisup.2012.3\nGarabedEknoyan,MD\nNorbertLameire,MD,PhD\nFoundingKDIGOCo-Chairs\nKai-UweEckardt,MDBertramLKasiske,MD\nKDIGOCo-ChairKDIGOCo-Chair\nOmarIAbboud,MD,FRCP\nMichelJadoul,MD\nSharonAdler,MD,FASN\nSimonJenkins,MBE,FRCGP\nRajivAgarwal,MDSuhnggwonKim,MD,PhD\nSharonPAndreoli,MD\nMartinKKuhlmann,MD\nGavinJBecker,MD,FRACP\nNathanWLevin,MD,FACP\nFredBrown,MBA,FACHEPhilipK-TLi,MD,FRCP,FACP\nDanielCCattran,MD,FRCPCZhi-HongLiu,MD\nAllanJCollins,MD,FACP\nPabloMassari,MD\nRosannaCoppo,MD\nPeterAMcCullough,MD,MPH,FACC,FACP\nJosefCoresh,MD,PhDRaﬁqueMoosa,MD\nRicardoCorrea-Rotter,MD\nMiguelCRiella,MD\nAdrianCovic,MD,PhD\nAdibulHasanRizvi,MBBS,FRCP\nJonathanCCraig,MBChB,MM(ClinEpi),DCH,FRACP,PhDBernardoRodriquez-Iturbe,MD\nAngeldeFrancisco,MD\nRobertSchrier,MD\nPauldeJong,MD,PhD\nJustinSilver,MD,PhD\nAnaFigueiredo,RN,MSc,PhD\nMarcelloTonelli,MD,SM,FRCPC\nMohammedBenghanemGharbi,MDYusukeTsukamoto,MD\nGordonGuyatt,MD,MSc,BSc,FRCPC\nTheodorVogels,MSW\nDavidHarris,MDAngelaYee-MoonWang,MD,PhD,FRCP\nLaiSeongHooi,MDChristophWanner,MD\nEnyuImai,MD,PhD\nDavidCWheeler,MD,FRCP\nLesleyAInker,MD,MS,FRCPElenaZakharova,MD,PhD\nNKF-KDIGOGUIDELINEDEVELOPMENTSTAFF\nKerryWillis,PhD,SeniorVice-PresidentforScientiﬁcActivities\nMichaelCheung,MA,GuidelineDevelopmentDirector\nSeanSlifer,BA,GuidelineDevelopmentManager\nKidneyInternationalSupplements(2012)2,3\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 6,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ReferenceKeys",
    "content": "KidneyInternationalSupplements(2012)2,4;doi:10.1038/kisup.2012.4\nNOMENCLATUREANDDESCRIPTIONFORRATINGGUIDELINE\nRECOMMENDATIONS\nWithineachrecommendation,thestrengthofrecommendationisindicatedasLevel1,Level2,orNotGraded,andthequalityofthe\nsupportingevidenceisshownasA,B,C,orD.\nImplications\nGrade*PatientsCliniciansPolicy\nLevel1MostpeopleinyoursituationwouldMostpatientsshouldreceivetheTherecommendationcanbeevaluated\n‘‘Werecommend’’wanttherecommendedcourseofactionrecommendedcourseofaction.asacandidatefordevelopingapolicy\nandonlyasmallproportionwouldnot.oraperformancemeasure.\nLevel2ThemajorityofpeopleinyoursituationDifferentchoiceswillbeappropriateforTherecommendationislikelytorequire\n‘‘Wesuggest’’wouldwanttherecommendedcoursedifferentpatients.Eachpatientneedssubstantialdebateandinvolvement\nofaction,butmanywouldnot.helptoarriveatamanagementdecisionofstakeholdersbeforepolicycanbe\nconsistentwithherorhisvaluesanddetermined.\npreferences.\n*Theadditionalcategory‘‘NotGraded’’wasused,typically,toprovideguidancebasedoncommonsenseorwherethetopicdoesnotallowadequateapplicationofevidence.\nThemostcommonexamplesincluderecommendationsregardingmonitoringintervals,counseling,andreferraltootherclinicalspecialists.Theungradedrecommendations\naregenerallywrittenassimpledeclarativestatements,butarenotmeanttobeinterpretedasbeingstrongerrecommendationsthanLevel1or2recommendations.\nGradeQualityofevidenceMeaning\nAHighWeareconfidentthatthetrueeffectliesclosetothatoftheestimateoftheeffect.\nBModerateThetrueeffectislikelytobeclosetotheestimateoftheeffect,butthereisapossibility\nthatitissubstantiallydifferent.\nCLowThetrueeffectmaybesubstantiallydifferentfromtheestimateoftheeffect.\nDVerylowTheestimateofeffectisveryuncertain,andoftenwillbefarfromthetruth.\nCONVERSIONFACTORSOFMETRICUNITSTOSIUNITS\nParameterMetricunitsConversionfactorSIunits\nAmikacin(serum,plasma)mg/ml1.708mmol/l\nBloodureanitrogenmg/dl0.357mmol/l\nCalcium,ionized(serum)mg/dl0.25mmol/l\nCreatinine(serum)mg/dl88.4mmol/l\nCreatinineclearanceml/min0.01667ml/s\nGentamicin(serum)mg/ml2.09mmol/l\nGlucosemg/dl0.0555mmol/l\nLactate(plasma)mg/dl0.111mmol/l\nTobramycin(serum,plasma)mg/ml2.139mmol/l\nUrea(plasma)mg/ml0.167mmol/l\nNote:Metricunitconversionfactor=SIunit.\n(cid:2)\nKidneyInternationalSupplements(2012)2,4\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 7,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "AbbreviationsandAcronyms",
    "content": "KidneyInternationalSupplements(2012)2,5;doi:10.1038/kisup.2012.5\nAAMIAmericanAssociationofMedical\nHFHemoﬁltration\nInstrumentation\nHITHeparin-inducedthrombocytopenia\nACCPAmericanCollegeofChestPhysicians\nHRHazardratio\nACD-AAnticoagulantdextrosesolutionA\ni.a.Intraarterial\nACE-IAngiotensin-convertingenzymeinhibitor(s)\nICUIntensive-careunit\nADQIAcuteDialysisQualityInitiative\nIGF-1Insulin-likegrowthfactor-1\nAHCPRAgencyforHealthCarePolicyandResearch\nIHDIntermittenthemodialysis\nAKDAcutekidneydiseasesanddisorders\nIITIntensiveinsulintherapy\nAKIAcutekidneyinjury\ni.v.Intravenous\nAKINAcuteKidneyInjuryNetwork\nKDIGOKidneyDisease:ImprovingGlobalOutcomes\nANPAtrialnatriureticpeptide\nKDOQIKidneyDiseaseOutcomesQualityInitiative\naPTTActivatedpartialthromboplastintime\nLOSLengthofstay\nARBAngiotensin-receptorblocker(s)\nMDRDModiﬁcationofDietinRenalDisease\nARFAcuterenalfailure\nMIMyocardialinfarction\nARFTNAcuteRenalFailureTrialNetwork\nMICMinimuminhibitoryconcentration\nATNAcutetubularnecrosis\nMRIMagneticresonanceimaging\nAUCAreaunderthecurve\nMWMolecularweight\nBMIBodymassindex\nNACN-acetylcysteine\nBUNBloodureanitrogen\nNICE-SUGARNormoglycemiainIntensiveCareEvaluation\nCDCCentersforDiseaseControl\nandSurvivalUsingGlucoseAlgorithm\nCHFCongestiveheartfailure\nRegulation\nCIConﬁdenceinterval\nNKDNoknownkidneydisease\nCI-AKIContrast-inducedacutekidneyinjury\nNKFNationalKidneyFoundation\nCITConventionalinsulintherapy\nNSFNephrogenicSystemicFibrosis\nCKDChronickidneydisease\nOROddsratio\nCrClCreatinineclearance\nPDPeritonealdialysis\nCRFChronicrenalfailure\nPICARDProgramtoImproveCareinAcuteRenal\nCRRTContinuousrenalreplacementtherapy\nDisease\nCTComputedtomography\nRCTRandomizedcontrolledtrial\nCVCCentralvenouscatheters\nRIFLERisk,Injury,Failure;Loss,End-StageRenal\nCVVHContinuousvenovenoushemoﬁltration\nDisease\nCVVHDFContinuousvenovenoushemodiaﬁltration\nRRRelativerisk\neCrClEstimatedcreatinineclearance\nRRTRenalreplacementtherapy\nEGDTEarlygoal-directedtherapy\nSAFESalinevs.AlbuminFluidEvaluation\neGFREstimatedglomerularﬁltrationrate\nSCrSerumcreatinine\nERTEvidenceReviewTeam\nCentralvenousoxygensaturation\nScvO\nESRDEnd-stagerenaldisease\nSLEDSustainedlow-efﬁciencydialysis\nFDAFoodandDrugAdministration\nTCCTunneledcuffedcatheter\nGFRGlomerularﬁltrationrate\nVISEPEfﬁcacyofVolumeSubstitutionandInsulin\nHDFHemodiaﬁltration\nTherapyinSevereSepsis\nHESHydroxyethylstarch\nKidneyInternationalSupplements(2012)2,5\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 8,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Abstract",
    "content": "KidneyInternationalSupplements(2012)2,6;doi:10.1038/kisup.2012.6\nThe2011KidneyDisease:ImprovingGlobalOutcomes(KDIGO)ClinicalPracticeGuidelinefor\nAcuteKidneyInjury(AKI)aimstoassistpractitionerscaringforadultsandchildrenatriskfor\norwithAKI,includingcontrast-inducedacutekidneyinjury(CI-AKI).Guidelinedevelopment\nfollowedanexplicitprocessofevidencereviewandappraisal.Theguidelinecontainschapterson\ndeﬁnition,riskassessment,evaluation,prevention,andtreatment.DeﬁnitionandstagingofAKI\narebasedontheRisk,Injury,Failure;Loss,End-StageRenalDisease(RIFLE)andAcuteKidney\nInjuryNetwork(AKIN)criteriaandstudiesonriskrelationships.Thetreatmentchapterscover\npharmacologicalapproachestopreventortreatAKI,andmanagementofrenalreplacementfor\nkidneyfailurefromAKI.Guidelinerecommendationsarebasedonsystematicreviewsofrelevant\ntrials.Appraisalofthequalityoftheevidenceandthestrengthofrecommendationsfollowedthe\nGRADEapproach.Limitationsoftheevidencearediscussedandspeciﬁcsuggestionsare\nprovidedforfutureresearch.\nKeywords:ClinicalPracticeGuideline;KDIGO;acutekidneyinjury;contrast-induced\nnephropathy;renalreplacementtherapy;evidence-basedrecommendation\nCITATION\nIncitingthisdocument,thefollowingformatshouldbeused:KidneyDisease:ImprovingGlobal\nOutcomes(KDIGO)AcuteKidneyInjuryWorkGroup.KDIGOClinicalPracticeGuideline\nforAcuteKidneyInjury.Kidneyinter.,Suppl.2012;2:1–138.\nKidneyInternationalSupplements(2012)2,6\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 9,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Foreword",
    "content": "KidneyInternationalSupplements(2012)2,7;doi:10.1038/kisup.2012.8\nItisourhopethatthisdocumentwillserveseveralusefulSomearguethatrecommendationsshouldnotbemade\npurposes.Ourprimarygoalistoimprovepatientcare.We\nwhenevidenceisweak.However,cliniciansstillneedtomake\nhopetoaccomplishthis,intheshortterm,byhelpingclinicaldecisionsintheirdailypractice,andtheyoftenask,\ncliniciansknowandbetterunderstandtheevidence(orlack\n‘‘Whatdotheexpertsdointhissetting?’’Weoptedtogive\nofevidence)thatdeterminescurrentpractice.Byproviding\nguidance,ratherthanremainsilent.Theserecommendations\ncomprehensiveevidence-basedrecommendations,thisguide-areoftenratedwithalowstrengthofrecommendationanda\nlinewillalsohelpdeﬁneareaswhereevidenceislackingand\nlowstrengthofevidence,orwerenotgraded.Itisimportant\nresearchisneeded.Helpingtodeﬁnearesearchagendaisan\nfortheusersofthisguidelinetobecognizantofthis(see\noftenneglected,butveryimportant,functionofclinical\nNotice).Ineverycasetheserecommendationsaremeantto\npracticeguidelinedevelopment.beaplaceforclinicianstostart,notstop,theirinquiriesinto\nWeusedtheGRADEsystemtoratethestrengthofevidence\nspeciﬁcmanagementquestionspertinenttothepatientsthey\nandthestrengthofrecommendations.Inall,therewereonly\nseeindailypractice.\n11(18%)recommendationsinthisguidelineforwhichtheWewishtothanktheWorkGroupCo-Chairs,DrsJohn\noverallqualityofevidencewasgraded‘A,’whereas20(32.8%)\nKellumandNorbertLameire,alongwithalloftheWork\nweregraded‘B,’23(37.7%)weregraded‘C,’and7(11.5%)\nGroupmemberswhovolunteeredcountlesshoursoftheir\nweregraded‘D.’Althoughtherearereasonsotherthanquality\ntimedevelopingthisguideline.WealsothanktheEvidence\nofevidencetomakeagrade1or2recommendation,inReviewTeammembersandstaffoftheNationalKidney\ngeneral,thereisacorrelationbetweenthequalityofoverall\nFoundationwhomadethisprojectpossible.Finally,weowea\nevidenceandthestrengthoftherecommendation.Thus,there\nspecialdebtofgratitudetothemanyKDIGOBoardmembers\nwere22(36.1%)recommendationsgraded‘1’and39(63.9%)andindividualswhovolunteeredtimereviewingtheguide-\ngraded‘2.’Therewere9(14.8%)recommendationsgraded\nline,andmakingveryhelpfulsuggestions.\n‘1A,’10(16.4%)were‘1B,’3(4.9%)were‘1C,’and0(0%)were\n‘1D.’Therewere2(3.3%)graded‘2A,’10(16.4%)were‘2B,’\n20(32.8%)were‘2C,’and7(11.5%)were‘2D.’TherewereKai-UweEckardt,MDBertramL.Kasiske,MD\n26(29.9%)statementsthatwerenotgraded.\nKDIGOCo-ChairKDIGOCo-Chair\nKidneyInternationalSupplements(2012)2,7\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 10,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "SummaryofRecommendationStatements",
    "content": "KidneyInternationalSupplements(2012)2,8–12;doi:10.1038/kisup.2012.7",
    "page": 11,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section2:AKIDefinition",
    "content": "2.1.1:AKIisdeﬁnedasanyofthefollowing(NotGraded):\nXX\nIncreaseinSCrby0.3mg/dl(26.5mol/l)within48hours;or\nIncreaseinSCrto1.5timesbaseline,whichisknownorpresumedtohaveoccurredwithintheprior7days;or\nUrinevolume0.5ml/kg/hfor6hours.\n2.1.2:AKIisstagedforseverityaccordingtothefollowingcriteria(Table2).(NotGraded)\nTable2|StagingofAKI\nStageSerumcreatinineUrineoutput\n11.5–1.9timesbaseline0.5ml/kg/hfor6–12hours\nOR\nXX\n0.3mg/dl(26.5mmol/l)increase\n22.0–2.9timesbaseline0.5ml/kg/hfor12hours\n33.0timesbaseline0.3ml/kg/hfor24hours\nOROR\nXXX\nIncreaseinserumcreatinineto4.0mg/dl(353.6mmol/l)Anuriafor12hours\nOR\nInitiationofrenalreplacementtherapy\nOR,Inpatients18years,decreaseineGFRto35ml/minper1.73m\noo\n2.1.3:ThecauseofAKIshouldbedeterminedwheneverpossible.(NotGraded)\n2.2.1:WerecommendthatpatientsbestratiﬁedforriskofAKIaccordingtotheirsusceptibilitiesandexposures.(1B)\n2.2.2:ManagepatientsaccordingtotheirsusceptibilitiesandexposurestoreducetheriskofAKI(seerelevantguideline\nsections).(NotGraded)\n2.2.3:TestpatientsatincreasedriskforAKIwithmeasurementsofSCrandurineoutputtodetectAKI.(NotGraded)\nIndividualizefrequencyanddurationofmonitoringbasedonpatientriskandclinicalcourse.(NotGraded)\n2.3.1:EvaluatepatientswithAKIpromptlytodeterminethecause,withspecialattentiontoreversiblecauses.\n(NotGraded)\n2.3.2:MonitorpatientswithAKIwithmeasurementsofSCrandurineoutputtostagetheseverity,accordingto\nRecommendation2.1.2.(NotGraded)\n2.3.3:ManagepatientswithAKIaccordingtothestage(seeFigure4)andcause.(NotGraded)\n2.3.4:Evaluatepatients3monthsafterAKIforresolution,newonset,orworseningofpre-existingCKD.(NotGraded)\nIfpatientshaveCKD,managethesepatientsasdetailedintheKDOQICKDGuideline(Guidelines7–15).\n(NotGraded)\nIfpatientsdonothaveCKD,considerthemtobeatincreasedriskforCKDandcareforthemasdetailedin\ntheKDOQICKDGuideline3forpatientsatincreasedriskforCKD.(NotGraded)",
    "page": 11,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section3:PreventionandTreatmentofAKI (Part 1)",
    "content": "3.1.1:Intheabsenceofhemorrhagicshock,wesuggestusingisotoniccrystalloidsratherthancolloids(albuminor\nstarches)asinitialmanagementforexpansionofintravascularvolumeinpatientsatriskforAKIorwithAKI.(2B)\n3.1.2:Werecommendtheuseofvasopressorsinconjunctionwithﬂuidsinpatientswithvasomotorshockwith,oratrisk\nfor,AKI.(1C)\nKidneyInternationalSupplements(2012)2,8–12\nsummaryofrecommendationstatements\nFigure4|Stage-basedmanagementofAKI.Shadingofboxesindicatespriorityofaction—solidshadingindicatesactionsthatareequally\nappropriateatallstageswhereasgradedshadingindicatesincreasingpriorityasintensityincreases.AKI,acutekidneyinjury;ICU,intensive-\ncareunit. 3.1.3:Wesuggestusingprotocol-basedmanagementofhemodynamicandoxygenationparameterstopreventdevelopment\norworseningofAKIinhigh-riskpatientsintheperioperativesetting(2C)orinpatientswithsepticshock(2C). 3.3.1:Incriticallyillpatients,wesuggestinsulintherapytargetingplasmaglucose110–149mg/dl(6.1–8.3mmol/l).(2C)\n3.3.2:Wesuggestachievingatotalenergyintakeof20–30kcal/kg/dinpatientswithanystageofAKI.(2C)\n3.3.3:WesuggesttoavoidrestrictionofproteinintakewiththeaimofpreventingordelayinginitiationofRRT.(2D)\n3.3.4:Wesuggestadministering0.8–1.0g/kg/dofproteininnoncatabolicAKIpatientswithoutneedfordialysis(2D),\n1.0–1.5g/kg/dinpatientswithAKIonRRT(2D),anduptoamaximumof1.7g/kg/dinpatientsoncontinuousrenal\nreplacementtherapy(CRRT)andinhypercatabolicpatients.(2D)\n3.3.5:WesuggestprovidingnutritionpreferentiallyviatheenteralrouteinpatientswithAKI.(2C)\n3.4.1:WerecommendnotusingdiureticstopreventAKI.(1B)\n3.4.2:WesuggestnotusingdiureticstotreatAKI,exceptinthemanagementofvolumeoverload.(2C)\n3.5.1:Werecommendnotusinglow-dosedopaminetopreventortreatAKI.(1A)\n3.5.2:WesuggestnotusingfenoldopamtopreventortreatAKI.(2C)\n3.5.3:Wesuggestnotusingatrialnatriureticpeptide(ANP)toprevent(2C)ortreat(2B)AKI.",
    "page": 11,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section3:PreventionandTreatmentofAKI (Part 2)",
    "content": "3.6.1:Werecommendnotusingrecombinanthuman(rh)IGF-1topreventortreatAKI.(1B)\n3.7.1:Wesuggestthatasingledoseoftheophyllinemaybegiveninneonateswithsevereperinatalasphyxia,whoareat\nhighriskofAKI.(2B)\n3.8.1:Wesuggestnotusingaminoglycosidesforthetreatmentofinfectionsunlessnosuitable,lessnephrotoxic,\ntherapeuticalternativesareavailable.(2A)\n3.8.2:Wesuggestthat,inpatientswithnormalkidneyfunctioninsteadystate,aminoglycosidesareadministeredasa\nsingledosedailyratherthanmultiple-dosedailytreatmentregimens.(2B)\n3.8.3:Werecommendmonitoringaminoglycosidedruglevelswhentreatmentwithmultipledailydosingisusedformore\nthan24hours.(1A)\n3.8.4:Wesuggestmonitoringaminoglycosidedruglevelswhentreatmentwithsingle-dailydosingisusedformorethan48\nhours.(2C)\n3.8.5:Wesuggestusingtopicalorlocalapplicationsofaminoglycosides(e.g.,respiratoryaerosols,instilledantibiotic\nbeads),ratherthani.v.application,whenfeasibleandsuitable.(2B)\n3.8.6:WesuggestusinglipidformulationsofamphotericinBratherthanconventionalformulationsofamphotericinB.(2A)\n3.8.7:Inthetreatmentofsystemicmycosesorparasiticinfections,werecommendusingazoleantifungalagentsand/orthe\nechinocandinsratherthanconventionalamphotericinB,ifequaltherapeuticefﬁcacycanbeassumed.(1A)\nKidneyInternationalSupplements(2012)2,8–12\nsummaryofrecommendationstatements\n3.9.1:Wesuggestthatoff-pumpcoronaryarterybypassgraftsurgerynotbeselectedsolelyforthepurposeofreducing\nperioperativeAKIorneedforRRT.(2C)\n3.9.2:WesuggestnotusingNACtopreventAKIincriticallyillpatientswithhypotension.(2D)\n3.9.3:Werecommendnotusingoralori.v.NACforpreventionofpostsurgicalAKI.(1A)",
    "page": 11,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section4:Contrast-inducedAKI",
    "content": "4.1:DeﬁneandstageAKIafteradministrationofintravascularcontrastmediaasperRecommendations2.1.1–2.1.2.\n(NotGraded)\n4.1.1:Inindividualswhodevelopchangesinkidneyfunctionafteradministrationofintravascularcontrast\nmedia,evaluateforCI-AKIaswellasforotherpossiblecausesofAKI.(NotGraded)\n4.2.1:AssesstheriskforCI-AKIand,inparticular,screenforpre-existingimpairmentofkidneyfunctioninallpatients\nwhoareconsideredforaprocedurethatrequiresintravascular(i.v.ori.a.)administrationofiodinatedcontrast\nmedium.(NotGraded)\n4.2.2:ConsideralternativeimagingmethodsinpatientsatincreasedriskforCI-AKI.(NotGraded)\n4.3.1:UsethelowestpossibledoseofcontrastmediuminpatientsatriskforCI-AKI.(NotGraded)\n4.3.2:Werecommendusingeitheriso-osmolarorlow-osmolariodinatedcontrastmedia,ratherthanhigh-osmolar\niodinatedcontrastmediainpatientsatincreasedriskofCI-AKI.(1B)\n4.4.1:Werecommendi.v.volumeexpansionwitheitherisotonicsodiumchlorideorsodiumbicarbonatesolutions,\nratherthannoi.v.volumeexpansion,inpatientsatincreasedriskforCI-AKI.(1A)\n4.4.2:WerecommendnotusingoralﬂuidsaloneinpatientsatincreasedriskofCI-AKI.(1C)\n4.4.3:WesuggestusingoralNAC,togetherwithi.v.isotoniccrystalloids,inpatientsatincreasedriskofCI-AKI.(2D)\n4.4.4:WesuggestnotusingtheophyllinetopreventCI-AKI.(2C)\n4.4.5:WerecommendnotusingfenoldopamtopreventCI-AKI.(1B)\n4.5.1:Wesuggestnotusingprophylacticintermittenthemodialysis(IHD)orhemoﬁltration(HF)forcontrast-media\nremovalinpatientsatincreasedriskforCI-AKI.(2C)",
    "page": 13,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section5:DialysisInterventionsforTreatmentofAKI",
    "content": "5.1.1:InitiateRRTemergentlywhenlife-threateningchangesinﬂuid,electrolyte,andacid-basebalanceexist.\n(NotGraded)\n5.1.2:Considerthebroaderclinicalcontext,thepresenceofconditionsthatcanbemodiﬁedwithRRT,andtrendsof\nlaboratorytests—ratherthansingleBUNandcreatininethresholdsalone—whenmakingthedecisiontostart\nRRT.(NotGraded)\n5.2.1:DiscontinueRRTwhenitisnolongerrequired,eitherbecauseintrinsickidneyfunctionhasrecoveredtothepointthat\nitisadequatetomeetpatientneeds,orbecauseRRTisnolongerconsistentwiththegoalsofcare.(NotGraded)\n5.2.2:Wesuggestnotusingdiureticstoenhancekidneyfunctionrecovery,ortoreducethedurationorfrequencyofRRT.(2B)\n5.3.1:InapatientwithAKIrequiringRRT,basethedecisiontouseanticoagulationforRRTonassessmentofthepatient’s\npotentialrisksandbeneﬁtsfromanticoagulation(seeFigure17).(NotGraded)\n5.3.1.1:WerecommendusinganticoagulationduringRRTinAKIifapatientdoesnothaveanincreased\nbleedingriskorimpairedcoagulationandisnotalreadyreceivingsystemicanticoagulation.(1B)\n5.3.2:Forpatientswithoutanincreasedbleedingriskorimpairedcoagulationandnotalreadyreceivingeffective\nsystemicanticoagulation,wesuggestthefollowing:\n5.3.2.1:ForanticoagulationinintermittentRRT,werecommendusingeitherunfractionatedorlow-molecular-\nweightheparin,ratherthanotheranticoagulants.(1C)\n5.3.2.2:ForanticoagulationinCRRT,wesuggestusingregionalcitrateanticoagulationratherthanheparinin\npatientswhodonothavecontraindicationsforcitrate.(2B)\n5.3.2.3:ForanticoagulationduringCRRTinpatientswhohavecontraindicationsforcitrate,wesuggestusing\neitherunfractionatedorlow-molecular-weightheparin,ratherthanotheranticoagulants.(2C)\n10\nKidneyInternationalSupplements(2012)2,8–12",
    "page": 13,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "summaryofrecommendationstatements",
    "content": "Yes\nImpaired Proceed without\ncoagulation? anticoagulation\nNo\nRec\n5.3.1.1\nUnderlying\nYes\nUse anticoagulation\ncondition requires\nadapted to this\nsystemic\ncondition\nanticoagulation?\nNo\nChoose RRT\nCRRT Intermittent RRT\nModality\nRecs\nNo\n5.3.2.2\nRegional Citrate\nContraindication\nto Citrate?\nAnticoagulation\n5.3.3.1\nYes\nNo\nIncreased\nRec\nHeparin\nBleeding Risk?\n5.3.2.3\nYes\nProceed without\nRec\nanticoagulation\n5.3.3.2\nNo\nIncreased\nBleeding Heparin\nRisk?\nRec\n5.3.2.1\nYes\nProceed without\nanticoagulation\nFigure17|Flow-chartsummaryofrecommendations.Heparinincludeslow-molecular-weightorunfractionatedheparin.\nCRRT,continuousrenalreplacementtherapy;RRT,renalreplacementtherapy.",
    "page": 14,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "bleeding.(2C) (Part 1)",
    "content": "11\nKidneyInternationalSupplements(2012)2,8–12\nsummaryofrecommendationstatements\n5.3.4:Inapatientwithheparin-inducedthrombocytopenia(HIT),allheparinmustbestoppedandwerecommend\nusingdirectthrombininhibitors(suchasargatroban)orFactorXainhibitors(suchasdanaparoidor\nfondaparinux)ratherthanotherornoanticoagulationduringRRT.(1A)\n5.3.4.1:InapatientwithHITwhodoesnothavesevereliverfailure,wesuggestusingargatrobanratherthan\notherthrombinorFactorXainhibitorsduringRRT.(2C)\n5.4.1:WesuggestinitiatingRRTinpatientswithAKIviaanuncuffednontunneleddialysiscatheter,ratherthana\ntunneledcatheter.(2D)\n5.4.2:WhenchoosingaveinforinsertionofadialysiscatheterinpatientswithAKI,considerthesepreferences\n(NotGraded):\nFirstchoice:rightjugularvein;\nSecondchoice:femoralvein;\nThirdchoice:leftjugularvein;\nLastchoice:subclavianveinwithpreferenceforthedominantside.",
    "page": 14,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "bleeding.(2C) (Part 2)",
    "content": "5.4.3:Werecommendusingultrasoundguidancefordialysiscatheterinsertion.(1A)\n5.4.4:Werecommendobtainingachestradiographpromptlyafterplacementandbeforeﬁrstuseofaninternaljugular\norsubclaviandialysiscatheter.(1B)\n5.4.5:WesuggestnotusingtopicalantibioticsovertheskininsertionsiteofanontunneleddialysiscatheterinICU\npatientswithAKIrequiringRRT.(2C)\n5.4.6:Wesuggestnotusingantibioticlocksforpreventionofcatheter-relatedinfectionsofnontunneleddialysis\ncathetersinAKIrequiringRRT.(2C)\n5.5.1:WesuggesttousedialyzerswithabiocompatiblemembraneforIHDandCRRTinpatientswithAKI.(2C)\n5.6.1:UsecontinuousandintermittentRRTascomplementarytherapiesinAKIpatients.(NotGraded)\n5.6.2:WesuggestusingCRRT,ratherthanstandardintermittentRRT,forhemodynamicallyunstablepatients.(2B)\n5.6.3:WesuggestusingCRRT,ratherthanintermittentRRT,forAKIpatientswithacutebraininjuryorothercausesof\nincreasedintracranialpressureorgeneralizedbrainedema.(2B)\n5.7.1:Wesuggestusingbicarbonate,ratherthanlactate,asabufferindialysateandreplacementﬂuidforRRTin\npatientswithAKI.(2C)\n5.7.2:Werecommendusingbicarbonate,ratherthanlactate,asabufferindialysateandreplacementﬂuidforRRT\ninpatientswithAKIandcirculatoryshock.(1B)\n5.7.3:Wesuggestusingbicarbonate,ratherthanlactate,asabufferindialysateandreplacementﬂuidforRRTin\npatientswithAKIandliverfailureand/orlacticacidemia.(2B)\n5.7.4:WerecommendthatdialysisﬂuidsandreplacementﬂuidsinpatientswithAKI,ataminimum,complywith\nAmericanAssociationofMedicalInstrumentation(AAMI)standardsregardingcontaminationwithbacteriaand\nendotoxins.(1B)\n5.8.1:ThedoseofRRTtobedeliveredshouldbeprescribedbeforestartingeachsessionofRRT.(NotGraded)We\nrecommendfrequentassessmentoftheactualdelivereddoseinordertoadjusttheprescription.(1B)\n5.8.2:ProvideRRTtoachievethegoalsofelectrolyte,acid-base,solute,andﬂuidbalancethatwillmeetthepatient’s\nneeds.(NotGraded)\n5.8.3:WerecommenddeliveringaKt/Vof3.9perweekwhenusingintermittentorextendedRRTinAKI.(1A)\n5.8.4:Werecommenddeliveringanefﬂuentvolumeof20–25ml/kg/hforCRRTinAKI(1A).Thiswillusuallyrequire\nahigherprescriptionofefﬂuentvolume.(NotGraded)\n12\nKidneyInternationalSupplements(2012)2,8–12\nchapter1.1\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 14,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section1:IntroductionandMethodology",
    "content": "KidneyInternationalSupplements(2012)2,13–18;doi:10.1038/kisup.2011.31",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 1)",
    "content": "Theconceptofacuterenalfailure(ARF)hasundergoneVolumedepletionandhypotensionareprofoundstimulifor\nsigniﬁcantre-examinationinrecentyears.Mountingevi-\nvasopressinsecretion.Asaconsequencethedistaltubulesand\ndencesuggeststhatacute,relativelymildinjurytothekidneycollectingductsbecomefullypermeabletowater.Concen-\norimpairmentofkidneyfunction,manifestbychangesintratingmechanismsintheinnermedullaarealsoaided\nurineoutputandbloodchemistries,portendseriousclinicalbylowﬂowthroughtheloopsofHenleandthus,urine\n1–5\nconsequences.Traditionally,mostreviewsandtextbook\nvolumeisminimizedandurineconcentrationmaximized\nchaptersemphasizethemostseverereductioninkidney(500mOsmol/kg).Conversely,whenthetubulesare\nfunction,withsevereazotemiaandoftenwitholiguriaorinjured,maximalconcentratingabilityisimpairedandurine\nanuria.Ithasonlybeeninthepastfewyearsthatmoderate\nvolumemayevenbenormal(i.e.,nonoliguricrenalfailure). decreasesofkidneyfunctionhavebeenrecognizedasAnalysisoftheurinetodeterminetubularfunctionhasa\nandinstudies\npotentiallyimportant,inthecriticallyill,longhistoryinclinicalmedicine.Indeed,ahighurine\noncontrast-inducednephropathy.osmolalitycoupledwithalowurinesodiuminthefaceof\noliguriaandazotemiaisstrongevidenceofintacttubular\nfunction.However,thisshouldnotbeinterpretedas\nGlomerularfiltrationrateandserumcreatinine\nTheglomerularﬁltrationrate(GFR)iswidelyacceptedasthe\n‘‘benign’’orevenprerenalazotemia.Intacttubularfunction,\nbestoverallindexofkidneyfunctioninhealthanddisease. particularlyearlyon,maybeseenwithvariousformsofrenal\nHowever,GFRisdifﬁculttomeasureandiscommonly\ndisease(e.g.,glomerulonephritis).Sepsis,themostcommon\nestimatedfromtheserumlevelofendogenousﬁltration\nconditionassociatedwithARFintheintensive-careunit\nmarkers,suchascreatinine.Recently,Chertowetal.found\n(ICU)mayalterrenalfunctionwithoutanycharacteristic\n8,9\nthatanincreaseofserumcreatinine(SCr)of0.3mg/dl\nchangesinurineindices.Automaticallyclassifyingthese\n4m\n(26.5mol/l)wasindependentlyassociatedwithmortality. abnormalitiesas‘‘prerenal’’willundoubtedlyleadto\nSimilarly,Lassniggetal.saw,inacohortofpatientswho\nincorrectmanagementdecisions.Classiﬁcationas‘‘benign\nunderwentcardiacsurgery,thateitheranincreaseofSCr\nazotemia’’or‘‘acuterenalsuccess’’isnotconsistentwith\nXX\nm4\n0.5mg/dl(44.2mol/l)oradecrease0.3mg/dl\navailableevidence.Finally,althoughsevereoliguriaandeven\n4m\n(26.5mol/l)wasassociatedwithworsesurvival.The\nanuriamayresultfromrenaltubulardamage,itcanalsobe\nreasonswhysmallalterationsinSCrleadtoincreasesin\ncausedbyurinarytractobstructionandbytotalarterialor\nhospitalmortalityarenotentirelyclear.Possibleexplanations\nvenousocclusion.Theseconditionswillresultinrapidand\nincludetheuntowardeffectsofdecreasedkidneyfunction\nirreversibledamagetothekidneyandrequireprompt\nsuchasvolumeoverload,retentionofuremiccompounds,\nrecognitionandmanagement.",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 2)",
    "content": "acidosis,electrolytedisorders,increasedriskforinfection,\nandanemia.Although,thesechangesinSCrcouldsimplybe\nAcutetubularnecrosis(ATN)\nWhenmammaliankidneysaresubjectedtoprolongedwarm\ncolinearwithunmeasuredvariablesthatleadtoincreased\nischemiafollowedbyreperfusion,thereisextensivenecrosis\nmortality,multipleattemptstocontrolforknownclinical\ndestroyingtheproximaltubulesoftheouterstripeofthe\nvariableshasledtotheconsistentconclusionthatdecreased\nmedulla,andtheproximalconvolutedtubulesbecome\nkidneyfunctionisindependentlyassociatedwithoutcome. 10\nnecroticaswell.Distalnephroninvolvementinthese\nFurthermore,moreseverereductionsinkidneyfunctiontend\nanimalexperimentsisminimal,unlessmedullaryoxygena-\ntobeassociatedwithevenworseoutcomeascomparedto\n11\ntionisspeciﬁcallytargeted.Althoughtheseanimalsdevelop\nmilderreductions. severeARF,asnotedbyRosenandHeyman,notmuchelse\n12\nIndeedthese\nresemblestheclinicalsyndromeinhumans. Oliguriaandanuria\nauthorscorrectlypointoutthattheterm‘‘acutetubular\nAlthoughurineoutputisbothareasonablysensitive\nnecrosisdoesnotaccuratelyreﬂectthemorphological\nfunctionalindexforthekidneyaswellasabiomarkerof\n12\nchangesinthiscondition’’.Instead,thetermATNisused\ntubularinjury,therelationshipbetweenurineoutputand\ntodescribeaclinicalsituationinwhichthereisadequate\nGFR,andtubularinjuryiscomplex.Forexample,oliguria\nrenalperfusiontolargelymaintaintubularintegrity,butnot\nmaybemoreprofoundwhentubularfunctionisintact. 13\nKidneyInternationalSupplements(2012)2,13–18\nchapter1.1\ntosustainglomerularﬁltration.Datafromrenalbiopsiesin\n13\npatientswithATNdatingbacktothe1950sconﬁrmthe\nlimitedparenchymalcompromiseinspiteofsevereorgan\n12\ndysfunction.Thus,thesyndromeofATNhasverylittleto\ndowiththeanimalmodelstraditionallyusedtostudyit. Morerecently,investigatorshaveemphasizedtheroleof\nendothelialdysfunction,coagulationabnormalities,systemic\ninﬂammation,endothelialdysfunction,andoxidativestress\nincausingrenalinjury,particularlyinthesettingof\n14,15\nTrueATNdoes,infact,occur.Forexample,\nsepsis. patientswitharterialcatastrophes(rupturedaneurysms,\nacutedissection)cansufferprolongedperiodsofwarm\nischemiajustlikeanimalmodels.However,thesecases\ncompriseonlyasmallfractionofpatientswithAKI,and\nironically,thesepatientsareoftenexcludedfromstudies\nseekingtoenrollpatientswiththemorecommonclinical\nFigure1|TheRIFLEcriteriaforAKI.ARF,acuterenalfailure;GFR,\nsyndromeknownasATN.",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 3)",
    "content": "glomerularfiltrationrate;Screat,serumcreatinineconcentration;\nUO,urineoutput.ReprintedfromBellomoR,RoncoC,KellumJA,\nARF\netal.Acuterenalfailure—definition,outcomemeasures,animal\nmodels,fluidtherapyandinformationtechnologyneeds:the\nInarecentreview,Eknoyannotesthattheﬁrstdescriptionof\nSecondInternationalConsensusConferenceoftheAcuteDialysis\nARF,thentermedischuriarenalis,wasbyWilliamHeberden\nQualityInitiative(ADQI)Group.CritCare2004;8:R204-212with\n16\nin1802.Atthebeginningofthetwentiethcentury,ARF,\n22\npermissionfromBellomoRetal.;accessedhttp://ccforum.com/\nthennamedAcuteBright’sdisease,waswelldescribedin\ncontent/8/4/R204\nWilliamOsler’sTextbookforMedicine(1909),asaconsequence\noftoxicagents,pregnancy,burns,trauma,oroperationsonthe\nAKI:acutekidneyinjury/impairment\nkidneys.DuringtheFirstWorldWarthesyndromewasnamed\n17\nImportantly,bydeﬁningthesyndromeofacutechangesin\n‘‘warnephritis’’,andwasreportedinseveralpublications. renalfunctionmorebroadly,RIFLEcriteriamovebeyond\nThesyndromewasforgottenuntiltheSecondWorldWar,\nARF.Theterm‘‘acutekidneyinjury/impairment’’hasbeen\nwhenBywatersandBeallpublishedtheirclassicalpaperon\n18\nproposedtoencompasstheentirespectrumofthesyndrome\ncrushsyndrome.However,itisHomerW.Smithwhois\nfromminorchangesinmarkersofrenalfunctionto\ncreditedfortheintroductionoftheterm‘‘acuterenalfailure’’,\n23\nrequirementforrenalreplacementtherapy(RRT).Thus,\ninachapteron‘‘Acuterenalfailurerelatedtotraumatic\ntheconceptofAKI,asdeﬁnedbyRIFLEcreatesanew\ninjuries’’inhistextbookThekidney-structureandfunctionin\nparadigm.AKIisnotATN,norisitrenalfailure.Instead,it\nhealthanddisease(1951).Unfortunately,aprecisebiochemical\nencompassesbothandalsoincludesother,lesssevere\ndeﬁnitionofARFwasneverproposedand,untilrecently,there\nconditions.Indeed,asasyndrome,itincludespatients\nwasnoconsensusonthediagnosticcriteriaorclinical\nwithoutactualdamagetothekidneybutwithfunctional\ndeﬁnitionofARF,resultinginmultipledifferentdeﬁnitions. impairmentrelativetophysiologicdemand.Includingsuch\nArecentsurveyrevealedtheuseofatleast35deﬁnitionsinthe\n19\npatientsintheclassiﬁcationofAKIisconceptuallyattractive\nliterature.Thisstateofconfusionhasgivenrisetowide\nbecausethesearepreciselythepatientsthatmaybeneﬁtfrom\nvariationinreportedincidenceandclinicalsigniﬁcanceof\nearlyintervention.However,itmeansthatAKIincludesboth\nARF.Dependingonthedeﬁnitionused,ARFhasbeen\ninjuryand/orimpairment.Ratherthanfocusingexclusively\nreportedtoaffectfrom1%to25%ofICUpatientsandhas\n7,20,21\nonpatientswithrenalfailureoronthosewhoreceivedialysis\nleadtomortalityratesfrom15–60%.",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 4)",
    "content": "oronthosethathaveaclinicalsyndromedeﬁnedby\npathology,whichisusuallyabsent(ATN),thestrong\nRIFLEcriteria\nassociationofAKIwithhospitalmortalitydemandsthatwe\nTheAcuteDialysisQualityInitiative(ADQI)groupdeveloped\nchangethewaywethinkaboutthisdisorder.Inastudyby\nasystemfordiagnosisandclassiﬁcationofabroadrangeof\nonly14%ofpatientsreachingRIFLE‘‘F’’\nHosteetal.,\nacuteimpairmentofkidneyfunctionthroughabroad\n22\nreceivedRRT,yetthesepatientsexperiencedahospital\nconsensusofexperts.Thecharacteristicsofthissystemare\nmortalityratemorethanﬁvetimesthatofthesameICU\nsummarizedinFigure1.TheacronymRIFLEstandsforthe\npopulationwithoutAKI.Isrenalsupportunderutilizedor\nincreasingseverityclassesRisk,Injury,andFailure;andthetwo\ndelayed?Arethereothersupportivemeasuresthatshouldbe\noutcomeclasses,LossandEnd-StageRenalDisease(ESRD). employedforthesepatients?SustainedAKIleadstoprofound\nThethreeseveritygradesaredeﬁnedonthebasisofthe\nalterationsinﬂuid,electrolyte,acid-baseandhormonal\nchangesinSCrorurineoutputwheretheworstofeach\nregulation.AKIresultsinabnormalitiesinthecentral\ncriterionisused.Thetwooutcomecriteria,LossandESRD,\nnervous,immune,andcoagulationsystems.Manypatients\naredeﬁnedbythedurationoflossofkidneyfunction. 14\nKidneyInternationalSupplements(2012)2,13–18\nchapter1.1\nXX\nwithAKIalreadyhavemultisystemorganfailure.Whatisthe\n(0.3mg/dlor26.5mol/l)whentheyoccurwithina\n23\nincrementalinﬂuenceofAKIonremoteorganfunctionand48-hourperiod.Tworecentstudiesexamininglarge\n2829\nhowdoesitaffectoutcome?ArecentstudybyLevyetal.databasesintheUSAandEuropevalidatedthese\nexaminedoutcomesforover1000patientsenrolledinthemodiﬁedcriteria.Thakaretal.foundthatincreasedseverity\n24\ncontrolarmsoftwolargesepsistrials.EarlyimprovementofAKIwasassociatedwithanincreasedriskofdeath\n28\n(within24hours)incardiovascular(P¼0.0010),renalindependentofcomorbidity.PatientswithStage1\nXX\n(P0.0001),orrespiratory(P0.0469)functionwas(0.3mg/dlor26.5mol/l)increaseinSCrbutlessthan\nsigniﬁcantlyrelatedtosurvival.Thisstudysuggeststhatatwo-foldincreasehadanoddsratioof2.2;withStage2\noutcomesforpatientswithseveresepsisintheICUare(correspondingtoRIFLE-I),therewasanoddsratioof6.1;\ncloselyrelatedtoearlyresolutionofAKI.WhilerapidandinStage3(RIFLE-F),anoddsratioof8.6forhospital\nresolutionofAKImaysimplybeamarkerofagoodmortalitywascalculated.Anadditionalmodiﬁcationtothe\nprognosis,itmayalsoindicateawindowoftherapeuticRIFLEcriteriahasbeenproposedforpediatricpatientsin\nopportunitytoimproveoutcomeinsuchpatients.ordertobetterclassifysmallchildrenwithacute-on-chronic\n32\ndisease.",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 5)",
    "content": "ValidationstudiesusingRIFLE\nAsofearly2010,overhalfamillionpatientshavebeen\nLimitationstocurrentdefinitionsforAKI\nstudiedtoevaluatetheRIFLEcriteriaasameansofUnfortunately,theexistingcriteria—whileextremelyuseful\n25–28\nclassifyingpatientswithAKI.Largeseriesfromtheandwidelyvalidated—arestilllimited.First,despiteeffortsto\n2829,3025\nUSA,Europe,andAustralia,eachincludingseveralstandardizethedeﬁnitionandclassiﬁcationofAKI,thereis\n26,27\nthousandpatients,haveprovidedaconsistentpicture.AKIstillinconsistencyinapplication.Aminorityofstudies\ndeﬁnedbyRIFLEisassociatedwithsigniﬁcantlydecreasedhaveincludedurinaryoutputcriteriadespiteitsapparent\n6,29\nsurvivalandfurthermore,increasingseverityofAKIdeﬁnedabilitytoidentifyadditionalcasesandmanystudieshave\nbyRIFLEstageleadstoincreasedriskofdeath.excludedpatientswhoseinitialSCrisalreadyelevated. AnearlystudyfromUchinoetal.focusedonthePreliminarydatafroma20000-patientdatabasefromthe\npredictiveabilityoftheRIFLEclassiﬁcationinacohortUniversityofPittsburghsuggeststhatroughlyathirdofAKI\n33\nof20126patientsadmittedtoateachinghospitalforcasesarecommunity-acquiredandmanycasesmaybe\n24hoursovera3-yearperiod.TheauthorsusedanmissedbylimitinganalysistodocumentedincreasesinSCr. electroniclaboratorydatabasetoclassifypatientsintoIndeed,themajorityofcasesofAKIinthedevelopingworld\nRIFLE-R,I,andFandfollowedthemtohospitaldischargearelikelytobecommunity-acquired.Thus,fewstudiescan\nordeath.Nearly10%ofpatientsachievedamaximumprovideaccurateincidencedata.Anadditionalproblem\nRIFLE-R,5%I,and3.5%F.TherewasanearlylinearrelatestothelimitationsofSCrandurineoutputfor\nincreaseinhospitalmortalitywithincreasingRIFLEclass,detectingAKI.Inthefuture,biomarkersofrenalcellinjury\nwithpatientsatRhavingmorethanthreetimesthemortalitymayidentifyadditionalpatientswithAKIandmayidentify\nrateofpatientswithoutAKI.PatientswithIhadclosetothemajorityofpatientsatanearlierstage. twicethemortalityofRandpatientswithFhad10times\nthemortalityrateofhospitalizedpatientswithoutAKI. RationaleforaguidelineonAKI\nAKIisaglobalproblemandoccursinthecommunity,inthe\nTheinvestigatorsperformedmultivariatelogisticregression\nanalysistotestwhetherRIFLEclassiﬁcationwasanhospitalwhereitiscommononmedical,surgical,pediatric,\nindependentpredictorofhospitalmortality.Theyfoundandoncologywards,andinICUs.Irrespectiveofitsnature,\nthatclassRcarriedanoddsratioofhospitalmortalityof2.5,AKIisapredictorofimmediateandlong-termadverse\nIof5.4,andFof10.1.outcomes.AKIismoreprevalentin(andasigniﬁcantrisk\nAlietal.studiedtheincidenceofAKIinNorthernfactorfor)patientswithchronickidneydisease(CKD).",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 6)",
    "content": "Scotland,ageographicalpopulationbaseof523390.TheIndividualswithCKDareespeciallysusceptibletoAKI\n31\nincidenceofAKIwas2147permillionpopulation.Sepsiswhich,inturn,mayactasapromoterofprogressionofthe\nwasaprecipitatingfactorin47%ofpatients.RIFLEunderlyingCKD.TheburdenofAKImaybemostsigniﬁcant\n34,35\nclassiﬁcationwasusefulforpredictingrecoveryofrenalwithlimitedresourcesforthe\nindevelopingcountries\nfunction(P0.001),requirementforRRT(P0.001),lengthcareofthesepatientsoncethediseaseprogressestokidney\noo\nofhospitalstayforsurvivors(P0.001),andin-hospitalfailurenecessitatingRRT.Addressingtheuniquecircum-\nmortality(P0.035).Althoughnolongerstatisticallystancesandneedsofdevelopingcountries,especiallyinthe\nsigniﬁcant,subjectswithAKIhadahighmortalityat3anddetectionofAKIinitsearlyandpotentiallyreversiblestages\n6monthsaswell.topreventitsprogressiontokidneyfailurerequiringdialysis,\nMorerecently,theAcuteKidneyInjuryNetwork(AKIN),isofparamountimportance. aninternationalnetworkofAKIresearchers,organizedaResearchoverthepastdecadehasidentiﬁednumerous\nsummitofnephrologyandcriticalcaresocietiesfromaroundpreventableriskfactorsforAKIandthepotentialof\ntheworld.ThegroupendorsedtheRIFLEcriteriawithimprovingtheirmanagementandoutcomes.Unfortunately,\nasmallmodiﬁcationtoincludesmallchangesinSCrthesearenotwidelyknownandarevariablypracticed\n15\nKidneyInternationalSupplements(2012)2,13–18\nchapter1.1\nworldwide,resultinginlostopportunitiestoimprovethecare\nThesecriteriawereformulatedasfollows:\nandoutcomesofpatientswithAKI.Importantly,thereisnoAKIiscommon. unifyingapproachtothediagnosisandcareofthesepatients.AKIimposesaheavyburdenofillness(morbidityand\nThereisaworldwideneedtorecognize,detect,andintervenemortality). tocircumventtheneedfordialysisandtoimproveoutcomesThecostperpersonofmanagingAKIishigh. ofAKI.ThedifﬁcultiesanddisadvantagesassociatedwithanAKIisamenabletoearlydetectionandpotentialprevention. increasingvariationinmanagementandtreatmentofThereisconsiderablevariabilityinpracticetoprevent,\ndiseasesthatwereampliﬁedintheyearsaftertheSeconddiagnose,treat,andachieveoutcomesofAKI. WorldWar,ledin1989tothecreationintheUSAoftheClinicalpracticeguidelinesinthefieldhavethepotential\ntoreducevariations,improveoutcomes,andreducecosts. AgencyforHealthCarePolicyandResearch(nowtheAgency\nforHealthcareResearchandQuality).ThisagencywasFormalguidelinesdonotexistonthistopic. createdtoprovideobjective,science-basedinformationto\nimprovedecisionmakinginhealth-caredelivery.Amajor\nSummary\ncontributionofthisagencywastheestablishmentofa\nSmallchangesinkidneyfunctioninhospitalizedpatientsare\nsystematicprocessfordevelopingevidence-basedguidelines. importantandassociatedwithsigniﬁcantchangesinshort-\nItisnowwellacceptedthatrigorouslydeveloped,evidence-\nandlong-termoutcomes.TheshiftofterminologyfromATN\nbasedguidelines,whenimplemented,haveimprovedquality,\n36,37\nandARFtoAKIhasbeenwellreceivedbytheresearchand\ncost,variability,andoutcomes.",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.1:Introduction (Part 7)",
    "content": "clinicalcommunities.RIFLE/AKINcriteriaprovideauni-\nRealizingthatthereisanincreasingprevalenceofacute\nformdeﬁnitionofAKI,andhavebecomethestandardfor\n(andchronic)kidneydiseaseworldwideandthatthe\ndiagnosticcriteria.AKIseveritygradesrepresentpatient\ncomplicationsandproblemsofpatientswithkidneydisease\ngroupswithincreasingseverityofillnessasillustratedbyan\nareuniversal,KidneyDisease:ImprovingGlobalOutcomes\nincreasingproportionofpatientstreatedwithRRT,and\n(KDIGO),anonproﬁtfoundation,wasestablishedin2003\nincreasingmortality.Thus,AKIasdeﬁnedbytheRIFLE\n‘‘toimprovethecareandoutcomesofkidneydiseasepatients\ncriteriaisnowrecognizedasanimportantsyndrome,\nworldwidethroughpromotingcoordination,collaboration,\nalongsideothersyndromessuchasacutecoronarysyndrome,\nandintegrationofinitiativestodevelopandimplement\n38\nacutelunginjury,andseveresepsisandsepticshock.The\nclinicalpracticeguidelines’’. RIFLE/AKINclassiﬁcationforAKIisquiteanalogoustothe\nBesidesdevelopingguidelinesonanumberofother\nKidneyDiseaseOutcomesQualityInitiative(KDOQI)for\nimportantareasofnephrology,theBoardofDirectors\nCKDstaging,whichiswellknowntocorrelatedisease\nofKDIGOquicklyrealizedthatthereisroomforimproving\nseveritywithcardiovascularcomplicationsandothermor-\ninternationalcooperationinthedevelopment,dissemi-\n39\nbidities.AsCKDstageshavebeenlinkedtospeciﬁc\nnation,andimplementationofclinicalpracticeguide-\ntreatmentrecommendations,whichhaveprovedextremely\nlinesintheﬁeldofAKI.AtitsmeetinginDecemberof\n39\nusefulinmanagingthisdisease,wehavedeveloped\n2006,theKDIGOBoardofDirectorsdeterminedthatthe\nrecommendationsforevaluationandmanagementof\ntopicofAKImeetsthecriteriafordevelopingclinicalpractice\npatientswithAKIusingthisstage-basedapproach. guidelines. 16\nKidneyInternationalSupplements(2012)2,13–18\nchapter1.2\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 16,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.2:Methodology (Part 1)",
    "content": "INTRODUCTION\nsurgery.WeexcludedstudiesonAKIfromrhabdomyolysis,\nThischapterprovidesaverybriefsummaryofthemethods\nspeciﬁcinfections,andpoisoningordrugoverdose.Overall,\nusedtodevelopthisguideline.Detailedmethodsare\nwescreened18385citations. providedinAppendixF.Theoverallaimoftheprojectwas\ntocreateaclinicalpracticeguidelinewithrecommendations\nOutcomeselectionjudgments,values,andpreferences\nforAKIusinganevidence-basedapproach.AftertopicsandWelimitedoutcomestothoseimportantfordecisionmaking,\nrelevantclinicalquestionswereidentiﬁed,thepertinentincludingdevelopmentofAKI,needforordependenceon\nRRT,andall-causemortality.Whenweightingtheevidence\nscientiﬁcliteratureonthosetopicswassystematically\nsearchedandsummarized.acrossdifferentoutcomes,weselectedasthe‘‘crucial’’outcome\nthatwhichweighedmostheavilyintheassessmentofthe\nGroupmemberselectionandmeetingprocess\noverallqualityofevidence.Valuesandpreferencesarticulated\nTheKDIGOCo-ChairsappointedtheCo-ChairsoftheWork\nbytheWorkGroupincluded:i)adesiretobeinclusivein\nGroup,whothenassembledtheWorkGrouptoberesponsible\ntermsofmeetingcriteriaforAKI;ii)aprogressiveapproachto\nforthedevelopmentoftheguideline.TheWorkGroupconsisted\nriskandcostsuchthat,asseverityincreased,thegroupput\nofdomainexperts,includingindividualswithexpertisein\ngreatervalueonpossibleeffectivenessofstrategies,but\nnephrology,criticalcaremedicine,internalmedicine,pediatrics,\nmaintainedhighvalueforavoidanceofharm;iii)intentto\ncardiology,radiology,infectiousdiseasesandepidemiology.For\nguidepracticebutnotlimitfutureresearch. supportinevidencereview,expertiseinmethods,andguideline\ndevelopment,theNKFcontractedwiththeEvidenceReview\nGradingthequalityofevidenceandthestrengthof\nrecommendations\nTeam(ERT)basedprimarilyattheTuftsCenterforKidney\nThegradingapproachfollowedinthisguidelineisadopted\nDiseaseGuidelineDevelopmentandImplementationatTufts\n40,41\nfromtheGRADEsystem.Thestrengthofeachrecom-\nMedicalCenterinBoston,Massachusetts,USA.TheERT\nmendationisratedaslevel1whichmeans‘‘strong’’orlevel2\nconsistedofphysician-methodologistswithexpertiseinnephrol-\nwhichmeans‘‘weak’’ordiscretionary.Thewordingcorres-\nogyandinternalmedicine,andresearchassociatesandassistants. pondingtoalevel1recommendationis‘‘Werecommend\nTheERTinstructedandadvisedWorkGroupmembersinall\nshould’’andimpliesthatmostpatientsshouldreceivethe\nstepsofliteraturereview,criticalliteratureappraisal,and\ncourseofaction.Thewordingforalevel2recommendation\nguidelinedevelopment.TheWorkGroupandtheERT\nis‘‘Wesuggestmight’’whichimpliesthatdifferentchoices\ncollaboratedcloselythroughouttheproject.TheWorkGroup,\nwillbeappropriatefordifferentpatients,withthesuggested\nKDIGOCo-Chairs,ERT,liaisons,andNKFsupportstaffmetfor\ncourseofactionbeingareasonablechoiceinmanypatients. four2-daymeetingsfortrainingintheguidelinedevelopment\nInaddition,eachstatementisassignedagradeforthequality\nprocess,topicdiscussion,andconsensusdevelopment.",
    "page": 20,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.2:Methodology (Part 2)",
    "content": "ofthesupportingevidence,A(high),B(moderate),C(low),\norD(verylow).Table1showstheimplicationsofthe\nEvidenceselection,appraisal,andpresentation\nWeﬁrstdeﬁnedthetopicsandgoalsfortheguidelineand\nguidelinegradesanddescribeshowthestrengthofthe\nidentiﬁedkeyclinicalquestionsforreview.TheERTrecommendationsshouldbeinterpretedbyguidelineusers. performedliteraturesearches,organizedabstractandarticleFurthermore,ontopicsthatcannotbesubjectedto\nscreening,coordinatedmethodologicalandanalyticprocesses\nsystematicevidencereview,theWorkGroupcouldissue\nofthereport,deﬁnedandstandardizedthesearchmethodol-statementsthatarenotgraded.Typically,theseprovide\nogy,performeddataextraction,andsummarizedtheguidancethatisbasedoncommonsense,e.g.,remindersof\nevidence.TheWorkGroupmembersreviewedallincluded\ntheobviousand/orrecommendationsthatarenotsufﬁciently\narticles,dataextractionforms,summarytables,andevidencespeciﬁcenoughtoallowtheapplicationofevidence.The\nproﬁlesforaccuracyandcompleteness.ThefourmajortopicGRADEsystemisbestsuitedtoevaluateevidenceon\nareasofinterestforAKIincluded:i)deﬁnitionandcomparativeeffectiveness.Someofourmostimportant\nclassiﬁcation;ii)prevention;iii)pharmacologictreatment;\nguidelinetopicsinvolvediagnosisandstagingorAKI,and\nandiv)RRT.PopulationsofinterestwerethoseatriskforheretheWorkGroupchosetoprovideungradedstatements. AKI(includingthoseafterintravascularcontrast-mediaThesestatementsareindirectlysupportedbyevidenceonrisk\nexposure,aminoglycosides,andamphotericin)andthose\nrelationshipsandresultedfromunanimousconsensusofthe\nwithoratriskforAKIwithafocusonpatientswithsepsisorWorkGroup.Thus,theWorkGroupfeelstheyshouldnotbe\ntrauma,receivingcriticalcare,orundergoingcardiothoracicviewedasweakerthangradedrecommendations. 17\nKidneyInternationalSupplements(2012)2,13–18\nchapter1.2\nTable1|Implicationsofthestrengthofarecommendation\nImplications\nGrade*PatientsCliniciansPolicy\nLevel1MostpeopleinyoursituationMostpatientsshouldreceivetheTherecommendationcanbeevaluatedas\n‘‘Werecommend’’wouldwanttherecommendedrecommendedcourseofaction.acandidatefordevelopingapolicyora\ncourseofactionandonlyaperformancemeasure. smallproportionwouldnot. Level2ThemajorityofpeopleinyourDifferentchoiceswillbeappropriateforTherecommendationislikelytorequire\n‘‘Wesuggest’’situationwouldwantthedifferentpatients.Eachpatientneedshelptosubstantialdebateandinvolvementof\nrecommendedcourseofaction,arriveatamanagementdecisionconsistentstakeholdersbeforepolicycanbe\nbutmanywouldnot.withherorhisvaluesandpreferences.determined.",
    "page": 20,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter1.2:Methodology (Part 3)",
    "content": "SPONSORSHIP\nadvertisementshereinaretheresponsibilityofthecontributor,\nKDIGOgratefullyacknowledgesthefollowingsponsorsthat\ncopyrightholder,oradvertiserconcerned.Accordingly,the\nmakeourinitiativespossible:Abbott,Amgen,BeloFounda-\npublishersandtheISN,theeditorialboardandtheirrespective\ntion,Coca-ColaCompany,DoleFoodCompany,Genzyme,\nemployers,ofﬁceandagentsacceptnoliabilitywhatsoeverfor\nHoffmann-LaRoche,JCPenney,NATCO—TheOrganization\ntheconsequencesofanysuchinaccurateormisleadingdata,\nforTransplantProfessionals,NKF—BoardofDirectors,\nopinionorstatement.Whileeveryeffortismadetoensurethat\nNovartis,RobertandJaneCizikFoundation,Shire,\ndrugdosesandotherquantitiesarepresentedaccurately,\nTranswesternCommercialServices,andWyeth.KDIGOis\nreadersareadvisedthatnewmethodsandtechniques\nsupportedbyaconsortiumofsponsorsandnofundingis\ninvolvingdrugusage,anddescribedwithinthisJournal,\nacceptedforthedevelopmentofspeciﬁcguidelines. shouldonlybefollowedinconjunctionwiththedrug\nmanufacturer’sownpublishedliterature. DISCLAIMER\nWhileeveryeffortismadebythepublishers,editorialboard,\nSUPPLEMENTARYMATERIAL\nandISNtoseethatnoinaccurateormisleadingdata,opinion\nAppendixF:DetailedMethodsforGuidelineDevelopment. orstatementappearsinthisJournal,theywishtomakeitclear\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nthatthedataandopinionsappearinginthearticlesand\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n18\nKidneyInternationalSupplements(2012)2,13–18\nchapter2.1\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 20,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section2:AKIDefinition",
    "content": "KidneyInternationalSupplements(2012)2,19–36;doi:10.1038/kisup.2011.32",
    "page": 22,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.1:DefinitionandclassificationofAKI (Part 1)",
    "content": "INTRODUCTIONTable2|StagingofAKI\nAKIisoneofanumberofconditionsthataffectkidney\nStageSerumcreatinineUrineoutput\nstructureandfunction.AKIisdeﬁnedbyanabruptdecrease\n11.5–1.9timesbaseline0.5ml/kg/hfor\ninkidneyfunctionthatincludes,butisnotlimitedto,ARF.It\nOR6–12hours\nisabroadclinicalsyndromeencompassingvariousetiologies,\nXX\n0.3mg/dl(26.5mmol/l)increase\nincludingspeciﬁckidneydiseases(e.g.,acuteinterstitial\n22.0–2.9timesbaseline0.5ml/kg/hfor\nnephritis,acuteglomerularandvasculiticrenaldiseases);\n12hours\nnon-speciﬁcconditions(e.g,ischemia,toxicinjury);aswell\n33.0timesbaseline0.3ml/kg/hfor\nasextrarenalpathology(e.g.,prerenalazotemia,andacute\nOR24hours\npostrenalobstructivenephropathy)—seeChapters2.2and\nIncreaseinserumcreatininetoOR\nXXX\n4.0mg/dl(353.6mmol/l)Anuriafor12hours\n2.3forfurtherdiscussion.Morethanoneoftheseconditions\nOR\nmaycoexistinthesamepatientand,moreimportantly,\nInitiationofrenalreplacementtherapy\nepidemiologicalevidencesupportsthenotionthatevenmild,\nOR,Inpatients18years,decreasein\nreversibleAKIhasimportantclinicalconsequences,including\neGFRto35ml/minper1.73m\n2,5\nThus,AKIcanbethoughtofmore\nincreasedriskofdeath. likeacutelunginjuryoracutecoronarysyndrome. Furthermore,becausethemanifestationsandclinicalcon-\n2.1.2:AKIisstagedforseverityaccordingtothefollowing\nsequencesofAKIcanbequitesimilar(evenindistinguish-\ncriteria(Table2).(NotGraded)\nable)regardlessofwhethertheetiologyispredominantly\n2.1.3:ThecauseofAKIshouldbedeterminedwhenever\nwithinthekidneyorpredominantlyfromoutsidestresseson\npossible.(NotGraded)\nthekidney,thesyndromeofAKIencompassesbothdirect\ninjurytothekidneyaswellasacuteimpairmentoffunction. RATIONALE\nSincetreatmentsofAKIaredependenttoalargedegreeon\nConditionsaffectingkidneystructureandfunctioncanbe\ntheunderlyingetiology,thisguidelinewillfocusonspeciﬁc\nconsideredacuteorchronic,dependingontheirduration. diagnosticapproaches.However,sincegeneraltherapeutic\nAKIisoneofanumberofacutekidneydiseasesand\nandmonitoringrecommendationscanbemaderegardingall\ndisorders(AKD),andcanoccurwithorwithoutotheracute\nformsofAKI,ourapproachwillbetobeginwithgeneral\norchronickidneydiseasesanddisorders(Figure2).Whereas\nmeasures. CKDhasawell-establishedconceptualmodelanddeﬁnition\nthathasbeenusefulinclinicalmedicine,research,andpublic\n42–44\nhealth,thedeﬁnitionforAKIisevolving,andthe\nDefinitionandstagingofAKI\nAKIiscommon,harmful,andpotentiallytreatable.Even\nconceptofAKDisrelativelynew.Anoperationaldeﬁnition\naminoracutereductioninkidneyfunctionhasanadverse\nofAKDforuseinthediagnosticapproachtoalterations\nprognosis.EarlydetectionandtreatmentofAKImay\ninkidneyfunctionandstructureisincludedinChapter2.5,\nimproveoutcomes.TwosimilardeﬁnitionsbasedonSCr\nwithfurtherdescriptioninAppendixB. andurineoutput(RIFLEandAKIN)havebeenproposedand\nTheconceptualmodelofAKI(Figure3)isanalogousto\nvalidated.Thereisaneedforasingledeﬁnitionforpractice,\ntheconceptualmodelofCKD,andisalsoapplicableto\n42,45\nresearch,andpublichealth.",
    "page": 22,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.1:DefinitionandclassificationofAKI (Part 2)",
    "content": "AKD.Circlesonthehorizontalaxisdepictstagesinthe\ndevelopment(lefttoright)andrecovery(righttoleft)of\nAKI.AKI(inred)isdeﬁnedasreductioninkidneyfunction,\n2.1.1:AKIisdeﬁnedasanyofthefollowing(NotGraded):\nXX\nincludingdecreasedGFRandkidneyfailure.Thecriteriafor\nIncreaseinSCrby0.3mg/dl(26.5mol/l)\nthediagnosisofAKIandthestageofseverityofAKIare\nwithin48hours;or\nbasedonchangesinSCrandurineoutputasdepictedinthe\nIncreaseinSCrto1.5timesbaseline,which\ntriangleabovethecircles.KidneyfailureisastageofAKI\nisknownorpresumedtohaveoccurredwithin\nhighlightedherebecauseofitsclinicalimportance.Kidney\ntheprior7days;or\nfailureisdeﬁnedasaGFR15ml/minper1.73mbody\nUrinevolume0.5ml/kg/hfor6hours. 19\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.1\nsurfacearea,orrequirementforRRT,althoughitisExistingevidencesupportsthevalidityofbothRIFLEand\nrecognizedthatRRTmayberequiredearlierintheevolutionAKINcriteriatoidentifygroupsofhospitalizedpatientswith\n2,5,25,28–30\nofAKI.FurtherdescriptionisincludedinChapter2.5andincreasedriskofdeathand/orneedforRRT. AppendixA.Epidemiologicalstudies,manymulticentered,collectively\nItiswidelyacceptedthatGFRisthemostusefuloverallenrollingmorethan500000subjectshavebeenusedto\nindexofkidneyfunctioninhealthanddisease,andchangesestablishRIFLEand/orAKINcriteriaasvalidmethodsto\n29\ninSCrandurineoutputaresurrogatesforchangesinGFR.IndiagnoseandstageAKI.Recently,Joannidisetal.directly\nclinicalpractice,anabruptdeclineinGFRisassessedfromancomparedRIFLEcriteriawithandwithouttheAKIN\nincreaseinSCroroliguria.Recognizingthelimitationsofthemodiﬁcation.WhileAKIclassiﬁedbyeithercriteriawere\nassociatedwithasimilarlyincreasedhospitalmortality,the\nuseofadecreaseinkidneyfunctionfortheearlydetection\nandaccurateestimationofrenalinjury(seebelow),thereisatwocriteriaidentiﬁedsomewhatdifferentpatients.The\nbroadconsensusthat,whilemoresensitiveandspeciﬁcoriginalRIFLEcriteriafailedtodetect9%ofcasesthatwere\ndetectedbyAKINcriteria.However,theAKINcriteriamissed\nbiomarkersareneeded,changesinSCrand/orurineoutput\nformthebasisofalldiagnosticcriteriaforAKI.Theﬁrst26.9%ofcasesdetectedbyRIFLE.Examinationofthecases\ninternationalinterdisciplinaryconsensuscriteriafordiag-missedbyeithercriteria(Table4)showsthatcasesidentiﬁed\n32\nproposedbythebyAKINbutmissedbyRIFLEwerealmostexclusivelyStage1\nnosisofAKIweretheRIFLEcriteria\nADQI.Modiﬁcationstothesecriteriahavebeenproposedin(90.7%),whilecasesmissedbyAKINbutidentiﬁedbyRIFLE\n32\nordertobetteraccountforpediatricpopulations(pRIFLE)included30%withRIFLE-Iand18%RIFLE-F;furthermore,\nandforsmallchangesinSCrnotcapturedbyRIFLE(AKIN\nthesecaseshadhospitalmortalitysimilartocasesidentiﬁed\n23\ncriteria).Recommendations2.1.1and2.1.2representthebybothcriteria(37%forIand41%forF).However,cases\ncombinationofRIFLEandAKINcriteria(Table3).missedbyRIFLEbutidentiﬁedasStage1byAKINalsohad\nhospitalmortalityratesnearlytwicethatofpatientswhohad\nnoevidenceofAKIbyeithercriteria(25%vs.13%).These\ndataprovidestrongrationaleforuseofbothRIFLEand\nAKINcriteriatoidentifypatientswithAKI.",
    "page": 22,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.1:DefinitionandclassificationofAKI (Part 3)",
    "content": "StagingofAKI(Recommendation2.1.2)isappropriate\nAKIAKDCKD\nbecause,withincreasedstageofAKI,theriskfordeathand\n2,5,25,28–31\nFurthermore,thereisnow\nneedforRRTincreases. accumulatingevidenceoflong-termriskofsubsequent\nFigure2|OverviewofAKI,CKD,andAKD.Overlappingovals\ndevelopmentofcardiovasculardiseaseorCKDandmortality,\nshowtherelationshipsamongAKI,AKD,andCKD.AKIisasubset\n47–49\nofAKD.BothAKIandAKDwithoutAKIcanbesuperimposed\nevenafterapparentresolutionofAKI. uponCKD.IndividualswithoutAKI,AKD,orCKDhavenoknown\nForstagingpurposes,patientsshouldbestagedaccord-\nkidneydisease(NKD),notshownhere.AKD,acutekidneydiseases\ningtothecriteriathatgivethemthehigheststage.Thus\nanddisorders;AKI,acutekidneyinjury;CKD,chronickidney\nwhencreatinineandurineoutputmaptodifferentstages,\ndisease. Stages defined by\nComplications\ncreatinine and\nurine output\nare surrogates\nGFR\nIncreased\nKidney\n↓↓\nNormal\nDamageGFR\nDeath\nrisk\nfailure\nDamage\nAntecedentsMarkers such\nIntermediate Stageas NGAL, KIM-1,\nAKIand IL-18 are\nOutcomessurrogates\nFigure3|ConceptualmodelforAKI.RedcirclesrepresentstagesofAKI.YellowcirclesrepresentpotentialantecedentsofAKI,andthe\npinkcirclerepresentsanintermediatestage(notyetdefined).Thickarrowsbetweencirclesrepresentriskfactorsassociatedwiththe\ninitiationandprogressionofdiseasethatcanbeaffectedordetectedbyinterventions.PurplecirclesrepresentoutcomesofAKI. ‘‘Complications’’referstoallcomplicationsofAKI,includingeffortsatpreventionandtreatment,andcomplicationsinotherorgansystems. AKI,acutekidneyinjury;GFR,glomerularfiltrationrate.AdaptedfromMurrayPT,DevarajanP,LeveyAS,etal.Aframeworkandkeyresearch\nquestionsinAKIdiagnosisandstagingindifferentenvironments.ClinJAmSocNephrol2008;3:864–868withpermissionfromAmerican\n45\nSocietyofNephrologyconveyedthroughCopyrightClearanceCenter,Inc.;accessedhttp://cjasn.asnjournals.org/content/3/3/864.full\n20\nKidneyInternationalSupplements(2012)2,19–36",
    "page": 22,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter2.1",
    "content": "Table3|ComparisonofRIFLEandAKINcriteriafordiagnosisandclassificationofAKI\nAKIstagingRIFLE\nUrineoutput\nSerumcreatinine(commontoboth)ClassSerumcreatinineorGFR\nStage1Increaseofmorethanorequalto0.3mg/dlLessthan0.5ml/kg/hforRiskIncreaseinserumcreatinine1.5orGFR\n(cid:2)\n(26.5mmol/l)orincreasetomorethanorequaltomorethan6hoursdecrease425%\n150%to200%(1.5-to2-fold)frombaseline\nStage2Increasedtomorethan200%to300%Lessthan0.5ml/kgperhourInjurySerumcreatinine2orGFRdecreased\n(cid:2)\n(42-to3-fold)frombaselineformorethan12hours450%\nStage3Increasedtomorethan300%(43-fold)Lessthan0.3ml/kg/hforFailureSerumcreatinine3,orserumcreatinine\n(cid:2)\nfrombaseline,ormorethanorequalto4.0mg/dl24hoursoranuriafor44mg/dl(4354mmol/l)withanacute\n(354mmol/l)withanacuteincreaseofatleast12hoursrise40.5mg/dl(444mmol/l)orGFR\n0.5mg/dl(44mmol/l)oronRRTdecreased475%\nLossPersistentacuterenalfailure=complete\nlossofkidneyfunction44weeks\nEnd-stagekidneyESRD3months\ndisease\nNote:ForconversionofcreatinineexpressedinSIunitstomg/dl,divideby88.4.ForbothAKINstageandRIFLEcriteria,onlyonecriterion(creatinineriseorurineoutput\ndecline)needstobefulfilled.ClassisbasedontheworstofeitherGFRorurineoutputcriteria.GFRdecreaseiscalculatedfromtheincreaseinserumcreatinineabove\nbaseline.ForAKIN,theincreaseincreatininemustoccurin48hours.ForRIFLE,AKIshouldbebothabrupt(within1–7days)andsustained(morethan24hours).When\n23\nbaselinecreatinineiselevated,anabruptriseofatleast0.5mg/dl(44mmol/l)to44mg/dl(4354mmol/l)issufficientforRIFLEclassFailure(modifiedfromMehtaetal.and\n22\nthereportoftheAcuteDialysisQualityInitiativeconsortium).\nAKI,acutekidneyinjury;AKIN,AcuteKidneyInjuryNetwork;ESRD,end-stagerenaldisease;GFR,glomerularfiltrationrate;RIFLE,risk,injury,failure,loss,andendstage;RRT,\nrenalreplacementtherapy.ReprintedfromEndreZH.Acutekidneyinjury:definitionsandnewparadigms.AdvChronicKidneyDis2008;15:213–221withpermissionfrom\n46\nNationalKidneyFoundation;accessedhttp://www.ackdjournal.org/article/S1548-5595(08)00049-9/fulltext\nTable4|Cross-tabulationofpatientsclassifiedbyRIFLEvs.AKIN\nRIFLE\nAKINNon-AKIRiskInjuryFailureTotal(AKIN)\nNon-AKIn*8759(12.9%)781(27.7%)452(37.4%)271(41.3%)10263(15.9%)\nStage1n*457(25.2%)282(33.0%)243(44.0%)95(60.0%)1077(34.5%)\nStage2n*36(30.6%)21(47.6%)885(25.9%)91(54.9)1033(29.0%)\nStage3n*11(18.2%)8(12.5%)16(62.5%)1948(41.3)1983(41.2%)\nTotal(RIFLE)n*9263(13.6%)1092(29.2%)1596(32.3%)2405(42.6%)14356(21.7%)\n*NumberofpatientsclassifiedintotherespectivestagesofAKIbyAKINorRIFLEarecross-tabulatedagainsteachother.Hospitalmortalityofeachgroupisgivenin\nparentheses.ShadedfieldsdenotepatientsassignedtothesamedegreeofAKIbybothclassificationsystems.\nAKI,acutekidneyinjury;AKIN,AcuteKidneyInjuryNetwork;RIFLE,risk,injury,failure,loss,andendstage.WithkindpermissionfromSpringerScience+BusinessMedia:\nIntensiveCareMed.AcutekidneyinjuryincriticallyillpatientsclassifiedbyAKINversusRIFLEusingtheSAPS3database.35(2009):1692–1702.JoannidisM,MetnitzB,\n29\nBauerPetal.;accessedhttp://www.springerlink.com/content/r177337030550120/",
    "page": 24,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "4.0mg/dl(354mol/l)(providedthattheyﬁrstsatisfycriteria.Theapplicationofthediagnosticandstagingcriteria (Part 1)",
    "content": "21\nKidneyInternationalSupplements(2012)2,19–36\n[Table 1]\n8759(12.9%) |  |  |  | \n------------------------------------------------------------\n | 282(33.0%) |  |  | \n |  | 885(25.9%) |  | \n |  |  | 1948(41.3) | \n |  |  |  | 14356(21.7%)\n\nchapter2.1\nTable5|CausesofAKIanddiagnostictests\nsomepatientswithspeciﬁckidneydiseases(e.g.,glome-\nrulonephritis)forwhichaspeciﬁctreatmentisavailable.As\nSelectedcausesofAKIrequiring\nsuch,itisalwaysnecessarytosearchfortheunderlyingcause\nimmediatediagnosisandspecific\ntherapiesRecommendeddiagnostictests\nofAKI(seeChapter2.3). DecreasedkidneyperfusionVolumestatusandurinary\nResearchRecommendations\ndiagnosticindices\nAcuteglomerulonephritis,vasculitis,Urinesedimentexamination,\nTheroleofbiomarkersotherthanSCrintheearly\ninterstitialnephritis,thromboticserologictestingand\ndiagnosis,differentialdiagnosis,andprognosisofAKI\nmicroangiopathyhematologictesting\npatientsshouldbeexplored.Someimportantareasin\nUrinarytractobstructionKidneyultrasound\nwhichtofocusinclude:\nAKI,acutekidneyinjury. EarlydetectionwherethegoldstandardisAKIby\nclinicaldiagnosisafterthefactandthebiomarkeris\ncomparedtoexistingmarkers(SCrandurine\noutput)atthetimeofpresentation. isdiscussedingreaterdetail,alongwithspeciﬁcexamplesin\nPrognosiswhereabiomarkerisusedtopredictrisk\nChapter2.4. forAKIorriskforprogressionofAKI. Theuseofurineoutputcriteriafordiagnosisandstaging\nPrognosiswhereabiomarkerisusedtopredict\nhasbeenlesswellvalidatedandinindividualpatients\nrecoveryafterAKIvs.deathorneedforlong-termRRT. theneedforclinicaljudgmentregardingtheeffectsofdrugs\nTheinfluenceofurinaryoutputcriteriaonAKIstaging\n(e.g.,angiotensin-convertingenzymeinhibitors[ACE-I]),\nneedstobefurtherinvestigated.Influenceoffluid\nﬂuidbalance,andotherfactorsmustbeincluded.Forvery\nbalance,percentvolumeoverload,diureticuse,and\nobesepatients,urineoutputcriteriaforAKImayinclude\ndifferingweights(actual,idealbodyweight,leanbody\nsomepatientswithnormalurineoutput.However,these\nmass)shouldbeconsidered.Also,itiscurrentlynot\nrecommendationsserveasthestartingpointforfurther\nknownhowurinevolumecriteriashouldbeapplied(e.g.,\nevaluation,possiblyinvolvingsubspecialists,foragroupof\naveragevs.persistentreductionfortheperiodspecified). patientsrecognizedtobeatincreasedrisk. TheinfluenceofSCroreGFRcriteriaonAKIstaging\nFinally,itisaxiomaticthatpatientsalwaysbemanaged\nneedstobefurtherinvestigated.Theuseofdifferent\naccordingtothecauseoftheirdisease,andthusitis\nrelativeandabsoluteSCrincrementsoreGFRdecrements\nimportanttodeterminethecauseofAKIwheneverpossible. atdifferenttimepointsandwithdifferentlyascertained\nInparticular,patientswithdecreasedkidneyperfusion,acute\nbaselinevaluesrequiresfurtherexplorationandvalida-\nglomerulonephritis,vasculitis,interstitialnephritis,throm-\ntioninvariouspopulations. boticmicroangiopathy,andurinarytractobstructionrequire\nimmediatediagnosisandspeciﬁctherapeuticintervention,in\nadditiontothegeneralrecommendationsforAKIinthe\nSUPPLEMENTARYMATERIAL\nAppendixA:Background.",
    "page": 24,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "4.0mg/dl(354mol/l)(providedthattheyﬁrstsatisfycriteria.Theapplicationofthediagnosticandstagingcriteria (Part 2)",
    "content": "remainderofthisguideline(Table5). AppendixB:DiagnosticApproachtoAlterationsinKidneyFunction\nItisrecognizedthatitisfrequentlynotpossibletodeter-\nandStructure. minethecause,andoftentheexactcausedoesnotdictatea\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nspeciﬁctherapy.However,thesyndromeofAKIincludes\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n22\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.2\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 24,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.2:Riskassessment (Part 1)",
    "content": "Thekidneyisafairlyrobustorganthatcantolerateexposureto\nTable6|CausesofAKI:exposuresandsusceptibilitiesfor\nseveralinsultswithoutsufferingsigniﬁcantstructuralor\nnon-specificAKI\nfunctionalchange.Forthisreason,anyacutechangeinkidney\nExposuresSusceptibilities\nfunctionoftenindicatesseveresystemicderangementand\nSepsisDehydrationorvolumedepletion\npredictsapoorprognosis.RiskforAKIisincreasedbyexposure\nCriticalillnessAdvancedage\ntofactorsthatcauseAKIorthepresenceoffactorsthatincrease\nCirculatoryshockFemalegender\nsusceptibilitytoAKI.Factorsthatdeterminesusceptibilityofthe\nBurnsBlackrace\nkidneystoinjuryincludedehydration,certaindemographic\nTraumaCKD\nCardiacsurgery(especiallyChronicdiseases(heart,lung,liver)\ncharacteristicsandgeneticpredispositions,acuteandchronic\nwithCPB)\ncomorbidities,andtreatments.Itistheinteractionbetween\nMajornoncardiacsurgeryDiabetesmellitus\nsusceptibilityandthetypeandextentofexposuretoinsultsthat\nNephrotoxicdrugsCancer\ndeterminestheriskofoccurrenceofAKI. RadiocontrastagentsAnemia\nPoisonousplantsandanimals\nUnderstandingindividual‘‘riskfactors’’mayhelpin\nCKD,chronickidneydisease;CPB,cardiopulmonarybypass. preventingAKI.Thisisparticularlygratifyinginthehospital\nsetting,wherethepatient’ssusceptibilitycanbeassessed\nbeforecertainexposuresassurgeryoradministrationof\nHowever,thechancesofdevelopingAKIafterexposuretothe\npotentiallynephrotoxicagents.Accordingly,somesuscept-\nsameinsultdifferamongdifferentindividuals.Thisis\nibilityfactorsmaybemodiﬁed,andcontemplatedexposures\nattributedtoanumberofsusceptibilityfactorswhichvary\navoidedortailoredtoreducetheriskofAKI. widelyfromindividualtoindividual.Ourunderstandingof\nRiskassessmentincommunity-acquiredAKIisdifferent\nsusceptibilityfactors(Table6)isbasedonmanyobserva-\nfromhospital-acquiredAKI,fortwomainreasons:i)Available\ntionalstudiesthataddressdifferentsettingswithregardsto\nevidenceonriskfactorsislargelyderivedfromhospitaldataand\nthetype,severity,duration,andmultiplicityofinsults.While\nextrapolationtothecommunitysettingisquestionable.ii)The\nthisheterogeneityprovidesinsightintosomesusceptibility\nopportunitytointervene,priortoexposure,isquitelimited. factorsthatarecommonacrossvariouspopulations,the\nMostpatientsareseenonlyafterhavingsufferedanexposure\ngeneralizabilityofresultsfromoneparticularsettingtothe\n(trauma,infection,poisonousplant,oranimal).However,there\nnextisuncertain.",
    "page": 26,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.2:Riskassessment (Part 2)",
    "content": "isstillroomtoassesssuchpatients,albeitafterexposure,in\nThecourseandoutcomeofAKIaremodiﬁedbyother\nordertoidentifythosewhoaremorelikelytodevelopAKI,\nfactors,butsincethesearemanifestedwithinthecontextof\ntherebyrequiringclosermonitoringandgeneralsupportive\nactualdisease,theymustbecategorizedas‘‘prognostic’’\nmeasures.Itmayalsobehelpfultoidentifysuchpatientsin\nratherthan‘‘risk’’factors,hencebeingdiscussedseparatelyin\nordertoavoidadditionalinjury.Amorecompletediscussionof\nAppendixD.Lastly,thefactthatsome30%ofpatientswho\ntheapproachtoidentiﬁcationandmanagementofriskforAKI\nrecoverfromAKIremainatincreasedriskofCKD,\nisprovidedinAppendicesCandD. cardiovasculardisease,anddeathcallsfortheidentiﬁcation\noftheriskfactorsthatcanidentifysuchpatientsinthehopes\n50–52\n2.2.1:WerecommendthatpatientsbestratiﬁedforriskofAKI\nofprovidingthemwithtimelypreventivemeasures. accordingtotheirsusceptibilitiesandexposures.(1B)\nFinally,itisimportanttoscreenpatientswhohave\n2.2.2:Managepatientsaccordingtotheirsusceptibilitiesand\nundergoneanexposure(e.g.,sepsis,trauma)andtocontinue\nexposurestoreducetheriskofAKI(seerelevant\nmonitorhigh-riskpatientsuntiltheriskhassubsided.Exact\nguidelinesections).(NotGraded)\nintervalsforcheckingSCrandinwhichindividualsto\n2.2.3:TestpatientsatincreasedriskforAKIwithmeasure-\nmonitorurineoutputremainmattersofclinicaljudgment;\nmentsofSCrandurineoutputtodetectAKI.(Not\nhowever,asageneralrule,highriskin-patientsshouldhave\nGraded)Individualizefrequencyanddurationof\nSCrmeasuredatleastdailyandmorefrequentlyafteran\nmonitoringbasedonpatientriskandclinicalcourse. exposure,andcriticallyillpatientsshouldhaveurineoutput\n(NotGraded)\nmonitoring.Thiswillnecessitateurinarybladdercatheteriza-\ntioninmanycases,andtherisksofinfectionshouldalsobe\nconsideredinthemonitoringplan. ArecentclinicalpracticeassessmentintheUKconcluded\nRATIONALE\nTherearemanytypesofexposuresthatmaycauseAKI\nthatonly50%ofpatientswithAKIwereconsideredtohave\n(Table6)andthesearediscussedindetailinAppendixC. receiveda‘‘good’’overallstandardofcare.Thisﬁgurefellto\n23\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.2\njustover30%ifAKIdevelopedduringahospitaladmissionStudiesareneededtodevelopandvalidatescoringsystems\n53\nratherthanbeingdiagnosedbeforeadmission.TheauthorsforAKIriskpredictioninvarioussettings,inadditionto\nalsofeltthattherewasanunacceptabledelayinrecognizingcardiacsurgeryandexposuretoradiocontrastmaterial. AKIin43%ofthosethatdevelopedtheconditionafterGenome-wideassociationstudiesareneededtodeter-\nadmission,andthatinaﬁfthofsuchpatientsitsdevelop-mineriskofAKIindifferenthospitalsettingsandwith\nmentwaspredictableandavoidable.Theirrecommendationsrespecttolong-termoutcomes.",
    "page": 26,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.2:Riskassessment (Part 3)",
    "content": "weresimple:riskassessmentforAKIaspartoftheinitialStudiesareneededonriskfactorsforthedevelopmentof,\nevaluationofemergencyadmissions,alongwithappropriaterecoveryfrom,andlong-termoutcomesofcommunity-\nserumbiochemistryonadmissionandatfrequentintervalsacquiredAKI,includingsepsis,trauma,tropicalinfec-\n53\ntions,snakebites,andingestionoftoxicplants,etc. thereafter. RESEARCHRECOMMENDATIONS\nSUPPLEMENTARYMATERIAL\nAppendixC:RiskDetermination. Betterdelineationofriskforhospital-andcommunity-\nAppendixD:EvaluationandGeneralManagementGuidelinesfor\nacquiredAKIisneeded. PatientswithAKI. BetterdelineationoftheeffectsofageontheriskforAKI\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nisneeded. http://www.kdigo.org/clinical_practice_guidelines/AKI.php\n24\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.3\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 26,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "patientswithandatriskforAKI (Part 1)",
    "content": "GiventhatAKIisassociatedwithsigniﬁcantmorbidityand\nwithAKIincludebothreducingkidneyinjuryandcomplica-\nmortality,andbecausenospeciﬁctreatmentisavailableto\ntionsrelatedtodecreasedkidneyfunction. reverseAKI,earlyrecognitionandmanagementispara-\nmount.Indeed,recognitionofpatientsatriskforAKI,or\n2.3.1:EvaluatepatientswithAKIpromptlytodetermine\nwithpossibleAKIbutpriortoclinicalmanifestations,is\nthecause,withspecialattentiontoreversible\nlikelytoresultinbetteroutcomesthantreatingonly\ncauses.(NotGraded)\nestablishedAKI.Chapter2.2introducedtheapproachto\n2.3.2:MonitorpatientswithAKIwithmeasurementsof\nriskassessmentwithfurtherdetailprovidedinAppendixC. SCrandurineoutputtostagetheseverity,\nThischapterwillconcernitselfwiththeevaluation\naccordingtoRecommendation2.1.2.(NotGraded)\nandgeneralmanagementofpatientswith,orevenatrisk\n2.3.3:ManagepatientswithAKIaccordingtothestage\nfor,AKI.FurtherdetailisprovidedinAppendixD.We\n(seeFigure4)andcause.(NotGraded)\nhighlighttheimportanceofbeginningmanagementatthe\n2.3.4:Evaluatepatients3monthsafterAKIforresolu-\nearliestpointinthedevelopmentofAKI—inpatientswith\ntion,newonset,orworseningofpre-existingCKD. suspectedAKIoreveninthoseatincreasedriskwhohave\n(NotGraded)\nbeenexposedtothevariousfactorsdiscussedinChapters2.2\nIfpatientshaveCKD,managethesepatientsas\nandAppendixC. detailedintheKDOQICKDGuideline(Guide-\nAlthoughmuchoftheremainingchaptersinthisguide-\nlines7–15).(NotGraded)\nlinepertaintomanagementofspeciﬁcaspectsofAKI,there\nIfpatientsdonothaveCKD,considerthemtobe\naregeneralmanagementprinciplesthatarecommontoall\natincreasedriskforCKDandcareforthemas\npatientsandthesewillbediscussedhereandfurther\ndetailedintheKDOQICKDGuideline3for\nexpoundeduponinAppendixD.Treatmentgoalsinpatients\npatientsatincreasedriskforCKD.(NotGraded)\nFigure4|Stage-basedmanagementofAKI.Shadingofboxesindicatespriorityofaction—solidshadingindicatesactionsthatare\nequallyappropriateatallstageswhereasgradedshadingindicatesincreasingpriorityasintensityincreases.AKI,acutekidneyinjury;\nICU,intensive-careunit. 25\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.3\nRATIONALE\nTheclinicalevaluationofAKIincludesacarefulhistory\nAsemphasizedinChapter2.2,AKIisnotadiseasebut\nandphysicalexamination.Drughistoryshouldincludeover-\nratheraclinicalsyndromewithmultipleetiologies.While\nthe-counterformulationsandherbalremediesorrecreational\nmuchoftheliteratureexaminingepidemiologyandclinical\ndrugs.Thesocialhistoryshouldincludeexposuretotropical\nconsequencesofAKIappeartotreatthissyndromeasa\ndiseases(e.g.,malaria),waterwaysorsewagesystems,and\nhomogeneousdisorder,therealityisthatAKIishetero-\nexposuretorodents(e.g.,leptospirosis,hantavirus).Physical\ngeneousandoftenistheresultofmultipleinsults.Figure5\nexaminationshouldincludeevaluationofﬂuidstatus,signs\nillustratesanapproachtoevaluationofAKI.Further\nforacuteandchronicheartfailure,infection,andsepsis. discussionofevaluationinclinicalpracticeisprovidedin\nMeasurementofcardiacoutput,preload,preloadrespon-\nAppendixD.",
    "page": 28,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "patientswithandatriskforAKI (Part 2)",
    "content": "siveness,andintra-abdominalpressureshouldbeconsidered\nFigure5|EvaluationofAKIaccordingtothestageandcause. 26\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.3\nintheappropriateclinicalcontext.Laboratoryparameters—\nvariableslikecentralvenouspressurearenotnearlyasuseful\nincludingSCr,bloodureanitrogen(BUN),andelectrolytes,\nasdynamicvariables,suchaspulse-pressurevariation,\ncompletebloodcountanddifferential—shouldbeobtained.inferiorvenacavaﬁllingbyultrasoundandechocardio-\nUrineanalysisandmicroscopicexaminationaswellas\ngraphicappearanceoftheheart(seealsoAppendixD). urinarychemistriesmaybehelpfulindeterminingthe\nNotethatwhiletheactionslistedinFigure4provide\nunderlyingcauseofAKI.Imagingtests,especiallyultrasound,anoverallstartingpointforstage-basedevaluationand\nareimportantcomponentsoftheevaluationforpatientswith\nmanagement,theyareneithercompletenotmandatoryfor\nAKI.Finally,anumberofbiomarkersoffunctionalchange\nanindividualpatient.Forexample,themeasurementofurine\nandcellulardamageareunderevaluationforearlydiagnosis,\noutputdoesnotimplythattheurinarybladdercatheteriza-\nriskassessmentfor,andprognosisofAKI(seeAppendixDtionismandatoryforallpatients,andcliniciansshould\nfordetaileddiscussion). balancetherisksofanyprocedureswiththebeneﬁts. Individualizefrequencyanddurationofmonitoringbased\nFurthermore,cliniciansmustindividualizecaredecisions\nonpatientrisk,exposureandclinicalcourse.Stageisapredictorbasedonthetotalityoftheclinicalsituation.However,itis\noftheriskformortalityanddecreasedkidneyfunction(see\nadvisabletoincludeAKIstageinthesedecisions. Chapter2.4).Dependentonthestage,theintensityoffuture\nTheevaluationandmanagementofpatientswithAKI\npreventivemeasuresandtherapyshouldbeperformed.requiresattentiontocauseandstageofAKI,aswellasfactors\nBecausethestageofAKIhasclearlybeenshowntothatrelatetofurtherinjurytothekidney,orcomplications\n2,5,27,29\ncorrelatewithshort-termandevenlonger-termout-\nfromdecreasedkidneyfunction.SinceAKIisariskfactorfor\n31\ncomes,itisadvisabletotailormanagementtoAKIstage. CKD,itisimportanttoevaluatepatientswithAKIfornew\nFigure4listsasetofactionsthatshouldbeconsideredfor\nonsetorworseningofpre-existingCKD.Ifpatientshave\npatientswithAKI.Notethatforpatientsatincreasedrisk(see\nCKD,managepatientsasdetailedintheKDOQICKD\nChapters2.2and2.4),theseactionsactuallybegineven\nGuideline(Guidelines7–15).IfpatientsdonothaveCKD,\nbeforeAKIisdiagnosed. considerthemtobeatincreasedriskforCKDandcarefor\nNotethatmanagementanddiagnosticstepsareboth\nthemasdetailedintheKDOQICKDGuideline3forpatients\nincludedinFigure4.Thisisbecauseresponsetotherapyisan\natincreasedriskforCKD. importantpartofthediagnosticapproach.Therearefew\nRESEARCHRECOMMENDATIONS\nspeciﬁcteststoestablishtheetiologyofAKI.However,a\nClinicalresearchaimedattestingearlymanagement\npatient’sresponsetotreatment(e.g.,discontinuationofa\nstrategiesisurgentlyneeded.Suchtrialsshouldalso\npossiblenephrotoxicagent)providesimportantinformation\naddresstherisksandbenefitsofcommonlyusedfluid-\nastothediagnosis.",
    "page": 28,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "patientswithandatriskforAKI (Part 3)",
    "content": "managementstrategies,includingintravenous(i.v.)fluids\nNephrotoxicdrugsaccountforsomepartofAKIin20–30%\nanddiuretics. ofpatients.Often,agentslikeantimicrobials(e.g.,aminoglyco-\nMethodstobetterassessfluidstatusincriticallyilland\nsides,amphotericin)andradiocontrastareusedinpatientsthat\notherhospitalizedpatientsatriskforAKIareneeded. arealreadyathighriskforAKI(e.g.,criticallyillpatientswith\nResearchisneeded,withfollow-upbeyondhospitalstay,\nsepsis).Thus,itisoftendifﬁculttodiscernexactlywhat\ntobetterunderstandtheclinicalconsequencesofAKIin\ncontributiontheseagentshaveontheoverallcourseofAKI. patientswithandwithoutunderlyingCKD. Nevertheless,itseemsprudenttolimitexposuretotheseagents\nwheneverpossibleandtoweightheriskofdevelopingor\nworseningAKIagainsttheriskassociatedwithnotusingthe\nSUPPLEMENTARYMATERIAL\nAppendixC:RiskDetermination. agent.Forexample,whenalternativetherapiesordiagnostic\nAppendixD:EvaluationandGeneralManagementGuidelinesfor\napproachesareavailabletheyshouldbeconsidered. PatientswithAKI. Inordertoensureadequatecirculatingbloodvolume,itis\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nsometimesnecessarytoobtainhemodynamicvariables.Static\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n27\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.4\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 28,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.4:Clinicalapplications (Part 1)",
    "content": "ThischapterprovidesadetailedapplicationoftheAKI\ndiagnosepatientsasrapidlyaspossible.Forexample,caseA\ndeﬁnitionandstagingforclinicaldiagnosisandmanagement.canbediagnosedwithAKIonday2bytheﬁrstcriterion,\nThedeﬁnitionsandclassiﬁcationsystemdiscussedinwhereasthesecondcriterionisnotsatisﬁeduntilday3\nChapter2.1canbeusedeasilyinmanypatientsandrequires\n(increasefrom1.3to1.9).However,thisisonlytruebecause\nlittleclinicalinterpretation.However,inrealtime,clinicianstheepisodeofAKIbeganpriortomedicalattention,andthus\ndonotalwayshaveacompletedatasettoworkwiththeday1SCrlevelwasalreadyincreased.Ifcreatinine\nandindividualpatientspresentwithuniquehistories.Asmeasurementshadavailablewith48hourspriortoday1and\ndiscussedinthepreviouschapter,itisdifﬁculttodistinguish\nifthislevelhadbeenatbaseline(1.0mg/dl[88.4mol/l]),it\nAKIfromCKDinmanycases.Inaddition,asmanyaswouldhavebeenpossibletodiagnoseAKIonday1usingthe\ntwo-thirdsofallcasesofAKIbeginpriortohospitali-secondcriterion. zation(community-acquiredAKI).Therefore,clinicians\nCasesF-HdonothaveabaselinemeasurementofSCr\nmaybefacedwithpatientsinwhomkidneyfunctionavailable.ElevatedSCr(reducedeGFR)onday1ofthe\nisalreadydecreasedand,duringthehospitalization,hospitalizationisconsistentwitheitherCKDorAKD\nimprovesratherthanworsens.Finally,manypatientswithoutAKI.InCaseF,baselineSCrcanbeinferred\ndonothaveapriormeasurementofkidneyfunction\ntobebelowtheday1valuebecauseofthesubsequent\navailableforcomparison.Thischapterprovidesdetailedclinicalcourse;thus,wecaninferthepatienthashadan\nexamplesoftheapplicationofthesedeﬁnitionstotheclinicalepisodeofAKI.IncaseG,AKIcanbediagnosedby\nsetting. applicationofcriterion2,butthepatientmayhaveunder-\nlyingCKD.CaseHdoesnotfulﬁllthedeﬁnitionfor\nAKIbasedoneithercriteria,andhaseitherCKDorAKD\nExamplesofapplicationofAKIdefinitions\nTable7illustratesanumberofexampleswherebypatients\nwithoutAKI. presentingwithpossibleAKIcanbediagnosed.CasesA-F\nTheexampleofCaseAraisesseveralimportantissues. haveameasurementofbaselineSCr.Tosimplifydecision-\nFirst,frequentmonitoringofSCrinpatientsatincreasedrisk\nmaking,baselineestimatedglomerularﬁltrationrate(eGFR)\nofAKIwillsigniﬁcantlyimprovediagnostictimeand\nexceeds60ml/minper1.73minthesepatients,sononehas\naccuracy.IfCaseAhadnotpresentedtomedicalattention\npre-existingCKD.CasesA-FcanallbediagnosedwithAKI\n(orifSCrhadnotbeenchecked)untilday7,thecaseofAKI\nbyapplyingtheﬁrsttwocriteriainRecommendation2.1.1.(a\nwouldlikelyhavebeenmissed.FrequentmeasurementofSCr\n4m\ndocumentedincreaseofatleast0.3mg/dl(26.5mol/l)inhigh-riskpatients,orinpatientsinwhichAKIissuspected,\n[within48hoursora50%increasefrompresumedbaseline).",
    "page": 31,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter2.4:Clinicalapplications (Part 2)",
    "content": "isthereforeencouraged—seeChapter2.3.Thesecondissue\nNotethatapatientcanbediagnosedwithAKIbyfulﬁlling\nhighlightedbyCaseAistheimportanceofbaselineSCr\neithercriterion1or2(or3,urineoutput)andthuscases\nmeasurements.Hadnobaselinebeenavailableitwouldstill\nB,C,D,andFallfulﬁllthedeﬁnitionofAKI.Notealsothat\nhavebeenpossibletodiagnoseAKIonday3(byeitherusing\npatientsmaybediagnosedearlierusingcriterion1or2.Early\ncriterion2orbyusingcriterion1andacceptingthebaseline\ndiagnosismayimproveoutcomesoitisadvantageousto\nSCras1.3);however,notonlywouldthishaveresultedina\nTable7|AKIdiagnosis\nSerumcreatininemg/dl(lmol/l)DiagnosisAKI? Criterion1Criterion2\nXX\nCaseBaselineDay1Day2Day3Day750%frombaseline0.3mg/dl(26.5lmol/l)risein48hours\nA1.0(88)1.3(115)1.5(133)2.0(177)1.0(88)YesYes\nB1.0(88)1.1(97)1.2(106)1.4(124)1.0(88)NoYes\nC0.4(35)0.5(44)0.6(53)0.7(62)0.4(35)YesNo\nD1.0(88)1.1(97)1.2(106)1.3(115)1.5(133)YesNo\nE1.0(88)1.3(115)1.5(133)1.8(159)2.2(195)YesYes\nF?3.0(265)2.6(230)2.2(195)1.0(88)YesNo\nG?1.8(159)2.0(177)2.2(195)1.6(141)?Yes\nH?3.0(265)3.1(274)3.0(265)2.9(256)?No\n28\nKidneyInternationalSupplements(2012)2,19–36",
    "page": 31,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter2.4",
    "content": "Table8|OverviewoftheapproachestodeterminebaselineSCrintheapplicationofRIFLEclassificationinpreviousstudies\nNo.ofptsMulti-/Criteria%%\nStudyanalyzedsingle-centerusedMethodtodeterminebaselineSCrrecordedestimated\n25\nBagshaw120123multicr+uoestimatedbyMDRDformula0100\n30\nOstermann41972multicrestimatedbyMDRDformula0100\nUchino20126singlecrretrievedfromhospitaldatabase,orestimatedbyMDRDformulaN/AN/A\n54\nBell8152singlecr+uoretrievedfromhospitaldatabase,orestimatedbyMDRDformulaN/AN/A\nHoste5383singlecr+uoestimatedbyMDRDformula,oradmissioncreatininevalue,N/AN/A\nwhateverwaslower\n31\nAli5321multicrretrievedfromhospitaldatabase,oradmissioncreatininevalue1000\n55\nCruz2164multicr+uoretrievedfromhospitaldatabase,orestimatedbyMDRDformula7822\n56\nPerez-Valdivieso1008singlecrestimatedbyMDRDformula0100\n57\nKuitunen813singlecr+uopreoperativevalue1000\n58\nCoca304singlecrthelowests-creatininevalueinthefirst5hospitaldays1000\n59\nArnaoutakis267singleN/AN/AN/AN/A\n60\nAbosaif247singlecr+uoretrievedfromhospitaldatabase,oradmissioncreatininevalue1000\n61\nMaccariello214multicr+uoretrievedfromhospitaldatabase,orestimatedbyMDRDformulaN/AN/A\n62\nJenq134singlecr+uoadmissioncreatininevalue,orestimatedbyMDRDformula9010\ncr,creatininecriteria;MDRD,ModificationofDietinRenalDisease;N/A,notavailable;pts,patients;SCr,serumcreatinine;uo,urineoutputcriteria.\nReprintedfromZavadaJ,HosteE,Cartin-CebaRetal.AcomparisonofthreemethodstoestimatebaselinecreatinineforRIFLEclassification.NephrolDialTransplant2010;\n25(12):3911–3918(Ref.64)bypermissionfromTheEuropeanRenalAssociation-EuropeanDialysisandTransplantAssociation;accessedhttp://ndt.oxfordjournals.org/content/\n25/12/3911.long\nTable9|EstimatedbaselineSCr\nAge(years)Blackmalesmg/dl(lmol/l)Othermalesmg/dl(lmol/l)Blackfemalesmg/dl(lmol/l)Otherfemalesmg/dl(lmol/l)\n20–241.5(133)1.3(115)1.2(106)1.0(88)\n25–291.5(133)1.2(106)1.1(97)1.0(88)\n30–391.4(124)1.2(106)1.1(97)0.9(80)\n40–541.3(115)1.1(97)1.0(88)0.9(80)\n55–651.3(115)1.1(97)1.0(88)0.8(71)\n4651.2(106)1.0(88)0.9(80)0.8(71)\nEstimatedglomerularfiltrationrate=75(ml/minper1.73m)=186(serumcreatinine[S])1.154(age)0.203(0.742iffemale)(1.210ifblack)=exp(5.2281.154\n(cid:2)(cid:3)(cid:2)(cid:3)(cid:2)(cid:2)(cid:3)(cid:2)\nCr\nIn[S])0.203In(age)(0.299iffemale)+(0.192ifblack).\n(cid:3)(cid:2)(cid:3)\nCr\nReprintedfromBellomoR,RoncoC,KellumJAetal.Acuterenalfailure-definition,outcomemeasures,animalmodels,fluidtherapyandinformationtechnologyneeds:the\n22\nSecondInternationalConsensusConferenceoftheAcuteDialysisQualityInitiative(ADQI)Group.CritCare2004;8:R204-212withpermissionfromBellomoRetal.;accessed\nhttp://ccforum.com/content/8/4/R204\nEstimatingbaselineSCr",
    "page": 32,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "earlyasday1. (Part 1)",
    "content": "29\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.4\nTable10|AKIstaging\nSerumcreatininemg/dl(lmol/l)\nCaseBaselineDay1Day2Day3Day7ReferencecreatinineMaxAKIstage\nA1.0(88)1.3(115)1.5(133)2.0(177)1.0(88)1.0(88)2\nB1.0(88)1.1(97)1.2(106)1.4(124)1.0(88)1.0(88)1\nC0.4(35)0.5(44)0.6(53)0.7(62)0.4(35)0.4(35)1\nD1.0(88)1.1(97)1.2(106)1.3(115)1.5(133)1.0(88)1\nE1.0(88)1.3(115)1.5(133)1.8(159)2.2(195)1.0(88)2\nF?3.0(265)2.6(230)2.2(195)1.0(88)1.0(88)3\nG?1.8(159)2.0(177)2.2(195)1.6(141)?1\nH?3.0(265)3.1(274)3.0(265)2.9(256)?? AKI,acutekidneyinjury. presenceofCKD.Furthermore,CKDandAKImaycoexist.1.2mg/dl(106mol/l)(Table9)andhisinitialstageon\nByusingallavailableclinicaldata(laboratory,imaging,\nadmission(day1)wouldbeassumedtobe2.However,once\nhistory,andphysicalexam)itshouldbepossibletoarriveat\nhisSCrrecoveredto1.0mg/dl(88mol/l)onday7,itwould\nbothanaccuratediagnosisaswellasanaccurateestimateofbepossibletorestagehimashavinghadStage3.Oncehehas\nbaselineSCr.Importantly,excludingsomecasesofhemo-recovered,theremaybenodifferencebetweenStage2or3in\ndilutionsecondarytomassiveﬂuidresuscitation(discussed\ntermsofhiscareplan.Ontheotherhand,accuratelystaging\nbelow),thelowestSCrobtainedduringahospitalizationtheseverityofAKImaybeimportantforintensityoffollow-\nisusuallyequaltoorgreaterthanthebaseline.ThisSCr\nupandfuturerisk. shouldbeusedtodiagnose(andstage)AKI.Forexample,if\nNotethatCasesGandHcanonlybestagedifthe\nnobaselineSCrwasavailableinCaseA,diagnosisofAKIreferenceSCrcanbeinferred.CaseGmaybeasmildasstage\ncouldbemadeusingtheMDRDestimatedSCr(Table9).If1ifthebaselineisequaltothenadirSCronday7.Onthe\nCaseAwerea70-year-oldwhitefemalewithnoevidenceorotherhand,ifthiscasewerea70-year-oldwhitefemalewith\nhistoryofCKD,thebaselineSCrwouldbe0.8mg/dl\nnoknownevidenceorhistoryofCKD,thereferenceSCr\n(71mol/l)andadiagnosisofAKIwouldbepossiblewouldbe0.8mg/dl(71mol/l)basedonanestimated\nevenonday1(criterion1,50%increasefrombaseline). baseline(Table9).Inthiscase,theseverityonday1would\nHowever,ifthepatientwasa20-year-oldblackmale,hisalreadybestage2. baselineSCrwouldbeestimatedat1.5mg/dl(133mol/l).",
    "page": 32,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "earlyasday1. (Part 2)",
    "content": "SincehisadmissionSCrislower,thisisassumedtobethe\nUrineoutputvs.SCr\nbaselineSCruntilday7whenhereturnstohistruebaseline,BothurineoutputandSCrareusedasmeasuresofanacute\nandthisvaluecanbetakenasthebaseline.ThesedynamicchangeinGFR.Thetheoreticaladvantageofurineoutput\noverSCristhespeedoftheresponse.Forexample,ifGFR\nchangesininterpretationarenotseeninepidemiologic\nstudies,whichareconductedwhenallthedataarepresent,weretosuddenlyfalltozero,ariseinSCrwouldnotbe\nbutarecommoninclinicalmedicine.Notethattheonlydetectableforseveralhours.Ontheotherhand,urineoutput\nwouldbeaffectedimmediately.Lessisknownabouttheuse\nwaytodiagnoseAKI(bySCrcriteria)inCaseHistousean\nestimatedSCr.ofurineoutputfordiagnosisandstagingcomparedtoSCr,\nsinceadministrativedatabasesusuallydonotcaptureurine\nExamplesofapplicationofAKIstages\noutput(andfrequentlyitisnotevenmeasured,especially\nOnceadiagnosisofAKIhasbeenmade,thenextstepisto\noutsidetheICU).However,studiesusingbothSCrandurine\nstageit(Recommendation2.1.2).Likediagnosis,staging\noutputtodiagnoseAKIshowincreasedincidence,suggesting\nrequiresreferencetoabaselineSCrwhenSCrcriteriaare\nthattheuseofSCralonemaymissmanypatients.Theuse\nused.ThisbaselinebecomesthereferenceSCrforstaging\nofurineoutputcriteria(criterion3)willalsoreducethe\npurposes.Table10showsthemaximumstageforeach\nnumberofcaseswherecriterion1andcriterion2are\nCasedescribedinTable7.StagingforCaseAwasalready\ndiscordant(casesB,C,D,andFinTable7),asmanyofthese\nmentioned.Themaximumstageis2becausereferenceSCris\ncaseswillbepickedupbyurineoutputcriteria. 1.0mg/dl(88mol/l)andthemaximumSCris2.0mg/dl\nmm\n(177mol/l).HadthereferenceSCrbeen0.6mg/dl(53mol/\nTimeframefordiagnosisandstaging\nThepurposeofsettingatimeframefordiagnosisofAKIisto\nl),themaximumstagewouldhavebeen3.CaseFwasstaged\nbyusingthelowestSCr(1.0mg/dl[88mol/l])astheclarifythemeaningoftheword‘‘acute’’.Adiseaseprocess\nreference.Ofcourse,theactualbaselineforthiscasemightthatresultsinachangeinSCrovermanyweeksisnotAKI\nhavebeenlowerbutthiswouldnotaffectthestage,sinceitis(thoughitmaystillbeanimportantclinicalentity:see\nAppendixB).Forthepurposeofthisguideline,AKIis\nalreadyStage3.Notethatifthispatientwasa35-year-old\nwhitemale,hisMDRDestimatedbaselineSCrwouldbedeﬁnedintermsofaprocessthatresultsina50%increasein\n30\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.4\nClinicaljudgment\nSCrwithin1weekora0.3mg/dl(26.5mol/l)increase\nWhilethedeﬁnitionsandclassiﬁcationsystemdiscussedin\nwithin48hours(Recommendation2.1.1).Importantly,there\nChapter2.1provideaframeworkfortheclinicaldiagnosisof\nisnostipulationastowhenthe1-weekor48-hourtime\nAKI,theyshouldnotbeinterpretedtoreplaceortoexclude\nperiodscanoccur.Itisstatedunequivocallythatitdoesnot\nclinicaljudgment.Whilethevastmajorityofcaseswill\nneedtobetheﬁrstweekor48hoursofahospitalorICUstay.",
    "page": 32,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "earlyasday1. (Part 3)",
    "content": "ﬁtbothAKIdiagnosticcriteriaaswellasclinicaljudgment,\nNeitherdoesthetimewindowrefertodurationofthe\nAKIisstillaclinicaldiagnosis—notallcasesofAKIwillﬁt\nincitingevent.Forexample,apatientmayhavea2-week\nwithintheproposeddeﬁnitionandnotallcasesﬁttingthe\ncourseofsepsisbutonlydevelopAKIinthesecondweek. deﬁnitionshouldbediagnosedasAKI.However,exceptions\nImportantly,the1-weekor48-hourtimeframeisfor\nshouldbeveryrare. diagnosisofAKI,notstaging.Apatientcanbestagedover\nAswithotherclinicaldiagnosesdeﬁnedby\nPseudo-AKI. theentireepisodeofAKIsuchthat,ifapatientdevelopsa\nlaboratoryresults(e.g.,hyponatremia),theclinicianmustbe\n50%increaseinSCrin5daysbutultimatelyhasathree-fold\ncautioustointerpretlaboratorydataintheclinicalcontext. increaseover3weeks,heorshewouldbediagnosedwithAKI\nThemostobviousexampleiswithlaboratoryerrorsorerrors\nandultimatelystagedasStage3.",
    "page": 32,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "earlyasday1. (Part 4)",
    "content": "inreporting.Erroneouslaboratoryvaluesshouldobviously\nAswithanyclinicalcriteria,thetimeframeforAKIis\nnotbeusedtodiagnosediseaseandsuspiciouslabresults\nsomewhatarbitrary.Forexample,adiseaseprocessthat\nshouldalwaysberepeated.AnotherexampleiswhentwoSCr\nresultsina50%increaseinSCrover2weekswouldnotfulﬁll\nmeasurementsareobtainedbydifferentlaboratories.While\ndiagnosticcriteriaforAKIevenifitultimatelyresultedin\nthecoefﬁcientofvariationforSCrisverysmall(5%)by\ncompletelossofkidneyfunction.Similarly,aslowprocess\nvariousclinicaltestingmethods,variation(bias)fromone\nthatresultedinasteadyriseinSCrover2weeks,andthena\nlaboratorytothenextmaybeconsiderablyhigher,although\nsuddenincreaseof0.3mg/dl(26.5mol/l)ina48-hour\nitisunlikelytoapproach50%.GiventhattheSCrdeﬁnition\nperiod,wouldbeclassiﬁedasAKI.Sucharetheinevitable\nofAKIalwaysusesatleasttwovalues,thevariationandbias\nvagariesofanydiseaseclassiﬁcation.However,onescenario\nbetweeneachmeasureisfurthermagniﬁed—thecoefﬁcient\ndeservesspeciﬁcmention,andthatisthecaseofthepatient\nofvariationforcomparisonoftwolabtestsisequaltothe\nwithanincreasedSCratpresentation.Asalreadydiscussed,\nsquarerootofthesumofeachcoefﬁcientsquared.Although\nthediagnosisofAKIrequiresasecondSCrvaluefor\ntheinternationalstandardizationofSCrmeasurementswill\ncomparison.ThisSCrcouldbeasecondmeasuredSCr\nlargelyeliminateinterlaboratorybiasinthefuture,careis\nobtainedwithin48hours,andifitis0.3mg/dl\nneededininterpretinglabvaluesobtainedfromdifferent\n(26.5mol/l)greaterthantheﬁrstSCr,AKIcanbe\nlabs.Furthermore,dailyvariationinSCrduetodifferencesin\ndiagnosed.Alternatively,thesecondSCrcanbeabaseline\ndietandactivitymaybeasgreatas10%.Finally,endogenous\nvaluethatwasobtainedpreviouslyorestimatedfromthe\nchromogens(e.g.,bilirubin,ascorbicacid,uricacid)and\nMDRDequation(seeTable9).However,thisposestwo\nexogenouschromogensanddrugs(e.g.,cephalosporins,\ndilemmas.First,howfarbackcanabaselinevaluebe\ntrimethoprim,cimetidine)mayinterferewiththecreatinine\nretrievedandstillexpectedtobe‘‘valid’’;second,howcan\nassay.Thecumulativeeffectofthesevariousfactors\nweinferacuitywhenweareseeingthepatientfortheﬁrst\ninﬂuencingprecision,bias,andbiologicalvariationmay\ntime? approachthelevelatwhichitcouldimpactthediagnosisof\nBothoftheseproblemswillrequireanintegrated\nAKI.Asimilarproblemexistswithurineoutput.Particularly\napproachaswellasclinicaljudgment.Ingeneral,itis\noutsidetheICU,urineoutputisnotoftenreportedandurine\nreasonableinpatientswithoutCKDtoassumethatSCr\ncollectionsmaybeinaccurate,especiallyinnoncatheterized\nwillbestableoverseveralmonthsorevenyears,sothat\npatients.Finally,asdiscussedinChapter2.1,aweight-based\naSCrobtained6monthsoreven1yearpreviouslywould\ncriterionforurineoutputwillmeanthatsomeveryobese\nreasonablereﬂectthepatient’spremorbidbaseline.However,\npatientswillfulﬁllthedeﬁnitionofAKIwithoutanykidney\ninapatientwithCKDandaslowincreasingSCroverseveral\nabnormality.Clinicaljudgmentshouldalwaysbeexercisedin\nmonths,itmaybenecessarytoextrapolatethebaselineSCr\ninterpretingsuchdata.",
    "page": 32,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "earlyasday1. (Part 5)",
    "content": "basedonpriordata.Intermsofinferringacuityitismost\nAcomplementaryproblemtopseudo-AKIis\nAtypicalAKI. reasonabletodeterminethecourseofthediseaseprocess\nthesituationwhereacaseofAKIfailstomeetthedeﬁnition. thoughttobecausingtheepisodeofAKI.Forexample,fora\nThesecasesshouldbedistinguishedfromconditionsinwhich\npatientwitha5-dayhistoryoffeverandcough,andchest\ndataaresimplymissing(discussedabove)andreferto\nradiographshowinganinﬁltrate,itwouldbereasonableto\nsituationsinwhichexistingdataareunreliable.Forexample,\ninferthattheclinicalconditionisacute.IfSCrisfoundtobe\napatientmightreceiveverylargequantitiesofintravascular\n50%increasedfrombaseline,thisﬁtsthedeﬁnitionofAKI. 65\nﬂuidssuchthatSCrisfalselylowered.Similarly,massive\nConversely,apatientpresentingwithanincreasedSCrinthe\nbloodtransfusionswillresultintheSCrmoreclosely\nabsenceofanyacutediseaseornephrotoxicexposurewill\nreﬂectingthekidneyfunctionoftheblooddonorsthanthe\nrequireevidenceofanacuteprocessbeforeadiagnosiscanbe\npatient.Itisunusualforthesecasesnottoresultinoliguria\nmade.EvidencethattheSCrischangingishelpfulin\nand,thus,mostpatientswillbediagnosedwithAKIevenif\nestablishingacuity. 31\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.4\nSCrisnotincreased.Nevertheless,theclinicianshould\nisdecreased.Creatinineproductionmayalsobedecreasedin\n66\nbecognizantofpossibilitythatSCrmaybefalselyloweredsepsispossiblyduetodecreasedmuscleperfusion. bylarge-volumeﬂuidresuscitationortransfusion;thus,a\nSUPPLEMENTARYMATERIAL\nnormalvaluemaynotruleoutAKI.Changesincreatinine\nAppendixB:DiagnosticApproachtoAlterationsinKidneyFunction\nproductionarealsowellknowninconditionssuchasmuscle\nandStructure. breakdownwhereproductionincreasesandinmuscle\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nwasting(includingadvancedliverdisease)whereproduction\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n32\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.5\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 32,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "kidneyfunctionandstructure (Part 1)",
    "content": "DefinitionsofAKI,CKDandAKDGFRandSCr\nAKIandCKDweredeﬁnedbyseparateWorkGroupsCKD,AKD,andAKIaredeﬁnedbyparametersexpressing\naccordingtodifferentcriteria.Thedeﬁnitionforeachisthelevelofkidneyfunction.Table12givesexamplesofeach\nbasedonalterationsinkidneyfunctionorstructure.AKIandconditionbasedonGFRanddifferentmagnitudesofincrease\nCKDhavemanycauseswhichmayleadtoalterationsofinSCr. kidneyfunctionandstructurethatdonotmeetthecriteriaToillustratetherelationshipofchangesinSCrtochanges\nforthedeﬁnitionofeitherAKIorCKD,yetpatientswithineGFR,wesimulatedchangesineGFRthatwouldresult\nthesediseasesanddisordersmayneedmedicalattentiontofromchangesinSCrcorrespondingtotheKDIGOdeﬁnition\nrestorekidneyfunctionandreversedamagetokidneyofAKIintheChronicKidneyDiseaseEpidemiology\n67,68\nFigure6showstherelationship\nstructuretoavoidadverseoutcomes.AuniformandCollaborationcohort. systematicnomenclaturecouldenhanceunderstandingandofthesechangesineGFRtothedeﬁnitionandstagesofAKI. communicationaboutthesediseasesanddisorders,andleadNotallpatientswithAKIwouldmeettheeGFRcriteriafor\nthedeﬁnitionofAKD. toimprovedmedicalcare,research,andpublichealth.For\nthesereasons,theWorkGroupproposedanoperational\nGFR/SCralgorithm\ndeﬁnitionforAKDtoprovideanintegratedclinicalapproach\nFigure7providesadiagnosticalgorithmbasedona\ntopatientswithabnormalitiesofkidneyfunctionand\nsequentialapproachthroughthreequestions:i)IsGFR\nstructure. decreasedorisSCrincreased(accordingtothecriteriain\nTable11comparesthedeﬁnitionsforAKI,CKD,and\nTable12)?;ii)IsSCrincreasingorGFRdecreasing(according\nAKD.Wehavealsoincludedanoperationaldeﬁnitionof‘‘no\ntothecriteriainTable12)?;andiii)DoesthedecreaseinGFR\nknownkidneydisease’’(NKD)forthosewhodonotmeet\norincreaseinSCrresolvewithin3months?Basedona‘‘yes’’\nthesecriteria,withtheunderstandingthatclinicaljudgment\nor‘‘no’’responsetothesethreesequentialquestions,all\nisrequiredtodeterminetheextentoftheevaluationthatis\ncombinationsofAKI,AKD,andCKDcanbeidentiﬁed.In\nnecessarytoassesskidneyfunctionandstructure.Inthe\nthissection,wereviewthealgorithmandillustrateitsuse\nfollowingsections,wewillelaborateoneachcomponentof\nforclassiﬁcationofpatientswithacuteandchronickidney\nthesedeﬁnitions. diseaseintwopreviouslyreportedcohorts.",
    "page": 36,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "kidneyfunctionandstructure (Part 2)",
    "content": "Table11|DefinitionsofAKI,CKD,andAKD\nFunctionalcriteriaStructuralcriteria\nTable12|ExamplesofAKI,CKD,andAKDbasedonGFRand\nincreasesinSCr\nAKIIncreaseinSCrby50%within7days,ORNocriteria\nIncreaseinSCrby0.3mg/dl(26.5mmol/l)\nBaselineGFRIncreaseinGFRduring\nwithin2days,OR\n(ml/minperSCrduringnext\nOliguria\n1.73m)7consecutivedays3monthsDiagnosis\nCKDGFR60ml/minper1.73mforKidneydamage\n46041.5NAAKI\n(cid:2)\n43monthsfor43months\n601.560AKDwithoutAKI\n(cid:2)\nAKDAKI,ORKidneydamage\noo\n4601.5460NKD\n(cid:2)\nGFR60ml/minper1.73mforfor3months\noo\n3months,OR\nBaselineGFRChangeinSCrGFRduring\nDecreaseinGFRby35%orincrease\n(ml/minperduringnextnext\ninSCrby450%for3months\n1.73m)7days3monthsDiagnosis\nNKDGFR60ml/minper1.73mNodamage\nStableSCr\n6041.5NAAKI+CKD\n(cid:2)\nGFRassessedfrommeasuredorestimatedGFR.EstimatedGFRdoesnotreflect\n601.5435%decreaseAKDwithout\n(cid:2)\noo\nmeasuredGFRinAKIasaccuratelyasinCKD.Kidneydamageassessedbypathology,\nAKI+CKD\nurineorbloodmarkers,imaging,and—forCKD—presenceofakidneytransplant.NKD\n601.535%decreaseCKD\n(cid:2)\nooo\nindicatesnofunctionalorstructuralcriteriaaccordingtothedefinitionsforAKI,AKD,\nGFRassessedfrommeasuredorestimatedGFR.EstimatedGFRdoesnotreflect\norCKD.Clinicaljudgmentisrequiredforindividualpatientdecision-makingregarding\nmeasuredGFRinAKIasaccuratelyasinCKD. theextentofevaluationthatisnecessarytoassesskidneyfunctionandstructure. AKD,acutekidneydiseasesanddisorders;AKI,acutekidneyinjury;CKD,chronic\nAKD,acutekidneydiseasesanddisorders;AKI,acutekidneyinjury;CKD,chronic\nkidneydisease;GFR,glomerularfiltrationrate;NKD,noknownkidneydisease;\nkidneydisease;GFR,glomerularfiltrationrate;NKD,noknownkidneydisease;\nSCr,serumcreatinine. SCr,serumcreatinine. 33\nKidneyInternationalSupplements(2012)2,19–36",
    "page": 36,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter2.5",
    "content": "Figure6|ChronicKidneyDiseaseEpidemiologyCollaborationcohortchangesineGFRandfinaleGFRcorrespondingtoKDIGO\ndefinitionandstagesofAKI.Panels(a)and(b)showthefinaleGFRandthepercentchangesineGFR,respectively,correspondingtothe\nKDIGOdefinitionandstagesofAKI.ThehorizontallineinpanelaandbindicatesthethresholdvalueforAKD(60ml/minper1.73mand\n435%reductionininitialGFR,respectively).PointsabovethehorizontallineindicatesubjectswhomeettheSCrcriteriaforthedefinitionof\nAKIbutdonotmeeteGFRcriteriaforthedefinitionofAKD.AKD,acutekidneydisorder/disease;AKI,acutekidneyinjury;eGFR,estimated\nglomerularfiltrationrate;KDIGO,KidneyDisease:ImprovingGlobalOutcomes;SCr,serumcreatinine.(LesleyInker,personal\ncommunication.)\nGFR/S cr\nIs GFR decreased or is serum creatinine increased ?\nNoYesYes\n>3 mo<3 mo or\nunknown\nNKDCKDAKD\nIs Scr increasing or GFR decreasing ?\nYes-IYes-INoNoYes-DYes-DYes-INoYes-D\nAKDAKDAKD\nCKD+\nCKD +AKD\nCKDNKD\nAKIAKI\nwithoutwithoutwithout\nwithout AKI\nAKI\nAKIAKIAKI\nYes-D, change in Scr meets AKD criteria but not AKI criteria\nCKD+\nAKD\nCKD+\nAKD without\nwithout\nAKI\nAKI\nAKI\nAKI\nDoes the decrease in GFR or increase in Scr\nresolve within 3 months?\nNoNoYesNoYesNoYesYes\nCKDCKDCKDCKDCKDCKD\nNKDNKD\nStableStableWorseWorseNewNew\nFigure7|GFR/SCralgorithm.Seetextfordescription.AKD,acutekidneydisease/disorder;AKI,acutekidneyinjury;CKD,chronickidney\ndisease;GFR,glomerularfiltrationrate;NKD,noknownkidneydisease;SCr,serumcreatinine.",
    "page": 37,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "duringtheintervalofobservation.TheanswerclassiﬁesSCrordecreaseinGFRaftertheindexmeasuredoesnot (Part 1)",
    "content": "34\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.5\nTable13|MarkersofkidneydamageinAKDandCKD\nmeetAKIorAKDcriteria;‘‘Yes-D’’indicatesthatincreasein\nSCranddecreaseinGFRmeetstheAKDcriteriabutnotAKI\nMarkersAKDCKD\ncriteria;and‘‘Yes-I’’indicatesthatincreaseinSCrmeetsAKI\nPathologyXX\ncriteria.Question3requiresrepeatascertainmentofGFR/\nSCr3monthsaftertheindexmeasure.‘‘Yes’’indicatesGFR\nUrinarymarkers\n60,indicatingNKD.NoindicatesGFR60,andbasedon\nRBC/castsXX\nWBC/castsXX\npriorlevelofGFR,mayindicatestable,new,orworseCKD. RTE/castsXX\nFineandcoarsegranularcastsXX\nOliguriaasameasureofkidneyfunction\nProteinuriaXX\nAlthoughurineﬂowrateisapoormeasureofkidney\nBloodmarkers(tubularsyndromes)XX\nfunction,oliguriagenerallyreﬂectsadecreasedGFR.IfGFR\nisnormal(approximately125ml/min,correspondingto\nImaging\napproximately107ml/kg/hfora70-kgadult),thenreduction\nLargekidneysXX\ninurinevolumeto0.5ml/kg/hwouldreﬂectreabsorption\nSmallkidneys—X\nSizediscrepancy—X\nofmorethan99.5%ofglomerularﬁltrate.Suchprofound\nHydronephrosisXX\nstimulationoftubularreabsorptionusuallyaccompanies\nCystsXX\ncirculatorydisturbancesassociatedwithdecreasedGFR. StonesXX\nOliguriaisunusualinthepresenceofanormalGFRandis\nHistoryofkidneytransplantation—X\nusuallyassociatedwiththenon–steadystateofsolutebalance\nKidneydamageisnotrequiredfordiagnosisofAKI.InthepresenceofAKI,findings\nandrisingSCrsufﬁcienttoachievethecriteriaforAKI.Asa\nofkidneydamagedonotindicateaseparatediagnosisofAKD. corollary,ifGFRandSCrarenormalandstableoveran\nAKD,acutekidneydiseasesanddisorders;CKD,chronickidneydisease;RBC,red\nbloodcells;RTE,renaltubularepithelialcells;WBC,whitebloodcells. intervalof24hours,itisgenerallynotnecessarytomeasure\nurineﬂowrateinordertoassesskidneyfunction. Inprinciple,oliguria(asdeﬁnedbythecriteriaforAKI)\nTable14|Integratedapproachtointerpretmeasuresof\nkidneyfunctionandstructurefordiagnosisofAKI,AKD,and\ncanoccurwithoutadecreaseinGFR.Forexample,low\nCKD\nintakeofﬂuidandsolutecouldleadtourinevolumeofless\nthan0.5ml/kg/hfor6hoursor0.3ml/kg/hfor24hours.On\nMeasures\ntheotherhand,severeGFRreductioninCKDusuallydoes\nDiagnosisGFR/SCrOliguriaKidneydamageSmallkidneys\nnotleadtooliguriauntilaftertheinitiationofdialysis. AKIXX\nAsdescribedinChapter2.1,thethresholdsforurineﬂow\nAKDXX\nforthedeﬁnitionofAKIhavebeenderivedempiricallyand\nCKDXXXX\narelesswellsubstantiatedthanthethresholdsforincrease\nXindicatesthatthemeasurescancontributetothediagnosisindicated. inSCr.Urinarydiagnosticindices,suchastheurinary\nAKD,acutekidneydiseasesanddisorders;AKI,acutekidneyinjury;CKD,chronic\nkidneydisease. concentrationsofsodiumandcreatinineandthefractional\nreabsorptionofsodiumandurea,remainhelpfulto\ndistinguishamongcausesofAKI,butarenotusedinthe\ndeﬁnition(seeAppendixD).",
    "page": 37,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "duringtheintervalofobservation.TheanswerclassiﬁesSCrordecreaseinGFRaftertheindexmeasuredoesnot (Part 2)",
    "content": "theleftsideand10.9cmontherightside.Renalsize\ndecreasedwithage,almostentirelybecauseofparenchymal\nth\nKidneydamage\nreduction.Thelowest10percentilesforlengthoftheleft\nTable13describesmeasuresofkidneydamageinAKDand\nandrightkidneywereapproximately10.5and10.0cm,\nCKD.Kidneydamageismostcommonlyascertainedby\nrespectively,atage30years,and9.5and9.0cm,respectively,\nurinarymarkersandimagingstudies.Mostmarkersand\natage70years. abnormalimagescanindicateAKDorCKD,basedonthe\ndurationofabnormality.Onenotableexceptionissmall\nIntegratedapproachtoAKI,AKD,andCKD\nkidneys,eitherbilateralorunilateral,indicatingCKD,whichClinicalevaluationisnecessaryforallpatientswith\narediscussedseparatelybelow.Kidneydamageisnotaalterationsinkidneyfunctionorstructure.Theexpectation\ncriterionforAKI;however,itmaybepresent.RenaltubularoftheWorkGroupisthatthediagnosticapproachwill\nepithelialcellsandcoarsegranularcasts,oftenpigmentedandusuallybeginwithassessmentofGFRandSCr.However,\ndescribedas‘‘muddybrown’’,remainhelpfulindistinguish-evaluationofkidneyfunctionandstructureisnotcomplete\ningthecauseofAKI,butarenotpartofthedeﬁnition.unlessmarkersofkidneydamage—includingurinalysis,\nexaminationoftheurinarysediment,andimagingstudies—\nhavebeenperformed.Table14showsasummaryofthe\nSmallkidneysasamarkerofkidneydamage\nLossofrenalcortexisconsideredafeatureofCKD,andisdiagnosticapproachusingmeasuresforkidneyfunction\noftensoughtasaspeciﬁcdiagnosticsignofCKD.Kidneysizeandstructure.Basedoninterpretationofeachmeasure\nismostoftenevaluatedbyultrasound.Inastudyof665\nseparately,theclinicaldiagnosisindicatedbyan‘‘X’’canbe\n69\nnormalvolunteers,medianrenallengthswere11.2cmonreached. 35\nKidneyInternationalSupplements(2012)2,19–36\nchapter2.5\nSPONSORSHIP\ncontributor,copyrightholder,oradvertiserconcerned. KDIGOgratefullyacknowledgesthefollowingsponsorsthat\nAccordingly,thepublishersandtheISN,theeditorialboard\nmakeourinitiativespossible:Abbott,Amgen,BeloFounda-\nandtheirrespectiveemployers,ofﬁceandagentsacceptno\ntion,Coca-ColaCompany,DoleFoodCompany,Genzyme,\nliabilitywhatsoeverfortheconsequencesofanysuch\nHoffmann-LaRoche,JCPenney,NATCO—TheOrganization\ninaccurateormisleadingdata,opinionorstatement.While\nforTransplantProfessionals,NKF—BoardofDirectors,\neveryeffortismadetoensurethatdrugdosesandother\nNovartis,RobertandJaneCizikFoundation,Shire,Trans-\nquantitiesarepresentedaccurately,readersareadvisedthat\nwesternCommercialServices,andWyeth.KDIGOis\nnewmethodsandtechniquesinvolvingdrugusage,and\nsupportedbyaconsortiumofsponsorsandnofundingis\ndescribedwithinthisJournal,shouldonlybefollowedin\nacceptedforthedevelopmentofspeciﬁcguidelines. conjunctionwiththedrugmanufacturer’sownpublished\nliterature. DISCLAIMER\nWhileeveryeffortismadebythepublishers,editorialboard,\nSUPPLEMENTARYMATERIAL\nandISNtoseethatnoinaccurateormisleadingdata,opinion\nAppendixD:EvaluationandGeneralManagementGuidelinesfor\norstatementappearsinthisJournal,theywishtomake\nPatientswithAKI.",
    "page": 37,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "duringtheintervalofobservation.TheanswerclassiﬁesSCrordecreaseinGFRaftertheindexmeasuredoesnot (Part 3)",
    "content": "itclearthatthedataandopinionsappearinginthearticles\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nandadvertisementshereinaretheresponsibilityofthe\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n36\nKidneyInternationalSupplements(2012)2,19–36\nchapter3.1\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 37,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section3:PreventionandTreatmentofAKI",
    "content": "KidneyInternationalSupplements(2012)2,37–68;doi:10.1038/kisup.2011.33",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 1)",
    "content": "AsdiscussedinChapters2.3andAppendixD,patientswithstatusandcorrectionofanyvolumedeﬁcitwillhavea\nAKIandatincreasedriskforAKIrequirecarefulattentiontosalutaryeffectonkidneyfunction,willhelpminimizefurther\nbepaidtotheirhemodynamicstatus.Thisisﬁrstbecauseextensionofthekidneyinjury,andwillpotentiallyfacilitate\nhypotensionresultsindecreasedrenalperfusionand,ifsevererecoveryfromAKIwithminimizationofanyresidualfunc-\norsustained,mayresultinkidneyinjury.Second,theinjuredtionalimpairment.AKIischaracterizedbyacontinuum\nkidneylosesautoregulationofbloodﬂow,amechanismthatofvolumeresponsivenessthroughunresponsiveness\n78,82\nmaintainsrelativelyconstantﬂowdespitechangesinpressure(Figure8),andlargemulticenterstudieshaveshown\naboveacertainpoint(roughly,ameanof65mmHg).thatapositiveﬂuidbalanceisanimportantfactorassociated\n78,83,84\nManagementofbloodpressureandcardiacoutputwithincreased60-daymortality. requirecarefultitrationofﬂuidsandvasoactivemedication.Theamountandselectionofthetypeofﬂuidthatshould\nbeusedintheresuscitationofcriticallyillpatientsisstill\nVasopressorscanfurtherreducebloodﬂowtothetissuesif\nthereisinsufﬁcientcirculatingbloodvolume.Conversely,controversial.Thisguidelinefocusesontheselectionofthe\npatientswithAKIarealsoatincreasedriskforﬂuidoverloadﬂuid(colloidvs.crystalloidﬂuidinthepreventionandearly\n(seeChapter3.2)andcontinuedﬂuidresuscitationdespitemanagementofAKI).Thethreemainend-pointsofthe\nstudiesexploredweretheeffectsonmortality,needforRRT,\nincreasedintravascularvolumecancauseharm.Fluidsand\nvasoactivemedicationsshouldbemanagedcarefullyandinand—ifpossible—theincidenceofAKI.Althoughmany\nconcertwithhemodynamicmonitoring.Hemodynamictrialshavebeenconductedtocompareﬂuidtypesfor\nresuscitation,studieswithoutAKIoutcomeswerenot\nevaluationandmonitoringarediscussedinAppendixD. Inthischaptertherapiesaimedatcorrectinghemo-systematicallyreviewedforthisGuideline.SupplTable1\ndynamicinstabilitywillbediscussed.AvailabletherapiestosummarizestheRCTsexaminingtheeffectofstarchforthe\npreventionofAKI. managehypotensionincludeﬂuids,vasopressorsandproto-\ncolswhichintegratethesetherapieswithhemodynamicgoals. Albuminvs.Saline\nThereisanextensivebodyofliteratureinthisﬁeldandfora\nTheroleofalbuminphysiologyincriticallyillpatients,and\nbroaderaswellasmoreindepthreviewthereaderisdirected\ntheprosandconsforadministeringalbumintohypoalbu-\ntothevariousreviewsandtextbooksdevotedtocriticalcare\n85\n70–81\nminemicpatients,haverecentlybeendiscussed.Resultsof\nandnephrology.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 2)",
    "content": "theSalinevs.AlbuminFluidEvaluation(SAFE)study,aRCT\ncomparing4%humanalbuminin0.9%salinewithisotonic\nFLUIDS\nsalineinICUpatients,seemtoindicatethatalbuminissafe,\nalbeitnomoreeffectivethanisotonicsaline(thestandardof\n3.1.1:Intheabsenceofhemorrhagicshock,wesuggest\ncarechoiceofisotonicsodiumchlorideinmostcenters)for\nusingisotoniccrystalloidsratherthancolloids\nﬂuidresuscitation.SAFEdemonstratedfurthernodifference\n(albuminorstarches)asinitialmanagementfor\ninrenaloutcomes,atleastbasedontheneedforand\nexpansionofintravascularvolumeinpatientsat\n86\ndurationofRRT.TheSAFEstudywasadouble-blindstudy\nriskforAKIorwithAKI.(2B)\nanditwasnotedthatpatientsinthealbuminarmreceived\n27%lessstudyﬂuidcomparedtothesalinearm(2247vs. 3096ml)andwereapproximately1llesspositiveinoverall\nRATIONALE\n86\nDespitetherecognitionofvolumedepletionasanimportantﬂuidbalance.Furthermore,veryfewpatientsinthetrial\nriskfactorforAKI,therearenorandomizedcontrolledtrialsreceivedlargevolumeﬂuidresuscitation(5l)andthusthe\n(RCTs)thathavedirectlyevaluatedtheroleofﬂuidsvs.resultsmaynotbeapplicabletoallpatients.TheWorkGroup\nplacebointhepreventionofAKI,exceptintheﬁeldofnotedthatwhileisotoniccrystalloidsmaybeappropriatefor\ncontrast-inducedacutekidneyinjury(CI-AKI)(seeChapterinitialmanagementofintravascularﬂuiddeﬁcits,colloids\n4.4).Itisacceptedthatoptimizationofthehemodynamicmaystillhavearoleinpatientsrequiringadditionalﬂuid. 37\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.1\nandduringtheperioperativeperiod’’(forasummaryofthis\n9091\ncontroversy,seedeSaint-Aurinetal.andVincent). Theﬁrstmajorrandomizedtrialinpatientswithsepsis\ncomparedHES200/0.60to0.66withgelatinandshoweda\ngreaterincidenceofAKIintheHESgroup,butnoeffecton\n92\nsurvival.Criticismsofthisstudyincludeahigherbaseline\nSCrlevelintheHESgroup,smallsamplesize,andshort\nfollow-updurationof34days.IntheEfﬁcacyofVolume\nSubstitutionandInsulinTherapyinSevereSepsis(VISEP)\n93\npatientswithseveresepsiswererandomlyassignedto\nstudy,\nFigure8|Conceptualmodelfordevelopmentandclinical\nreceiveahypertonic(10%)solutionoflowMWHES(HES\ncourseofAKI.TheconceptofAKIincludesbothvolume-\n200/0.5),oranisotonicmodiﬁedRinger’slactatesolution. responsiveandvolume-unresponsiveconditions.These\nPatientsintheHESgroupreceivedamediancumulativedose\nconditionsarenotmutuallyexclusive,andagivenpatientmay\nof70.4mlperkilogramofbodyweight.Themortalitywas\nprogressfromonetotheother.Timerunsalongthex-axis,and\nthefiguredepictsaclosing‘‘therapeuticwindow’’asinjury\nnotsigniﬁcantlydifferent,althoughshowingatrendtoward\nevolvesandkidneyfunctionworsens.Biomarkersofinjuryand\ngreatermortalityat90days.However,thehypertonicHES\nfunctionwillbegintomanifestastheconditionworsens,but\ngrouphadasigniﬁcantlyhigherrateofAKI(34.9%vs. traditionalmarkersoffunction(e.g.,ureanitrogenandcreatinine)\n22.8%)andmoredaysonwhichRRTwasrequired(Suppl\nwilllagbehindhypothetical‘‘sensitive’’markersofkidneyinjury.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 3)",
    "content": "Mortalityincreasesaskidneyfunctiondeclines.AKI,acutekidney\nTable1).Also,thisstudyhasbeencriticizedfor:i)usinga\ninjury.ReproducedfromHimmelfarbJ,JoannidisM,MolitorisB,\nhyperoncoticcolloidsolutionwithpotentiallyharmfulrenal\netal.Evaluationandinitialmanagementofacutekidneyinjury. 94\neffectsasshowninexperimentalresearch;ii)markedly\nClinJAmSocNephrol2008;3:962–967withpermissionfrom\n82\nAmericanSocietyofNephrologyconveyedthroughCopyright\nexceedingthepharmaceuticallyrecommendeddailydose\nClearanceCenter,Inc;accessedhttp://cjasn.asnjournals.org/\nlimitfor10%HES200/0.5bymorethan10%in38%of\ncontent/3/4/962.long\npatients;andiii)pre-existingrenaldysfunctionin10%of\nstudypatients,whichrepresentsacontra-indicationfor\n95\ninfusionof10%HES200/0.5.Posthocanalysesofthe\nVISEPstudyshowedthecumulativedoseofHEStobea\nHydroxyethylstarchvs.Saline\nHydroxyethylstarch(HES)isawidelyused,relatively\nsigniﬁcantindependentpredictorforbothmortalityand\ninexpensivealternativetohumanalbuminforcorrecting\nRRTat90days.ThemediancumulativedoseofHESinthe\nhypovolemia.DifferentHESpreparationsareavailablethat\nVISEPStudywas70ml/kgcomparedto31ml/kginthestudy\n92\nvarywithregardtoconcentration,meanmolecularweight\nbySchortgenetal. (MW),molarsubstitution,andsubstitutionofhydroxyethyl\nAsystematicreviewofRCTsontheuseofHESforﬂuid\nforhydroxylgroups.ThemeanMWofthedifferentHES\nmanagementinpatientswithsepsistotaling1062patients,\npreparationsrangesbetween70000and670000Da.The\nincluding537patientsfromtheVISEPstudy,showedan\ncolloidosmoticpressureeffectisstronglydependentupon\nalmosttwo-foldincreasedriskofAKIwithHEScomparedto\n96\ntheconcentrationofcolloidinthesolution;e.g.,6%HESis\ncrystalloids.Giventheselimitations,theresultsofthese\niso-oncotic,whereas10%HESishyperoncotic.Thenumber\nstudiesshouldbeinterpretedwithcaution.Furthermore,a\nofhydroxyethylgroupsperglucosemoleculeisspeciﬁedby\nlarge,prospectiveobservationalstudyfoundthatHES\nthemolarsubstitution,rangingbetween0.4(tetrastarch)\ninfusionofanytype(medianvolume555ml/d;intraquartile\nand0.7(heptastarch).Accordingly,HESsolutionswitha\nrange500–1000)didnotrepresentanindependentriskfactor\n97\nmolarsubstitutionof0.5or0.6arereferredtoas\n;however,recentlyinalargecohortof\nforrenalimpairment. ‘‘pentastarch’’or‘‘hexastarch’’,respectively.Morerecently,\ncriticallyillpatients(approximately8000subjects),infusion\ntetrastarches(HES130/0.4andHES130/0.42)havealsobeen\nof10%HES200/0.5insteadofHES130/0.4appearedtobe\n87\n87\nintroduced.Highmolecularsubstitutionstarchmayimpair\nanindependentriskfactorforRRT.Finally,arecent\n98\ncoagulationbyreducingtheconcentrationoffactorVIII:\ncomprehensiveCochranereviewconcludedthatthereisno\nVIIIcandvonWillebrandfactor.Plateletactivitymayalsobe\nevidencefromRCTsthatresuscitationwithcolloids,instead\naffectedbyblockadeoftheplateletﬁbrinogenreceptor\nofcrystalloids,reducestheriskofdeathinpatientswith\nglycoproteinIIb/IIIa.Smallerstarchmoleculesandthose\ntrauma,burns,orfollowingsurgery.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 4)",
    "content": "withlessmolecularsubstitutionproducenegligiblecoagula-\nThemechanismsofcolloid-inducedrenalinjuryare\n88\ntiondefects. incompletelyunderstood,butmayinvolvebothdirect\n99\nAsidefromthesenegativeeffectsoncoagulation,develop-\nmoleculareffectsandeffectsofelevatedoncoticpressure. mentofrenaldysfunctionhasbeenaconcernassociatedwith\nTheseconcernshaveledtothewidespreadadoptionoflower\ntheuseofmainlyhypertonicHES.HypertonicHESmay\nMWstarchesasiso-oncoticsolution,asresuscitationﬂuids. induceapathologicalentityknownas‘‘osmoticnephrosis’’\nTheoretically,suchsolutionsmayhavelowernephrotoxicity;\n89\nwithpotentialimpairmentofrenalfunction.Ithaseven\nhowever,asyet,noappropriatelypoweredprospective\nbeenrecommendedthat‘‘HESshouldbeavoidedinICUs\nrandomizedstudieshavereportedtheclinicalbeneﬁtand\n38\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.1\nVASOPRESSORS\nsafetyofsuchsolutionsincomparisonwithcrystalloids.A\nrecentstudybyMagderetal.compared10%250/0.45HESto\n3.1.2:Werecommendtheuseofvasopressorsinconjunc-\nisotonicsalinein262patientswhounderwentcardiac\n100\ntionwithﬂuidsinpatientswithvasomotorshock\nsurgery.Theseinvestigatorstestedwhetherfewerpatients\nwith,oratriskfor,AKI.(1C)\nrequiredcatecholaminesthemorningaftercardiacsurgery\n(achiefdeterminantofICUdischarge)withHEScompared\ntosaline,andfoundindeedthiswasthecase(10.9%vs. 28.8%;P0.001).Importantly,thestudyfoundnoevidence\nRATIONALE\nSepsisandsepticshockaremajorcontributingfactorsto\nofnephrotoxicity:nodifferenceinthedailycreatinine,deve-\nAKIandvasopressorrequirementappearstobehighly\nlopmentofAKIbyRIFLEcriteriaduringhospitalstay(16%\nassociatedwithAKIinthispopulation.Despitethehigh\ninbothgroups),orneedforRRT(1%ineachgroup). prevalenceofAKIduringcriticalillnessingeneral,andsevere\nImportantly,patientsinthesalinegroupreceivednearly60%\nsepsisspeciﬁcally,successhasbeenlimitedinimprovingthe\nmorevolumeforﬂuidresuscitationintheICUcomparedto\n104\noutcomeofthiscomplication.Septicshockistheproto-\nHES(887vs.1397ml;P0.0001).Whileoverallvolumes\ntypeofahighoutput–lowresistancecondition,although\nweresmall,advocatesforcolloidresuscitationwillnotethat\nseverepancreatitis,anaphylaxis,burns,andliverfailure\nthisisexactlythereasoncolloidsarepreferredforpatients\nsharesimilarphysiologicalterations.Persistenthypotension,\nrequiringlarge-volumeresuscitation. despiteongoingaggressiveﬂuidresuscitationorafter\nThetonicityofcolloidpreparationsmayalsovaryby\n101\noptimizationofintravascularvolumeinpatientswithshock,\ndescribed11randomized\nagent.Arecentmeta-analysis\nplacespatientsatriskfordevelopmentofAKI.Inthesetting\ntrialswithatotalof1220patients:sevenevaluating\nofvasomotorparalysis,preservationorimprovementof\nhyperoncoticalbuminandfourevaluatinghyperoncotic\nrenalperfusioncanonlybeachievedthroughuseof\nstarch.HyperoncoticalbumindecreasedtheoddsofAKIby\nsystemicvasopressorsonceintravascularvolumehasbeen\n76%whilehyperoncoticstarchincreasedthoseoddsby92%\n105\nrestored.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 5)",
    "content": "(oddsratio[OR]1.92;CI1.31–2.81;P0.0008).Parallel\nItisnotknownwhichvasopressoragentismosteffective\neffectsonmortalitywereobserved.Thismeta-analysiscon-\nforpreventionortreatmentofpatientswithAKIandseptic\ncludedthattherenaleffectsofhyperoncoticcolloidsolutions\nshock.Moststudieshavefocusedonnorepinephrine,\nappeartobecolloid-speciﬁc,withalbumindisplaying\ndopamine,orvasopressin.Smallopen-labelstudieshave\nrenoprotectionandhyperoncoticstarchshowingnephro-\nshownimprovementincreatinineclearance(CrCl)following\ntoxicity.A7000-patientstudycomparing6%HES130/0.4in\n106\na6-to8-hourinfusionofnorepinephrineorterlipres-\nsalinewithsalinealonewasscheduledtobegininAustralia\n107\nsin,whilevasopressinreducedtheneedfornorepinephrine\nandNewZealandin2010.Thisstudywillprovidefurther\n108109\n102\nandincreasedurineoutputandCrCl.AlargeRCT\nhigh-qualitydatatohelpguideclinicalpractice. comparingdopaminetonorepinephrineasinitialvasopres-\nThus,theuseofisotonicsalineasthestandardofcarefor\nsorinpatientswithshockshowednosigniﬁcantdifferences\nintravascularvolumeexpansiontopreventortreatAKIis\nbetweengroupswithregardtorenalfunctionormortality. baseduponthelackofclearevidencethatcolloidsare\nHowever,thereweremorearrhythmiceventsamongthe\nsuperiorforthispurpose,alongwithsomeevidencethat\npatientstreatedwithdopaminethanamongthosetreated\nspeciﬁccolloidsmaycauseAKI,inadditiontohighercosts.It\nwithnorepinephrine,andasubgroupanalysisshowedthat\nisacknowledgedthatcolloidsmaybechoseninsomepatients\ndopaminewasassociatedwithanincreasedrateofdeathat\ntoaidinreachingresuscitationgoals,ortoavoidexcessive\n28daysamongthepatientswithcardiogenicshock,butnot\nﬂuidadministrationinpatientsrequiringlargevolume\namongthepatientswithsepticshockorthosewithhypo-\nresuscitation,orinspeciﬁcpatientsubsets(e.g.,acirrhotic\nvolemicshock.Thus,althoughtherewasnodifferencein\npatientwithspontaneousperitonitis,orinburns).Similarly,\nprimaryoutcomewithdopamineastheﬁrst-linevasopressor\nalthoughhypotonicorhypertoniccrystalloidsmaybeusedin\nagentandthosewhoweretreatedwithnorepinephrine,the\nspeciﬁcclinicalscenarios,thechoiceofcrystalloidwith\nuseofdopaminewasassociatedwithagreaternumberof\nalteredtonicityisgenerallydictatedbygoalsotherthan\n109\nadverseevents. intravascularvolumeexpansion(e.g.,hypernatremiaor\nVasopressinisgainingpopularityinthetreatmentof\nhyponatremia).Oneoftheconcernswithisotonicsalineis\n110\nshockrefractorytonorepinephrine.Comparedtonor-\nthatthissolutioncontains154mmol/lchlorideandthat\nepinephrine,itincreasesbloodpressureandenhances\nadministrationinlargevolumeswillresultinrelativeor\n103\ndieresis,buthasnotasyetbeenproventoenhancesurvival\n). absolutehyperchloremia(forareview,seeKaplanetal. 111\nnortoreducetheneedforRRT.Arecentposthocanalysis\nAlthoughdirectproofofharmarisingfromsaline-induced\noftheabovementionedRCTusedtheRIFLEcriteriaforAKI\nhyperchloremiaislacking,bufferedsaltsolutionsapproxi-\n112\ntocomparetheeffectsofvasopressinvs.norepinephrine.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 6)",
    "content": "matephysiologicalchlorideconcentrationsandtheiradmin-\nInpatientsintheRIFLE-Rcategory,vasopressinascompared\nistrationislesslikelytocauseacid-basedisturbances. tonorepinephrinewasassociatedwithatrendtoalowerrate\nWhetheruseofbufferedsolutionsresultsinbetteroutcomes\nofprogressiontoForLcategoriesrespectively,andalower\nis,however,uncertain. 39\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.1\n93,113,114115\nrateofuseofRRT.MortalityratesintheRcategorypatientssepticshock.In2001,Riversetal.publishedthe\ntreatedwithvasopressincomparedtonorepinephrinewereresultsofasmall(n263),open-label,single-centerstudy\n30.8vs.54.7%,P¼0.01,butthisdidnotreachsigniﬁcanceinthatcomparedatreatmentprotocolthattheauthorsreferred\namultiplelogisticregressionanalysis.ThisstudysuggeststoasEGDTintheemergencymanagementofsepticshock. thusthatvasopressinmayreduceprogressiontorenalfailureEGDTispredicateduponthepremisethatanearly,\nandmortalityinpatientsatriskofkidneyinjurywhohaveprotocolizedresuscitationprogramwithpredeﬁnedphysio-\nsepticshock.TheWorkGroupconcludedthatcurrentlogicend-pointswillpreventorganfailureandimprovethe\nclinicaldataareinsufﬁcienttoconcludethatonevasoactiveoutcomeofpatientspresentingwithsepticshock. agentissuperiortoanotherinpreventingAKI,butHypotensivepatientswithsevereinfectionarerapidly\nemphasizedthatvasoactiveagentsshouldnotbewithheldassessedforevidenceoftissuehypoperfusionandmicro-\nfrompatientswithvasomotorshockoverconcernforkidneycirculatorydysfunctionbymeanarterialbloodpressure\n115\nperfusion.Indeed,appropriateuseofvasoactiveagentscanmeasurementandplasmalactatelevels.Bloodlactatelevels\nareneithersensitivenorspeciﬁcbutarereadilyavailable\nimprovekidneyperfusioninvolume-resuscitatedpatients\nwithvasomotorshock.measuresoftissuehypoperfusionanddocorrelatewith\n116,117\nadverseoutcomesinsepsis.Earlyrecognitionofseptic\nPROTOCOLIZEDHEMODYNAMICMANAGEMENT\nshocktheninitiatesaprotocolofresuscitationwiththegoal\nofreestablishingtissueperfusioninpatientswithin6hoursof\n3.1.3:Wesuggestusingprotocol-basedmanagementof\ndiagnosis.Thephysiologicgoalsare:i)returnofmean\nhemodynamicandoxygenationparametersto\narterialbloodpressureto65mmHg;ii)centralvenous\npreventdevelopmentorworseningofAKIin\npressurebetween8–12mmHg;iii)improvementinblood\nhigh-riskpatientsintheperioperativesetting(2C)\nlactatelevels;iv)centralvenousoxygensaturation(ScvO)\norinpatientswithsepticshock(2C). 70%;andv)aurineoutputof0.5ml/kg/h. InthestudybyRiversetal.theprotocol-drivenprocess\nresultedinmorerapiduseofﬂuids,morebloodtransfusions,\nRATIONALE\nandinasmallnumberofpatients,earlieruseofdobutamine\nAresuscitationstrategydevisedforpatientswithhypotension\noverthe6-hourtimeperiodthanstandardemergencycare. fromsepticshockthatisbaseduponachievingspeciﬁc\nThein-hospitalmortalityrateinthecontrolgroupwas\nphysiologicend-pointswithin6hoursofhospitaladmis-115\nFollow-up,\n46.5%vs.30.5%intheEGDTgroup(P0.01). sionhasbeentermedEarlyGoal-DirectedTherapy(EGDT).",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 7)",
    "content": "predominantlyobservationalstudies,havefoundlessdra-\nThisapproachhasbeenendorsedbythe‘‘Surviving\n118–122\nmaticbutgenerallysimilareffects,thoughnotwithout\n113\nSepsisCampaign’’andhasgainedconsiderableacceptance123\nexception. despiteonlyone,single-center,RCTevaluatingitseffective-\nTheRiversstudydidnotspeciﬁcallylookatAKIout-\nness.Thisprotocolizedstrategy,consistingofﬂuids,vaso-\ncomes,butmultiple-organfunction-scoringsystems(i.e.,\nactivemedication,andbloodtransfusionstargetingphysio-\nAPACHEIIandSAPS2)bothshowedsigniﬁcantimprove-\nlogicalparameters,isrecommendedbymanyexpertsforthe\nmentswithEGDT.Inasubsequentstudy,preventionof\npreventionoforganinjuryinseptic-shockpatients. AKIwassigniﬁcantlyimprovedinpatientsrandomizedtoa\nSimilarly,protocolizedcarestrategiesinsurgicalpatients\nmodiﬁedEGDTstrategy(withoutmeasurementofScvO)\nathighriskforpostoperativeAKIhavebeenextensively\n119\ncomparedtoastandard-caregroup.Criticismsofthe\nstudiedinanefforttoprovideoptimaloxygendeliveryto\nRiversstudyinclude:i)acomplex,multistepprotocolfor\ntissuesintheperioperativeperiod.Inthesepatients,goal-\nwhichindividualinterventionshavenotbeenvalidated;ii)\ndirectedtherapyisdeﬁnedashemodynamicmonitoringwith\ntheuseofatreatmentteamintheactive-therapyarm,thus\ndeﬁnedtargetvaluesandwithatimelimittoreachthese\nriskingaHawthorneffect;iii)highmortalityinthestandard-\nstatedgoals.Togethertheseprotocolswithbundled,hemo-\ncarearm;andiv)thestudywasasmallsingle-centerstudy. dynamic,andtissue-supportmeasureshavethepotentialto\nThreelargemulticenterclinicaltrialsintheUSA,UK,and\nreducetheriskofAKIfollowingmajorsurgicalprocedures\nAustraliaarecurrentlyunderwaytodeﬁnitivelyevaluatethis\ninhigh-riskpatients(e.g.,age60years,emergentsurgery,\npromisingtherapy. elevatedAmericanSocietyofAnesthesiologistsscore,\npreoperativecomorbidillnesses). Goal-directedtherapyforhemodynamicsupportduring\ntheperioperativeperiodinhigh-risksurgicalpatients\nEffortstoimprovetissueoxygendeliverybyoptimizing\nProtocolizedhemodynamicmanagementstrategies\nhemodynamicsupportinhigh-risksurgicalpatientsto\ninsepticshock\nEarlyﬂuidresuscitationinthemanagementofhypotensivepreventAKIandotheradversepatientoutcomeshavebeen\n124–126\nArecentmeta-analysisof\npatientswithsepticshockhasbeenastandardtreatmentinvestigatedformanyyears. 93,113,114127\nparadigmfordecades.Whathasnotbeenclear,thesestudiesbyBrienzaetal.concludedthatprotocolized\nhowever,ishowmuchﬂuidtogive,forhowlong,orwhattherapies(regardlessoftheprotocol)withspeciﬁcphysio-\ntypeofﬂuidtherapyisoptimalinthephysiologicsupportoflogicalgoalscansigniﬁcantlyreducepostoperativeAKI.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 8)",
    "content": "40\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.1\nAmajorproblemininterpretingthesestudiesisthelackofStudiesareneededthatcomparedifferenttypesof\nstandardizedhemodynamicandtissueoxygenationtargetsvasopressorsforpreventionandtreatmentofAKIin\nandmanagementstrategiesusedtoverifytheefﬁcacyofthesehemodynamicallyunstablepatients.Someevidence\nmeasuresoverstandardperioperativecare.Aheterogeneoussuggeststhatcertainvasopressorsmaypreserverenal\ncollectionofstudypopulations,typesofsurgicalprocedures,functionbetterthanothers(e.g.,vasopressinanalogues\nmonitoringmethods,andtreatmentstrategiescomprisethisvs.catecholamines)andstudiesareneededtocompare\n127\nrecentmeta-analysis.Thebasicstrategyofgoal-directedtheminthissetting. therapytopreventAKIintheperioperativeperiodisbasedThechoiceofatargetmeanarterialperfusionpressure\nonprotocolsthatavoidhypotension,optimizeoxygenrangeof65–90mmHgasacomponentofresuscitation\ndelivery,andincludecarefulﬂuidmanagement,vasopressors(perhapsinthecontextofage,chronicbloodpressure,or\nwhenindicated,andinotropicagentsandbloodproductsifothercomorbidities)alsoneedsfurtherstudy. 127\nneeded.Thespecificcomponentsofgoal-directedtherapythat\nTherelativemeritsandrisk:beneﬁtratioofeachdiscreteaccruebenefitsforpatientsatriskforAKIneedtobe\nelementofEGDTinthesuccessfulresuscitationofpatientsdetermined.Isitthetimingofprotocolizedhemodynamic\nwithsepticshockrequiresfurtherstudy.Giventhelimita-managementthatisbeneficial:prophylacticallyinhigh-\ntionsofthecurrentstudiesandlackofcomparativerisksurgicalpatients,orearlyinthecourseofseveresepsis? effectivenessstudiescomparingindividualprotocols,weIncontrasttothebenefitsofprophylacticorEGDT,\ncanonlyconcludethatprotocolsforresuscitationintheprotocolizeduseofinotropestonormalizemixedvenous\nsettingofsepticshockandhigh-risksurgeryappeartobeoxygensaturationorsupranormalizeoxygendeliveryin\n128\nsuperiortonoprotocol.‘‘late’’criticalillnessdidnotresultindecreasedAKIor\n128,129\nimprovedoutcomes.Alternatively,isitattention\ntohemodynamicmonitoring,theprotocolitselfthat\nRESEARCHRECOMMENDATIONS\nRandomizedtrialsofisotoniccrystalloidvs.colloidstandardizessupportivecaretoachievethestatedgoals,or\ntherapyforintravascularvolumeexpansiontopreventasingleorcombinationofthemultiplepossibleinterven-\nortreatAKIshouldbeconductedinavarietyofsettingstionsthatimprovesoutcome?Thus,furtherresearchis\n(criticalillness,high-risksurgery,sepsis),includingrequiredtodeterminethespecificcomponentsofgoal-\npatientsubsets.Inparticular,colloidsmayimprovedirectedtherapythataccruebenefitsforpatientsatriskfor\nefficiencyoffluidresuscitationbutsome(starch)alsoAKI,ifsuchbenefitsactuallyoccur. carrysomeconcernsregardingeffectsonthekidneys.If\ncolloidresultsinlessvolumeoverload,itmayleadto\nSUPPLEMENTARYMATERIAL\nimprovedoutcomes. SupplementaryTable1:SummarytableofRCTsexaminingtheeffect\nofstarchforthepreventionofAKI.",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpreventionandmanagementofAKI (Part 9)",
    "content": "Comparisonsofspecificsolutions,withspecificelectrolyte\nAppendixD:EvaluationandGeneralManagementGuidelinesfor\ncompositionorcolloidtype,foreffectivenessinpreventing\nPatientswithAKI. AKIshouldbeconducted.Specifically,thereisaneedto\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nexaminephysiologicelectrolytesolutionsvs.saline. http://www.kdigo.org/clinical_practice_guidelines/AKI.php\n41\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.2\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 40,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "complications",
    "content": "130–133\nSupportivemanagementtopreventAKIwasdiscussedinthecomplicationsthatarisefromAKI;thereaderisreferred\npreviouschapterand,formanypatients,manyofthesupportivetothesesources.Particularattentionshouldbegiventothe\ntherapieswillcontinueevenifAKIdevelops.Furthermore,assessmentofthecirculatingvolumeandﬂuidadministration,\nanimportantgoalofearlymanagementofAKIistopreventthepreventionand/ortreatmentofhyperkalemiaandmetabolic\nfurtherinjuryandtofacilitaterecoveryofrenalfunction.Theseacidosis,theknowledgeofthechangesinpharmacokineticsof\ngoalscanoftenbestbeachievedbystrictattentiontosupportivemanydrugswithdiscontinuationofallpotentiallynephrotoxic\ntherapy.However,asrenalfunctiondeteriorates,complicationsdrugs,anddoseadaptationofdrugsexcretedbythekidneysto\narisethatrequiredifferentmanagement.Someoftheseissuesthepatient’srenalfunction.Finally,manyoftheotherchapters\nhavebeendiscussedinChapter2.3andseveralbookshaveinthissectionoftheguidelinedealwithsupportivemeasures\nbeendevoted,inlargepart,tomanagementofthemany(e.g.,diureticsforﬂuidmanagement).\n42\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.3\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 45,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 1)",
    "content": "patients),theprimaryend-pointofin-hospitalmortality\nGLYCEMICCONTROLINCRITICALILLNESS:RENALEFFECTS\nANDOUTCOMES\ndidnotdifferbetweengroups(40%CITgroupvs.37.3%IIT\n141\nAsintheoriginalsurgicalICUstudy,a\ngroup;P¼0.33). 3.3.1:Incriticallyillpatients,wesuggestinsulin\nvarietyofsecondaryend-pointswereimprovedinthisstudy,\ntherapytargetingplasmaglucose110–149mg/dl\nincludingalowerincidenceofAKIandneedforRRT.Inthe\n(6.1–8.3mmol/l).(2C)\noriginalsurgicalICUstudy,severeAKI(peakSCr2.5mg/dl\n4m\n[221mol/l])developedin7.2%oftheIITgroup,\ncomparedto11.2%oftheCITgroup(P0.04);the\nincidenceofRRTwasalsolowerintheIITgroupthanthe\nRATIONALE\n134138\nAsoutlinedinarecentreview,stresshyperglycemiaisaCITgroup(4.8%vs.8.2%,respectively;P0.007).Inthe\ndistinctiveclinicalfeatureofcriticalillness.Stressmediators,medicalICUstudy,theIITgroupsimilarlyhadasigniﬁcantly\nandcentralandperipheralinsulinresistanceappearspivotallowerrateofAKI(doublingofSCr,5.4%)thantheCIT\ntotheoccurrenceofstresshyperglycemia.Inﬂammatorygroup(8.9%,P0.04),althoughRRTincidencewasnot\n141142\nmediatorsandcounter-regulatoryhormoneshavebeendecreased.Inarecentanalysis,Schetzetal.combined\nshowntoimpedecrucialelementsoftheinsulin-signalingtherenalend-pointsofbothofthesetrialsandusedamodi-\npathway.Still,exogenousinsulinadministrationnormalizesﬁedversionoftheRIFLEclassiﬁcationofAKItodemonstrate\nbloodglucoselevelsinthissetting.Insulintreatmentmaythattightglycemiccontrolreducedtheincidenceofsevere\ncounteracthepaticinsulinresistanceduringacutecriticalAKI(peakSCrincrementstwo-orthree-foldincreasedfrom\nbaseline)from7.6%to4.5%(P0.0006)inacombined\nillness.Extensiveobservationaldatahaveshownaconsistent,¼\nalmostlinear,relationshipbetweenbloodglucoselevelsinpatientpopulationof2707.TheneedforRRTwasnot\npatientshospitalizedwithMIandadverseclinicaloutcomes,decreasedintheoverallpopulationorthemedicalICU\n135,136\neveninpatientswithoutestablisheddiabetes.population,butwassigniﬁcantlylowerinthesurgicalICU\nIthasneverbeenentirelyclear,however,whetherglycemiapatientsmanagedwithIIT(4%vs.7.4%,P0.008).",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 2)",
    "content": "servesasamediatoroftheseoutcomesormerelyasamarker\nSeveralnewerstudieshaveprovidedadditionalinsight\nofthesickestpatients,whopresentwiththewell-knownconcerningtheefﬁcacyandsafetyoftightglycemiccontrolin\n13793,95,143–146145\ncounter-regulatorystressresponsetoillness.Interestingly,criticallyillpatients.Thomasetal.conducteda\n135\nKosiborodetal.recentlyshowed,inapopulationwithMI,systematicreviewofrandomizedtrialsoftightglycemic\nthatwhilehypoglycemiawasassociatedwithincreasedcontrolin2864criticallyillpatients,andfounda38%risk\nmortality,thisriskwasconﬁnedtopatientswhodevelopedreductionofAKIwithIIT,andanonsigniﬁcanttrendtowards\nspontaneoushypoglycemia.Incontrast,iatrogenichypo-lessacutedialysisrequirement.However,IITwasalso\nglycemiaafterinsulintherapywasnotassociatedwithhigherassociatedwithagreaterthanfour-foldincreaseintherisk\nmortalityrisk.ofhypoglycemia.Abodyofliteraturedemonstratingthat\nTightglycemiccontrolisfrequentlyusedinpatientsatriskuncontrolledhyperglycemiawasassociatedwithincreased\nofAKI,andinthemanagementofthosewhodevelopAKI.ItAKIfollowingcardiacsurgeryledtotheconductofa400-\nhasbeenproposedthattightglycemiccontrolcanreducethepatient,single-centerRCToftightvs.conventionalintra-\n143,144\nincidenceandseverityofAKI.SincethelandmarktrialofVanoperativeglucosecontrol.Theinvestigatorsfoundthat\n138\nadditionalstudiesprovidedinitialthisapproachdidnotdecreaseperioperativemorbidityor\ndenBergheetal.,\nconﬁrmationofthebeneﬁts(reducedmorbidityandmortality(includedinacompositeend-pointthatincluded\nmortality),andsomeadditionalmechanisticinsightsoftightAKIwithin30daysofsurgery):thecompositeend-point\n139\nglycemiccontrolincriticallyillpatients.Furthersecondaryoccurredin44%oftheIITgroupvs.46%oftheCITgroup. analysisoftheoriginaltrial,whichwasconductedin1548Althoughtheincidenceofhypoglycemiawassimilarinthe\nmechanicallyventilatedsurgicalICUpatients,foundthatgroups,therewasasigniﬁcantlyhigherincidenceofstrokein\nintensiveinsulintherapy(IIT)targetplasmaglucosetheIITgroup(4.3%)comparedtotheCITgroup(0.54%),as\n80–110mg/dl(4.44–6.11mmol/l)wasassociatedwithsub-wellastrendstowardshighermortalityandmorepost-\nstantialcostsavingscomparedtoconventionalinsulinoperativeheartblockintheIITgroup,raisingconcernsabout\ntherapy(CIT)targetplasmaglucose180–200mg/dl(9.99–thesafetyofthisapproach. 140\n11.1mmol/l).However,whenVandenBergheetal.FurtherprospectivecomparisonofIITvs.CITincritically\nrepeatedtheiroriginalstudyinadifferentpopulationofillsepticpatientswasprovidedintheVISEPtrial,which\ncriticallyillpatients(medicalratherthansurgicalICU\nalsoincorporatedacomparisononcrystalloidvs.colloid\n43\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.3\n93148\ninfusionsina22factorialdesign.PatientswithsevereTheprimaryoutcomewas\n(cid:2)180mg/dl[9.99mmol/l]). pp\nsepsisorsepticshockin18ICUswererandomizedtoIITmortalityfromanycausewithin90daysafterrandomization.",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 3)",
    "content": "(targetglycemia80–110mg/dl[4.44–6.11mmol/l];n¼247)Thetwogroupshadsimilarcharacteristicsatbaseline.Atotal\norCIT(targetglycemia180–200mg/dl[9.99–11.1mmol/l];of829patients(27.5%)intheintensive-controlgroupand\nn290)(SupplTables2and3).Therewerenosigniﬁcant751(24.9%)intheconventional-controlgroupdied(OR\ndifferencesin28-dayor90-daymortality,SequentialOrganforintensivecontrol,1.14;95%CI1.02–1.28;P¼0.02).The\nFailureAssessmentscores,orAKIratesbetweenthegroups.treatmenteffectdidnotdiffersigniﬁcantlybetweensurgical\nHowever,hypoglycemia(bloodglucoselevel40mg/dlpatientsandmedicalpatients.Therewasnosigniﬁcant\n[2.22mmol/l])wasmorefrequentintheIITgroup(12%differencebetweenthetwotreatmentgroupsinincidenceof\nvs.2%;P0.001)andledtoearlyterminationoftheIITnewRRT(15.4%vs.14.5%),respectively.Severehypo-\nstudyarm.Followingpublicationofthisstudy,Thomasetal.,glycemia(bloodglucoselevel40mg/dl[2.22mmol/l])\npp\nupdatedthemeta-analysis(discussedabove)toincludethesewasreportedin6.8%intheintensive-controlgroupandin\ndata,andreportedthat,withtheadditionoftheVISEPdata,0.5%intheconventional-controlgroup(P0.001).In\ntheanalysisofa3397-patientgroupfounda36%risksummary,thelargestrandomizedtrialofintensivevs. reductionofAKIwithIIT,butthispooledestimatewasnoconventionalinsulintherapyfoundthatintensiveglucose\nlongerstatisticallysigniﬁcant(relativerisk[RR]0.74;95%CIcontrolactuallyincreasedmortalityamongadultsintheICU:\n95\nInadetailedreviewoftheVISEPtrial,Thomas\n0.47–1.17).abloodglucosetargetof180mg/dl(9.99mmol/l)\npp\netal.,alsonotedthatanothermulticentermixedICUtrialofresultedinlowermortalitythandidatargetof81–108mg/\nintensiveinsulintherapy(theGLUCOCONTROLStudy:dl(4.50–5.99mmol/l).Furthermore,thistrialconﬁrmedthe\nComparingtheeffectsoftwoglucosecontrolregimensby\nconsistentﬁndingofanincreasedincidenceofhypoglycemia\ninsulininintensivecareunitpatients;availableat:http://associatedwithIIT,withoutanyprovenbeneﬁtinreducing\nwww.clinicaltrials.gov/ct/show/NCT00107601)wasstopped\nmortality,organdysfunction,orbacteremia.",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 4)",
    "content": "after1101patientswereenrolledbecauseofgreaterratesof\nThereweresomemethodologicaldifferencesbetweenthe\n95\nhypoglycemiawithIIT.SuchdatahaveraisedsigniﬁcantLeuvenandNICE-SUGARstudies,possiblyexplainingthe\n149\nconcernsregardingtheeffectivenessandsafetyofusingIITdifferentoutcomes.Thesecompriseddifferenttarget\nwithtightglycemiccontroltopreventoramelioraterangesforbloodglucoseincontrolandinterventiongroups,\nmorbidityandmortalityinpatientsathighriskofAKIanddifferentroutesforinsulinadministrationandtypesofinfu-\notherformsoforganinjury.sionpumps,differentsamplingsites,anddifferentaccuracies\n146\nTherecentmeta-analysisofIITvs.CITbyWieneretal.ofglucometers,aswellasdifferentnutritionalstrategiesand\n150\ncontinuedtoﬁndagreaterincidenceofhypoglycemiawithvaryinglevelsofexpertise.Finally,Griesdaleetal.per-\nIIT,butthebalanceofevidencenowsuggestsnoimprove-formedameta-analysisoftrialsofintensivevs.conventional\nmentinsurvivalwiththisapproach.Twenty-nineRCTsglycemiccontrolthatincludedmostofthestudiesinthe\ntotaling8432patientscontributeddataforthismeta-analysis.Wienermeta-analysis,inadditiontosomenewerstudies,\nTwenty-sevenstudiesreportednodifferenceinhospitalincludingdatasuppliedbytheNICE-SUGARinvestigators. mortality(21.6%inIITvs23.3%inCIT)withapooledRRAll26trialsthatreportedmortalityfoundapooledRRof\nof0.93(95%CI0.85–1.03;PNS).NinestudiesreportednodeathwithIITcomparedtoCITof0.93(95%CI0.83–1.04). differenceinincidenceofnewRRT.TherewasasigniﬁcantAmongthe14trialsreportinghypoglycemia,thepooledRR\nbeneﬁtoftightglycemiccontrolinreducingtheincidenceofwithIITwas6.0(95%CI4.5–8.0).However,insubset\nsepticemiabutthiswasassociatedwithasigniﬁcantlyanalysis,patientsinsurgicalICUsappearedtobeneﬁtfrom\nincreasedriskofhypoglycemia(bloodglucose40mg/dlIITwhilepatientsintheotherICUsettings(medicalor\n[2.22mmol/l])inpatientsrandomizedtoIITwithapooledmixed)didnot.Althoughresultsfromtheearlytrialswere\n138\nRRof5.13(95%CI4.09–6.43;P0.05).betterinstudiesthatincludedsurgicalratherthanpurely\n141\nInsummary,pooledanalysisofearlymulticenterstudiesmedicalICUpatients,andthislatestmeta-analysisappears\ntoconﬁrmthattrend,itshouldbenotedthatnosuch\nhasfailedtoconﬁrmtheearlyobservationsofbeneﬁcial\neffectsofIITonrenalfunction;theriskofhypoglycemiawithphenomenonwasnotedintheNICE-SUGARtrial.Overall,\nthisapproachissigniﬁcant,andeventhesurvivalbeneﬁtsofthedatadonotsupporttheuseofIITaimingtocontrol\nplasmaglucosebelow110mg/dl(6.11mmol/l)incriticallyill\nIITareindoubt.Morerecently,theinternationalNormogly-\ncemiainIntensiveCareEvaluationandSurvivalUsingpatients,althoughsubsetanalysessuggestthatfurthertrials\nGlucoseAlgorithmRegulation(NICE-SUGAR)study,withamaydisclosebeneﬁtsinperioperativepatients,andperhaps\ntargetedenrolmentof6100patients,setouttodeﬁnitivelythroughtheuseofless-intensiveglucosecontroltargets.",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 5)",
    "content": "Consideringthebalancebetweenpotentialbeneﬁtsand\ndeterminetherisk-beneﬁtcomparisonoftightglycemic\n147,148\ncontrolincriticallyillpatients(SupplTable3).Inthisharm(seeSupplTable2),theWorkGroupsuggestsusing\ntrial,adultpatientswererandomizedwithin24hoursafter\ninsulinforpreventingseverehyperglycemiaincriticallyill\nadmissiontoanICUtoreceiveeitherintensiveglucosepatients,butinviewofthedangerofpotentiallyserious\ncontrol(targetbloodglucoserangeof81–108mg/dl[4.50–hypoglycemia,werecommendthattheaveragebloodglucose\n5.99mmol/l]),orconventionalglucosecontrol(targetof\nshouldnotexceed150mg/dl(8.33mmol/l),butthatinsulin\n44\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.3\ntherapyshouldnotbeusedtolowerbloodglucosetolessthan25–30kcal/kg/d,equivalentto100–130%ofresting\nthan110mg/dl(6.11mmol/l).TheWorkGrouprecognizesenergyexpenditure.Energyprovisionshouldbecomposedof\nthattheseproposedthresholdshaveneverdirectlybeen3–5(maximum7)gperkilogrambodyweightcarbohydrates\nexaminedinRCTsbutareinterpolatedfromthecomparisonsand0.8–1.0gperkilogrambodyweightfat. testedinthetrialssofar. 3.3.3:Wesuggesttoavoidrestrictionofproteinintake\nNUTRITIONALASPECTSINTHEPREVENTIONAND\nwiththeaimofpreventingordelayinginitiationof\nTREATMENTOFCRITICALLYILLPATIENTSWITHAKI\nRRT.(2D)\nProtein-caloriemalnutritionisanimportantindependent\n3.3.4:Wesuggestadministering0.8–1.0g/kg/dofprotein\npredictorofin-hospitalmortalityinpatientswithAKI.Ina\ninnoncatabolicAKIpatientswithoutneedfor\nprospectivestudyof300AKIpatients,42%presentedwith\ndialysis(2D),1.0–1.5g/kg/dinpatientswithAKIon\n151\nsignsofseveremalnutritiononadmission. RRT(2D),anduptoamaximumof1.7g/kg/din\nThenutritionalmanagementofAKIpatientsmust\npatientsoncontinuousrenalreplacementtherapy\nconsiderthemetabolicderangementsandproinﬂammatory\n(CRRT)andinhypercatabolicpatients.(2D)\nstateassociatedwithrenalfailure,theunderlyingdisease\nprocessandcomorbidities,aswellasthederangementsin\nnutrientbalancecausedbyRRT.Veryfewsystematicstudies\nRATIONALE\nhaveassessedtheimpactofnutritiononclinicalend-points\nProteinhypercatabolismdrivenbyinﬂammation,stress,\nusedintheseguidelines(i.e.,mortality,needforRRT,\nandacidosisisacommonﬁndingincriticallyill\n157,165,166\nandincidenceofAKI).Recommendationsaretherefore\npatients.Theoptimalamountofproteinsupple-\nlargelybasedonexpertopinion.Severalexpertpanelshave\nmentationinAKIpatientsisunknown.PatientswithAKIare\ndevelopedclinicalpracticeguidelinesforthenutritional\nathighriskofmalnutrition.Sincemalnutritionisassociated\nmanagementofpatientswithAKI,whethertreatedwithor\nwithincreasedmortalityincriticallyillpatients,nutritional\n152–156\nwithoutRRT.Arecentnarrativereviewhasalso\nmanagementshouldaimatsupplyingsufﬁcientproteinto\n157\nprovidedupdatedinformationonthistopic.",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 6)",
    "content": "maintainmetabolicbalance.Hence,nutritionalprotein\nadministrationshouldnotberestrictedasameansto\n3.3.2:Wesuggestachievingatotalenergyintakeof\nattenuatetheriseinBUNassociatedwithdecliningGFR.On\n20–30kcal/kg/dinpatientswithanystageofAKI.(2C)\ntheotherhand,thereislittleevidencethathypercatabolism\ncanbeovercomesimplybyincreasingproteinintaketo\nsupraphysiologiclevels.While,inacrossoverstudyofAKI\npatients,nitrogenbalancewasrelatedtoproteinintake\nRATIONALE\nCarbohydratemetabolisminAKIischaracterizedbyandwasmorelikelytobepositivewithintakeslargerthan\n158,159167\nhyperglycemiaduetoperipheralinsulinresistanceonly35%ofpatientsachievedapositivenitrogen\n2g/kg/d,\nandacceleratedhepaticgluconeogenesis,mainlyfromcon-balanceinastudyapplyinganutrientintakeashighas\n168\nversionofaminoacidsreleasedduringproteincatabolism2.5g/kg/dprotein.Nooutcomedataarecurrently\n160\nthatcannotbesuppressedbyexogenousglucoseinfusions.availableconcerningtheclinicalefﬁcacyandthesafetyof\nInaddition,hypertriglyceridemiacommonlyoccursduesuchhighproteinintakes,whichmaycontributetoacidosis\ntoinhibitionoflipolysis.Theclearanceofexogenouslyandazotemia,andincreasedialysisdoserequirements. 161\nadministeredlipidscanbereduced.ThemodiﬁcationsofDuetotheircontinuousnatureandthehighﬁltration\nenergymetabolismareusuallynotcausedbyAKIpersebutrates,CRRTtechniquescanbettercontrolazotemiaandﬂuid\n162\nrelatedtoacutecomorbiditiesandcomplications.Energyoverloadassociatedwithnutritionalsupportbutmayalso\nconsumptionisnotincreasedbyAKI.Eveninmultiple-organ\nresultinadditionallossesofwater-soluble,low-molecular-\n169\nfailure,theenergyexpenditureofcriticallyillpatientsweightsubstances,includingnutrients.Normalizedpro-\namountstonotmorethan130%ofrestingenergyteincatabolicratesof1.4to1.8g/kg/dhavebeenreported\n170–172\nexpenditure.Theoptimalenergy-to-nitrogenratioduringinpatientswithAKIreceivingCRRT.Inarecentstudy\nAKIhasnotbeenclearlydetermined.InaretrospectivestudyincriticallyillcancerpatientswithAKIandtreatedwith\nofAKIpatientsundergoingcontinuousvenovenoushemoﬁl-sustainedlow-efﬁciencydialysis(SLED),thosewithhigher\ntration(CVVH),lessnegativeorweaklypositivenitrogenBUNandserumalbuminlevels,whichwereassociatedwith\nbalancewasassociatedwithanenergyintakeofapproxi-infusionofhigheramountoftotalparenteralnutrition,hada\n163173\nmately25kcal/kg/d.InarandomizedtrialinAKIpatientslowermortalityrisk. comparing30and40kcal/kg/denergyprovision,thehigherInCRRT,about0.2gaminoacidsarelostperliterof\nenergyprescriptiondidnotinduceamorepositivenitrogenﬁltrate,amountingtoatotaldailylossof10–15gamino\nbalancebutwasassociatedwithahigherincidenceofacids.Inaddition,5–10gofproteinarelostperday,\nhyperglycemiaandhypertriglyceridemiaandamorepositivedependingonthetypeoftherapyanddialyzermembrane.",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 7)",
    "content": "164\nﬂuidbalance.TheseobservationsprovidearationaletoSimilaramountsofproteinandaminoacidsaretypicallylost\nmaintainatotalenergyintakeofatleast20,butnotmorebyperitonealdialysis(PD).Nutritionalsupportshould\n45\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.3\naccountforthelossesrelatedtoCRRT,includingPD,bynutritionalrequirementsinchildrenwithcriticalillnessand\nprovidingamaximumof1.7gaminoacids/kg/d.AKIislimitedtoobservationalstudies.Withrespecttocalorie\nprovision,itisgenerallyagreedthatcriticallyillchildren,\n3.3.5:Wesuggestprovidingnutritionpreferentiallyvialikeadults,shouldreceive100–130%ofthebasalenergy\ntheenteralrouteinpatientswithAKI.(2C)expenditure,whichcanbeestimatedwithacceptableprecision\n179\nandaccuracybytheCaldwell-Kennedyequation:(resting\nRATIONALE\nenergyexpenditure[kcal/kg/d]2231.05weight[kg]\n¼þ(cid:2)þ\nEnteralfeedingmaybemoredifﬁcultinpatientswithAKI\n1.16age[years]). (cid:2)\nbecauseofimpairedgastrointestinalmotilityanddecreased\nInarecentsurveyofthenutritionalmanagementof195\n174\nabsorptionofnutrientssecondarytoboweledema. childrenwithAKIonCRRT,themaximalcalorieprescription\nMoreover,multiplefactorsnegativelyaffectgastrointestinal\ninthecourseoftreatmentaveraged53,31,and21kcal/kg/d,\nfunctionincriticallyillpatients,e.g.,medications(sedatives,\nandthatforproteinintake2.4,1.9,and1.3g/kg/dinchildren\n180\nopiates,catecholamines,etc.),glucoseandelectrolytedis-\naged1,1–13,and13years,respectively.Althoughnot\norders,diabetes,ormechanicalventilation.However,the\nvalidatedbyoutcomestudies,theseﬁguresprovidean\nprovisionofnutrientsviathegutlumenhelpsmaintaingut\norientationforthemacronutrientsupplytypicallyachieved\nintegrity,decreasesgutatrophy,anddecreasesbacterialand\ninandtoleratedbychildrenwithAKIreceivingCRRT. endotoxintranslocation.Furthermore,AKIisamajorrisk\n175\nfactorforgastrointestinalhemorrhage.Enteralnutrition\nRESEARCHRECOMMENDATIONS\nshouldexertprotectiveeffectsontheriskofstressulcersorTherisk-benefitratioofdietswithlow,medium,and\nbleeding.ClinicalstudieshavesuggestedthatenteralfeedinghighproteincontentsindifferentstagesofAKIshouldbe\nisassociatedwithimprovedoutcome/survivalinICUaddressedinRCTs. 176,177\npatients.Hence,enteralnutritionistherecommendedGivengastrointestinaltractdysfunctioninAKI,the\nformofnutritionalsupportforpatientswithAKI.Iforalpossiblebenefitofenteralvs.parenteralfeedinginAKI\nfeedingisnotpossible,thenenteralfeeding(tubefeeding)patientsshouldbefurtherevaluatedinprospectiveRCTs. shouldbeinitiatedwithin24hours,andhasbeenshownto\n178\nbesafeandeffective. SUPPLEMENTARYMATERIAL\nSupplementaryTable2:EvidenceprofileofRCTsexamininginsulinvs. conventionalglucosetherapyforthepreventionofAKI. Pediatricconsiderations\nSupplementaryTable3:SummarytableofRCTsexaminingtheeffect\nInchildrenwithAKI,physiologicalmacronutrientrequire-\nofinsulinforthepreventionofAKI.",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.3:Glycemiccontrolandnutritionalsupport (Part 8)",
    "content": "mentsareage-dependent,reﬂectingthedevelopmental\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\ndynamicsofgrowthandmetabolism.Researchexploring\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n46\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.4\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 46,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.4:TheuseofdiureticsinAKI (Part 1)",
    "content": "DiureticsarefrequentlyusedinpatientsatriskofAKI,andinfurosemideisbeneﬁcialforpreventionortreatmentofAKI. themanagementofthosewhodevelopAKI.SinceﬂuidSpeciﬁcally,prophylacticfurosemidewasfoundtobe\noverloadisoneofthemajorsymptomsofAKI,diureticsareineffectiveorharmfulwhenusedtopreventAKIaftercardiac\n189,190\noftenusedforpatientswithAKItofacilitateﬂuidmanage-surgery,andtoincreasetheriskofAKIwhengivento\n191\nment.Recentobservationalstudiesshowedthat59–70%ofpreventCI-AKI.Epidemiologicdatahavesuggestedthat\npatientswithAKIweregivendiureticsatthetimeoftheuseofloopdiureticsmayincreasemortalityinpatients\n181,182181\nnephrologyconsultationorbeforethestartofRRT.withcriticalillnessandAKI,alongwithconﬂictingdata\n182\nInaddition,oliguricAKIhasaworseprognosisthanthatsuggestnoharminAKI.Finally,furosemidetherapy\nnonoliguricAKIandphysiciansoftenprescribediureticstowasalsoineffectiveandpossiblyharmfulwhenusedtotreat\n183188,192\nconvertoligurictononoliguricAKI.DiureticsarealsoAKI. usedtocontrolﬂuidbalanceandpermitadministrationofThereisnoevidencethattheuseofdiureticsreducesthe\n192,193\nconductedtwo\nnutritionandmedications.Furthermore,severaldiureticsincidenceorseverityofAKI.Hoetal. havepotentiallyrenoprotectiveeffectsthatmightpreventcomprehensivesystematicreviewsontheuseoftheloop\ndevelopmentofAKIandhastenitsrecovery.However,diureticfrusemide(furosemide)topreventortreatAKI. diureticscanalsobeharmful,byreducingthecirculatingFurosemidehadnosigniﬁcanteffectonin-hospitalmortality,\nvolumeexcessivelyandaddingaprerenalinsult,worseningriskforrequiringRRT,numberofdialysissessions,oreven\nestablishedAKI.Therefore,itisessentialtoevaluatetheproportionofpatientswithpersistentoliguria.Results\n193\nusefulnessofdiureticstoimproveoutcomeofpatientswithfromthemostrecentreviewareshowninFigure9and\nFigure10.Theprimarypreventionstudiesincludedpatients\nAKI,notjustforﬂuidmanagement. 189191\nwhounderwentcardiacsurgery,coronaryangiography,\n194\n3.4.1:Werecommendnotusingdiureticstopreventandmajorgeneralorvascularsurgery.Intwoofthese\nAKI.(1B)studies,allparticipantshadmildpre-existingrenalimpair-\n3.4.2:WesuggestnotusingdiureticstotreatAKI,exceptment.Twoofthethreestudiesreportedmortalityinpatients\nrandomizedtofurosemide(n103)vs.placebo(n99),\ninthemanagementofvolumeoverload.(2C)¼¼\nwithapooledRRof2.67(95%CI0.75–7.25;P0.15).All\nthreestudiesreportedRRTincidenceinpatientsrandomized\ntofurosemide(n128)vs.placebo(n127),withapooled\n¼¼\nRATIONALE\nLoopdiureticshaveseveraleffectsthatmayprotectagainstRRof4.08(95%CI0.46–35.96;P0.21).Thus,subanalysis\nAKI.Theymaydecreaseoxygenconsumptionintheloopoftoseparateprimaryandsecondarypreventiontrialsdidnot\nHenlebyinhibitingsodiumtransport,thuspotentiallyaltertheconclusionthat,withinthesamplesizelimitations\nlesseningischemicinjury.Loopdiureticsactattheluminalofthisstudy,furosemideisnoteffectivefortheprevention\nsurfaceofthethickascendinglimboftheloopofHenleandofAKI.",
    "page": 50,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.4:TheuseofdiureticsinAKI (Part 2)",
    "content": "184,185\nresultinginaloss\ninhibittheNa-K-2Clcotransporter,Thesystematicreviewandmeta-analysisbyHoand\n193\nofthehighmedullaryosmolalityanddecreasedabilitytoalsoincludedsixstudiesthatusedfurosemideto\nPower\nreabsorbwater.InhibitionofactivesodiumtransportalsotreatAKI,withdosesrangingfrom600to3400mg/d\n192\nreducesrenaltubularoxygenconsumption,potentially(Figure9andFigure10).Nosigniﬁcantreductionwas\ndecreasingischemicdamageofthemostvulnerableouterfoundforin-hospitalmortalityorforRRTrequirement.The\n183\nmedullarytubularsegments;therefore,furosemidemightlargestsinglestudyoffurosemidefortreatingAKIwas\n186188\nprotectkidneysagainstischemicinjury.FurosemidealsoconductedbyCantarovichetal.,whichincluded338\nmighthastenrecoveryofAKIbywashingoutnecroticdebrispatientswithAKIrequiringdialysis.Patientswererandomly\nblockingtubules,andbyinhibitingprostaglandindehydro-assignedtotheadministrationofeitherfurosemide(25mg/\ngenase,whichreducesrenovascularresistanceandincreaseskg/di.v.or35mg/kg/dorally)orplacebo.Althoughtimeto\n186,187\nrenalbloodﬂow.Basedontheseproperties,loopreach2l/dofdiuresiswasshorterwithfurosemide(5.7days)\ndiureticsmightbeexpectedtopreventorameliorateAKI.thanplacebo(7.8days,P0.004),therewasnodifferencein\nHowever,thereareonlyminimaldatatosupportthistheory,survivalandnumberofdialysissessions.Atpresent,the\nandthereissomeevidenceofharmassociatedwithloop\ncurrentevidencedoesnotsuggestthatfurosemidecanreduce\n188–191\ndiureticusetopreventortreatAKI.FurosemideisthemortalityinpatientswithAKI. mostcommonlyprescribeddiureticintheacute-careFurosemidemay,however,beusefulinachievingﬂuid\n183–185\nsetting,andanumberofRCTshavetestedwhetherbalancetofacilitatemechanicalventilationaccordingtothe\n47\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.4\nFigure9|Effectoffurosemidevs.controlonall-causemortality.ReprintedfromHoKM,PowerBM.Benefitsandrisksoffurosemidein\n193\nacutekidneyinjury.Anaesthesia2010;65:283–293withpermissionfromJohnWileyandSons;accessedhttp://onlinelibrary.wiley.com/\ndoi/10.1111/j.1365-2044.2009.06228.x/full\nFigure10|Effectoffurosemidevs.controlonneedforRRT.ReprintedfromHoKM,PowerBM.Benefitsandrisksoffurosemideinacute\n193\nkidneyinjury.Anaesthesia2010;65:283–293withpermissionfromJohnWileyandSons;accessedhttp://onlinelibrary.wiley.com/doi/\n10.1111/j.1365-2044.2009.06228.x/full\nlung-protectiveventilationstrategyinhemodynamicallyconcludethatthereisnoevidencethattheuseofloop\nstablepatientswithacutelunginjury.Ontheotherhand,diureticsreducestheseverityofAKI,orimprovesoutcomes\ntheliteraturealsosuggeststhathigh-dosefurosemideinthissyndrome.Althoughtheuseofloopdiureticsinearly\n(1g/d)maycauseototoxicity.Intheﬁrstmeta-analysisorestablishedAKIfacilitatesmanagementofﬂuidbalance,\n192\nbyHoandSheridan,highdosesoffurosemide(rangehyperkalemia,andhypercalcemia,andisindicatedforthese\n1–3.4g/d)causeddeafnessortinnitusmorefrequentlythanclinicalpurposes,anyputativeroleinthepreventionor\nthecontrol(RR3.97;95%CI1.00–15.78;P¼0.05).WhenameliorationofAKIcourseisunproven.",
    "page": 50,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.4:TheuseofdiureticsinAKI (Part 3)",
    "content": "administeredascontinuousinfusionadoseof0.5mg/kg/Tworecentstudieshaveinvestigatedwhethertheadmin-\n195\nhourwasnotassociatedwithototoxicity.TakentogetheristrationoffurosemidetopatientstreatedwithCVVHcould\nwithseveralsmallstudiesshowingthattheprophylacticuse\nbeassociatedwithamorerapiddiscontinuationofthe\nofdiureticstopreventAKIactuallyincreasedAKIincidence,dialysistherapy.vanderVoortetal.,observed,asexpected,\nthesedataraisesigniﬁcantconcernsregardinguseofloopanincreasedurinaryvolumeandsodiumexcretion,butthis\ndiureticstopreventortreatAKIinanysetting.Wesimilarlyinterventiondidnotleadtoashorterdurationofrenalfailure\n48\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.4\n195\normorefrequentrenalrecovery.Thesecondstudyby\nrenaldysfunction,buttheresultsofthesestudiesarenotvery\n196198\nUchinoetal.,analyzeddatafromtheB.E.S.T.kidneyandconvincing.Twosmallrandomizedtrials—oneinpatients\n199\nfoundthat,fromatotalof529criticallyillpatientswhowithpre-existingnormalrenalfunction,thesecondin\n200\nsurvivedduringCRRT,313patientswereremovedsuccess-patientswithestablishedrenaldysfunction—didnotﬁnd\nfullyfromCRRTwhile216patientsneeded‘‘repeatRRT’’differencesforanymeasuredvariableofrenalfunction. aftertemporarydiscontinuation.Urineoutput(duringthe24Moreconvincingaretheresultsobtainedwiththepreventive\nhoursbeforestoppingCRRT)wasidentiﬁedasasigniﬁcantadministrationofmannitol,justbeforeclamprelease,during\n201,202\npredictorofsuccessfulcessation,butthepredictiveabilityofrenaltransplantation.Thesparsecontrolleddata\nurineoutputwasnegativelyaffectedbytheuseofdiuretics.availablehaveshownthat250mlofmannitol20%given\nimmediatelybeforevesselclampremovalreducestheinci-\nThus,abeneﬁcialroleforloopdiureticsinfacilitating\ndiscontinuationofRRTinAKIisnotevident.denceofpost-transplantAKI,asindicatedbyalowerrequire-\nmentofpost-transplantdialysis.However,3monthsafter\nMannitol\ntransplantation,nodifferenceisfoundinkidneyfunction\n203\nMannitolhasbeenfrequentlyusedinthepastforprevention\ncomparedtopatientswhodidnotreceivemannitol. ofAKI;however,mostofthestudiesareretrospective,\nIthasalsobeensuggestedthatmannitolisbeneﬁcialin\nunderpowered,and,overall,thestudiesdidnotmeetthe\nrhabdomyolysisbystimulatingosmoticdiuresisandby\ncriteriaoftheWorkGrouptobeincludedinformulationof\nloweringtheintracompartmentalpressureintheaffected\n204–206\nrecommendations.Prophylacticmannitolhasbeenpromoted\ncrushedlimbs;again,thesestudieswereeithernot\ninpatientsundergoingsurgery.Whileinmostofthese\nrandomizedorunderpowered.Aseparateguidelineoncrush\ninstancesmannitolincreasesurineﬂow,itishighlyprobable\ninjuryassociatedwithdisasters,mainlyearthquakevictims,is\nthatmannitoldoesnotconveyadditionalbeneﬁcialeffects\nunderpreparationbytheISNRenalDisasterReliefTask\nbeyondadequatehydrationontheincidenceofAKI. Force.",
    "page": 50,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.4:TheuseofdiureticsinAKI (Part 4)",
    "content": "Inradiocontrast-inducednephropathy,loopdiuretics\nInsummary,despiteexperimentalanimaldataandthe\nandmannitolinonestudyhavebeenshowntoexacerbate\nanecdotalhumanevidenceforthebeneﬁcialeffectsof\n191197\nARF.Weisbergetal.,randomizedpatientsunder-\nmannitol,therearenoadequatelypoweredprospectiveRCTs\ngoingcontrast-mediuminvestigationstoreceivesalineor\ncomparingmannitolvs.otherstrategies.Basedonthese\noneofthreerenalvasodilator/diureticdrugs(dopamine\nconsiderations,theWorkGroupconcludesthatmannitolis\n[2g/kg/min],mannitol[15g/dlinaone-halfisotonicsaline\nnotscientiﬁcallyjustiﬁedinthepreventionofAKI. solutiongivenat100ml/h]oratrialnatriureticpeptide). Dopamine,mannitol,andatrialnatriureticpeptidewere\nRESEARCHRECOMMENDATION\nassociatedwithamuchhigherincidenceofrenaldysfunctionGiventhepotentialtomitigatefluidoverloadbutalsoto\nindiabeticsubjectscomparedtopatientsreceivingsalinealone.worsenrenalfunctionandpossiblycausekidneyinjury,\nfurtherstudyisrequiredtoclarifythesafetyofloop\nMannitolisoftenaddedtotheprimingﬂuidofthe\ncardiopulmonarybypasssystemtoreducetheincidenceofdiureticsinthemanagementofpatientswithAKI. 49\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.5\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 50,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 1)",
    "content": "DOPAMINEFORTHEPREVENTIONORTREATMENTOFAKI\nanalyzed61randomizedorquasi-randomizedcontrolled\nDopaminewasoncecommonlyusedforrenalprotectionin\ntrialsoflow-dosedopamine,andfoundnoimprovementof\nthecriticallyill.However,withmultiplenegativestudies,\nsurvival(Figure11),nodecreaseindialysisrequirement\nincludingarandomized,double-blind,placebo-controlled\n(Figure12),noimprovementinrenalfunction,and\n207\ntrialofadequatesizeandpower,itsusehasbeen\nimprovedurineoutputonlyontheﬁrstdayofdopamine\n212\nabandonedbymost.Low-dosedopamineadministration\nSimilarly,althoughthereweretrendstowards\ntherapy. (1–3g/kg/min)tohealthyindividualscausesrenalvasodila-\ntransientlygreaterurineoutput,lowerSCr,andhigherGFR\ntion,natriuresis,andincreasedGFR;becauseoftheseeffects,\nindopamine-treatedpatientsonday1oftherapy(butnot\nithasbeengivenasprophylaxisforAKIassociatedwith\ndays2and3),therewasnoevidenceofasustainedbeneﬁcial\nradiocontrastadministration,repairofaorticaneurysms,\neffectonrenalfunction.Inanearliersystematicreview,\n210\northotopiclivertransplantation,unilateralnephrectomy,\nKellumetal.,performedananalysisofstudiesthat\n208\nrenaltransplantation,andchemotherapywithinterferon. reportedincidenceofAKIasanoutcome,whichdevelopedin\nThemajorityofpreventiontrialswithlow-dosedopamine\n15.3%inthedopaminearmsand19.5%inthecontrolarms\nhavebeensmall,inadequatelyrandomized,oflimited\n(RR0.79[0.54–1.13]).Similartotheearlieranalysisby\nstatisticalpower,andwithend-pointsofquestionableclinical\nKellumetal.,restrictionoftheWorkGroup’sanalysisto\nsigniﬁcance.Furthermore,recentdatasuggestthattherenal\npreventiontrialsdidnotdiscloseanybeneﬁtofdopaminevs. vasodilatoryeffectofdopaminefoundinhealthypopulations\nplacebotherapy.Similarly,analysisofadequatetrials\nisnotpreservedinpatientswithAKI.UsingDoppler\nrestrictedtopatientstreatedforAKIdoesnotsuggesta\n209\nultrasound,Lauschkeetal.foundthatdopaminesigni-\nbeneﬁtofdopaminetherapy.Speciﬁcally,arelativelylarge\nﬁcantlyincreasedrenalvascularresistanceinAKIpatients. randomized,placebo-controlledtrialin328criticallyill\n210\nKellumandDeckerfoundnobeneﬁtofdopaminefor\npatientswithearlyAKIsufﬁcientlypoweredtodetectasmall\n207\npreventionortherapyofAKIinanadequately-powered\nTherewasnoeffectoflow-dose\nbeneﬁtwasreported. 211\nmeta-analysis,andMarikfoundnobeneﬁtinasystematic\ndopamineonrenalfunction,needfordialysis,ICUor\nreview. hospitallengthofstay(LOS),ormortality(SupplTable4). Thereisalsolimitedevidencethattheuseofdopamineto\nTakentogether,theseanalysesfoundnoevidencethat\npreventortreatAKIcausesharm.Althoughthemeta-analysis\ndopaminetherapyiseffectiveinthepreventionortreatment\n212\nbyFriedrichetal.,foundnosigniﬁcantincreaseinadverse\nofAKI.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 2)",
    "content": "eventsorevidenceofharmfromlow-dosedopamine,thereis\nsigniﬁcantliteraturedemonstratingadverseeffectsofdopa-\nFENOLDOPAMFORTHEPREVENTIONORTREATMENTOFAKI\nmine,evenatlowdoses.ItcantriggertachyarrhythmiasFenoldopammesylateisapuredopaminetype-1receptor\nandmyocardialischemia,decreaseintestinalbloodﬂow,agonistthathassimilarhemodynamicrenaleffectsas\n208\nab\ncausehypopituitarism,andsuppressT-cellfunction.Takenlow-dosedopamine,withoutsystemic-or-adrenergic\n213\ntogetherwiththelackofpositivetrialstosupporttheuseofstimulation. dopamineforAKIpreventionortherapy,theaforementioned\npotentialdeleteriouseffectsofthisdrugprovideadditional3.5.2:Wesuggestnotusingfenoldopamtopreventor\nargumentsforabandoningitsuseentirelyforthepreventiontreatAKI.(2C)\nandtherapyofAKI. RATIONALE\n3.5.1:Werecommendnotusinglow-dosedopamineto\nTheresultsofanimalexperimentsandsmallhumanstudies\npreventortreatAKI.(1A)\nmeasuringperioperativeGFRinpatientsundergoingcoro-\nnaryarterybypassgraftandaorticcross-clampsurgery\nsuggestedthatfenoldopammightpreventoramelioratethe\nRATIONALE\n212139214\nIntheirmeta-analysis,Friedrichetal.,didnotspeciﬁcallycourseofAKI.Cogliatietal.,conductedadouble-blind,\nseparateprophylactictrialsfromtrialswheredopaminewasrandomizedtrialoffenoldopaminfusionforrenalprotec-\nusedtherapeuticallyinpatientswithestablishedAKI,becausetionin193high-riskcardiacsurgerypatients,whowere\n210\nmanyoftheoriginaltrialsfailedtodoso.Theauthorsrandomizedtoreceiveacontinuousinfusionoffenoldopam,\n50\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.5\nFigure11|Effectoflow-dosedopamineonmortality.ReprintedfromFriedrichJO,AdhikariN,HerridgeMSetal.Meta-analysis:low-dose\ndopamineincreasesurineoutputbutdoesnotpreventrenaldysfunctionordeath.AnnInternMed2005;142:510–524withpermission\n212\nfromAmericanCollegeofPhysicians;accessedhttp://www.annals.org/content/142/7/510.full\n0.1g/kg/min(95patients)orplacebo(98patients)forThefenoldopamgrouphadasigniﬁcantlylowerrateofAKI\n24hours.AKIwasdeﬁnedasapostoperativeSCrlevelof(29vs.51patients,P0.006;ORof0.47,P0.005),and\n¼¼\nXX\n2mg/dl(177mol/l)withanincreaseinSCrlevelofshorterICUstays,withoutanyincreaseincomplications.The\nXX\n0.7mg/dl(61.9mol/l)frompreoperativetomaximumincidenceofsevereAKI,dialysis,anddeathwerenotdifferent\npostoperativevalues.AKIdevelopedin12of95(12.6%)betweenthegroups.Thisstudyrequiresalargerconﬁrmatory\npatientsreceivingfenoldopamandin27of98(27.6%)trial,whichshouldbepoweredtotesteffectivenessin\npatientsreceivingplacebo(P¼0.02),andRRTwasstartedinimprovingdialysis-freesurvival. 0of95and8of98(8.2%)patients,respectively(P0.004).EmergingdatafromexperimentalAKImodelssuggest\nTheseresultssuggestedthata24-hourinfusionofthatfenoldopammayhavemultipleprotectiveeffectsinAKI,\n0.1g/kg/minoffenoldopampreventedAKIinahigh-riskincludinganti-inﬂammatoryeffectsindependentofanyvaso-\n217,218\nFurtherlargestudieswillberequired\npopulationundergoingcardiacsurgery.Ameta-analysisofdilatoryaction.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 3)",
    "content": "1059patientsin13studiesthatincludedthistrialfoundthattodetermineiffenoldopamisaneffectiverenoprotec-\n213,219\nfenoldopamreducestheneedforRRTandin-hospitaldeathtiveagent.Asdiscussedelsewhereinthisguideline\n215\nHowever,thepooled(Section4),despitepromisingpilotstudyﬁndings,fenoldo-\nincardiovascularsurgerypatients. studiesincludedbothprophylacticandearlytherapeuticpamwasultimatelyfoundtobeineffectivefortheprevention\n220\nstudies,aswellaspropensity-adjustedcase-matchedstudiesofCI-AKI,andasapotentantihypertensive(theonly\n(ratherthanpurelyrandomizedtrials).A1000-patientRCTapprovedindicationforthedrug),fenoldapamcarriesa\noffenoldopamtopreventtheneedforRRTaftercardiacsigniﬁcantriskofhypotension. surgeryiscurrentlyunderway(ClinicalTrials.govidentiﬁer:Fenoldopammesylatehasalsobeenstudiedforearly\n221\nconductedarandomized,\nNCT00621790);meanwhile,thisremainsanunproventreatmentofAKI.Tumlinetal.,\nindicationforfenoldopamtherapy.placebo-controlledpilottrialoflow-dosefenoldopam\n216\nFinally,Morellietal.,inaprospective,double-blindmesylateinICUpatientswithearlyAKIandfoundno\ntrial,randomized300septicpatientswithoutrenaldysfunc-beneﬁt,thoughtheydidshowatrendtowardslower21-day\ntiontoreceiveinfusionsoffenoldopam(0.09g/kg/min)mortalityanddecreasedneedfordialysisinfenoldopam-\nandcomparedtheseindividualstoaplacebogroup;thetreatedpatients(11%differenceindialysis-freesurvival). treatmentcontinuedaslongasthepatientwasintheICU.Insecondaryanalyses,fenoldopamtendedtoreducethe\n51\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.5\nFigure12|Effectoflow-dosedopamineonneedforRRT.ReprintedfromFriedrichJO,AdhikariN,HerridgeMSetal.Meta-analysis:\nlow-dosedopamineincreasesurineoutputbutdoesnotpreventrenaldysfunctionordeath.AnnInternMed2005;142:510–524\n212\nwithpermissionfromAmericanCollegeofPhysicians;accessedhttp://www.annals.org/content/142/7/510.full\nprimaryend-pointinpatientswithoutdiabetesandpost-\notherpositivetrendsintheliterature,theseresultsaddtothe\noperativecardiothoracicsurgerypatientswithearlyATN. discoursearoundfenoldopam’susetotreatearlyAKIin\n222223\nBrienzaetal.,conductedaprospective,multicenter,criticallyillpatients.Similarly,Landonietal.,inarecently\nRCToffenoldopamtherapyforearlyAKIincriticallyillpublishedmeta-analysisfoundthatfenoldopamdecreased\npatients.ThestudyincludedhemodynamicallystableadultstheriskofrequiringacuteRRTandresultedinalowerall-\nwithrenaldysfunction.This100-subjectstudycompared4-cause,in-hospitalmortality(15.1%)comparedtocontrols\ndayinfusionsoffenoldopam(0.1g/kg/min)ordopamine(18.9%;OR0.64;95%CI0.4–0.91),alongwithanon-\n(2g/kg/min);therewasnoplaceboarm.Theprimaryend-signiﬁcanttrendtowardsmorehypotensionorpressorusein\npointofthestudywasabetween-groupcomparisonofthethefenoldopamgroup.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 4)",
    "content": "maximumchangeofSCrovertimeduringthe4-daystudyOuranalysisrevealedthreesuitableprophylacticstudiesof\nperiod.ThepeakSCrvaluesandmaximumincrementsadequatesizeandstudydesign(SupplTables5and6)that\nduringthestudydidnotdifferbetweenthefenoldopamandreportedAKIincidenceinpatientsrandomizedtofenoldo-\ndopaminegroups;however,inthefenoldopamgroupatthepam(n¼1790)vs.placebo(n¼1839).ThepooledRRand\nendofinfusion,SCrhaddecreasedby0.290.77mg/dl95%CIwas0.96(0.76–1.2),P¼NS.Onlyonestudyreported\n(25.668.1mol/l),avaluesigniﬁcantlydifferentfromthemortality(8-day)insepsispatientsrandomizedtofenoldo-\n±±\ndopaminegroup(0.090.94mg/dl[7.9683.1mol/l];pam(35%,n150)vs.placebo(44%,n150),withaRRof\n¼¼\nP¼0.05).Also,themaximumdecreasesofSCrlevelsfrom0.79(95%CI0.59–1.05;P¼0.1). studyentryweresigniﬁcantlylargerinthefenoldopamInouranalysisofthetwosuitablestudiesoffenoldopam\n221\ngroup.Therewasnodifferenceinheartrate,bloodpressure,therapyforAKI,onlyonestudyreported(21-day)\nmortalityincriticallyillpatientswithearlyAKIrandomized\nincidenceofhypotension,orurinaryoutput(apartfroma\ntransientlyhighervaluewithintheﬁrststudydayinthetofenoldopam(11/80;13.8%)vs.placebo(n19/75,25.3%;\n222\ndopaminegroup).Theauthorsconcludedthat,forcriticallyP0.068)(SupplTables7and8).Theotherstudy\nreportedthechangeinrenalfunctioninAKIpatients\nillpatientswithimpairedrenalfunction,acontinuous\nrandomizedtofenoldopam(n50)vs.dopamine(n50),\ninfusionoffenoldopam0.1g/kg/minimprovesrenalfunc-¼¼\ntionwhencomparedtorenal-dosedopamine,withoutdeﬁnedbytheabsoluteSCrchangebetweenthebeginning\nandendofthestudydruginfusionandmaximumdecrease\nsigniﬁcantadverseeffects.Thestudyhas,however,anumber\nfromstudyentry,whichweresigniﬁcantlylargerinthe\nofdeﬁciencies,includingthelackofatruecontrol,\nunblindingoftheinvestigators,andanunorthodoxAKIfenoldopamgroupwithapooledRRof0.96(95%CI\n0.76–1.2;PNS).ThesetwostudiesreportednewRRT\ndeﬁnition,amongotherlimitations,buttakentogetherwith¼\n52\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.5\n231\nincidenceinpatientswithAKIrandomizedtofenoldopamillpatientswithAKIwasconducted.Patientsreceived24-\n(n130)vs.placebo(n125).InthestudybyTumlinetal.,houri.v.infusionofeitherANP(0.2g/kg/min)orplacebo.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 5)",
    "content": "¼¼\nnodifferenceinrequirementofRRTwasfound(withTheprimaryoutcomewasdialysis-freesurvivalfor21days\nfenoldopam,13of80patients;16.25%);withplacebo(19ofaftertreatment.Despitethelargesizeofthetrial,ANP\n75patients;25.3%;P0.163).RequirementofRRTwasveryadministrationhadnoeffecton21-daydialysis-freesurvival,\nrareinthestudyofBrienzaetal.,andwasprescribedinamortality,orchangeinplasmacreatinineconcentration.Of\ntotalofonlyﬁvepatients;threeinthedopaminegroupandnote,themeanSCratenrollment(anaritidegroup:4.4mg/dl\nmm\ntwoinfenoldopamgroup(PNS).Overall,nodatafrom[389mol/l];placebogroup:5.0mg/dl[442mol/l])inthis\nadequatelypoweredmulticentertrialswithclinicallysig-studyconﬁrmsthatinterventioninthistrialwasextremely\nniﬁcantend-pointsandadequatesafetyareavailabletolateinthecourseofAKI.Insubgroupanalysis,dialysis-free\nrecommendfenoldopamtoeitherpreventortreatAKI.Thesurvivalwashigherinthetreatmentgroupforpatientswith\nguidelinerecommendationagainstusingfenoldopamplacesaoliguria(400ml/d;ANP27%,placebo7%,P0.008).A\nhighvalueonavoidingpotentialhypotensionandharmsubsequenttrialin222patientswitholiguricrenalfailure,\n232\nassociatedwiththeuseofthisvasodilatorinhigh-riskhowever,failedtodemonstrateanybeneﬁtofANP.The\nperioperativeandICUpatients,andalowvalueonpotentialdoseanddurationofANPtreatmentandprimaryoutcome\nwerethesameasthepreviousstudy.ThedoseofANPmight\nbeneﬁt,whichiscurrentlyonlysuggestedbyrelativelylow-\nhavebeentoohigh(0.2g/kg/min)inbothstudies:\nqualitysingle-centertrials. hypotension(systolicbloodpressure90mmHg)occurred\nmorefrequentlyintheANPgroupsofbothtrials(intheﬁrst\nRESEARCHRECOMMENDATION\nstudy,46%vs.18%,P0.001;andinthesecondstudy,97%\nWhilerandomizedtrialsoffenoldopamtotreatAKIina\nvs.58%,P0.001),andthismayhavenegatedanypotential\nvarietyofsettings(criticalillness,high-risksurgery—\nbeneﬁtofrenalvasodilationinthesepatients.Inadditionto\nparticularcardiac,sepsis)maybeconsidered,the\nanexcessivedose,thefailureoftheselargestudieshasalso\npharmacologicstrategyofrenalvasodilatationhasnot\nbeenattributedinsubsequentanalysestothelateinitiationof\nbeensuccessfultodateanddifferentapproachesarelikely\nthedrugtopatientswithsevereAKIandaninadequate\nneeded. durationofinfusion(only24hours). Apromising,butunderpowered,studyofANPtotreat\nNATRIURETICPEPTIDESFORTHEPREVENTIONOR\nAKIimmediatelyfollowingcardiacsurgeryshoweda\nTREATMENTOFAKI\ndecreasedrateofpostoperativeRRTcomparedtoplacebo-\nSeveralnatriureticpeptidesareinclinicaluseorin\n233\ntreatedpatients.Inthisstudy,Swardetal.randomized61\ndevelopmentfortreatmentofcongestiveheartfailure\npatientswithAKIfollowingcardiacsurgery(deﬁnedasaSCr\n(CHF)orrenaldysfunction,andcouldpotentiallybeuseful\nincrease50%fromabaseline1.8mg/dl[159mol/l])\noo\ntopreventortreatAKI. toreceiveinfusionofANPorplacebountiltheSCrdecreased\nAtrialnatriureticpeptide(ANP)isa28-amino-acidpep-\nbelowthebaselinevalueatenrollment,thepatientdied,or\n224\ntidewithdiuretic,natriuretic,andvasodilatoryactivity.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 6)",
    "content": "oneoffourprespeciﬁeddialysiscriteriawasreached.Ofnote,\nANPismainlyproducedinatrialmyocytes,andtherateof\nallpatientsreceivedinfusionsoffurosemide(20–40mg/h)\nreleasefromtheatriumincreasesinresponsetoatrial\nandoliguria,deﬁnedasaurineoutput0.5ml/kg/hfor3\n225\nstretch.EarlyanimalstudiesshowedthatANPdecreases\nhours,wasanexclusioncriterionandanautomaticdialysis\npreglomerularvascularresistanceandincreasespostglomer-\nindication.Theprimaryend-pointwastherateofdialysis\n226\nularvascularresistance,leadingtoincreasedGFR.Italso\nwithin21daysofenrollment.CrClwassigniﬁcantlyhigher\ninhibitsrenaltubularsodiumreabsorption.IncreasesinGFR\nonthethirdstudydayinANP-treatedsubjects(P¼0.04). 227\nanddiuresishavealsobeenconﬁrmedinclinicalstudies.It\nUsingprespeciﬁeddialysiscriteria,21%ofpatientsinthe\ncouldthusbeexpectedthatANPmightbeusefulfor\nANPgroupand47%intheplacebogroupweredialyzed\ntreatmentofAKI,andseveralRCTshavebeenconductedto\nwithin21days(hazardratio[HR]0.28;95%CI0.10–0.73;\ntestthishypothesis. P0.009).Thecombinedsecondaryend-pointofdeath-or-\ndialysiswassimilarlyimprovedintheANPgroup(28%)\n3.5.3:Wesuggestnotusingatrialnatriureticpeptide\ncomparedtoplacebo(57%;HR0.35;95%CI0.14–0.82;\n(ANP)toprevent(2C)ortreat(2B)AKI. P0.017).Theincidenceofhypotensionduringtheﬁrst24\nhourswas59%intheANPgroupand52%incontrols\n(PNS). RATIONALE\nTherehavebeenseveralnegativestudiesofprophylacticANP\nItisintriguingtospeculateonthepotentialreasonsforthe\ntherapy;forexample,ANPfailedintwostudiestopreventpositiveoutcomeofthistrial,comparedtolargerprior\n228,229\nprimaryrenaltransplantdysfunctionandANPpro-\nstudiesofANPforAKIpreventionandtherapy.Apartfrom\n230\nphylaxisalsofailedtopreventCI-AKI.Basedonthe\nthepossibilitythatthisisafalse-positive,underpowered\npositiveresultsofsmallclinicalstudiesusingANPtotreatstudy,possibleexplanationsincludetheuseofANPearlierin\nAKI,arandomizedplacebo-controlledtrialin504critically\nthecourseofAKI(themeanSCrinthepriorANPstudies\n53\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.5\nwasmuchhigher),andatlowerdoses(50ng/kg/minvs. whereasitwassigniﬁcantlyhigherintheANPgroupinthe\n200ng/kg/min)thatavoidedthesigniﬁcantrateofhypoten-high-doseANPstudies(OR4.13;95%CI1.38–12.41).",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 7)",
    "content": "sionobservedinpriortrials.TheuseofprespeciﬁeddialysisFinally,apooledanalysisofstudiesthatexaminedoliguric\ncriteriawasanotherstrengthofthistrial.Morerecently,\nAKIdidnotshowanysigniﬁcantbeneﬁtfromANPforRRT\n234\nSwardetal.,comparedtherenalhemodynamiceffectsrequirement(OR0.46;95%CI0.19–1.12;P0.09)or\nofANPandfurosemidein19mechanicallyventilatedmortality(OR0.94;95%CI0.62–1.43;P0.79).Onlytwo\npost–cardiacsurgerypatientswithnormalrenalfunction,\nofthetreatmentstudiesincludedintheNigwekaranaly-\n231,232\nmeasuringrenalbloodﬂow,GFR,andrenaloxygensiswereofadequatesizeandqualitytomeetthecriteria\nextraction.ANPinfusion(25–50ng/kg/min)increasedGFR,foroursystematicreview(SupplTables12and13),which\nfoundnosigniﬁcantinconsistenciesintheﬁndingsofboth\nﬁltrationfraction,fractionalexcretionofsodium,andurine\noutput,accompaniedbya9%increaseintubularsodiumtrialsthat(combined)included720subjects(351treated\nabsorptionanda26%increaseinrenaloxygenconsumption.withANP)(SupplTable12).Thus,althoughsubsetanalyses\nFurosemideinfusion(0.5mg/kg/h)increasedurineoutputseparatinglow-dosefromhigh-doseANPtrialssuggest\n10-foldandfractionalexcretionofsodium15-fold,whilepotentialbeneﬁts,thepreponderanceoftheliterature\ndecreasingtubularsodiumabsorptionby28%andloweringsuggestsnobeneﬁtofANPtherapyforAKI.Therefore,the\nrenaloxygenconsumptionby23%.FurosemidealsoloweredWorkGroupsuggeststhattheseagentsnotbeusedtoprevent\nGFRby12%andﬁltrationfractionby7%.Thus,althoughortreatAKI.Thisconclusionisbasedonplacingahighvalue\nthebalanceofrenalhemodynamicandtubulareffectsoftheonavoidingpotentialhypotensionandharmassociatedwith\ntwodrugsappearstofavorfurosemideforimprovingrenaltheuseofavasodilatorinhigh-riskperioperativeandICU\noxygendelivery-consumptionbalance,ANPismorelikelytopatients,andalowvalueonpotentialbeneﬁtwhichis\nacutelyimproveGFR.Onemightspeculatethattheuseofsupportedbyrelativelylow-qualityevidencefromretro-\nfurosemideinfusioninallofthesubjectsinthesuccessfulspectivesubsetanalysesfromnegativemulticentertrials. ANPtrialmayhaveprovidedanimportantprotectionUrodilatinisanothernatriureticpeptidethatisproduced\nagainstrenalischemiabyreducingtubularsodiumabsorp-byrenaltubularcells,andwasfoundtohavethesamerenal\ntionandassociatedoxygenconsumption,despiteanincreasehemodynamiceffectasANPwithoutsystemichypotensive\n236\nLimiteddatasuggestthaturodilatinimprovesthe\ninGFRintheANPgroup.AlargerprospectivetrialofANPeffects. 237\ntoimprovedialysis-freesurvivalinthissettingisrequired,courseofestablishedpostoperativeAKI.Fifty-onepatients\nperhapswithandwithoutfurosemideinfusion.whoreceivedorthotopichearttransplantsreceivedurodilatin\n(6–20ng/kg/min)upto96hourspostoperatively.AKI\nPooledanalysisof11studiesinvolving818participantsin\nthepreventioncohortshowedatrendtowardreductioninoccurredin6%ofthesepatients,comparedto20%ina\n237\nhistoricalcontrolgroupthatdidnotreceiveurodilatin.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 8)",
    "content": "theneedforRRTintheANPgroup(OR0.45;95%CI\nHowever,inanothersmall,placebo-controlledstudyof24\n0.21–0.99;P¼0.05).Restrictingtheanalysistostudiesthat\npatientswhounderwentorthotopichearttransplants,the\nusedlow-doseANPpreparationsdidnotchangetheoverall\n238\neffectforthisoutcome.TherewasnosigniﬁcantdifferenceincidenceofAKIwasunchanged,althoughdurationof\nhemoﬁltration(HF)wassigniﬁcantlyshorterandthe\nnotedbetweentheANPandcontrolgroupsformortalityin\nfrequencyofintermittenthemodialysis(IHD)lessinthose\nthepreventioncategory(OR0.67;95%CI0.19–2.35;\nP0.53),andthiseffectwasunchangedbyrestrictingthewhoreceivedurodilatin.Takentogether,thesedatasuggest\nthatnatriureticpeptidesmayhavearoleinthetherapyof\nanalysistostudiesthatusedlow-doseANPpreparations. earlyAKIfollowingcardiacsurgery,butfurtherprospective\nHowever,thesestudiesweregenerallyofpoorquality,several\nwithoutreportedbaselineSCrvaluesorcleardeﬁnitionsoftrialsareneededtoconﬁrmthispotentialindication. AKIorRRTindications(SupplTables10and11),andonlyNesiritide(brainnatriureticpeptide)isthelatestnatriuretic\npeptideintroducedforclinicaluse,andisapprovedbythe\nonewasofadequatequality.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 9)",
    "content": "FoodandDrugAdministration(FDA)onlyforthetherapy\nNigwekaretal.,recentlyconductedasystematicreview\n235\nThey\nandmeta-analysisofANPformanagementofAKI.ofacute,decompensatedCHF.Meta-analysisofoutcome\nfound19relevantstudies,amongwhich11studieswerefordatafromtheseandsomeothernesiritideCHFtrials\n239–241\npreventionandeightwerefortreatmentofAKI.Pooledhasgeneratedsomecontroversy.Sackner-Bernstein\n239\nanalysisoftheeighttreatmentstudies,involving1043etal.,analyzedmortalitydatafrom12randomizedtrials;\nparticipants,didnotshowsigniﬁcantdifferenceforRRTinthreetrialsthatprovided30-daymortalitydata,they\nrequirementbetweentheANPandcontrolgroups(OR0.59;foundatrendtowardsanincreasedriskofdeathinnesiritide-\n95%CI0.32–1.08;P¼0.12).Therewasalsonosigniﬁcanttreatedsubjects.Inanothermeta-analysisofﬁverandomized\n240\ndifferenceformortality(OR1.01;95%CI0.72–1.43;trialsthatincluded1269subjects,thesameinvesti-\nP0.89).However,low-doseANPpreparationsweregatorsalsofoundthattherewasarelationshipbetween\nnesiritideuseandworseningrenalfunction,deﬁnedas\nassociatedwithsigniﬁcantreductioninRRTrequirement\n44m\n(OR0.34;95%CI0.12–0.96;P0.04).TheincidenceofaSCrincrease0.5mg/dl(44.2mol/l).Nesiritidedoses\nhypotensionwasnotdifferentbetweentheANPandcontrol0.03g/kg/minsigniﬁcantlyincreasedtheriskofrenal\ndysfunctioncomparedtonon–inotrope-basedcontrolsor\ngroupsforlow-dosestudies(OR1.55;95%CI0.84–2.87),\n54\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.5\ncomparedtoallcontrolgroups(includinginotropes).Even\nTable9).Thesetrendsweremorepronouncedinthesmall,\nm4\natdoses0.015g/kg/min,nesiritidewasassociatedwith62-patientsubsetwithpreoperativeSCrvalues1.2mg/dl\n4m\nincreasedrenaldysfunctioncomparedtocontrols.Therewas(106mol/l).AlthoughSCrincreasedpostoperativelyin\nnodifferenceindialysisratesbetweenthegroups.Anotherbothgroups,itreturnedtobaselinewithin12hoursinthe\nretrospectivestudydeterminedindependentriskfactorsfornesiritidegroup,andremainedelevatedthroughouthospi-\n60-daymortalitybymultivariateanalysisinacohortof682talizationintheplacebogroup.Useofvasoactivedrugsand\nelderlyheart-failurepatientstreatedwithnesiritidevs.thosehemodynamicparametersdidnotdiffersigniﬁcantlybetween\n242\nwhowerenot.Whenpatientswerestratiﬁedaccordingtothegroups.Adverseeventsalsoweresimilarbetweenthe\nnesiritideusage,AKIemergedasanindependentriskfactorgroups,aswas30-dayand180-daymortality(although\nformortalityonlyamongpatientswhoreceivedthedrug. captureofmortalitydatawasincomplete).Thus,itappears\nStrikingly,amongtheseheart-failurepatientswhodevelopedthatadministrationofnesiritideinfusionduringandafter\nAKI,nesiritideusageemergedastheonlyindependentcardiacsurgerywithcardiopulmonarybypassinpatients\npredictorofmortality.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 10)",
    "content": "withpreoperativeleftventriculardysfunctionhasfavorable\nThemanufacturersofnesiritideconvenedanexpertpanel,short-termeffectsonrenalfunction,withshort-termadverse\nwhichconcludedthatfurthertrialdataareneededtodiscerneffectscomparabletoplaceboinfusion;however,asmen-\ntheeffectsofnesiritidetherapyonrenalfunctionandsurvival\ntionedearlier,thisisnotanFDA-approvedindicationforthis\ninpatientswithdecompensatedCHF.Thepanelalsore-\ndrug.Itisinterestingtospeculatethat,baseduponthese\nemphasizedthattheindicationfornesiritidetherapyisacuteresults,anyrenoprotectiveeffectofthisvasoactivedrug\ndecompensatedCHF,notchronicintermittenttherapyorduringandaftercardiopulmonarybypassisnotmediatedby\notheruses,andinparticularnotedthatthedrugshouldnot\neffectsonsystemicperfusion(similarinbothgroups),but\nbeusedtoimproverenalfunctionorinplaceofdiureticrathersuggestinganeffectonregionalperfusionora\ntherapyinCHFpatients,asthereisnoproofoftheutilityofpleiotropicphenomenon.Unfortunately,thesepromising\nthedrugforthesepurposes.A7000-patientmulticenterRCT\npilotstudyﬁndingshavenotbeenfollowedupwitha\ninacutedecompensatedheartfailureiscurrentlyinprogressconﬁrmatoryprospectiveclinicaltrial. todeterminetheclinicaleffectivenessofnesiritidetherapyforAprospective,randomizedclinicaltrial(theNesiritide\nacutedecompensatedheartfailure(theAcuteStudyofStudy),foundnobeneﬁtofnesiritidefor21-daydialysisand/\nClinicalEffectivenessofNesiritideinDecompensatedHeart\nordeathinpatientsundergoinghigh-riskcardiovascular\n244\nHowever,thestudydiddemonstratethatthe\nFailure;Clinicaltrials.govidentiﬁerNCT00475852).Mean-surgery. prophylacticuseofnesiritidewasassociatedwithreduced\nwhile,nesiritideisapprovedfortreatmentofsymptomatic\nacutedecompensatedheartfailure.incidenceofAKI,thelatterdeﬁnedbytheAKINGroup,in\ntheimmediatepostoperativeperiod(nesiritide6.6%vs. Uncontrolledstudiesusingnesiritideforcardiovascular\n245\nplacebo28.5%,P0.004).Recently,Lingegowdaetal.",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "fenoldopam,andnatriureticpeptides (Part 11)",
    "content": "supportofpatientswithCHFundergoingcardiacsurgery¼\ninvestigatedwhethertheobservedrenalbeneﬁtsofnesiritide\nhavesuggestedbeneﬁcialeffectsonrenalfunction.Mentzer\n243\netal.,conducteda303-patient,multicenter,randomized,hadanylong-termimpactoncumulativepatientsurvivaland\ndouble-blindtrialofa24-to96-hourinfusionof0.01g/kg/renaloutcomes.Dataonall94patientsfromtheNesiritide\nminofnesiritidevs.placeboinpatientswithchronicleftStudywereobtainedwithameanfollow-upperiodof20.8\nventriculardysfunction(ejectionfraction40%)under-10.4months.Nodifferencesincumulativesurvivalbetween\ngoingcardiacsurgeryusingcardiopulmonarybypass.Thethegroupswerenoted,butpatientswithin-hospital\nNesiritideAdministeredPeri-AnesthesiainPatientsUnder-incidenceofAKIhadahigherrateofmortalitythanthose\ngoingCardiacSurgerytrialwasanexploratory,safety-withnoAKI(41.4%vs.10.7%;P¼0.002).Itseemed,thus,\norientedstudywithﬁveprimaryend-points,includingthreethatthepossiblerenoprotectionprovidedbynesiritideinthe\nrenalend-pointsandtwohemodynamicend-points.Thereimmediatepostoperativeperiodwasnotassociatedwith\nwerenosigniﬁcantdifferencesbetweenthegroupsinbase-improvedlong-termsurvivalinpatientsundergoinghigh-\nlinepatientcharacteristics;SCrvalueswere1.1mg/dlriskcardiovascularsurgery. (97.2mol/l),witheGFR80ml/minper1.73m.TheInsummary,althoughevidencefromavarietyofsmall\nmeandurationofstudydruginfusionwas40hoursinstudiessuggeststhepotentialfortherapywithnatriuretic\nbothgroups.Perioperativerenalfunctionquantiﬁedbythe\npeptidestobeusefulforthepreventionortreatmentofAKI\nthreerenalprimaryend-pointswasbetterinthenesiritideinavarietyofsettings,therearenodeﬁnitivetrialstosupport\ngroup(peakSCrincreaseof0.15mg/dl[13.3mol/l]vs.theuseofANP,BNP,ornesiritideforthesepurposes.Thus,\nplacebogroup0.34mg/dl[30.1mol/l];P0.001;eGFRtheWorkGroupsuggeststhattheseagentsnotbeusedfor\ndecreaseof10.2ml/minper1.73mvs.placebo17.8ml/\n(cid:3)(cid:3)preventionortreatmentofAKI. minper1.73m,P0.001;initial24-hoururinaryoutput\n±±\nRESEARCHRECOMMENDATION\n2.91.2lvs.placebo2.31l;P0.001).TheRRofAKIin\nWerecommendfurthertrialsofANPatdosesbelow\nthenesiritidegroupcomparedtoplacebowas0.58\n0.1g/kg/min,forthepreventionortreatmentofAKI. (0.27–1.21);the180-daymortalitywasalsoreducedinthe\nThereisapossibilitythatANPmightbeeffectiveifitis\nnesiritidegroup(RR0.48[0.22–1.05];P0.046)(Suppl\n55\nKidneyInternationalSupplements(2012)2,37–68",
    "page": 53,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter3.5",
    "content": "SupplementaryTable8:SummarytableofRCTsofexaminingthe",
    "page": 59,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "prophylacticallyorwithearlyAKI,andduringalonger",
    "content": "SupplementaryTable9:SummarytableofRCTsofnesiritidevs.control",
    "page": 59,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "periodthaninpreviouslargestudies.",
    "content": "forthepreventionofAKI.\nSupplementaryTable10:EvidenceprofileofRCTsexamininganaritide\nSUPPLEMENTARYMATERIAL\nvs.controlforthepreventionofAKI.\nSupplementaryTable4:SummarytableofRCTsexaminingtheeffect\nSupplementaryTable11:SummarytableofRCTsexaminingtheeffect\nofdopaminevs.placeboforthetreatmentofAKI.\nofanaritidevs.controlforthepreventionofAKI.\nSupplementaryTable5:EvidenceprofileofRCTsexaminingfenoldo-\nSupplementaryTable12:EvidenceprofileofRCTsexamininganaritide\npamvs.controlforthepreventionofAKI.\nvs.placeboforthetreatmentofAKI.\nSupplementaryTable6:SummarytableofRCTsexaminingtheeffect\nSupplementaryTable13:SummarytableofRCTsexaminingtheeffect\noffenoldopamforthepreventionofAKI.\nofANPvs.placeboforthetreatmentofAKI.\nSupplementaryTable7:EvidenceprofileofRCTsoffenoldopamvs.\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nplaceboforthetreatmentofAKI.\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n56\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.6\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 59,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.6:Growthfactorintervention (Part 1)",
    "content": "RecoveryfromAKIinvolvesincreasedexpressionofvariousleastequivocal,andconsideringthatthereisnobeneﬁtand\ngrowthfactorsactingviaautocrine,paracrine,andendocrinetheconcernoverpotentialharmandcostassociatedwiththis\nmechanisms.Theadventofrecombinantgrowthfactorshas\ndrug,theWorkGrouprecommendsagainstitsuseinpatients\nstimulatedresearchexploringtheirtherapeuticpotentialwithAKI. inAKI.Experimentalstudieshaveyieldedpromisingresults\n246\nErythropoietin\nwithindividualgrowthfactorsincludinginsulin-like\nAsmallpilottrialevaluatedtheeffectivenessoferythro-\ngrowthfactor-1(IGF-1),hepaticgrowthfactor,and,more\npoietininthepreventionofAKIafterelectivecoronary\nrecently,erythropoietin.Thephysiologicalbasisfortheuseof\n255\narterybypassgraft.Patientsreceivedeither300U/kgof\nerythropoietininthepreventionofAKIhasrecentlybeen\n247\nerythropoietinorsalinei.v.beforesurgery.AKIwasdeﬁned\ndescribed. asa50%increaseinSCrlevelsoverbaselinewithinthe\nﬁrstﬁvepostoperativedays.Of71patients,13developed\n3.6.1:Werecommendnotusingrecombinanthuman\npostoperativeAKI:threeofthe36patientsintheerythro-\n(rh)IGF-1topreventortreatAKI.(1B)\npoietingroup(8%)and10ofthe35patientsintheplacebo\ngroup(29%;P0.035).TheincreaseinpostoperativeSCr\nconcentrationandthedeclineinpostoperativeeGFRwere\nRATIONALE\nIGF-1isapeptidewithrenalvasodilatory,mitogenicandsigniﬁcantlylowerintheerythropoietingroupthaninthe\nanabolicproperties.rhIGF-1hasbeendemonstratedto\nplacebogroup.",
    "page": 60,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.6:Growthfactorintervention (Part 2)",
    "content": "256\nacceleratetherecoveryofrenalfunctioninseveralanimalMorerecently,Endreetal.,performedapros-\n248–251\nmodelsofAKI.Threedouble-blind,placebo-controlledpectiverandomizedtrialwitherythropoietinintheprimary\nRCTshaveaddressedtheusefulnessofIGF-1inadultspreventionofAKIinICUpatientsatriskforAKI(Suppl\n252–254252\nwithimminentorestablishedAKI.Franklinetal.,Table14).Asaguideforchoosingthepatientsfortreatment\nadministeredrhIGF-1every12hoursfor3dayspost-\ntheurinarylevelsoftwobiomarkers,theproximaltubular\noperativelyto54patientsundergoingabdominalaorticbrushborderenzymesc-glutamyltranspeptidaseandalkaline\nsurgery.WhilenopatientdevelopedARF,asmallerpropor-phosphataseweremeasured.Randomizationtoeither\ntionofIGF-1–treatedpatientsshowedadeclineinGFRasplaceboortwodosesoferythropoietinwastriggeredbyan\ncomparedtotheplacebogroup(22%vs.33%).Hladunewich\nincreaseinthebiomarkerconcentrationproducttolevels\n254\netal.,administeredrhIGF-1orplaceboin43patientsabove46.3.Theprimaryoutcomewastherelativeaverage\nundergoingcadavericrenaltransplantationathighriskofSCrincreasefrombaselineover4–7days.Thetriggering\ndelayedgraftfunction.Treatmentwasstartedwithin5hoursbiomarkerconcentrationproductselectedpatientswith\noftransplantationandcontinuedfor6days.Onday7,moresevereillnessandatgreaterriskofAKI,dialysis,\nneitherinulinclearance,norurineﬂoworfractionalsodiumordeath;however,theurinarymarkerelevationswere\nexcretiondifferedbetweenthetreatmentarms,nordidtransient.Theuseofthebiomarkersallowedrandomization\nthenadirSCrafter6weeksortheproportionofpatientswithinanaverageof3.5hoursofapositivesample.There\n253\nrequirepost-transplantationdialysis.Hirschbergetal.,wasnodifferenceintheincidenceoferythropoietin-speciﬁc\ntreated72patientssufferingfromAKImainlyduetosepsisor\nadverseevents;however,therewasalsonodifference\nhemodynamicshockwitheitherrhIGF-1orplaceboforaintheprimaryoutcomebetweentheplaceboandtreatment\nmeanof10.6days.Nodifferenceswereobservedwithrespectgroups. tochangesinGFR,urineoutput,needforRRT,and\nmortality.Hence,despiteitstherapeuticefﬁcacyinvarious\nRESEARCHRECOMMENDATION\nanimalmodelsofARF,rhIGF-1largelyfailedtopreventRecentanimalstudiessuggestapotentialclinicalbenefit\noracceleraterecoveryfromestablishedAKIinhumans.oferythropoietininAKI.Invariousrodentmodelsof\nInaddition,thehighcostofthistreatmentshouldbeAKI,erythropoietinconsistentlyimprovedfunctional\nmentioned.recovery.Therenoprotectiveactionoferythropoietin\nmayberelatedtopleomorphicpropertiesincluding\nBasedonananalysisofthethreeRCTswithrhIGF-1that\narecurrentlyavailableandwhichwereoverallnegativeoratantiapoptoticandantioxidativeeffects,stimulationofcell\n57\nKidneyInternationalSupplements(2012)2,37–68",
    "page": 60,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "proliferation,andstem-cellmobilization.Although",
    "content": "SupplementaryTable14:SummarytableofRCTsexaminingtheeffect",
    "page": 61,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "negative,theusefulnessoferythropoietininhumanAKI",
    "content": "Supplementarymaterialislinkedtotheonlineversionofthepaperat",
    "page": 61,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "shouldbefurthertestedinRCTs.",
    "content": "http://www.kdigo.org/clinical_practice_guidelines/AKI.php\n58\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.7\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 61,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.7:Adenosinereceptorantagonists (Part 1)",
    "content": "Theactivationoftubuloglomerularfeedbackinresponseto\nislessevidentinviewofthecompletelong-termrecoveryof\nelevatedluminalchlorideconcentrationsinthedistalrenalrenalfunctionintheplacebo-treatedcontrolsandtheabsence\ntubulesisanearlyeventinischemicAKI.Adenosinereleasedofaneffectonpatientsurvival. aspartofthetubuloglomerularfeedbackloopbindsto\nInrecentyears,theadventofselectiveadenosineA1\nglomerularadenosineA1receptor,causingvasoconstrictionreceptorantagonistshaspromptedtheconductofsome\noftheafferentarteriole,decreasedrenalbloodﬂowandGFR,interestingclinicaltrials,whichtodatehavefocusedonthe\nandsodiumandwaterretention.Thiswell-knownroleofpreventionandtreatmentofcardiorenalsyndrome.Ina\nadenosineinthisphenomenonhasstimulatedabodyof\ndouble-blindplacebo-controlledtrialof63patientswith\nresearchseekingtopreventortreatAKIwithadenosineCHF,singledosesoftheadenosineA1antagonistBG9719\nreceptorantagonists,primarilyinthreeclinicalsyndromeshadamarkedstimulatoryeffectondiuresisandincreased\n263\nwithincreasedriskofAKI:perinatalasphyxia,radiocontrastGFR.Whencoadministeredwithfurosemide,BG9719\nexposure,andcardiorenalsyndrome.Theophyllineisashowedasynergisticdiureticeffectandpreventedthe\ndecreaseinGFRassociatedwiththeloopdiuretic. nonselectiveadenosinereceptorantagonist. Rolofylline,anotheradenosineA1receptorantagonist,\n3.7.1:Wesuggestthatasingledoseoftheophyllinemaywastestedintwodouble-blindplacebo-controlledRCTsin\nbegiveninneonateswithsevereperinatalasphyxia,patientswithacutedecompensatedheartfailure.Intheﬁrst\nstudy,rolofyllineorplacebowasadministeredeither\nwhoareathighriskofAKI.(2B)\nconcomitantlywithfurosemidefor3days(146patients),or\n264\nInboth\nasasingleinfusionin35diureticresistantpatients. RATIONALE\nsubstudies,rolofyllineimprovedurineoutputandCrCl\nAKIoccursin60%ofneonatessufferingfromperinatal\ncomparedtoplacebo.Thesecondtrialinvolved301patients\n257\nasphyxia.Experimentalstudiesindicatedanimportantrole\nhospitalizedforacuteheartfailurewithrenalimpairment\nofadenosine-mediatedvasoconstrictioninneonatalkidneys\nwhoreceivedeitherplacebooroneofthreedosesof\n258\n265\nexposedtonormocapnichypoxemia.Apotentialrenoprotec-\nrolofyllinefor3days.Rolofyllineadministrationdose-\ntiveeffectoftheophyllineinperinatalasphyxiahasbeenassessed\ndependentlyattenuatedtheriseinSCrobservedinthe\n259–261\ninthreerandomized,placebo-controlledclinicaltrials,\nplacebogroupwithin14days,andtendedtoreduce60-day\nincludingatotalof171termneonates.Theophyllinewas\nmortalityorreadmissionforcardiovascularorrenalcauses. uniformlyadministeredintheﬁrsthouroflifeasasinglei.v.",
    "page": 62,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter3.7:Adenosinereceptorantagonists (Part 2)",
    "content": "ThreepivotalphaseIIItrialsinatotalof2500patients\n259,261260\nbolusatadoseof5mg/kgor8mg/kg.Thethreestudies\nwererecentlycompleted,aimingtocorroboratethereno-\nallobservedsigniﬁcantlyhigherGFR,higherurineoutputwith\nprotectiveeffectsofrolofyllineinpatientswithcardiorenal\nmorenegativeﬂuidbalance,andlowerurinary2-microglobu-\nsyndrome,andtoestablishdrugsafety.Theﬁnalresultsofthe\n266\nlinexcretion,withtheophyllineascomparedtoplaceboduring\nRolofylline,\nPROTECTtrialhaverecentlybeenpublished. theﬁrst3–5daysoflife.Ineachstudy,theophyllinetreatment\nascomparedtoplacebo,didnotprovideabeneﬁtwith\nwasassociatedwithasigniﬁcantlyreducedriskofsevererenal\nrespecttothethreeprimaryend-points:survival,heart-\ndysfunction(17–25%vs.55–60%inplacebogroup,RR\nfailurestatus,andchangesinrenalfunction.Persistentrenal\n0.3–0.41).Thebeneﬁcialeffectwasselectiveforkidneyfunction,\nimpairmentdevelopedin15.0%ofpatientsintherolofylline\nwhereastheincidenceofcentralnervoussystem,cardiac,\ngroupandin13.7%ofpatientsintheplacebogroup\npulmonary,andgastrointestinalcomplicationswasunaltered. (P0.44).By60days,deathorreadmissionforcardiovas-\nPatientsurvivalwasnotaffectedbytreatment.Inlinewiththese\ncularorrenalcauseshadoccurredinsimilarproportionsof\nstudiesinmatureneonates,asimilarimprovementofGFRand\npatientsassignedtorolofyllineandplacebo(30.7%and\nurineoutputwasobservedduringtheﬁrst2daysoflifeby\n31.9%,respectively;P¼0.86).Adverse-eventrateswere\nadministrationof1mg/kgtheophyllinevs.placeboin50very\nsimilaroverall;however,onlypatientsintherolofylline\n262\npretermneonateswithrespiratorydistresssyndrome.The\ngrouphadseizures,aknownpotentialadverseeffectof\nfurtherevolutionofrenalfunctionwasfollowedthroughoutthe\nA1-receptorantagonists.Thus,rolofyllinedoesnotappearto\n260\nﬁrstyearoflifebyBhatetal.,whofoundequallynormal\nbeeffectivefortreatmentofcardiorenalAKI. glomerularandtubularfunctioninbothgroupsfrom6weeksof\nageonward.Hence,whiletheophyllineclearlyimprovesrenal\nRESEARCHRECOMMENDATION\nfunctionintheﬁrstweekoflifeinpostasphycticneonates,theItappearsthatiftherearebenefitsofusingadeno-\noverallbeneﬁtfromthisinterventioninneonatalintensivecaresinereceptorantagoniststodecreasetubuloglomerular\n59\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.7\nfeedback-mediatedvasoconstrictionandincreaserenaldistalsaltdeliverymightharmfullyincreasetubular\nbloodflowandGFRinAKI,theymaybelimitedtoveryoxygenconsumptioninthepresenceofATN),and\nspecificpopulations(e.g.,asphycticneonates).Thesenonrenal(lowerseizurethreshold).Thus,furtherstudies\nbenefitsmustbebalancedagainstpotentialadversearestillneededtoclarifytherolefortheophyllinein\ndrugeffects:bothrenal(increasedrenalbloodflowandneonates. 60\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.8\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 62,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 1)",
    "content": "271–276,278\nAMINOGLYCOSIDENEPHROTOXICITY\npopulationstudied)thattheyshouldnolongerbe\nAminoglycosideantimicrobialagentsarehighlypotent,\nusedforstandardempiricalordirectedtreatment,unlessno\nbactericidalantibioticseffectiveagainstmultipleGram-\nothersuitablealternativesexist.TheintrinsicriskofAKIwith\nnegative,andselectedGram-positivebacterialpathogens\ntheadministrationofaminoglycosideshasledsomeauthors\nwhenadministeredwithbeta-lactamsandothercell-wall\ntorecommendtheeliminationofaminoglycosidesasa\n267–269\n277\nactiveantimicrobialagents.Progressiveantimicrobial\nCertainlytheiruseshouldbe\nclinicaltreatmentoption. resistancetootherantimicrobialagentsandlackofnew\nrestrictedtotreatsevereinfectionswhereaminoglycosidesare\nalternativestoaminoglycosideantibioticshavecauseda\nthebest,oronly,therapeuticoption. recentincreaseintheiruse.Aminoglycosideshavemany\nAminoglycosidesshouldbeusedforasshortaperiodof\nfavorableattributes,includingtheirremarkablestability,\ntimeaspossible.Repeatedadministrationofaminoglycosides\npredictablepharmacokinetics,lowincidenceofimmuno-\noverseveraldaysorweekscanresultinaccumulationof\nlogicallymediatedside-effects,andlackofhematologicor\naminoglycosideswithintherenalinterstitiumandwithin\n279\nhepatictoxicity.Nephrotoxicity,andtoalesserdegree\nthetubularepithelialcells.Thiscanresultinahigher\nototoxicityandneuromuscularblockade,continuetobe\nincidenceofnephrotoxicitywithrepeatedexposureto\nthemajordose-limitingtoxicitiesoftheaminoglycosides. aminoglycosidesovertime.Olderpatients(65years),\nCarefuldosingandtherapeuticdrugmonitoringofamino-\npatientswithpre-existingrenaldysfunction,andseptic\nglycosidesusingpharmacokineticandpharmacodynamic\npatientswithintravascularvolumedepletionandrapid\nprinciplescanmitigatetheriskofAKIwiththeseclinically\nalterationsinﬂuiddynamicsmaybeatgreaterriskfor\n270\nuseful,yetnephrotoxicantibiotics.Anumberofmeta-\naminoglycosidenephrotoxicity.Otherriskfactorsforami-\nanalysesandtreatmentguidelineshavebeenpublished\nnoglycoside-inducedAKIarediabetesmellitus,concomitant\nrecentlyindicatingthattheriskofAKIattributableto\nuseofothernephrotoxicdrugs,prolongeduse,excessive\naminoglycosidesissufﬁcientlyfrequentthattheyshouldno\nbloodlevels,orrepeatedexposuretoseparatecoursesof\n267–279\nlongerbeaddedtootherstandardantimicrobialagentsfor\naminoglycosidetherapyoverashorttimeinterval. theempiricalordirectedtreatmentofanumberofsevere\n271–276\nGram-positiveorGram-negativebacterialinfections.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 2)",
    "content": "3.8.2:Wesuggestthat,inpatientswithnormalkidney\nTheintrinsicriskofAKIwiththeadministrationof\nfunctioninsteadystate,aminoglycosidesare\naminoglycosideshasledsomeauthorstocallforelimination\nadministeredasasingledosedailyratherthan\nofaminoglycosidesasatherapeuticoptionincurrentclinical\nmultiple-dosedailytreatmentregimens.(2B)\n277\nmanagementofinfectiousdiseases.Theanticipateddemise\nofaminoglycosidesfromourtherapeuticarmamentarium\nRATIONALE\nhasnotoccurred,however,inlightofrecentdevelopments\nAminoglycosidedemonstratesconcentration-dependentbac-\nwithprogressiveantimicrobialresistancetobeta-lactams,\ntericidalactivity,withaprolonged‘‘postantibioticeffect’’,\nquinolones,andanumberofotherclassesofantimicrobial\ntherebypermittingextendedintervaldosinginaneffortto\nagents. optimizeefﬁcacyandminimizetoxicity.Thisdosingstrategy\nandanumberofothermeasurestolimitaminoglycoside\n3.8.1:Wesuggestnotusingaminoglycosidesforthetreat-\nuptakeinrenaltubularcells,preventapoptosis,limitoxygen\nmentofinfectionsunlessnosuitable,lessnephro-\ninjury,andprotectmitochondrialfunctionhaveallbeen\ntoxic,therapeuticalternativesareavailable.(2A)\nrecommendedtominimizetheriskofAKIandpreserve\nthetherapeuticvalueoftheseimportantantimicrobial\n280–296\nagents.Single-dosedailyorextended-intervaldosing\nRATIONALE\nAminoglycosidesexhibitanumberoffavorablepharmaco-ofaminoglycosidesofferanumberoftheoreticaland\nkineticandpharmacodynamicadvantages,butamajordose-practicaladvantagestomaintainantimicrobialactivitywhile\nlimitingtoxicityoftheaminoglycosidesremainstherisklimitingpossiblenephrotoxicity.Thisconvenientand\n270\nofdrug-inducedAKI.TheriskofAKIattributabletoinexpensiveaminoglycosidedosingstrategyhasbeenwidely\naminoglycosidesissufﬁcientlyhigh(upto25%insomeadoptedatmanycenterswhenusingthispotentiallytoxic,yet\nseries,dependinguponthedeﬁnitionofAKIusedandthehighlyeffective,classofantibiotics. 61\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.8\nWhenfeasibleinpatientswithnormalandstablekidneyTheuseofsingle-dailydosingofaminoglycosidesis\nfunction,once-daily(oftenreferredtoasextended-interval)generallywell-toleratedbutbolusinfusionsofaminoglyco-\ndosingofaminoglycosidesshouldbeusedtolimitamino-sidesshouldbeavoided.Thehigh-dose,once-dailyamino-\nglycosidenephrotoxicity.Thepharmacokineticandpharma-glycosideregimensshouldbeadministeredover60minutes\ncodynamicpropertiesofaminoglycosidesfavorhighdosingtoavoiduntowardeventssuchasneuromuscularblockade. strategieswithextendedintervalsbetweendoses.ThekeyThisrecommendationisparticularlyimportantwhen\ntherapeuticparameterforefﬁcacyispeakbloodleveldividedpatientsarereceivingotherpotentialneuromuscularblock-\nbyminimuminhibitoryconcentration(MIC)oftheinfectingingagents,orhaveunderlyingdisordersaffectingneuro-\norganism(C/MIC)inanefforttoobtain10-foldmusculartransmission(e.g.,myastheniagravis).",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 3)",
    "content": "max\nC/MIC.Aminoglycosidesinduceaprolongedpostanti-\nmax\nbioticeffect(inhibitionofbacterialgrowthafterbloodlevels3.8.3:Werecommendmonitoringaminoglycosidedrug\nhavefallenbelowtheMICoftheorganism).Thelengthofthelevelswhentreatmentwithmultipledailydosingis\npostantibioticeffectisdirectlyrelatedtothepeakblood\nusedformorethan24hours.(1A)\nlevels.Thesepharmacokinetic/pharmacodynamicparameters\nRATIONALE\nmakesingle-dosedailystrategiesanattractiveoptionwhen\nTherapeuticdrugmonitoringhasbeenthestandardofcare\nusingaminoglycosides. whenadministeringaminoglycosidesformanyyears.Amino-\nThenephrotoxicityofaminoglycosideshasbeenverywell\n280–282,284–293,295,296\nglycosidelevelsarevariableamongindividuals,andsubtle\nstudiedandisprimarilyrelatedtouptake\nchangesinthevolumedistribution,renalbloodﬂow,and\nofaminoglycosidesthroughareceptorknownasmegalin,\nﬁltrationratecanaffectrenalhandlingofaminoglycosides\nexpressedonepithelialcellsalongtheproximalconvoluted\n293\nandaltertheriskofnephrotoxicity.Forthesereasons,\ntubule.Aminoglycosidesareconcentratedintheproximal\ntherapeuticdrugmonitoring,incombinationwithor\nconvolutedtubules,wheretheybindavidlytopolyanionic,\nindependentfrom,single-dosedailytreatmentregimensis\nphospholipid-containingmembranes.Aminoglycosidesin-\n318–321\nWhenusingtherapeuticdrugmonitor-\nrecommended. ducemyeloidbodyformation,impairproteinsynthesis,\ninginsingle-doseorextended-dosetreatmentstrategies,the\ndegrademitochondrialfunction,andculminateinapoptosis\nCshouldbeatleast10-foldgreaterthantheMICofthe\nandeventualnecrosisofrenaltubularepithelialcells.Direct\nmax\n288\ninfectingmicroorganism.ThisC(troughlevel)shouldbe\nglomerularinjurycanoccurbutisusuallyasecondary\nmin\nundetectableby18–24hourstolimitaccumulationof\nconsequenceofaminoglycoside-inducedtubularimpairment. aminoglycosidesinrenaltubularcellsandtominimizethe\nAsthereceptoruptakeofaminoglycosidesissaturable,high-\nriskofAKI.Theusualdosingstrategyforonce-daily\nlevelintermittentdosesofaminoglycosidesactuallyreduced\naminoglycosidesis5mg/kg/dforgentamicinandtobramycin\nthedailyuptakeandaccumulationofaminoglycosideswhen\n(withnormalrenalfunction);6mg/kg/dfornetilmicin;and\ncomparedtomultiple-dailydosingstrategies.Thisshould\n15mg/kg/dforamikacin.Themultiple-dosedailyregimen\nlimittheriskofnephrotoxicity,atleastinprinciple.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 4)",
    "content": "forgentamicinandtobramycinisusually1.7mg/kgevery\nThepotentialefﬁcacyofsingle-dosedailyregimens(or\n±±\nmm\n8hourswithpeakbloodlevelsat82g/ml(174mol/l)\notherextendeddosingtreatmentprograms)ofaminoglyco-\nmm\nandtroughof1–2g/ml(2–4mol/l).Amikacinlevelswith\nsidesvs.multiple-dailydosingstrategieshasbeenextensively\nthemultiple-dosedailydosingstrategyshouldbeapeak\nstudiedinnumerouscontrolledanduncontrolledclinical\n±±\n297–308\nmmm\nof205g/ml(349mol/l)andatroughof5–8g/ml\nstudiesovermanyyears,andthesubjecthasbeenthe\n309–314\n(9–14mol/l).Werecommendtherapeuticdrugmonitoring\nfocusofanumberofformalmeta-analyses.These\nwhenusingprolongedcoursesofaminoglycosidestolimit\ninvestigationsincludepediatricpopulations,elderlypopula-\ntheriskofnephrotoxicitywhenusingmultiple-dailydosing,\ntions,empiricaltherapy,targetedtherapy,treatmentdirected\nandsuggesttherapeuticdrugmonitoringwhenusingsingle-\ntowardsGram-negativebacterialpathogensandGram-\ndailydosingstrategies. positivebacterialpathogens. Thecumulativeresultsofthisevidence-basedreviewand\nnumerousmeta-analysesindicatethatonce-dailydosing3.8.4:Wesuggestmonitoringaminoglycosidedruglevels\nstrategiesgenerallytendtoresultinlessAKIwhencomparedwhentreatmentwithsingle-dailydosingisusedfor\ntomultiple-dosedosingstrategies,althoughthebeneﬁt\nmorethan48hours.(2C)\naccruedbythesingle-dailydosestrategyismodestand\ninconsistentacrossanumberofthesestudies.Forthisreason,\nalevel2recommendationissuggestedinsupportofthe\nRATIONALE\nuseofsingle-dailydosestrategiesovermultiple-dosedailyThetimingofmeasurementofpeakdosesofaminoglycosides\nstrategies.Itshouldbenotedthatmultiple-dailydosingwithsingle-dailydosingstrategiesisnotstandardizedand\nremainssomewhatcontroversial.Someinvestigatorsdonot\nstrategiescontinuetobethestandardofcareforenterococcal\nendocarditis;nodetailed,randomizedtrialshavebeenmeasuretherapeuticdruglevelsatallinpatientsreceiving\nreportedcomparingsingle-dailyvs.multiple-dailyregimensthisdosingstrategy.Othersrecommendatleastasinglepeak\n272,315–317\nmeasurementtoensurethatthebloodlevelsare10-fold\nforenterococcalendocarditis. 62\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.8\ngreaterthantheMICoftheinfectingorganism.Many\nandmethodoftherapeuticdrugmonitoringwithsingle-\n319\ninvestigatorsrecommendatleastoneoratleastaweeklydailydosingregimens,wouldbeofgreatassistance.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 5)",
    "content": "Clevelobtainedateither12,18,or24hoursaftertheItisgenerallyrecommendedthatpatientsreceiving\nmin\n267–270\naminoglycosidedose.TheClevelshouldbebelowextended-dosingintervalaminoglycosidesshouldhave\nmin\nthelimitsofdetectionoftheassay(1g/ml)atthesetimeaminoglycosidesadministeredatevengreaterdosing\nintervals.intervalsifmildormoderatedegreesofunderlyingrenal\nMeasuringaminoglycosidelevelswithmultiple-dailyimpairmentexist.Optimaltherapeuticmonitoringin\ndosingstrategieshavebeenstandardizedforCtobethesettingofinfrequentdosingintervalsforpatients\nmax\nobtained30minutesaftera30-minuteinfusion,andCwithunderlyingCKDneedstobestandardizedand\nmin\nrightbeforethenextdosefortroughlevels.Theaminoglyco-\nuniformrecommendationsneedtobeprovidedby\nsidesshouldbeadministeredinpatientswhoarevolume-carefulpharmacokinetic/pharmacodynamicobserva-\nreplete;volumedepletionincreasestheriskofnephrotoxicitytionalstudies. inexperimentalstudiesandissuggestedinclinicalstudies.TheimpactofIHDandhigh-fluxCRRTupontheefficacy\nAdditionally,potassiumrepletionhasbeenshownexperi-andtoxicityofextended-durationdosingofaminoglyco-\nmentallyandclinicallytodiminishtheriskofAKIrelatedtosidesneedsfurtherstudy.Asmembraneswithgreater\naminoglycosideadministration.sievingcoefficientscomeintogreateruse,theimpacton\nSingle-dosedailyregimensaredifﬁculttoapplyinpatientsaminoglycosideeliminationneedstobecarefullycon-\nwithpre-existingkidneydisease,andpatientswithvacillatingsidered.ThiscouldbeinvestigatedbyRCTsusing\neGFRandhemodynamics,suchascriticallyillpatientsinthestandarddosingintervalsvs.individualizeddosingregi-\nICUsetting.Thechangingpharmacokineticsandpharma-mens,withfrequentdrug-levelmonitoringandtheuse\ncodynamicsofantibioticsingeneralandaminoglycosidesinofefficacymeasuresandkidneyinjurymarkersas\nparticular,inthecriticallyillpatient,aresuchthattheoutcomes. avoidanceofsingle-dailydosingandapplicationoffrequentTheinteractionbetweenaminoglycosidesandotheranti-\n322\ntherapeuticdrugmonitoringisindicated.microbialagents,andothertherapeuticagentswith\nnephrotoxicpotentialneedstobemorecarefully\n3.8.5:Wesuggestusingtopicalorlocalapplicationsofquantified.Thedegreeofaminoglycoside-induced\naminoglycosides(e.g.,respiratoryaerosols,instillednephrotoxicityalonevs.combinationeffectswithsuch\nantibioticbeads),ratherthani.v.application,whendrugsasvancomycin,amphotericinB,cephalosporins,\nfeasibleandsuitable.(2B)extended-spectrumpenicillins,colistin,loopdiuretics,\nclindamycin,cisplatin,andnonsteroidalanti-inflamma-\ntoryagentsneedstobemorecarefullyexaminedin\nobservationalstudies.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 6)",
    "content": "RATIONALE\nLocalinstillationofaminoglycosidesforavarietyof\nindicationsisgainingmorewidespreaduseinaselectedset\nAMPHOTERICINBNEPHROTOXICITY\nofclinicalsituationswhereaminoglycosidelevelscanbeAmphotericinBhasbeenthestandardoftreatmentforlife-\nconcentratedatspeciﬁctissuesites.Theuseofaminoglyco-threateningsystemicmycosesforover50years.Thispolyene\nside-loadedbeadsforthepreventionandtreatmentofboneantifungalagentisinsolubleinwaterandneedstobe\nandjointinfectionshavebecomecommonplaceasastrategysolubilizedwithdeoxycholateandgiveni.v.intheabsenceof\ntolimitnephrotoxicity,whileprovidingantimicrobialelectrolytesolutionstomaintainsolubility.Despiteits\n323\nLocal\nactivityofaminoglycosidesatthetissuelevel.broad-spectrumfungicidalactivityagainstalargenumber\nconcentrationsofaminoglycosideareachievedforprolonged\nofinvasivesystemicmycoses,drug-inducednephrotoxicityis\nperiodswhenadministeredbythisroute.Aminoglycosidecommonandremainstheprincipaldose-limitingtoxicityof\n328–330\naerosoldeliverysystemsarenowinusetoprovidehighamphotericinB.AmphotericinBhasnumerousother\nintrapulmonaryantibioticlevelswithminimalsystemicandsigniﬁcanttoxicities,includingthrombophlebitis,electrolyte\nkidneyconcentrationsoftheantibiotic.Thisstrategyhasdisturbances,hypoplasticanemia,andsystemictoxicity\nbeenusedsuccessfullyincysticﬁbrosispatientsfortheassociatedwithfever,chills,hypotension,andcytokine\n331,332\nmanagementofdifﬁcult-to-treatGram-negativebacillaryrelease.AKIrelatedtoamphotericinBisclinically\n324,325\npneumonia.However,signiﬁcantnephrotoxicitywithsigniﬁcantandisassociatedwithhighermortalityrates,\ntheuseofinhaledtobramycinhasbeendescribedinatleastincreasedLOS,andincreasedtotalcostsofhealthcarewhen\n326,327328,330\ntwocases. managingpatientswithsystemicfungalinfection. Overthepasttwodecades,threemajoradvancesin\nRESEARCHRECOMMENDATIONS\nantifungaltherapyhavebecomeclinicallyavailable:i)the\nNostandardmethodexistsfortherapeuticdrugmoni-\nlipidformulationsofamphotericinB;ii)theintroductionof\ntoringofaminoglycosidesbysingledailydosing.Uniform\ntheechinocandinclassofantifungalagents;andiii)an\nguidance,baseduponcarefullyperformedpharmaco-\nexpandingnumberofazoleswithextendedactivityagainst\nkinetic/pharmacodynamicstudiesontheoptimaltiming\navarietyoffungalpathogens.Therapeuticalternativesto\n63\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.8\namphotericinBhavebeenawelcomeadditioninthe\nofvolumerepletionandpotassiumsupplementationduring\nmanagementofsystemicmycosesandselected,protozoan,amphotericinBtherapysupportstheirroutineuse,despite\nparasiticinfections,buttheirincrementalcostsandtradeoffstherelativelackofcompellingclinicalevidencetorecom-\ninspectrumofactivityagainstfungalpathogensneedtobe\nmendthesemaneuvers. considered,inadditiontotheirfavorabletoxicityproﬁlesandVariousdosingstrategieshavealsobeeninstitutedinan\nreducedpotentialfornephrotoxicity.Anumberoftherapeu-attempttolimitamphotericinB–inducednephrotoxicity.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 7)",
    "content": "ticoptionsarenowavailabletotheclinicianwhendecidingOnestrategyistogiveamphotericinBasacontinuous\nuponthechoiceforempiricordirectedantifungaltherapy.infusionratherthana2-to4-hourinfusiontolimit\n329,334\nAvoidanceofriskofnephrotoxicityisoneofthemajor,butnephrotoxicity.Whilethereissomesuggestionthata\ncontinuousinfusionmaylimitnephrotoxicity,enthusiasm\nnottheonly,determinantswhenselectingantifungaltherapy\natpresent.forthisstrategyistemperedbythepotentiallossofsome\nantifungalactivity.AmphotericinBexhibitsconcentration-\ndependentantifungalactivity,andcontinuousinfusionof\n3.8.6:Wesuggestusinglipidformulationsofampho-\ntericinBratherthanconventionalformulationsoflow-dosesofamphotericinBcouldresultinsuboptimal\namphotericinB.(2A)protectionforsomepatientswithinvasivefungalinfec-\n334\ntions. Anothercommonstrategyistheadministrationof\nalternate-daydosesofamphotericinB,ratherthandaily\nRATIONALE\n335,336\nThebroad-spectrum,polyene,antifungalagentamphotericinThisstrategyisbettertoleratedandmightreduce\ndoses. Bdeoxycholatehasbeenthemainstayoftreatmentfornephrotoxicitywithoutsacriﬁcingefﬁcacyinstablepatients. systemicmycosesfordecades.Despiteitswell-knowntoxicityHowever,clearevidencethatthisstrategyreducesnephro-\nproﬁle,thepotentantifungalactivityofamphotericinB,intoxicityisnotsupportedbylarge,adequatelycontrolled\nadditiontoitsactivityagainstcertainprotozoanparasitesclinicaltrialsasyet. (Plasmodiumspp.,Leishmaniaspp.,Naegleriaspp.),indicatesOneofthemajorinnovationsinamphotericinBtherapy\nthatthistherapywillremainastandardagentinclinicaloverthelast15yearshasbeentheintroductionoflipid\nmedicinefortheforeseeablefuture.formulationsofamphotericintolimittheproblemof\nAmphotericinB–inducednephrotoxicityisrelatedtonephrotoxicityassociatedwithconventionalamphotericinB\nmultiplemechanisms,includingischemicinjuryanddirectdeoxycholate.Threelipidformulationsareavailableinclud-\ntubular-andglomerular-cellmembranetoxicity.Amphoter-ing:amphotericinBcolloidaldispersion,amphotericinB\nicincausesvasoconstrictionoftheafferentrenalarteriolelipidcomplex,andliposomalamphotericinB.Amphotericin\nalongwithasystemicinﬂammatoryresponsethatmayBcolloidaldispersionisformulatedbyamphotericinB\nreducerenalbloodﬂow.AmphotericinBalsodirectlyinsertscomplexedwithcholesterylsulfate.AmphotericinBlipid\nintohumancellularmembranes,whereitdisruptsmembranecomplexiscomposedofamphotericinBcomplexedwith\n331,332\npermeabilityandphysiology.Tubularepithelialcellsdimyristoylphosphatidylcholineanddimyristoylphospha-\nresidinginthedeepmedullaryregionsofthekidneyare\ntidylglycerol.Liposomalamphotericinconsistsofamphoter-\nparticularlysusceptibletoinjurywhereconsiderableosmoticicinBcomplexedwithhydrogenatedsoyphosphatidyl-\n337–340\nstressexistsacrosscellmembranesevenunderphysio-choline,distearoylphosphatidylcholine,andcholesterol.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 8)",
    "content": "logicconditions.Theendresultisenzymuria,lossofOtherformulationsthatmightfurtherreducetheriskofAKI\nrenaltubularconcentratingability,renaltubularacidosis,fromamphotericinBincludenanoparticlepackagingin\n340\nmicelleswithpolyasparticacid. increasingurinarylossesofpotassiumandmagnesium,and\nThesafetyandefﬁcacy(inincidenceofnephrotoxicity)of\ndecreasedglomerularfunction,resultinginazotemiaand\ndecreasedsynthesisoferythropoietin.AmphotericinB–lipidformulationsofamphotericinhavebeenstudiedin\ninducednephrotoxicityisoftenaccompaniedbyconcomitantnumerousexperimentalandclinicaltrialswithconventional\n337–339,341–350\namphotericinBdeoxycholateasthecomparator. administrationofotherpotentiallynephrotoxicagents\nsuchascyclosporineA,aminoglycosides,chemotherapeuticAdetailedanalysisofthesevarioustrials,andanumberof\nagents,andanumberofotherpotentiallynephrotoxicmeta-analysesthathaveanalyzedthisclinicalquestion,\n328,329,333\nconcludedthatthelipidformulationsarelessnephrotoxic\nagents. 344,346\nConsiderableeffortshavebeenundertakentotrytolimitthanamphotericinBdeoxycholate.Whenfeasible,we\nnephrotoxicityandpermitthecontinueduseofamphotericinrecommendthatlipidformulationssupplanttheuseof\nBdeoxycholateforthemanagementofsystemicmycoses.conventionalamphotericinBdeoxycholatetoreducetherisk\nSimplemaneuvers,suchassaltrepletionandprovisionofofnephrotoxicity. adequateamountsofpotassium,arebeneﬁcialinanimalTheincrementalcostsassociatedwiththelipidformula-\nmodelsinthepreventionofamphotericinBnephrotoxicity.tionsandtheirrelativeefﬁcacyforsystemicmycosesremains\nThesemeasureshaveamixedrecordinclinicalpractice,andthesubjectofconsiderabledebate.Theexistingevidence\ntheircapacitytopreventAKIwhentreatingseverefungalwouldsuggestthattheoverallrisk-beneﬁtratioandcost-\ninfectionsremainunclear.Therelativeeaseandsimplelogiceffectivenesswiththeselipidformulationsisessentially\n64\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.8\n337,339\ncost-neutralwithamphotericinBdeoxycholate. Thereiscurrentlyinsufﬁcientevidenceastowhetherthe\nAttemptstoincreasethedosesoflipidformulationsofechinocandins,theazoles,orthelipidformulationsof\namphotericinfurthertoimproveefﬁcacyhaveresultedinamphotericinBdiffersigniﬁcantlyfromeachotherwith\n342,343\nmixedresultsandarenotrecommendedatpresent. respecttotheriskofnephrotoxicity.Noadequately\nLipidformulationsofamphotericinarelessnephrotoxicbutcontrolled,large,randomizedstudieshavebeenreportedto\nrequiredifferentdosingstrategies(three-toﬁve-foldhigherdatecomparingtherelativeriskofnephrotoxicityamphoter-\ndosesthandeoxycholateformulationsofamphotericinB).",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 9)",
    "content": "icinBlipidformulationswitheitherazoleorechinocandin\nSomeoftheseagentscontinuetoinducegeneralsystemicantifungalagents.Suchstudiesfacethedifﬁcultyofrecruiting\ntoxicityreactionssimilartothoseobservedwiththedeoxy-sufﬁcientnumbersofpatientswithsimilarbaselineriskfor\ncholateformulation(e.g.,amphotericinBcolloidaldispersion).drug-inducedAKI,andwithabalanceofexposuretoother\npotentiallynephrotoxicagents.Untilsuchtimeasthese\n3.8.7:Inthetreatmentofsystemicmycosesorparasiticstudiesarecompleted,noevidence-basedrecommendations\ninfections,werecommendusingazoleantifungal\ncanbegivenabouttherelativeriskofAKIattributable\nagentsand/ortheechinocandinsratherthandirectlytotheseantifungalagents. conventionalamphotericinB,ifequaltherapeutic\nRESEARCHRECOMMENDATIONS\nefﬁcacycanbeassumed.(1A)\nSomestudiesindicatethattheliposomalformof\namphotericinBislessnephrotoxicthanamphotericinB\nlipidcomplexoramphotericinBcolloidaldispersion. RATIONALE\nAnotherapproachtopreventamphotericinBnephrotoxicityRCTsinpatientswithsystemicmycosis,withtherateof\nistoavoidpolyeneantifungalagentsentirelyandusealte-AKIasaprimaryorsecondaryend-point,shouldbe\n351–355\nrnativeagents,suchastheazolesandechinocandins.conductedtoanswerthisquestion. AzoleantifungalagentsinhibitsterolsynthesisinfungalcellInnovativestrategiestoformulateamphotericinBin\nmembranesbyblockingtheactivityofthe14-demethylasemicrovesicles,nanoparticles,ormicellesshouldbeunder-\nenzymeessentialforergosterolsynthesis.Nephrotoxicitytakentolimitnephrotoxicityintreatingfungalinfections. isanunusualeventfollowingtheuseofazolecompounds.Clinicaltrialsshouldcompareexistingformulationsto\nTheechinocandinsarebeta-glucaninhibitorsthatinter-thesenovelformulations,andcouldgeneratecost-effective,\nferewithcell-wallsynthesisoffungalelements,andhaveanyetnon-nephrotoxicderivativesofamphotericinB. entirelydifferentmechanismofactionfromthatofCarefullyselectedcombinationsofantifungaltherapiesto\namphotericinB.Boththeazolecompounds(voriconazole,enhanceefficacyandshortendurationoftherapymay\nﬂuconazole,itraconazole,andposaconazole)andtheechi-limittoxicityandreducecostsinthetreatmentoffungal\nnocandins(caspofungin,anidulafungin,andmicafungin)infections.Investigationsneedtobecarriedoutinthe\ncomparefavorablytoamphotericinBwithrespecttotheirlaboratoryandinclinicalstudiestoimprovethecareof\nefﬁcacyagainstavarietyofthesystemicmycoses.Bothpatientswithseverefungalinfections.Thecostsand\nclassesofantifungalagentshavetheadvantageoflackingcomplicationratesofAKI,andothertoxicitiesofshort-\ntheintrinsicnephrotoxicityassociatedwithamphotericinBcoursecombinationtreatment,shouldbecomparedto\ndeoxycholate.Boththeazolecompoundsandechinocandinsstandarddosingregimensofantifungaltherapy. haveproventobelessnephrotoxicthanconventionalMarkersofearlynephrotoxicityandmechanismstoavoid\namphotericinBdeoxycholateinobservationalstudies,nephrotoxicitywithamphotericinBformulationsneed\n355\ntobestudiedfurtherinclinicalinvestigations.These\nhistoricalcontrolstudies,andinsmallcomparativetrials.",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "amphotericin-relatedAKI (Part 10)",
    "content": "Animportantconsiderationinusingtheseantifungalantifungalagentsaregivenforprolongedperiods,and\nagentsistheirrelativeefﬁcacywithrespecttothelikely\nshouldallowampleopportunitytotestthevalidityof\npathogenthatistargetedfortreatment.Candidakruseiisnovelbiomarkersofdrug-inducednephrotoxicity.A\nintrinsicallyresistanttotheazolesandCandidaparapsilosisisgroupmonitoredwithnovelAKIbiomarkersshouldbe\nfrequentlyresistanttotheechinocandins.AmphotericincomparedtoconventionalmonitoringofAKI,to\nB-resistantstrainsofselectedAspergillusspp.andPseudal-\ndetermineifoneormoreearlybiomarkersofkidney\nlescheriaboydiiarewelldescribedandrequirealternativeinjuryaddtostandardclinicalcareinthepreventionof\ntherapies.drug-inducedAKI. 65\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.9\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 64,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inthecriticallyill (Part 1)",
    "content": "4m\nON-PUMPVS.OFF-PUMPCORONARYARTERYBYPASS\n[133mol/l])(SupplTable16).Therewasnosigniﬁcant\nSURGERY\ndifferencebetweenoff-pumpandon-pumpcoronaryartery\nThetypeofcardiacsurgeryisimportantinthediscussionon\nbypassgraftintherateofthe30-daycompositeoutcome. riskforkidneyproblemsassociatedwiththissurgery. Therateofthe1-yearcompositeoutcomewashigherfor\nValvularproceduresoraortasurgeryareassociatedwitha\noff-pumpthanforon-pumpcoronaryarterybypassgraft. higherrisk.Oneofthemostcontroversialriskfactorsis\nFollow-upangiogramsinthemajorityofthepatients\non-pumpvs.off-pumpcoronaryarterybypasssurgery. revealedthattheoverallrateofgraftpatencywaslowerin\nOff-pumpcoronaryarterybypassobviouslyremovesthe\ntheoff-pumpgroupthanintheon-pumpgroup(82.6%vs. bypasscircuitbutcanbeassociatedwithgreaterhemo-\n87.8%,P0.01). dynamicinstabilitysecondarytoventricularcompressionas\nAcomprehensivemeta-analysisincludingRCTs,and\n356\ntheheartismanipulatedtoaccessthecoronaryarteries. abstractsfromtheproceedingsofscientiﬁcmeetingsthrough\nItispossible,withstandardoperativetechniques,toperform358\nAKIwasdeﬁned\nFebruary2010,wasrecentlypublished. coronaryarterybypasssurgery(butnotvalvesurgery)\nbyamixtureofcriteria,includingbiochemicalparameter,\nwithoutusingcardiopulmonarybypass.Thistechniqueis\nurineoutput,anddialysisrequirement.Mortalitywas\nknownas‘‘off-pump’’coronaryarterybypasssurgery. evaluatedamongthestudiesthatreportedkidney-related\nIthasbeenhypothesizedthatpreservationofphysiologic\noutcomes.Thisanalysiscomparedoff-pumpwiththemore\nrenalperfusionbyavoidanceofcardiopulmonarybypass\ntraditionalon-pumptechnique.Off-pumpcoronaryartery\nwouldpartiallynullifytheriskofAKIinpatientsreceiving\nbypassgraftwasassociatedwithastatisticallysigniﬁcant\ncoronaryarterybypasssurgery.Potentialbeneﬁtsthathave\n40%loweroddsofpostoperativeAKIandanonsigniﬁcant\nbeenpositedforoff-pumpcoronaryarterybypass(compared\n33%loweroddsfordialysisrequirement.Withinthe\ntoon-pumpprocedures)arereducedmortality,reductionof\nselectedtrials,off-pumpcoronaryarterybypassgraftsurgery\nAKIrisk(andinparticular,acutedialysis,whichisassociated\nwasnotassociatedwithasigniﬁcantdecreaseinmortality.",
    "page": 69,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inthecriticallyill (Part 2)",
    "content": "withaperioperativemortalityof42%intheSocietyof\nItisapparentfromthismeta-analysisthatthetrials\nThoracicSurgeonsdatabase),reducedriskofcerebral\nwereclinicallyheterogeneous,particularlyinregardsto\ndysfunction(duetostrokeandneurocognitivedysfunction,\ntheirdeﬁnitionsofkidneyoutcomes,andmostlywereof\nthelattersometimesreferredtoas‘‘pumphead’’),reduction\npoortofairquality(basedontheJadadscore).Thevery\ninICUstayanddaysinhospital,andreductioninatrial\nloweventrates(often0–1patients)maketheestimates\nﬁbrillation.Asinotherareascoveredbytheseguidelinesonly\nsuspectandhighlyimprecise.Thereisalsoaquestionof\nmortality,riskforRRT,andAKIriskareaddressedasend-\npublicationbias.Thereareseverallargetrialsinprogress\npointmeasures.Itmust,however,berememberedthatthe\nthatarelikelytogeneratemoredeﬁnitivedata.Inchronic\npotentialbeneﬁtsofoff-pumpcoronaryarterybypassmight\ndialysispatients,thereareobservationalUSRenalData\nbepredominantlyoutsidetheseareasoffocus. Systemsdatatoweaklysupporttheuseofoff-pump\ntechnique(slightlylowermortality).However,withany\n3.9.1:Wesuggestthatoff-pumpcoronaryarterybypasstechnicaladvancethatisintroducedincertaincenters,\ngraftsurgerynotbeselectedsolelyforthepurposeinstitutionalfamiliaritywiththetechnique,operatorexperi-\nofreducingperioperativeAKIorneedforRRT.(2C)ence,andcharacteristicsofthepopulationreferredto\nthecenterarelikelytobeimportantmodulatorsofout-\ncomes.Inconclusion,basedontheanalysisoftheRCTs\nRATIONALE\nandtherecentmeta-analysis,theWorkGroupfound\nAsdetailedinSupplTables15and16,whichsummarize\nthattherewasnotenoughevidencetorecommendoff-\nRCTs,thebalanceofthepotentialbeneﬁtandharmsis\npumpcoronaryarterybypassforreducingAKIortheneed\nuncertainandthequalityoftheevidenceisweak,thatoff-\nforRRT. pumpsurgeryisassociatedwithbetteroutcomesofthethree\nend-pointsusedintheseguidelines:incidenceofAKI,need\nRESEARCHRECOMMENDATION\nforRRT,ormortality.Furtherstudiesareneededtoclarifytheroleofoff-pump\n357\nArecentgood-qualityRCTwasperformedin2203coronaryarterybypassinpatientswithincreasedrisk\npatients(only8%ofpatientswithSCr1.5mg/dlforAKI. 66\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.9\nN-ACETYLCYSTEINE(NAC)\ntestedthepotentiallyconfoundingeffectofNACinaCKD\npopulation(Stages3–5)followingdosesofNACcurrently\n3.9.2:WesuggestnotusingNACtopreventAKIin\nrecommendedforprophylaxisofAKI.Therewasnoeffectof\ncriticallyillpatientswithhypotension.(2D)\nNAConeitherSCrorcystatinClevels. ItisthussafetoconcludethatNAC,indosescurrently\nrecommendedforprophylaxisofAKI,has—byitself—no\nRATIONALE\neffectonSCrorcystatinClevels.Inaddition,NACis\nNAChasbeenmostfrequentlyappliedintheprevention\ninexpensiveandappearstobesafe,althoughitmayhave\nofCI-AKI,andthistopicisdiscussedinmoredetailin\nsomedetrimentaleffectsonmyocardialandcoagulation\n371–373\nChapter4.4. The‘‘safety’’ofNACshouldfurtherbe\nfunction.",
    "page": 69,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inthecriticallyill (Part 3)",
    "content": "NACisamodiﬁedformofL-cysteine,anaminoacidthat\namended,particularlywhenhighi.v.dosesareused,asin\nisaprecursortoreducedglutathionethatcanregenerate\nsomeoftheRCTsinCI-AKI.Whenprospectivelystudiedin\nglutathionestores.Itisknowntobeapotentantioxidantthat\nacetaminophenpoisoning,i.v.NACproducedanaphylactoid\n374\nscavengesoxygen-freeradicalsinthebody.Italsohas\nreactionsinupto48%ofparticipants.Althoughmostof\nvasodilatorypropertiesderivedfromenhancednitricoxide\nthesereactionsweremild,atleastonedeathhasbeen\n359\n375\navailability.NAChasbeenshowntoattenuateischemic\nreportedinapatientwithasthma.Itshouldalsobenoted\n360–363\nandnephrotoxicARFinanumberofanimalstudies,\nthatthedosesofacetaminophenusedarestillmuchhigher\nandthepharmacologicalcharacteristicsofNACthatcould\nthaninthe‘‘highdoses’’used,particularlyinAKItrials. playaroleinthepreventionofAKIhaverecentlybeen\nBesidesthepreventionofCI-AKI,NAChasalsobeentested\n364\nsummarized.NACundergoesextensiveﬁrst-passmetabo-\ninthesettingofcardiothoracicsurgeryandlivertransplanta-\nlizationinthegastricmucosaandliver.Thisresultsinavery\ntion,andinhypotensivecriticallyillpatients. loworalbioavailability,withsubstantialintrapatientvaria-\nbility(3–20%),aswellasinconsistencybetweenavailable\nNACINCRITICALLYILLPATIENTS\noralproducts.Theplasmahalf-lifeofacetylcysteineafter\ni.v.injectionisapproximately6–40minutes,andthereis3.9.3:Werecommendnotusingoralori.v.NACfor\nextensivebindingtoplasmaandtissueproteinsthroughpreventionofpostsurgicalAKI.(1A)\nthesulfhydrylgroup.Virtuallynoacetylcysteinecanbe\ndetectedinthesystemiccirculationafteri.v.ororal\nadministration,suggestingthatanypotentialtherapeutic\nRATIONALE\nbeneﬁtmustbeduetosecondaryeffectssuchasthe\nTheaboverecommendationisbasedonanevaluationof\ninductionofglutathionesynthesis,ratherthanduetodirect\ntheavailableliteratureonpreventionstudieswithNACin\neffects.Asthesesecondaryeffectsarenotdirectlymeasurable,\ncardiovascularandabdominalvascularsurgery,andliver\nthedeterminationoftheoptimaldosageschedulehasbeen\ntransplantation. 365\nnecessarilyempirical. ThetablessummarizetheRCTswhereeitheroralori.v. AparticularlyimportantproblemwithNACiswhetherit\nNACwascomparedtoplacebo;onlystudiescontaininga\ncanalterSCrindependentofachangeinGFR.NAChasbeen\nminimumof50patientsineachstudyarmhavebeen\n376\nreportedtodecreaseSCrlevelsinsubjectswithnormal\nincluded.Inaddition,arecentmeta-analysisisavailable,\nkidneyfunction.ThisreductioninSCrwasnotaccompanied\ncontaining10studiesinvolvingatotalof1193adultpatients\nbyachangeinserumcystatinClevels.Thissuggestsaneffect\nundergoingmajorsurgery.Sevenstudies(1003patients)\nindependentofachangeinGFR,suchasanincreasein\nevaluatedtheeffectsofNACinpatientsundergoingcardiac\ntubularsecretionofcreatinineoradecreaseincreatinine\nsurgery,andthreeofthese(508patients)exclusivelystudied\n366\nBycontrast,invitroanalysisontheeffectof\nproduction.",
    "page": 69,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inthecriticallyill (Part 4)",
    "content": "patientswithpre-existingrenalimpairment.Twostudies\n367\nNAConSCrshowednoanalyticalinterferencewiththe\n(111patients)evaluatedtheeffectsofNAConpatients\nmeasurementofSCrbyanyofthecommonlyusedanalytical\nundergoingabdominalaneurysmrepairsurgeryandone\n368\nmethods.Haaseetal.,studied30patientswithnormal\nstudy(79patients)wasofpatientsundergoingmajor\nkidneyfunctionwhoreceivedi.v.NACfor24hoursin\nabdominalcancersurgery.End-pointsinmostofthestudies\nassociationwithcardiacsurgery.Nochangeintheratioof\nweremortality,needforRRT,orvaryingincreasesin\nSCrtocystatinC,comparedtobaselinevalues,wasobserved\npostoperativeSCrconcentrationscomparedtopreoperative\nattheendofthe24-hourinfusionor48hoursafterthe\nSCrvalues. cessationoftheinfusion.Inaddition,therewasnoeffecton\nSupplTables17and18summarizetheﬁvestudieswhere\nurinarycreatinineexcretionduringtheinfusion.However,in\nNACwascomparedtoplaceboinpatientsundergoing\nclinicalpractice,NACisgenerallyrecommendedforpatients\ncardiacsurgeryandwhowerenotexposedtoradiocontrast\n377–381\nwithCKD,withaneGFR60ml/minper1.73m.Mainra\nAllﬁvestudiesanalyzedtheeffectsofNACin\nmedia. 369\netal.,observednochangeinSCrorcystatinCat4,24,or\npatientswithmoderate,pre-existingrenalfunctionalimpair-\n48hoursafteradministrationofasingle600-mgdoseofNAC\nment.Surgeryincludedelectiveoremergencycoronaryartery\n370\nto30patientswithCKDStage3.Finally,Rehmanetal.,\nbypassgraftoperationsorheartvalvesurgery.NACwasgiven\n67\nKidneyInternationalSupplements(2012)2,37–68\nchapter3.9\nSPONSORSHIP\ni.v.inmostofthestudies;mortalitywasevaluatedatdifferent\nKDIGOgratefullyacknowledgesthefollowingsponsorsthat\nfollow-uptimes;eitherin-hospitalorat30or90days.Only\n377\nmakeourinitiativespossible:Abbott,Amgen,BeloFounda-\nonestudyfoundasigniﬁcantlylowermortalityat30days. tion,Coca-ColaCompany,DoleFoodCompany,Genzyme,\nNoneofthestudiesfoundeitheradifferenceinneedforRRT,\nHoffmann-LaRoche,JCPenney,NATCO—TheOrganization\norinAKIdeﬁnedasvariablechangesinSCraftersurgery.All\nforTransplantProfessionals,NKF—BoardofDirectors,\nstudieswereofA-levelquality.Tworelativelysmallstudies\nNovartis,RobertandJaneCizikFoundation,Shire,Trans-\nevaluatedtheeffectsofNAConpatientsundergoing\n382,383\nwesternCommercialServices,andWyeth.KDIGOis\nabdominalaneurysmrepairsurgeryanddidnotﬁnd\nsupportedbyaconsortiumofsponsorsandnofundingis\nanyprotectiveeffectonrenalfunction. 376\nacceptedforthedevelopmentofspeciﬁcguidelines.",
    "page": 69,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inthecriticallyill (Part 5)",
    "content": "Further,onemeta-analysisdidnotﬁndevidencethat\nNACusedperioperativelycanaltermortalityorrenal\nDISCLAIMER\noutcomesaftermajorcardiovascularorabdominalcancer\nWhileeveryeffortismadebythepublishers,editorialboard,\nsurgerywhenradiocontrastagentsarenotused.Innoneof\nandISNtoseethatnoinaccurateormisleadingdata,opinion\nthestudiesweresigniﬁcanttreatment-relatedadverseeffects\norstatementappearsinthisJournal,theywishtomakeitclear\nofNACreported.ThesereportssuggestthatNAC,inthe\nthatthedataandopinionsappearinginthearticlesand\ncontextofcardiovascularsurgery,isnotassociatedwith\nadvertisementshereinaretheresponsibilityofthecontributor,\nincreasedriskofmortality,surgicalre-exploration,or\ncopyrightholder,oradvertiserconcerned.Accordingly,the\nallogeneictransfusion. publishersandtheISN,theeditorialboardandtheirrespective\nOnlyonesinglestudyhascomparedNACtoplaceboin\nemployers,ofﬁceandagentsacceptnoliabilitywhatsoeverfor\n384\ncriticallyillpatients(SupplTable18).Onehundredand\ntheconsequencesofanysuchinaccurateormisleadingdata,\nforty-twoICUpatientswithnew-onset(within12hours)of\nopinionorstatement.Whileeveryeffortismadetoensurethat\natleast30consecutiveminutesofhypotensionand/or\ndrugdosesandotherquantitiesarepresentedaccurately,\nvasopressorrequirementwererandomizedtoreceiveeither\nreadersareadvisedthatnewmethodsandtechniques\noralNACorplacebofor7days,inadditiontostandard\ninvolvingdrugusage,anddescribedwithinthisJournal,\nsupportivetherapy.AKIwasdeﬁnedas0.5mg/dl\nshouldonlybefollowedinconjunctionwiththedrug\n(44mol/l)increaseinSCr.PatientswhoreceivedNAC\nmanufacturer’sownpublishedliterature. hadanincidenceofAKIof15.5%,comparedto16.9%in\nthosereceivingplacebo(NS).Therewerenosigniﬁcant\nSUPPLEMENTARYMATERIAL\ndifferencesbetweentreatmentarmsinanyofthesecondary\nSupplementaryTable15:EvidenceprofileofRCTexaminingonvs.off\noutcomesexamined,includingincidenceofa50%increasein\npumpcardiothoracicsurgery. SCr,maximalriseincreatinine,recoveryofrenalfunction,\nSupplementaryTable16:SummarytableofRCTsexaminingtheeffect\nlengthofICUandhospitalstay,andrequirementforRRT. ofonvs.offpumpCABGforthepreventionofAKI. SupplementaryTable17:EvidenceprofileofRCTsexaminingNACvs. Mortalityinbotharmswas10%.Basedonthissinglestudy,\nplacebointhepreventionofAKI. whichisunderpoweredbutdidnotshowanybeneﬁcialeffect\nSupplementaryTable18:SummarytableofRCTsexaminingtheeffect\nonincidenceofAKI,needforRRT,orpatientmortality,we\nofNACvs.placebointhepreventionofAKI. suggestnotusingNACtopreventAKIincriticallyillpatients\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nwithhypotension.http://www.kdigo.org/clinical_practice_guidelines/AKI.php\n68\nKidneyInternationalSupplements(2012)2,37–68\nchapter4.1\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 69,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section4:Contrast-inducedAKI",
    "content": "KidneyInternationalSupplements(2012)2,69–88;doi:10.1038/kisup.2011.34",
    "page": 72,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "epidemiology,andprognosis (Part 1)",
    "content": "BACKGROUND\nadversecardiovasculareventsafterpercutaneouscoronary\n385\nContrast-relatedacutekidneyproblemsarefrequentand\nintervention.TheSocietyofUrogenitalRadiologyusedthe\noccurinbothambulatoryandhospitalizedpatients.Since\nsamedeﬁnition,butthecreatininechangesweresaidtooccur\nthereisaccumulatingevidencethatmanyriskfactors,\nwithin3daysafterintravascularadministrationofcontrast\n386\npreventivemeasures,andtheimmediateandlong-term\nmediawithoutanalternativeetiology.Itshouldbe\nprognosisoftheseproblemsarecommontotheothercauses\nrecognizedthat,inaminorityofcases,thepeakincreaseof\nofAKI,theWorkGroupbelievesthatthereisaneedfora\nSCrmayoccurupuntil5daysaftercontrastexposure. 387\nunifyingdeﬁnitionforallformsofAKIandtherefore\nshowedthatthe\nHowever,arecentprospectivestudy\nproposesthatthetermcontrast-inducedacutekidneyinjury\npercentagechangeofSCr12haftercontrastvs.thebasal\n(CI-AKI)beusedforpatientsdevelopingAKIsecondaryto\nvaluewasthebestpredictorofCI-AKI(P0.001).A5%\nintravascularradiocontrastmediaexposure. increaseofitsvalueyielded75%sensitivityand72%\nTheliteratureonCI-AKIispredominantlyrelatedtoAKI\nspeciﬁcity,withanareaunderthecurve(AUC)of0.80and\nfollowingiodinatedcontrast-mediaadministration.Aswill\nanORof7.37(95%CI3.34–16.23)forearlydetection. bediscussedinAppendixE,non–iodinecontrastmedia—\nFurthermore,this12-hourbasalvaluestronglycorrelated\nnotablyGd-containingcontrastmedia—mayalsooccasion-\nwiththedevelopmentofrenalimpairmentat30days\nallyinduceAKI. (P0.002;sensitivity87%,speciﬁcity70%;AUC0.85;OR\n13.29;95%CI2.91–60.64). IthasbeenshownthatsubstantialvariationinSCrmay\n4.1:DeﬁneandstageAKIafteradministrationofintra-\noccurfromdaytodayinhospitalizedpatientswhodonot\nvascularcontrastmediaasperRecommendations\n388\nreceivecontrast-mediainjections.Dependingonthe\n2.1.1–2.1.2.(NotGraded)\nthresholdcriterionforCI-AKIchosen,thisvariationcan\n4.1.1:Inindividualswhodevelopchangesin\nleadtoratesof6–35%ofinpatients,notexposedtocontrast\nkidneyfunctionafteradministrationofintra-\nmedia,whowouldbelabeledashavingCI-AKIhadthey\nvascularcontrastmedia,evaluateforCI-AKI\nreceivedcontrastmedia.Theexactcauseofthis‘‘hospital-\naswellasforotherpossiblecausesofAKI. 389\ninducednephropathy’’isnotknown,butotherstudies\n(NotGraded)\nhaveshownthatAKI(variousetiologies)iscommonin\nhospitalizedpatients. Themagnitudeoftheimpactofthe‘‘background\nRATIONALE\nﬂuctuationofkidneyfunction’’inpatientsreceivingiodinated\nPendingthevalidationoffuturebiomarkerswhichwould\ncontrasthasnotbeenprospectivelystudied,butarecentretro-\nallowamorestraightforwardcomparisonandintegrationof\nspectivestudycomparedtheincidenceofAKIamongpatients\nCI-AKIintheoverallframeworkofAKI,wesuggestthatthe\nundergoingenhancedcomputedtomography(CT)withi.v.",
    "page": 72,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "epidemiology,andprognosis (Part 2)",
    "content": "samecriteria,usingthechangesinSCrconcentrationsand\nlow-osmolar(iohexol)oriso-osmolar(iodixanol)contrast\nurineoutputbeusedasfortheotherformsofAKI.TheWork\nmediatotheAKIincidenceamongpatientsundergoingCT\nGroupisnotawareofanypathophysiologicalorepidemio-\n390\nwithoutcontrast-mediaadministration.Theincidenceof\nlogicalreasonwhythedeﬁnitionandstagingofCI-AKI\nAKI(deﬁnedasanincreaseofSCrof0.5mg/dl[44mol/l]or\nshouldbedifferentfromtheRIFLE/AKINcriteria.Itshould,\na25%decreaseineGFRwithin3daysafterCT)wassimilar\nhowever,bestressedthatforthedevelopmentofthis\ninallthreegroups(tworeceivingcontrastagentsandonenot)\nguideline,thetermcontrast-inducednephropathyiswidely\nuptoabaselineSCrlevelof1.8mg/dl(159mol/l).Ahigh\nusedintheliteratureandusuallydeﬁnedasariseinSCr\nXX\nincidenceof‘‘AKI’’amongcontrolsubjectsundergoing\nof0.5mg/dl(44mol/l)ora25%increasefrombase-\nnoncontrastCTwasthusidentiﬁed.Giventheresultsofthis\nlinevalue,assessedat48hoursafteraradiologicalproce-\nretrospectivestudy,itisclearthatAKIafteri.v.administration\ndure.Thisdeﬁnitionalsoconsistentlypredictedmajor\n69\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.1\n396\nofiodinecontrastmediacannotbeautomaticallyattributed\nincreasedriskofCI-AKIbut,asrecentlysummarized,\ntothecontrastagent,butmay,infact,reﬂectAKIfromotherthepublishedevidencetosupportthispremiseisrather\n397\ncauses,suchasworseningunderlyingdiseaseordrugtoxicity.scarce. Therefore,theWorkGroupstronglyrecommendsthat\nindividualsshowingincreasesofSCrcompatiblewiththe\nPrognosisofCI-AKI\ndeﬁnitionofAKIafteradministrationofintravascularcontrastManystudieshavenowshownthatpatientswhodevelop\nmediabealsoevaluatedforotherpossiblecausesofAKI.CI-AKIhaveagreaterriskfordeathorprolongedhospitali-\nInastudyusingcystatinCasanearlymarkerforAKI,zation,aswellasforotheradverseoutcomes,includingearly\nacut-offcystatinCincreaseconcentrationof10%at24orlatecardiovascularevents.Thelatteraremorecommon\nhoursaftercontrast-mediaexposurewasdetectedin87after,forexample,percutaneouscoronaryinterventions(for\n398\npatients(21.2%),andwasthebestcut-offvaluefortheearlyreview,seeMcCullough).Inaretrospectiveanalysis\nidentiﬁcationofpatientsatriskforCI-AKIwithanegativeincluding27608patientswhounderwentcoronaryangio-\ngraphyattheUniversityofPittsburghMedicalCenterduring\npredictivevalueof100%andapositivepredictivevalueof\n39%.AsinothercasesofAKI,itappearsthat,inpatientsa12-yearperiod,discreteproportionaloddsmodelswere\nwithCKD,cystatinCmaybeausefulmarkerfortheearlyusedtoexaminetheassociationbetweenincreasesinSCrand\n30-dayin-hospitalmortalityandLOS,respectively.Itappea-\ndiagnosisofCI-AKI.",
    "page": 72,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "epidemiology,andprognosis (Part 3)",
    "content": "redthatsmallabsolute(0.25–0.5mg/dl[22–44mol/l])and\nrelative(25–50%)increasesinSCrwereassociatedwith\nEpidemiologyofCI-AKI\nKeepingtheabove-mentionedproblemsofdeﬁnitionin\nrisk-adjustedORforin-hospitalmortalityof1.83and1.39,\nmind,itisnotsurprisingthatthereportedincidenceofrespectively;largerincreasesinSCrgenerallywereassociated\n399\nCI-AKIvarieswidelyacrosstheliterature,dependingonthewithgreaterrisksfortheseclinicaloutcomes.Moreover,\ndeﬁnitionsused,thepatientpopulation,andthebaselineriskwhenpatientswithCI-AKIrequiredialysis,themortalityis\nfactors.highercomparedtothosenotrequiringdialysis.Forexample,\n400\nThe.impactofdifferentdeﬁnitionsontheincidenceofinthestudybyMcCulloughetal.,thehospitalmortality\nCI-AKIcanbeillustratedbytherecentresultsoftheOxilanwas7.1%inCI-AKIand35.7%inpatientswhorequired\n391\nRegistry.Inthisregistry,CI-AKIwasdeﬁnedaseitheradialysis.By2years,themortalityrateinpatientswho\n44m\nSCrincrease0.5mg/dl(44mol/l),oraSCrincreaserequireddialysiswas81.2%. 44\n25%,oradecrease25%ofeGFR,orthecompositeofThemorerecentCardiacAngiographyinRenally\n401\nallthreedeﬁnitions.ThebaselineSCrwas1.120.3mg/dlImpairedPatientsstudy—alarge,multicenter,prospective,\n(9926.5mol/l)and24%hadaneGFR60ml/min.double-blindRCTofpatientswhohadmoderatetosevere\nCI-AKIrateswere3.3%(SCrincrease0.5mg/dlCKDandwereundergoingcardiacangiography—also\n4m4\n[44mol/l]),10.2%(SCrincrease25%),7.6%(eGFRshowedthattheadjustedincidencerateratioforadverse\ndecrease25%),and10.5%(composite),respectively.eventswastwiceashighinthosewithCI-AKI.However,\nItisacceptedthat,inpatientswithnormalrenalfunction—thesedatademonstratingatemporalassociationbetweenCI-\nAKIandshortorlong-termprognosisdonotestablisha\neveninthepresenceofdiabetes—theriskforCI-AKIislow\n392\n(1–2%).However,theincidencemaybeashighas25%incausalrelationship,sincemostofthepatientsinthese\npatientswithpre-existingrenalimpairmentorinpresenceofobservationalstudieshaveunderlyingriskfactorsthat,in\ncertainriskfactors,suchasthecombinationofCKDandadditiontoincreasingthepatient’sriskofCI-AKI,can\ndiabetes,CHF,advancedage,andconcurrentadministrationdirectlyincreasetheiroverallriskforthecomplications\n393\nCI-AKIwasdescribedasthethird\nofnephrotoxicdrugs.studied.Finally,manyoftheretrospectivestudiesmayalso\nmostcommoncauseofnewAKIinhospitalizedpatients\nhaveintroducedselectionbiasforpatientswhopresumably\n(afterdecreasedrenalperfusionandnephrotoxicmedications)hadaclinicalreasonforhavingtheirSCrconcentration\n394\nandwasresponsiblefor11%ofcases.followed.",
    "page": 72,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "epidemiology,andprognosis (Part 4)",
    "content": "TheepidemiologyofdenovoCI-AKIincriticallyill\nDataontheassociationbetweenriskofESRDandCI-AKI\npatientsisnotknown.Inagroupof75ICUpatientswithaarescarce.Incontemporarystudies,CI-AKIrequiring\nnormalbaselineSCrwhowereexposedtoCTscanswithandialysisdevelopedinalmost4%ofpatientswithunderlying\ni.v.low-osmolarcontrastmedium,anincreaseinSCr25%\nrenalimpairmentand3%ofpatientsundergoingprimary\nwasrecordedin18%ofthepatients.Therewasnochangeofpercutaneouscoronaryinterventionsforacutecoronary\ntheSCrinacontrolgroupofpatientsundergoingCTscanssyndrome.However,onlyasmallproportionofpatients\n395402,403\nThisrathersmallstudyAlthoughCI-AKI\nbutnotreceivingcontrastmedia.continuedonchronicdialysis. showsthatincriticallyillpatients,evenwithanapparentlyrequiringdialysisisrelativelyrare,theimpactonpatient\n‘‘normal’’renalfunction,i.v.administrationofiodinatedprognosisisconsiderable,withhighhospitaland1-year\n398\ncontrastmediaisassociatedwithasigniﬁcantincidenceofmortalityrates(forareview,seeMcCullough).Onlyone\n404\nCI-AKI.studyreportedtheincidenceofnewCKDStage4–5\nItcouldbeexpectedthatradiologicalprocedures(eGFR30ml/min)followingpercutaneouscoronaryinter-\nperformedinanemergencywouldbeassociatedwithanventionsandfoundthatthisoccurredin0.3%ofpatients\n70\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.1\nRESEARCHRECOMMENDATION\nwithaneGFR30ml/minatbaselineandnewlydiagnosed\nLargeprospectiveRCTsexaminingtheepidemiologyof\nkidneydiseasewithin6monthsaftertheprocedure,andin\nCI-AKIareneeded,especiallyonlong-termoutcomes,\n0.9%ofpatientswithaneGFR60ml/minatbaseline.These\nwithattentiontocontrollingforconfounders. percentagesarehigherthantheestimatedannualincidenceof\nCKDat0.17%thatwasfoundinaBritishgeneralpopulation\nSUPPLEMENTARYMATERIAL\n405\ncohortovera5.5-yearperiodoffollow-up.Thus,careful\nAppendixE:RiskswithGadolinium-BasedContrastAgents. long-termfollow-upofSCrfollowingcontrastexposureis\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nwarranted. http://www.kdigo.org/clinical_practice_guidelines/AKI.php\n71\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.2\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 72,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forCI-AKI (Part 1)",
    "content": "Atpresent,millionsofdosesofintravascularcontrastberequested,butanemergentimaging/intervention,where\n406,407\nmediaarebeingadministeredworldwide.Mostofthebeneﬁtofveryearlyimagingoutweighstheriskof\ntheseradiologicalexaminationsareperformedinambu-waiting,shouldnotbedelayed. latorypopulationswhodonotneedspecialpreventiveForitsrelativesimplicity,onlySCrisusedatmany\nmeasures.However,contrastmediaarealsoincreasinglyusedhospitalstodeterminewhetherapatientisacandidate\ninanelderlypopulation,manyofwhomhaveCKDandforintravascularcontrast-mediaadministration,butthe\ndiabetes—theprincipalriskfactorsforCI-AKI.Itis,thus,thresholdsusedandtheacceptabletimebetweenthe\nofutmostimportancetoscreenthepopulationatriskfordeterminedSCrvalueandadministrationofcontrastmedia\nCI-AKI.toperformtheradiologyexaminationdiffersamong\nradiologydepartments. 4.2.1:AssesstheriskforCI-AKIand,inparticular,\nscreenforpre-existingimpairmentofkidney\nRisk-factorquestionnaire\nfunctioninallpatientswhoareconsideredfora\nForoutpatientradiologicalstudieswhererenalfunctiondata\nprocedurethatrequiresintravascular(i.v.ori.a.)\nareunavailable,asimplesurveyorquestionnairemaybe\nadministrationofiodinatedcontrastmedium. usedtoidentifyoutpatientsathigherriskforAKIinwhom\n(NotGraded)\nappropriateprecautionsshouldbetaken. 411\nChoykeetal.(Figure13)usedaquestionnaireand\ncouldidentifyahighproportionofpatientswithnormalSCr\nRATIONALE\nconcentrations,andreducedby67%thenumberofpatients\nScreeningforpre-existingimpairmentofkidneyfunction\ninwhomSCrmeasurementwasnecessarybeforeimaging\nPre-existingrenalfunctionalimpairmentisthemost\nstudies. importantriskfactoraboveallotherriskfactorsfor\n386\nTheEuropeanSocietyofUrogenitalRadiologyrecom-\n408\ndevelopingCI-AKIandscreeningforbothacuteand\nmendsarisk-factoranalysisbasedontheChoykeques-\nchronickidneydiseaseishighlyrecommended.Thereisno\ntionnairetoidentifypatientswithahigherriskofabnormal\nsharpGFRthresholdbelowwhichtheriskforCI-AKIis\n410\nrenalfunction.TheCI-AKIConsensusWorkingPanel\nclearlyincreasing.BoththeKDOQIguidelineandKDIGO\nconsideredthatasurveyorquestionnairemaybeauseful\nrecommendthat,instablepatients,aneGFRshouldbe\nguideforidentifyingpatientsathigherriskforCI-AKI\n409\nused. comparedtothegeneralpopulation.",
    "page": 75,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forCI-AKI (Part 2)",
    "content": "410\nACI-AKIConsensusWorkingPanelagreedthattherisk\nofCI-AKIbecomesclinicallyimportantwhenthebaseline\nXX\nSCrconcentrationis1.3mg/dl(115mol/l)inmenand\nUrinaryproteinscreening\nXX\nTheCI-AKIConsensusWorkingPanelalsosupportedthe\n1.0mg/dl(88.4mol/l)inwomen,equivalenttoan\n2390\neGFR60ml/minper1.73m.However,Bruceetal.useofdipsticktestingforurineproteinasarapidscreento\nshowedthattheincidenceof‘‘true’’AKIbecamesigniﬁcantidentifypatientswhocanundergostudiesrequiringcontrast\n410\nonlybetweencontrolsandcontrast-mediaadministeredmediawithoutSCrmeasurement.Of310patientswitha\npatientsfromabaselineSCrconcentrationof1.8mg/dlnegativeurineproteintestandnohistoryofdiseasespoten-\n4m\n(159mol/l)onward.TheCI-AKIConsensusWorkingtiallyassociatedwithrenalimpairment,nonehadaSCr\n410\n44m\nPanelrecommendedthatprecautionstoreducetherisklevel2.0mg/dl(177mol/l),andonly1%hadalevel\n44m\nshouldbeimplementedinpatientswithabaseline1.7mg/dl(150mol/l). eGFR60ml/minper1.73m.InlightofmorerecentThus,theWorkGrouprecommendsthat,whenarecent\ninformation,thisthresholdcouldprobablybeloweredtoSCrisnotavailable,asimplequestionnaireoradipstick\n45ml/minper1.73m.testingforurineproteinmaybeusefulforidentifying\nInmanyinstitutions,point-of-careSCrtestingispresent,pre-existingkidneydisease.Riskstratiﬁcationhingesonage,\nandtheresultscanbeavailablequitefast.Inplaceswithoutbaselinekidneyfunction,othercomorbidities,andotherrisk\npoint-of-carelaboratories,theappropriatebloodtestsshould\nfactors. 72\nKidneyInternationalSupplements(2012)2,69–88",
    "page": 75,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter4.2",
    "content": "In the past 3 months have you been told there may have been a change in your kidney function?  Y/N\nIn the past 3 months have you been on any medications? Please list:\nHave you used any over-the-counter pain relievers within the last 10 days? Y/N  Please list:\nIn the past 3 months have you had any surgery?  Y/N\nDescribe:\nDo you feel dry or thirsty? Y/N\nCircle one\n*Have you ever been told you have kidney disease of any type?\nYN\nPlease describe:\n*Have you had kidney surgery?\nYN\n*Do you have diabetes?\nYN\nDo you use insulin?\nYN\nDo you use metformin or glucophage?\nYN\n*Do you have hypertension, heart disease, or vascular disease?\nYN\n*Do you have gout?\nYN\nDo you have multiple myleoma?\nYN\nHave you ever had x-ray contrast media (dye) for CT, angiography, or IVP?\nYN\nHave you had contrast media within the last 3 days?\nYN\nDo you have any allergies to x-ray contrast media (dye)?\nYN\nPlease describe:\nHave you received pretreatment with medication for this study?\nYN\nDo you have any allergies or asthma? Please describe:\nYN\nFigure13|Samplequestionnaire.Asterisksdenotequestionswiththehighestassociationwithabnormalrenalfunction.Adaptedfrom\nChoykePL,CadyJ,DePollarSLetal.Determinationofserumcreatininepriortoiodinatedcontrastmedia:isitnecessaryinallpatients?\n411\nTechUrol1998;4:65–69withpermission.\nTable15|CI-AKIrisk-scoringmodelforpercutaneous\nOtherriskfactorsofCI-AKI\ncoronaryintervention",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "contrastmedia,multiplemyeloma,femalegender,and",
    "content": "Note:Lowrisk:cumulativescore5;highrisk:cumulativescore416.",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "cirrhosishavebeenclassiﬁedasconﬂictingriskfactorsfor",
    "content": "CHF,congestiveheartfailure;eGFR,estimatedglomerularfiltrationrate;IABP,intra-\naorticballoonpump;SCr,serumcreatinine.ReprintedfromMehranR,AymongED,\n413",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "CI-AKI.ThereareconﬂictingdataontheimpactofACE-I",
    "content": "NikolskyEetal.Asimpleriskscoreforpredictionofcontrast-inducednephropathy",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "orARBbut,overall,thereiscurrentlyinsufﬁcientevidenceto",
    "content": "afterpercutaneouscoronaryintervention:developmentandinitialvalidation.JAm\n418\nCollCardiol2004;44:1393–1399etal.,copyright2004,withpermissionfrom",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "recommenddiscontinuationofthesemedicationspriorto",
    "content": "AmericanCollegeofCardiologyFoundation;accessedhttp://content.onlinejacc.org/",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "graphy. (Part 1)",
    "content": "73\nKidneyInternationalSupplements(2012)2,69–88\n[Table 1]\n | *Have you ever been told you have kidney disease of any type? |  | Y |  |  | N |  | \n------------------------------------------------------------\n | Please describe: |  |  |  |  |  |  | \n | *Have you had kidney surgery? |  |  | Y |  |  | N | \n | *Do you have diabetes? |  |  | Y |  |  | N | \n | Do you use insulin? |  |  | Y |  |  | N | \n | Do you use metformin or glucophage? |  |  | Y |  |  | N | \n | *Do you have hypertension, heart disease, or vascular disease? |  |  | Y |  |  | N | \n | *Do you have gout? |  |  | Y |  |  | N | \n | Do you have multiple myleoma? |  |  | Y |  |  | N | \n | Have you ever had x-ray contrast media (dye) for CT, angiography, or IVP? |  | Y\nY\nY | Y |  | N\nN\nN | N | \n | Have you had contrast media within the last 3 days? |  |  | Y |  |  | N | \n | Do you have any allergies to x-ray contrast media (dye)? |  |  | Y |  |  | N | \n | Please describe: |  |  |  |  |  |  | \n | Have you received pretreatment with medication for this study? |  |  | Y |  |  | N | \n | Do you have any allergies or asthma? Please describe: |  |  | Y |  |  | N | \n\n[Table 2]\nSCr41.5mg/dl(4132.6mmol/l) 4\n------------------------------------------------------------\nor\neGFRo60ml/minper1.73m2 2for40–60\n4for20–39\n6foro20\n\nchapter4.2\nRiskmodelsofCI-AKINephrogenicsystemicfibrosis(NSF)\nMostriskfactorsforCI-AKIcanbedetectedbyTheriskofdevelopingNSFwithGd,particularlyinpatients\nhistory-takingandphysicalexamination,andtheriskriseswithsevereAKIandCKD,isreviewedindetailinAppendixE. 416\nexponentiallywiththenumberofriskfactorspresent.ItshouldbenotedherethattheEuropeanMedicines\nValidatedrisk-predictionmodelsusingpatientandproce-Agencystatedacontraindicationforuseofgadodiamidein\nduralriskfactorstoassessforCI-AKIhavebeendevelopedpatientswithaGFR30ml/minper1.73m,andissueda\nforpatientsundergoingpercutaneouscoronaryinter-warningforitsuseinpatientswhohaveaGFRbetween30\n417,4184182\nvention.Forexample,theMehranriskmodelisand60ml/minper1.73m(EMEAPublicassessmentreport. giveninTable15.TheoveralloccurrenceofCI-AKIinthehttp://www.esur.org/ﬁleadmin/NSF/Public_Assessment_Report_\ndevelopmentsetofthescorewas13.1%(range7.5%toNSF_Gadolinium_26_June_2007.pdf;lastaccessedJanuary5,\n57.3%foralow[5]andhigh[16]riskscore,2012).TheUSFDArequestedthatvendorsaddwarnings\nrespectively);therateofCI-AKIincreasedexponentiallyabouttheriskfordevelopingNSFtothefullprescri-\nwithincreasingriskscore.Inthevalidationdataset,thebinginformationonthepackagingforallGd-containing\nincreasingriskscorewasagainstronglyassociatedwithcontrastagents(gadopentetatedimeglumine,gadodiamide,\n427\nCI-AKI(range8.4%to55.9%forthelowandhighriskscore,gadoversetamide,gadoteridol,gadobenatedimeglumine).",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "graphy. (Part 2)",
    "content": "respectively).ThesemodelscanhelpincounselingabouttheNewlabelingdescribestheriskforNSFfollowingexpo-\nrisksoftheprocedure,selectingprophylacticinterventions,suretoGdinpatientswithaGFR30ml/minper\n1.73mandinpatientswithAKIofanyseveritydueto\nandcanalsobeusedtocharacterizepatientsinstudiesof\nCI-AKI.hepato-renalsyndromeorintheperioperativelivertrans-\nplantationperiod.Additionalrecommendationswere\n420\nrecentlyproposedbyPerazellaandwereendorsedbythe\n4.2.2:Consideralternativeimagingmethodsinpatients\nWorkGroup:\natincreasedriskforCI-AKI.(NotGraded)\n(a)Useofamacrocyclicchelate(gadoteridolintheUSA),\nispreferredoverlinearchelates.Theriskassociated\nwiththevariousGd-containingagentsislikely\nRATIONALE\ndifferent.Gadodiamide,thelinearnonionicchelate–-\nTheselectionandadvantagesanddisadvantagesofnon-\nbasedformulation,maintainsthehighestriskonthe\niodinatedcontrastmediaarebeyondthescopeofthese\nbasisofepidemiologicdataandanimalstudies. guidelines.Detaileddiscussionsofallthesetechniquescan\nGadopentetate,thelinearionicchelate–basedproduct\nbefoundinradiologytextbooksandtheradiologylitera-\nprobablyhasamediumrisk,lessthanthelinear\nture.TheWorkGroupsuggeststhat,inpatientsatincreased\nnonionicchelatesbutmorethanthemacrocyclic\nriskforCI-AKI,therisksandbeneﬁtsofiodinated\nchelates.Gadoteridol,theonlyFDA-approvedmacro-\ncontrast-mediaadministrationshouldbediscussedwiththe\ncyclicchelate,maintainslessrisk.Clearly,highdosages\nradiologist. andlargecumulativedosagesofalltheseagentswill\nBecauseofthegreatrelevanceforthenephrologist,\nincreaseriskforNSF. radiologist,andcardiologistoftheside-effectsofGdchelates\n(b)Demonstrationofsignificantquantitiesofinsoluble\nusedinmagneticresonanceimaging(MRI),ashortoverview\nGdintheskinofNSFpatients,monthsafterexpo-\noftheirnephrotoxicityisgivenhere. suretoGd-basedcontrastmaterialandafterexten-\nsivetissueprocessing,suggeststhatGdmighthave\nNephrotoxicityofGdchelates\nGdchelatesarewidelyusedasMRIcontrastagents,andundergonetransmetallationinvivo.Supportingthe\nareconsideredtohaveagoodoverallsafetyproﬁle.Earlyimportanceoftransmetallation,allNSFcasesreported\non,phaseIIItrialsandsmallstudiesinlow-riskpatientsbefore2009havebeenassociatedwithlinearMRI\n428\nsuggestedabenignrenalproﬁle;however,morerecent)thathave\ncontrastagents(forareview,seeKay\nstudiesraisedthepossibilityofnephrotoxicity,althoughinferiorthermodynamicstabilityandakineticor\nitisnotclearwhetheritapproachestheincidenceofconditionalstabilitythatfavorstransmetallation.How-\nAKIassociatedwithiodine-containingcontrastmedia.ever,arecentcaseofNSFinadialysispatientafter\n429\nGd-relatedAKIappearstobeariskinpatientswithadvancedexposuretoamacrocyclicchelatehasbeendescribed,\n430\nandatleasttwoadditionalcasesareknown. kidneydisease,especiallythosewithdiabeticnephro-\n419,420420\nPerazellaetal.havesummarizedstudies(c)Usethelowestdosageoftheagentpossibletoachieve\npathy. showingGd-inducednephrotoxicAKIcomparedtotheimage. 421–425\nCI-AKI.Studiesinpatientswithunderlyingkidney(d)AvoidrepeatexposureswithGd.",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "graphy. (Part 3)",
    "content": "diseasedemonstratetheimportanceofrenalclearancein(e)ConsiderperformingIHDaftertheexposure(and\n426\ndeterminingthepharmacokineticproﬁleofGdchelates.thenext2days)inpatientswhoarealreadymain-\nMoredetailsonthepharmacokineticsofGdchelatesand\ntainedonIHD,recognizingthattherearenodata\ntheirdialyzabilityareprovidedinAppendixE.thatsupportpreventionofNSFwiththismodality. 74\nKidneyInternationalSupplements(2012)2,69–88",
    "page": 76,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Thisrecommendationisbasedonthepharmaco-",
    "content": "AppendixE:RiskswithGadolinium-BasedContrastAgents.",
    "page": 78,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "kineticsofGdandthetheoreticalbenefitofremoving",
    "content": "Supplementarymaterialislinkedtotheonlineversionofthepaperat",
    "page": 78,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "itwithIHD(95%plasmaclearance).PDclearsthese",
    "content": "http://www.kdigo.org/clinical_practice_guidelines/AKI.php",
    "page": 78,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "agentsratherpoorly.",
    "content": "75\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.3\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 78,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "strategiesofCI-AKI (Part 1)",
    "content": "Therehavebeenalargenumberofstrategies/agentsevaluatedtheexperimentallymeasuredAUCforthecontrastagent\n431\ntopreventCI-AKI.Sterlingetal.haverecentlysumma-iodixanol.TheexperimentallydeterminedAUCdatacorrelated\nrizedmostofthesestrategiesandclassiﬁedthemashavinghighlywiththedose:CrClratio.Thisratiocouldthusbearapid\neitherdeﬁnitive,possible,ordoubtfulvalue.FromthemanyandaccuratewaytoestimateAUCforaniodinatedcontrast\nstrategies,theseauthorsonlyretainparenteralvolumemedium,withouttheneedformultiplebloodsamples. 436\nexpansion,minimizingcontrast-mediavolume,useoflow-ArecentstudybyNymanetal.inpatientsundergoing\nosmolarandiso-osmolarcontrastmedia,andadministrationcoronaryangioplastycalculatedtheprobabilityofCI-AKI\n44m\nofnon-iodinatedcontrastmediaasstrategieswithdeﬁnitive(SCrrise0.5mg/dl[44.2mol/l]oroliguria/anuria)at\nvalue.Arecentcomprehensivemeta-analysisbyKellyvariouseGFRlevelsbasedong-I(gramsiodine)/eGFRratios\n432\netal.—includingRCTsthatadministeredNAC,theophyl-of1:2,1:1,2:1,and3:1.Ataratio1,theriskofCI-AKI\nline,fenoldopam,dopamine,iloprost,statins,furosemide,was3%,whileitwas25%ataratio1.This,andother\normannitol,andcoveringstudiesuptoNovember2006—\npreliminarystudies,indicatethatag-I/GFRratio1maybe\n436–438\nprovidesanexcellentoverview.relativelysafeinapatientwithoutmultipleriskfactors. Finally,theassociationbetweenabsoluteandbodyweight-\nDOSE/VOLUMEOFCONTRAST-MEDIAADMINISTRATION\nandSCr-adjustedcontrast-mediavolume,CI-AKIincidence\n(25%SCrincrease),andclinicaloutcomewasprospec-\n439\n4.3.1:Usethelowestpossibledoseofcontrastmediumin\nForeach\ntivelyinvestigatedinpatientswithacuteMI. patientsatriskforCI-AKI.(NotGraded)\npatient,themaximumcontrast-mediumdosewascalculated\naccordingtotheformula(5bodyweight[kg])SCr,and\n(cid:2)\nthecontrast-mediumratio—deﬁnedastheratiobetweenthe\nRATIONALE\ncontrast-mediumvolumeadministeredandthemaximum\nThecorrelationbetweenthevolumeofcontrastmedia\ndosecalculated—wasassessed.DevelopmentofCI-AKIwas\n433\nadministeredandtheriskofCI-AKIhasbeenrecognized. associatedwithbothcontrast-mediumvolumeandratio. InthevastmajorityofpapersdealingwithCI-AKIafter\nAdditionalradiologicalmeasurestoreduceCI-AKIcanbe\ncoronaryprocedures,contrast-mediadosesareonlyex-\nfoundinTable16. pressedinvolumes.TheWorkGroupfeelsthatsuch\nexpressioncanbemisleading,sincecommerciallyavailable\nRouteofadministrationofcontrastmedia\ncontrast-mediaconcentrationsrangefrom140to400\nTheriskofCI-AKIappearstobegreaterafterarterial\nmilligramsofiodinepermilliliter,adifferencewithalmost\ncomparedtovenousadministrationofcontrastmedia.",
    "page": 79,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "strategiesofCI-AKI (Part 2)",
    "content": "afactorof3.TheWorkGrouprecommends,therefore,that\nIndeed,intherarestudieswhereanappropriatecontrol\nthedoseofcontrastmediumshouldbebetterexpressedin\ngroupwithoutcontrastmediawasincluded,nosigniﬁcant\nrelationtobothvolumeandconcentration,e.g.,grams\ndifferencewasobservedintherateofCI-AKIbetweenthe\niodine,whichalsodirectlyrelatestothediagnosticcapacity,\npatientswhoreceivedi.v.iodinatedcontrastmediaandthe\n440–442\ntheprimarypurposeofthecontrastmedium.Such‘‘double’’\ncontrolsubjectswhodidnot.Thus,theriskofCI-AKI\nexpressionwouldalsofacilitatethecomparisonbetween\nwithi.v.contrastmediumisprobablyverylow.CI-AKI\ndifferentstudiesonepidemiologyandprognosisofCI-AKI. reportedlyoccursafteri.v.contrast-mediuminjectionforCT\n443444\nItiswellknownthat,whenmeasuringtheplasma\ninonly4%ofpatientswithCKD.KatzbergandLamba\nclearanceofaGFRmarker(e.g.,withthecontrastmedium\nsummarizedthesixstudiesonCI-AKIafteri.v.contrast-\niohexol),theAUCisdirectlyrelatedtothedoseofiohexol\nmediumadministrationinpatientsatriskandallsuffering\nandinverselyrelatedtotheGFR.Thus,bymathematically\nfrommoderateCKD.TheoverallincidenceofCI-AKIin\nestimatingtheAUCandknowingtheinjectediodine\nthesestudies,usingthecurrentgenerationoflow-osmolar\ndose,theGFRcanbecalculatedbydoseAUC.Thus,\ncontrastmedia,wasabout5%. AUCdoseGFR,andAUCisdirectlyrelatedtothe\nGiventhelogisticchallengesintheoutpatientsetting,the\nsystemicexposureofadrug,includingthecontrastmedium,\nuseofspeciﬁcprophylacticmeasurespriortoadministration\nwhich,inturn,ismostlycorrelatedwithitsefﬁcacyand\nofi.v.contrastmediacouldbelimitedtothosesubjects\n434435\nAninterestingexperimentalstudyinvestigated\ntoxicity. whoareathigherlevelsofbaselineriskthantheywouldbe\n445\nthecorrelationbetweenthecalculateddosetoCrClratioand\nwhenani.a.procedurewasplanned.Thisconclusion,may\n76\nKidneyInternationalSupplements(2012)2,69–88",
    "page": 79,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter4.3",
    "content": "Table16|AdditionalradiologicalmeasurestoreduceCI-AKI\nSomeCTstrategiesinpatientsatriskofCI-AKI\nPerformCT,whenpossible,withoutcontrastmedia;scrutinizetheexaminationanddiscusswiththereferralphysician-surgeonbeforedecidingon\ntheneedforcontrastmedia.\nDosingperkilogrambodyweighttoreducetheamountofcontrastmediaisneededinthinpatients.\nAdaptinjectiondurationtoscandurationwhenperformingCT-angiography,sothattheinjectionisnotstillrunningwhenthescanisfinished.\nUseasalinechasertodecreasetheamountofcontrastmedia,byusingthecontrastmediumthatotherwisewouldremaininthedeadspaceofthe\narmveins;thismaysave10–20mlofcontrastmedia.\nUse80kVp;contrast-mediumdosemaybereducedbyafactorof1.5–1.7comparedtothedoseusedat120kVpsinceiodineattenuationincreases,\nandcombinewithincreasedtubeloading(mAs)tomaintainsignal-to-noiseratio.\nFurtherreductionofcontrastmediamaybeinstitutedinpatientswithknowndecreasedcardiacoutput(notunusualinpatientswithrenal\nimpairment)undergoingCT-angiographicstudies.\nSomeangiographicstrategiesinpatientsatriskofCI-AKI\nUsebiplanewhenappropriate.\nAvoidtestinjections;thesameamountmaybeenoughforadiagnosticdigital-subtractionangiographyrun.\nScrutinizeeachseriesbeforeperformingthenext;avoidunnecessaryprojections.\nDecreasekilovoltageinathinpatient;aloweriodineconcentrationmaybeused.\nAssessthephysiologicsignificanceofastenosisbymeasurementoftranslesionalpressuregradientandfractionalflowreserve,atechniquewell\nacceptedandvalidatedforthecoronarycirculation.Fordifferentarterialbeds,performmanometryofaquestionablestenosisinsteadofmultiple\nprojections.\nAvoidventriculography:echocardiography(and‘‘echocontrast’’)isalwaysareasonablealternative.\nUseplasmaisotoniccontrast-mediaconcentrationsforrenalarteryinjections.\nWhenrenalarterystenosisissuspected,maptheoriginofmajorrenalarterieswithnoninvasiveprocedures(e.g.,CTwithoutcontrastmedia)for\nproperinitialrenalangiographicprojectionstoavoidunnecessaryruns,orperformprimarymanometry.\nCOmaybeusedascontrastmediuminvenousexaminationsandbelowthediaphragmforarterialexaminationsoralternativelyuseiodinated\ncontrastmediawiththesamecontrasteffect,i.e.,about40mgiodinepermilliliter.\nSincethecontrasteffectof0.5MGd-contrastmediahasbeenregardedasdiagnosticbymanyinvestigators(coronary,renal,aortofemoral\narteriography,etc.),iodinatedcontrastmediamaybedilutedtothesamedensity,i.e.,about75mgiodinepermilliliter.\nUseselectiveorsuperselectivecatheterizationswhenappropriate,e.g.,‘‘singlelegrun-off’’.\nReduceaorticflowandamountofcontrastmediumbytemporalocclusionoffemoralarterieswithtourniquetswhenperformingaortography.\nGd,gadolinium;kVp,peakkilovoltage.\nHigh-osmolarvs.iso-osmolarorlow-osmolarcontrastmedia",
    "page": 80,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Tables19–21). (Part 1)",
    "content": "77\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.3\nFigure14|Riskforcontrast-inducednephropathy.(a)Iodixanolvs.iohexolandriskforcontrast-inducednephropathy;(b)iodixanolvs. nonioniclow-osmolarcontrastmediaotherthaniohexolandriskforcontrast-inducednephropathy.ReprintedfromHeinrichMC,HaberleL,\nMullerVetal.Nephrotoxicityofiso-osmolariodixanolcomparedwithnonioniclowosmolarcontrastmedia:meta-analysisofrandomized\n457\ncontrolledtrials.Radiology2009;250:68–86withpermission,copyright2009,fromRadiologicalSocietyofNorthAmerica;accessed\nhttp://radiology.rsna.org/content/250/1/68.long\nIntotal,14RCTsfulﬁllingthesearchcriteriawerefound.iodixanolwascomparedtootherlow-osmolarcontrast\nTenRCTswerefoundwithi.a.andfourRCTswithi.v. agents(RR0.95;95%CI0.50–1.78;P¼0.86).Iodixanolis\ninjection,respectively(SupplTables19–21).ThereisonlythusnotassociatedwithasigniﬁcantlyreducedriskofCI-\nmoderatequalityofevidenceandoverall,nobeneﬁt—or,atAKIcomparedtothelow-osmolarcontrastmediapooled\nleast,noconsistentbeneﬁt—wasfoundofnonioniciso-together.However,inpatientswithdecreasedkidney\nosmolar(iodixanol)contrastmediacomparedtolow-\nfunction,iodixanolisassociatedwithareducedriskofCI-\nosmolarionicornonioniccontrastmedia.IneightstudiesAKIcomparedtoiohexol. 401,450–456\nsomeshowed\ncomparingcontrastmediagiveni.a.Theclinicalheterogeneitybetweenallthesestudies,asfar\nsuperiorityofiso-osmolarcontrastmedia(iodixanol),\nasbasalkidneyfunctionandprevalenceofdiabetesmellitus\n450455\ncomparedtoiohexolandiopromide.Therewasnoareconcerned,hamperstheabilitytocomparetheresults\n401,452\ndifferencewheniodixanolwascomparedtoiopamidol,\nacrossstudies,butcanwidentheapplicabilityofconsistent\n451,453456\niopromide,andioversal. ﬁndingsacrossdifferentriskgroupsprovidedthemechan-\nThemostrecentprospective,multicenter,randomized,\nismsofcontrast-inducednephrotoxicityarethesame.One\ndouble-blindstudycomparedtherenaleffectsofiodixanoltoshouldnote,also,thatinallthesestudiesdifferentdeﬁnitions\nthenonionic,low-osmolaragentiopamidol,in526subjects\nofCI-AKIhavebeenusedandthatthetimingofSCr\nwithCKDanddiabetesmellitusundergoingdiagnostic\nmeasurementsaftercontrast-mediainjectionwasnotuni-\n454\nand/ortherapeuticcoronaryangiography.Theoverallform.Ithasbeenshownthatdifferenttime-pointsforthe\n458\nCI-AKIincidencewas10.5%(11.2%%intheiodixanolOne\nmeasurementofCI-AKIcangivedifferentresults. armand9.8%intheiopamidolarm,NS).Thevolumeofmayexpectthatthosestudieswithastandardizedand\ncontrastmedium,volumeofsalineadministered,frequencysimultaneousmeasurementofrenalfunctionbetweenthe\ntwoarmsareprobablythemostconclusive.Finally,different\nofcoronaryinterventionalprocedures,andseverityof\nbaselinekidneydiseaseandofdiabetesmellitusweresimilartypesandamountsofvolumeexpansionanddifferent\nbetweentreatments.pharmacologicalpreventivestrategieshavebeenused\n457\nFinally,arecentmeta-analysis(Figure14)analyzedthroughoutthestudies,makingconclusivecomparisons\nstudiescomparingiodixanolwithlow-osmolarcontrastvirtuallyimpossible.",
    "page": 80,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Tables19–21). (Part 2)",
    "content": "media.ThepooledRRwas0.68(95%CI0.46–1.01;\ni.a.Iodixanolvs.ioxaglate\nP0.06).Instudiesthatincludedpatientswithnormal\n459\nTwostudiesfulﬁlledourinclusioncriteria;onestudy\nrenalfunctionafteri.a.contrast-mediaadministration,the\nshowedasuperiorityofiodixanolvs.ioxaglate,butthiswas\nRRwas0.82(95%CI0.45–1.51;P0.53).Inthestudiesthat\n460\nnotconﬁrmedinthestudybyMehranetal.,whofoundno\nincludedonlypatientswithdecreasedkidneyfunctionafter\ndifferencebetweenthesetwocontrastagents.Although\ni.a.contrast-mediaadministration,theRRwas0.59(95%CI\noverallthenumberofpatientsissubstantial,thereis\n0.33–1.07;P0.08).However,inallthreestudiesinwhich\nheterogeneityamongthecomparatorswithwhichiodixanol\niohexolwasthelow-osmolarcontrastmediumused,therisk\nhasbeencompared.Inaddition,thecostofiodixanolis\nofCI-AKIwassigniﬁcantlylowerwithiodixanol(RR0.38;\nprobablyhigherthanthecostofmostofthelow-osmolar\n95%CI0.21–0.68;P0.01).Incontrast,theriskofCI-AKI\ncontrastagents.Nostudiescomparingapossibledifference\ndidnotsigniﬁcantlydifferinthetwostudiesinwhich\n78\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.3\namonglow-osmolarcontrastmediahavebeenperformed. iopromide,butnottoiopamidolandiomeprol.Itis,\nBasedonevidenceproﬁles(SupplTables19and20)andhowever,difﬁculttodeterminewhetherthisissimplydue\n457\nthemostrecentmeta-analysis(Figure14)ofthestudiestospuriousﬁndingsinasmallernumberofcomparisons,or\ncomparingi.a.administrationofiso-vs.low-osmolar\nduetotruedifferencesbetweenlow-osmolaragents.Until\ncontrastmedia,theWorkGroupfoundnoevidencetobetterhead-to-headcomparativestudiesamongthedifferent\nrecommendapreferenceforeithertypeofagent.contrastmediaagentsareavailable,theWorkGroupis\nunabletodrawdeﬁniteconclusionsontheselectionof\ni.v.Administration\niso-osmolarvs.low-osmolarcontrastmedia. Therearefourstudiesfollowingi.v.injectionsfulﬁllingour\n443461\ninclusioncriteria:Barrettetal.,Kuhnetal.,Thomsen\nRESEARCHRECOMMENDATION\n462463\netal.,andNguyenetal.Theoverallconclusion,basedAdditionalstudieswithhead-to-headcomparisons\nontheevidenceproﬁlesummarizedinSupplTable20amongthedifferentcontrastmediashouldbeperformed\ncomparingi.v.iso-vs.low-osmolarcontrastmedia,isthatinordertodrawdefiniteconclusionsontheselection\nthereisnobeneﬁtforthenonioniciso-osmolaragentofiso-osmolarvs.low-osmolarcontrastmedia.Amore\n(iodixanol);theoverallqualityoftheevidenceismoderate.uniformdefinitionofCI-AKI,assuggestedinthis\nThisconclusionissupportedbytheabove-mentionedrecentguideline,shouldbeusedastheend-point. 457\nmeta-analysiswhich,insevenstudiescomparingi.v. SUPPLEMENTARYMATERIAL\ncontrast-mediaadministrationwithiodixanolvs.low-osmolar\nSupplementaryTable19:EvidenceprofileofRCTsexaminingtheeffect\ncontrastmedia,showednostatisticallysigniﬁcantdifference\nofintrarterialisosmolarvs.lowosmolarcontrastagentonthe\nforCI-AKI(RR1.08;95%CI0.62–1.89;P0.79).Subgroup\npreventionofCI-AKI.",
    "page": 80,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Tables19–21). (Part 3)",
    "content": "analysisdidnotshowsuperiorityofanyagentinstudiesof\nSupplementaryTable20:EvidenceprofileofRCTsexaminingtheeffect\nindividualswithnormalkidneyfunction(RR1.12;95%CI\nofintravenousisosmolarvs.lowosmolarcontrastagentonthe\npreventionofCI-AKI. 0.35–3.65;P0.85)orinstudiesofindividualswithreduced\nSupplementaryTable21:SummarytableofRCTsexaminingtheeffectof\nkidneyfunction(RR1.07;95%CI0.56–2.02;P¼0.84). isosmolarvs.lowosmolarcontrastagentonthepreventionofCI-AKI. Inhead-to-headcomparisonswithdifferentlow-osmolar\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nagents,iodixanolhasbeenshowntobesuperiorto\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n79\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 80,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 1)",
    "content": "FLUIDADMINISTRATION\nincidenceofCI-AKIwaslowestfollowingCT(range,\nExtracellularvolumeexpansionatthetimeofradiocontrast-\n0.0–10.9%)andwashighestfollowingnoncoronaryangio-\nmediaadministrationmayservetocounteractboththe\ngraphy(range,1.9–34.0%). intrarenalhemodynamicalterationsandthedirecttubulo-\nTheﬂuidsthathavebeentestedinthepreventionof\ntoxiceffectsthatplayaroleinthepathophysiologyofCI-\nCI-AKIarehypotonicsaline(0.45%),isotonicsaline(0.9%)\nAKI.Neurohumoraleffectsofvolumeexpansionthatmay\nandisotonicsodiumbicarbonate.Theinterpretationofall\nattenuateradiocontrast-inducedmedullaryhypoxiainclude\nthesestudiesishamperedbythefactthatnotallotherrisk\nsuppressionofvasopressinaswellasinhibitionoftherenin-\nfactors(susceptibilities)forCI-AKIwereexcludedor\nangiotensinaxis;butanincreasedsynthesisofvasodilatory\nconsideredineverystudy(i.e.,ageofthepatient,presence\n464\nrenalprostaglandinsmayalsoplayarole. ofCKDand/ordiabetespriortocontrast-mediaadministra-\nVolumeexpansionmayalsodirectlyreducecellular\ntion,typeanddoseofcontrastagent,associatedtherapywith\ndamagebydilutionofthecontrastmedium,particularlyin\nNAC,andotherriskfactors[seeChapter2.2]). themedullarytubularsegments.Likewise,aneffectof\nThereisnoclearevidencefromtheliteraturetoguidethe\nradiocontrastmediatoincreasetubularﬂuidviscositymay\nchoiceoftheoptimalrateanddurationofﬂuidinfusionin\n465\nItis\nbediminishedbyintravascularvolumeexpansion. CI-AKIprevention,butmoststudiessuggestthattheﬂuids\nimportanttonotethatthesepotentiallyattenuatingeffectsof\nshouldbestartedatleast1hbeforeandcontinuedfor3–6\nvolumeexpansionarespeculative,andtheprecisemechan-\nhoursaftercontrast-mediaadministration.A‘‘good’’urine\nismsbywhichvolumeexpansionprotectsagainstCI-AKI\noutput(150ml/h)inthe6hoursaftertheradiological\nremainunknown. procedurehasbeenassociatedwithreducedratesofAKIin\n468\nSincenotallofi.v.administeredisotonic\nonestudy. 4.4.1:Werecommendi.v.volumeexpansionwitheither\ncrystalloidremainsinthevascularspace,inordertoachieve\nisotonicsodiumchlorideorsodiumbicarbonate\naurineﬂowrateofatleast150ml/h,1.0–1.5ml/kg/hof\nsolutions,ratherthannoi.v.volumeexpansion,in\ni.v.ﬂuidhastobeadministeredfor3–12hoursbeforeand\npatientsatincreasedriskforCI-AKI.(1A)\n6–12hoursaftercontrast-mediaexposure. 469\nMuelleretal.foundthati.v.0.9%salinesolution,\ncomparedto0.45%salinesolutionindextrose,in1620\npatientsundergoingcoronaryangiographysigniﬁcantly\nRATIONALE\nDespitetherecognitionofvolumedepletionasanimportantreducedCI-AKI.Thesustainedadministrationofisotonic\nriskfactorforAKI,therearenoRCTsthathavedirectlysalinebeforeandafterradiocontrastinjectionseems,thus,\nevaluatedtheroleofﬂuidsvs.placebointhepreventionoftobemoreprotectivethanequivalentvolumesofhypotonic\n464\nAlthoughthemechanismbywhichsodium\nAKI.However,RCTshavecompareddifferentﬂuidsandhavesaline. 191\nFurthermore,bicarbonate,beyonditsvolume-expandingeffects,might\ncombinedﬂuidswithotherinterventions.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 2)",
    "content": "191\ncomparisonsbetweenoutcomesseeninthesetrialsandfurtherreduceCI-AKIremainspoorlydeﬁned,ithasbeen\n466\nhistoricaluntreatedcontrolsubjectssuggestalargebeneﬁtpostulatedthatsodiumbicarbonateinfusionmaydecrease\nfromﬂuids.Inparticular,volumeexpansionandtreatmentofgenerationoffreeradicalsmediatedbytheHaber-Weiss\ndehydrationarewell-establishedinterventionsinthepreven-reactionbyincreasingtubularpH.TheHaber-Weissreaction\n470\ntionofCI-AKI.Arecentpropensityanalysis,however,notedismostactiveatlowerpHlevels.Sodiumbicarbonate\nthatstrategiestopreventCI-AKIareimplementedratherinfusionmayalsoscavengethepotentoxidantperoxynitrate,\n467471\nnonuniformly.Pre–andpost–contrast-mediaadministra-producedviaanitricoxide–mediatedpathway.Reactive\ntioni.v.ﬂuidsweregiventoonly264of660studypatientsoxygenspeciesactivatecytokine-inducedinﬂammatory\n472\n(40.0%),morecommonlywithcoronaryangiographythanmediators,resultingindamagetoproximaltubularcells,\nwithCT(91.2%vs.16.6%).Otherpreventivemeasures,suchanditislikelythattheactivationofthesemediatorsis\nasadministrationofNACordiscontinuationofNSAIDs,inﬂuencedbytissuehypoxiaandintracellularmedullary\n473\nwereequallyrarelyapplied.Only39.2%ofpatientsreceivedacidosis. NAC,whileonly6.8%ofpatientswereinstructedtoItisworthnotingthat,comparedtoi.v.bicarbonate,the\ndiscontinueNSAIDs.Inapropensityanalysis,theuseofcombinationoforalazetazolamideinducinganalkaline\ni.v.ﬂuidswasassociatedwithareducedrateofCI-AKI.Theurine,plusi.v.saline,wasmoreeffectiveforthepreventionof\n80\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\nFigure15|Bicarbonatevs.salineandriskofCI-AKI.ReprintedfromZoungasS,NinomiyaT,HuxleyRetal.Systematicreview:sodium\nbicarbonatetreatmentregimensforthepreventionofcontrast-inducednephropathy.AnnInternMed2009;151:631–638withpermission\n481\nfromAmericanCollegeofPhysicians;accessedhttp://www.annals.org/content/151/9/631.full\nCI-AKIthansalinealone,inarelativelysmallstudyinstudies.Someheterogeneitywasduetothedifferenceinthe\n474\nchildrenwithstablechronicrenalfailure(CRF).Itcouldestimatesbetweenpublishedandunpublishedstudies:RR\nalsobehypothesizedthatsodiumbicarbonatehasastronger\n0.43(95%CI0.25–0.75)vs.0.78(95%CI0.52–1.17),\nimpactinloweringtheintratubularviscositycausedbytherespectively.Meta-regressionshowedthatsmall,poor-quality\ncontrastmedium,comparedtoisotonicsaline,becauseitstudiesthatassessedoutcomessoonaftercontrast-media\ncauseslesstubularsodiumreabsorptionthansaline. administrationweremorelikelytosuggestthebeneﬁtof\nSodiumbicarbonatesolutionshavebeentestedinthebicarbonate(P0.05forall).Nocleareffectsoftreatmenton\npreventionofCI-AKIincomparisonwithisotonicsaline,theriskfordialysis,heartfailure,andtotalmortalitywere\neitherwithorwithoutNAC.Anumberofsystematicreviewsidentiﬁed.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 3)",
    "content": "ontheroleofsodiumbicarbonatecomparedtoisotonic\nSupplTables22and23summarizetheevidencefrom\n475–481\nsalineinthepreventionofCI-AKIareavailable.RCTswhereisotonicbicarbonatewascomparedtoisotonic\nThemostrecentandprobablythemostcomplete\nsalinealone,withoutconcomitantother‘‘preventive’’inter-\n481\nsystematicreviewanalyzedMEDLINE,PubMed,EMBASE,\nventions.Inallstudies,aminimumof50patientsinboth\nandtheCochraneCentralRegisterofControlledTrialsfromarmsandpublicationasfullpaperwererequiredfor\n1950toDecember2008;conferenceproceedings;and\ninclusioninthetables.Onlythreestudiesdirectlycompared\n470,482,483\nClinicalTrials.gov,withoutlanguagerestriction(Figure15).Inafourth\nisotonicbicarbonatetoisotonicsaline. 484\nThissystematicreviewincludedRCTsofi.v.sodiumstudybyBraretal.,NACwasincludedin47%and46%of\nbicarbonatethatprespeciﬁedtheoutcomeofCI-AKIasathepatientsinbotharmsofthestudy(bicarbonatevs. 25%increaseinbaselineSCrconcentrationoranabsolutesaline),respectively.Theﬁrststudywasasmallsingle-center\n470\nincreaseof0.5mg/dl(44.2mol/l)aftercontrast-mediaRCTenrolling119patientswithstableSCrofatleast\n1.1mg/dl(97.2mol/l),randomizedtoeitherinfusionof\nadministration.Twenty-threepublishedandunpublished\ntrialswithinformationon3563patientsand396CI-AKIisotonicsalineorisotonicsodiumbicarbonatebeforeand\neventswereincluded.ThepooledRRwas0.62(95%CIaftercontrast-mediaadministration.CI-AKI(deﬁnedasan\n0.45–0.86),withevidenceofsigniﬁcantheterogeneityacrossincreaseof25%inSCrfrombaselinewithin48hours)\n81\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\ndevelopedin1.7%inthebicarbonategroup,comparedtoprophylacticadministrationof0.9%salineinfusionplus\n13.6%inthesalinesolutiongroup.NAC(n111),sodiumbicarbonateinfusionplusNAC\n483\nOzcanetal.includedthreeprophylacticregimens:(n108),and0.9%salineplusascorbicacidplusNAC\ninfusionofsodiumbicarbonate,sodiumchloride,andsodium(n107).CI-AKIwasdeﬁnedasanincreaseof25%inthe\nchlorideplusoralNAC(600mgb.i.d.).TheincidenceofSCrconcentration48hoursaftertheprocedure.CI-AKI\nCI-AKI,deﬁnedasanincreaseinSCrlevel25%or0.5mg/dloccurredin9.9%ofthesalineplusNACgroup,in1.9%of\n(44.2mol/l)after48hourswassigniﬁcantlylowerinthethebicarbonate/NACgroup(P0.019vs.salineplusNAC\nsodiumbicarbonategroup(4.5%)comparedtosodiumgroup),andin10.3%ofthesalineplusascorbicacidplus\nchloridealone(13.6%,P0.036).AfteradjustingfortheNACgroup(P1.00vs.salineplusNACgroup).Therewas\n¼¼\nMehrannephropathyriskscore,theriskofCI-AKIsigniﬁ-nodifferenceinmortalitynorinneedforRRTamongthe\ncantlyreducedwithsodiumbicarbonatecomparedtosodiumdifferentgroups.Whilethesetwostudiessuggestthat\nchloridealone(adjustedriskratio0.29;P0.043).isotonicbicarbonatemayprovidegreaterbeneﬁtthan\n482\ndidnotﬁnddifferencesinCI-\nBycontrast,Adolphetal.isotonicsaline,eitherinassociationwithNACornot,neither\nAKIbetweenthetwoﬂuidregimensonday1afterstudycanbeconsideredconclusive.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 4)",
    "content": "487\nangiography;evenonday2,mostparametersweresimilarMaiolietal.prospectivelycomparedtheefﬁcacyof\ninbothgroups.Innoneoftheabove-mentionedstudieswassodiumbicarbonatevs.isotonicsalineinadditiontoNACin\nthereneedforRRT.alargerpopulationof502patientswithanestimatedCrCl\n485\nFinally,arecentbutretrospectivestudydeﬁnedCI-AKI60ml/min,andundergoingcoronaryangiographyor\nasanincreaseinSCr25%within48hoursofreceiving\nintervention.CI-AKIwasdeﬁnedasanabsoluteincreaseof\nXX\ncontrastmedia,andcomparedsodiumbicarbonatetoSCr0.5mg/dl(44.2mol/l)measuredwithin5days.CI-\nnormalsalineinpatientsexposedtocardiacangiography.AKIoccurredin10.8%;10%weretreatedwithsodium\nOnegroupofpatients(n89)receivedprophylacticbicarbonateand11.5%withsaline.InpatientswithCI-AKI,\nbicarbonate;asecondgroup,normalsaline(n98).Thethemeanincreaseincreatininewasnotsigniﬁcantlydifferent\npatientsinthebicarbonategrouphadmoresevererenalinthetwostudygroups.Basedonthislastprospectivestudy,\n±±\ndiseasewithhigherbaselineSCr(1.580.5mg/dl;140bicarbonatedoesnotseemtobemoreefﬁcientthansaline. ±±\nmm\n44.2mol/l)vs.(1.280.3mg/dl;11326.5mol/l),\nFurthermore,aretrospectivecohortstudyattheMayoClinic\nP0.001andalowereGFR,comparedtothenormalsalineassessedtheriskofCI-AKIassociatedwiththeuseofsodium\ngroup.Aftercontrast-mediaexposure,therewassigniﬁcantbicarbonate,NAC,orthecombination.Surprisingly,i.v. dropineGFR(6.4%)andincreaseinSCr(11.3%)inthesodiumbicarbonatewasassociatedwithanincreased\n489\nnormalsalinegroupandnosigniﬁcantchangeintheincidenceofCI-AKI. Whileonemighttakethepositionthat,ifindoubt,one\nbicarbonategroup.Threepatients(3.4%)inthebicarbonate\ngroup,asopposedto14patients(14.3%)inthenormalsalineshouldchoosetheregimenthatispotentiallysuperior,the\ngroup,developedCI-AKI(P0.011).TwopatientsintheWorkGroupalsoconsideredthepotentialharm.Inaddition,\nnormalsalinegroupandnoneinthebicarbonategroupisotonicbicarbonatesolutionsareusuallycomposedby\nadding154mlof8.4%sodiumbicarbonate(i.e.,1mmol/\nneededdialysis.Thisstudysuggeststhattheuseofi.v. sodiumbicarbonateismoreeffectivethannormalsalineinml)to846mlof5%glucosesolution,resultinginaﬁnal\npreventingCI-AKI.sodiumandbicarbonateconcentrationof154mmol/leach. Sincethismixingofthesolutionisoftendoneatthebedside\nThreestudiescomparedbicarbonateandsalinesolutions\nassociatedwiththeadministrationofNACinbothstudyorinthehospitalpharmacy,thereisthepossibilityforerrors\n486–488488\nRecio-Mayoraletal.conductedaprospective\narms.leadingtotheinfusionofahypertonicbicarbonatesolution.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 5)",
    "content": "single-centerRCTin111consecutivepatientswithacute\nThepotentialforharmfromdosingerrors,andtheadded\ncoronarysyndromeundergoingemergencyangioplasty.Oneburdenfrompreparationofthebicarbonatesolution,hasto\ngroupofpatientsreceivedaninfusionofsodiumbicarbonatebetakenintoaccountinclinicalpracticewhenmakinga\nplusNACstartedjustbeforecontrast-mediainjectionand\nchoicebetweenusingbicarbonateratherthanstandard\ncontinuedfor12hoursafterangioplasty.Thesecondisotonicsalinesolutions.Takentogether,theWorkGroup\n(control)groupreceivedthestandardﬂuidprotocolconsist-concludedthatthereisapossiblebutinconsistentbeneﬁtof\ningofi.v.isotonicsalinefor12hoursafterangioplasty.In\nbicarbonatesolutionsbasedonoverallmoderate-quality\nbothgroups,twodosesoforalNACwereadministeredtheevidence(SupplTable22).Asdiscussedabove,thepotential\n44m\nnextday.ASCrconcentration0.5mg/dl(44.2mol/l)ofharmandtheadditionalburdenforpreparingthe\nfrombaselineafteremergencyangioplastywasobservedinbicarbonatesolutionsledtheWorkGroupnottoexpressa\n1.8%inthebicarbonategroupandin21.8%ofthesaline\npreferencefororagainstonesolution(isotonicsalineor\ngroup.MortalityandneedforRRTwerenotsigniﬁcantlyisotonicbicarbonate).Thus,eithercanbeusedforthe\n486\nrandomized\ndifferentbetweenbothgroups.Briguorietal.preventionofCI-AKI. XX\n326CKDpatients(SCr2mg/dl[177mol/l]and/or\neGFR40ml/minper1.73m),andreferredforcoronary4.4.2:Werecommendnotusingoralﬂuidsalonein\nand/orperipheralprocedurestothreedifferentprotocols:\npatientsatincreasedriskofCI-AKI.(1C)\n82\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\n497\nRATIONALE\nintoxication.Ameta-analysisofstudiesusinghighdoses\nOralvolumeexpansionmayhavesomebeneﬁt,butthereis\nofNACdeﬁnedthelatterasadailydosegreaterthan1200mg\nnotenoughevidencetoshowthatitisaseffectiveasi.v. orasingleperiproceduraldosegreaterthan600mg\n490491\nvolumeexpansion.OnesmallRCTof53patientswho\n(periproceduralbeingdescribedasimmediatelyorwithin4\nunderwentnonemergentcardiaccatheterizationfoundthat\nhoursoftheplannedcontrastexposure).Itshouldalsobe\ni.v.volumeexpansionwithsalinewasmoreeffectivethan\nrememberedthatnoFDAlabelisavailableforNACasa\n492\nunrestrictedoralﬂuidintake.Amorerecenttrialexamined\npreventivedrugofAKI. theeffectsoforalvolumeintakeonrenalfunctionin180\nSupplTables24and25summarizethequitenumerous\npatientswithpreservedrenalfunctionreferredforcoronary\nRCTswhereNAChasbeencomparedtoplaceboonthe\nCTangiography.Thepatientsweredividedintotwogroups:\nimpactofpatientmortality,needforRRT,orpreventionof\n106subjectswithanincreaseinSCraftercoronaryCT\nCI-AKI.Inmostofthestudies,i.v.ﬂuids,eitherwithisotonic\nangiography;and74without.Signiﬁcantcorrelationswere\nsalineorwithisotonicbicarbonate,wasusedinbotharms.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 6)",
    "content": "observedbetweentheamountoforalﬂuidintakeandthe\nMoreover,theimpactofNAConimportant‘‘hard’’patient\npercentagechangesinSCraswellastheabsolutechangesin\noutcomes,suchasall-causemortality,needforRRT,or\neGFR.Inmultipleregressionanalysis,theamountoforal\ndoublingofSCrlevelhasonlyrarelybeenstudied.Atpresent,\nﬂuidintakewastheonlyindependentpredictorforan\nthereisnocurrentevidencethateitheroralori.v.NACcan\nincreaseinSCr.However,arecentstudycomparedoralﬂuids\naltermortalityorneedforRRTaftercontrast-media\n(waterwithorwithoutbicarbonate)toi.v.ﬂuids(isotonic\nadministrationtopatientsatriskforCI-AKI.Theonlystudy\nsalineorbicarbonate)anddidnotﬁnddifferencesin\nshowingasigniﬁcantdecreaseinhospitalmortalityisthe\n498\nincidenceofCI-AKIpatientswithmildCKD.Ifconﬁrmed\ninpatientsundergoing\nthree-armstudyofMarenzietal. inlargerstudies,thisregimencouldofferanequivalentand\nprimaryangioplasty.Overallin-hospitalmortalitywashigher\nmorepracticalapproachinpreventingadeclineinrenal\ninpatientswithCI-AKI,deﬁnedasa25%increaseinSCr,\nfunctionaftercontrastexposure,withoutaccruingadditional\nthaninthosewithoutCI-AKI(26%vs.1%;P0.001). 493\ndelayinhospitaldaysorin-hospitalmortality. Thirteenpatients(11%)inthecontrolgroupdied,asdidﬁve\n(4%)inthestandard-doseNACandthree(3%)inthehigh-\nROLEOFNACINTHEPREVENTIONOFCI-AKI\ndoseNACgroup(P0.02).Allotherstudiesdidnotshowa\nbeneﬁcialeffectonmortality(SupplTable25).Overall,this\n4.4.3:WesuggestusingoralNAC,togetherwithi.v.iso-\nevidencewasdeemedtobeofmoderatequalityandthe\ntoniccrystalloids,inpatientsatincreasedriskof\npossiblepositiveeffectonmortalitydubious. CI-AKI.(2D)\nTheeffectofNAContheincidenceofCI-AKIisquite\nvariable.Asisshownintheevidenceproﬁle(SupplTable24),\ntheevidencethatNACreducesCI-AKI,asdeﬁnedinthe\ndifferenttrials,comesfromstudieswithratherheterogeneous\nRATIONALE\nNAC—inmany,butnotall,studies—hasbeenshowntohave\nresults;mostofthestudieswereofeitherhighormodest\naprotectiveeffectonCI-AKIwhenadministeredbeforethe\nquality.Inonestudy,aprotective—evendose-dependent—\n494\n498\nonsetofrenalinsult;forareview,seeMcCullough.In\neffectwasobserved.Inthatstudy,theriskforCI-AKIwas\naddition,NACisinexpensiveandappearstobesafe,\nreducedby54.5%inthestandard-doseNACgroupandby\nalthoughitmayhavesomedetrimentaleffectsonmyocardial\n75.8%inthehigh-doseNACgroup.Theseﬁndingsarein\n371–373\nandcoagulationfunction.The‘‘safety’’ofNACshould\nsharpcontrasttomanyotherstudiesshowingnoeffectand,\n499\nfurtherbeamended,particularlywhenhighi.v.dosesare\nwhichwas\ninparticular,withthelargestudyofWebbetal.,\nused,asinsomeoftheRCTsinCI-AKI.Whenprospectively\nterminatedearlyafterenrollmentof487patientsbecause\nstudiedinacetaminophenpoisoning,i.v.NACproduced\nofadeterminationoffutilitybytheDataSafetyMonitoring\n374\nanaphylactoidreactionsinupto48%ofparticipants.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 7)",
    "content": "Committee.Asmentionedearlier,combinationstudiesof\n486\nAlthoughmostofthesereactionsweremild,atleastone\nNACwithbicarbonateadministrationhavefounda\n375\ndeathhasbeenreportedinapatientwithasthma.Itshould\nmoderatebeneﬁtforthiscombination,comparedtothe\nbenotedthatthedosesusedinacetaminophenintoxication\ncombinationofNAC-saline. 364\narestillmuchhigherthaninthe‘‘highdoses’’usedinCI-AKI\nAsrecentlyremarkedbyFishbane,mostofthestudies\n495\npreventiontrials.Inarecentreview,dosesofNAC300mg/\npublishedonNACforthepreventionofCI-AKIarequite\nkgi.v.over21hours,980mg/kgi.v.over48hours,and\nsmallinsize,andmeta-analyseshavebeenperformedto\n1330mg/kgp.o.over72hourswerementionedtohavebeen\nincreasetheprobabilityofexplainingthefullspectrumof\nallcomparablyeffectiveatpreventinghepatotoxicityinmost\nutilityforNAC.Todate,sevenoutofthe11meta-analyses\nuncomplicatedearly-presentingacuteacetaminophenover-\nthathavebeenpublishedonthissubjectfoundanetbeneﬁt\n364\ndoses.AlthoughavarietyofdosesofNAChasbeen\nforNACinthepreventionofCI-AKI.However,aspointed\nadministeredinthepreventionofCI-AKI,thei.v.‘‘high\noutbefore,markedheterogeneityinthestudies,and\n496\ndoses’’usedinonestudyaremostly21200mgNACper\n(cid:2)\npublicationbiasmustleadtotheconclusionthat‘‘pooling\ndayfor2–3days,farbelowthedosesusedinacetaminophen\nofdatatoarriveatasummaryestimatefortreatmentefﬁcacy\n83\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\nshouldgenerallybeavoidedinsituationswherethetrials\nNACalone;onestudycomparedcombinationtherapyto\nexhibitsigniﬁcantstatisticaland/orclinicalhetero-NACwithnormalsaline,andaseparatearmwithNACand\n500,501502\ngeneity’’.ArecentprospectiveRCTwasperformedinascorbicacid.Collectively,combinationtreatmentofNAC\npatientswithdecreasedkidneyfunction(CrCl60ml/minwithi.v.sodiumbicarbonatereducedCI-AKIby35%\nXX\nand/orSCrlevelof1.1mg/dl[97.2mol/l]),comparingacomparedtotheotherabove-mentionedcombinations(RR\nhighoraldoseofNACwithhighdosesofvitaminC.All0.65;95%CI0.40–1.05).However,thecombinationofNAC\npatientsunderwentacoronaryangiography.Theprimaryend-plussodiumbicarbonatedidnotsigniﬁcantlyreducerenal\npointwasthemaximumincreaseofSCrlevel,andthefailurerequiringdialysis(RR0.47;95%CI0.16–1.41).Itwas\nsecondaryend-pointwastheincidenceofCI-AKI,deﬁnedasaconcludedthatcombinationprophylaxiswithNACand\nrelativeincreaseinbaselineSCrlevelof25%and/oransodiumbicarbonatesubstantiallyreducedtheoccurrence\nXX\nabsoluteincreaseof0.5mg/dl(44.2mol/l)within48ofCI-AKIoverall,butnotdialysis-dependentrenalfailure.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 8)",
    "content": "hoursaftercontrast-mediaadministration.ThemaximumThispapersuggeststhatcombinationprophylaxisshould\nincreaseofSCrlevelwassigniﬁcantlylowerintheNACgroupbeincorporatedforallhigh-riskpatients(emergentcases\n±±\nthanintheascorbicacidgroup(0.030.18mg/dl[2.65orpatientswithpre-existingCKD).Mostofthestudies\n(cid:3)(cid:3)\n±±\nmm\n15.9mol/l]vs.0.040.20mg/dl[3.5417.7mol/l]),administeredNACorally;somestudiesusedthei.v.routeor\nrespectively(P¼0.026).TheincidenceofCI-AKItendedtoevenacombinationoforalandi.v.Therewasalsoasubstantial\nbeinfavorofNACratherthanascorbicacid,1.2%vs.4.4%,variationindosesandtimingofNACadministration. respectively,althoughthisdifferencewasnotsigniﬁcantOneadditionalstudywasrecentlypublishedandwasthus\n(P0.370).ItwasconcludedthatanoralhighdoseofNACnotincludedinthemeta-analysisdiscussedabove.Koc\n504\ninvestigatedtheefﬁcacyofprophylactici.v.NACand\nseemedtobemorebeneﬁcialthanascorbicacidinpreventingetal.,\nCI-AKI,particularlyindiabeticpatientswithpre-existingCKD.ﬂuidsforthepreventionofCI-AKIinpatientswithmildto\nXX\nmoderaterenaldysfunction(SCr1.1mg/dl[97.2mol/l]\nFinally,arandomized,single-blind,controlledtrialwas\nrecentlypublishedtoassessNACeffectsonCI-AKIandoraCrCl60ml/min)whowereundergoingcoronary\nreperfusioninjuryinST-segmentelevationmyocardialangiography.Agroupofpatientswasassignedtoi.v.NAC\ninfarction(MI)patientsundergoingprimaryangioplasty(bolusof600mgtwicedailybeforeandonthedayofthe\nprocedure)plushigh-dosenormalsaline,asecondgroupto\nwithmoderatecontrast-mediavolumes(between120–230ml\n496\nofaniso-osmolarcontrastmedium).Thepatientsunder-onlyhigh-dosesaline,andathird(control)groupreceived\ngoingprimaryangioplastywererandomizedtoeitherhigh-standardsaline.PatientsintheNACplushigh-dosesaline\ndoseNAC(twotimes1200mg/dfor48hours;orplacebogroupreceivedani.v.bolusof600mgofNACtwicedaily\nplusﬂuids).CI-AKIoccurredin14%oftheNACgroupandbeforeandonthedayofthecoronaryprocedure(total2.4g)\nin20%oftheplacebogroup(P0.28).Themyocardial\n¼plusi.v.0.9%saline1ml/kg/hbefore,on,andafterthedayof\nsalvageindexwasalsonotdifferentbetweenbothtreatmentthecoronaryprocedure.Patientsinthehigh-dosearm\ngroups.Activatedoxygenproteinproductsandoxidizedlow-receivedthesameamountofisotonicsaline,whilepatients\ndensitylipoproteinasmarkersforoxidativestresswereinthecontrolgroupreceivedani.v.doseof0.9%saline\nreducedbyasmuchas20%intheNACgroup,whereasno\n1ml/kg/hfor12hoursbeforeand12hoursafterthecoronary\nchangewasevidentintheplacebogroup.procedure.TherateofCI-AKIintheNACplushigh-dose\nThus,despitehigh-dosei.v.NACreducingoxidativestress,salinegroupwaslowerthaninthehigh-dosesalinegroup\nitdoesnotprovideanadditionalclinicalbeneﬁt,compared\nwithoutNAC.Nosigniﬁcantdifferencesintheprimaryand\ntoplacebo,withrespecttoCI-AKIandmyocardialreper-secondaryend-pointswerefoundbetweenthehigh-dose\nfusioninjuryinnonselectedpatientsundergoingangioplasty.salineandcontrolgroups.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 9)",
    "content": "Arecentmeta-analysisofallprospectivetrialsofindividualsInconclusion,basedontheevidencetablesandeven\nrandomizedtoeitherorallyori.v.administeredhighdosesof\ntakingthelastrecentstudyintoaccount,theoverallbeneﬁtof\nNAC,deﬁnedasadailydosegreaterthan1200mgorasingleNACisnotconsistentoroverwhelming.Ontheotherhand,\nperiproceduraldose(within4hoursofcontrast-mediaoralNAChasalowriskofadverseeventsandusuallyalow\n497\nexposure)600mg,waspublishedbyTrivedietal.The\ncost. overalleffectsize,assumingacommonOR,was0.46(95%CI\nTHEOPHYLLINEANDFENOLDOPAMINPREVENTIONOFCI-AKI\n0.33–0.63)fortheoccurrenceofCI-AKIwiththeuseofhigh-\nTheophylline\ndoseNAC.Theresultsofthemoreconservativerandom-\neffectsapproachweresimilar(OR0.52;95%CI0.34–0.78). 4.4.4:Wesuggestnotusingtheophyllinetoprevent\nAnotherrecentlypublishedmeta-analysisofRCTsinclu-\n503\nCI-AKI.(2C)\ndedpublishedtrialsandconferenceabstracts(Figure16). Theprimaryandsecondaryoutcomesofinterestwere\nCI-AKI,andrenalfailurerequiringdialysis,respectively. TenRCTsmettheinclusioncriteria.Ninestudiescompared\nRATIONALE\ncombinationtreatment(bicarbonateandNAC)toNACandArationalefortheprophylacticuseofadenosineantago-\nnormalsaline;onestudycomparedcombinationtherapytonistsinpatientsundergoingradiocontrastprocedureswas\n84\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\nFigure16|NACandbicarbonatevs.NACforriskofCI-AKI.ReprintedfromBrown,JR,BlockCA,MalenkaDJetal.Sodiumbicarbonate\n503\nplusN-acetylcysteineprophylaxis:ameta-analysis.JACCCardiovascInterv2009;2:1116–1124,copyright2009,withpermissionfrom\nAmericanCollegeofCardiologyFoundation;accessedhttp://interventions.onlinejacc.org/cgi/content/full/2/11/1116\nsuggestedbyresultsshowingincreasedserumlevelsandNeithermeta-analysisincludedaRCTpublishedin2006\nurinaryexcretionofadenosineoccurringafterintravascular\nin150contrast-mediaexaminationsin91patients,inwhich\n505\nadministrationofcontrastmedia.Theefﬁcacyoftheo-therenoprotectiveeffectsoftheophylline,NAC,andthe\n507\nphyllineinpreventingCI-AKIhasbeenaddressedbyacombinationofbothweredirectlycompared.Allpatients\nsystematicreviewandmeta-analysisin2005(nineRCTs,585hadatleastoneriskfactorfordevelopingCI-AKI,and\n506\npatients),andanothermeta-analysisin2008(sixRCTs,receivedmorethan100mloflow-osmolarradiocontrast\n432\n629patients).Bothmeta-analysesindicatedanonsigni-agent.TheincidenceofCI-AKIwassigniﬁcantlylowerwith\nﬁcanttrendtowardarenoprotectiveeffectoftheophyllinetheophyllineascomparedtoNACpretreatment(2%vs.12%;\nprophylaxis.TheincidenceofCI-AKItendedtobeP0.045),anddidnotdifferbetweentheophyllinemono-\nlower(Bagshaw:OR0.4,CI0.14–1.16,P¼0.09;Kelly:ORtherapyandthecombinationtreatment.Therenoprotective\n0.49,CI0.23–1.06,P0.14),SCrconcentrations48hourssuperiorityoftheophylline,whichwasgivenasasinglei.v.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 10)",
    "content": "afterinterventionweresigniﬁcantlylower(0.17mg/dl;200mgdose30minutespriortotheprocedure,waseven\n(cid:3)\n95%CI0.2to0.06mg/dl[15.0mol/l,CI17.7tomoresigniﬁcantinpatientswithpre-existingrenaldamageas\n(cid:3)(cid:3)(cid:3)(cid:3)\nm44m\n(cid:3)5.30mol/l];P¼0.002)withtheophyllinecomparedtoindicatedbyanSCr1.5mg/dl(133mol/l)(P0.008). 508\ncontroltherapies.However,theoverallbeneﬁtwassmallandMoreover,arecentstudyrandomized217patientswith\nﬁndingswereinconsistentacrossstudies.ThebeneﬁteGFRbetween30and60ml/minwhowereundergoing\ncoronaryangiographytooneofthreeprophylactictreat-\nattributabletotheuseoftheophyllinetendedtobeless\nmarkedinpatientsreceivingiso-osmolar,nonioniccontrastments:i.v.isotonicsaline(1ml/kg/hfor12hoursbeforeand\nmedia,andinpatientsundergoingapredeﬁnedsalineaftercontrastmedia(group1,n¼72);isotonicsalineasin\nprotocol.group1togetherwithNAC(600mgp.o.twicedailythe\n85\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.4\nprecedingdayandthedayofangiography(group2,n73);wererandomizedtosalinealoneorwithfenoldopam\norisotonicsalineandNACasingroup2togetherwith(0.1g/kgperminutefor4hoursbeforeandafterthe\n200mgtheophyllineorallytwicedailyfortheprecedingdayprocedure);athirdarmwastreatedwithNAC.Theincidence\nandthedayofangiography(group3,n72).TheincidenceofCI-AKIwassimilarinthefenoldopam(15.7%)and\nofCI-AKI(0.5mg/dlor44.2mol/lSCrincreasewithin48control(15.3%)groups,andtherewasnobeneﬁtover\n220\nhoursofintravascularcontrast-mediainjection)was6.9%insalinealone.Asecond,largertrialalsoconﬁrmedthe\ngroup1,9.6%ingroup2,and0%ingroup3(P0.03),lackofbeneﬁtwithfenoldopam.Inthisdouble-blindtrial\nsuggestingabeneﬁcialeffectofaddingtheophyllinetoaof315patients,allwithsaline0.45%,wererandomizedto\nmm\nstandardregimeninthepreventionofCI-AKI.Notably,atfenoldopam(0.05g/kgperminutetitratedto0.1g/kg\nleastinthisstudy,NACadministrationhadnoadditiveperminute)orplacebostarting1hbeforetheprocedureand\nprotectiveeffectcomparedtoisotonicsalinealone.continuingfor12hoursafterward.Therewasnosigniﬁcant\n509\nAveryrecentstudyrandomlyassignedpatientstodifferenceintheincidenceofCI-AKIwithin96hoursin\nprophylacticadministrationofsalinewithsodiumbicarbo-thetwogroups(fenoldopam,33.6%;placebo,30.1%)orin\nnateplustheophylline(eitherorallyori.v.)orsodiumtheratesofdialysis,rehospitalization,ordeathat30days. bicarbonateonly.Theophyllineplusbicarbonateprophylaxis\nStatinsinthepreventionofCI-AKI\nsigniﬁcantlyreducedtheincidenceofCI-AKI(1.6%vs.7.9%;\nTworecentstudiesexaminedtheuseofstatinsinthe\nP0.015)comparedtobicarbonatealone.Theophyllinewas\n514\npreventionofCI-AKIpatientswithCKD.Intheﬁrststudy,\nadministeredeitherorally(200mgb.i.d.startingtheday\n31patientswereprospectivelyrandomizedtoreceiveatorvas-\nbeforethecontrastadministrationandcontinuingfor24\ntatin80mg/dorplacebofor48hoursbeforeand48hours\nhoursthereafter)ori.v.200mginashortinfusionbefore\naftercontrast-mediumadministration.Allpatientsreceivedi.v.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 11)",
    "content": "contrastadministrationandcontinuingorallyat200mg\nsalineandoralNAC.CI-AKIoccurredin16patients(11%)in\nb.i.d.for48hours.Theophyllineprophylaxissigniﬁcantly\ntheplacebogroupand15patients(10%)intheatorvastatin\nreducedtheincidenceofCI-AKIinmoderateandhigh-risk\ngroup.Persistentkidneyinjury,deﬁnedas1-monthincrease\npatients(0%vs.8.8%;P0.022and9.1%vs.42.1%;\nfrombaselinecreatininevalue25%,wasobservedin30%\nP0.014,respectively).Thisstudydidnotmentionside-\nintheplacebogroupandin31%intheatorvastatingroup. effectsoftheophylline. 515\nThesecondstudyfollowed431patients,194ofwhomwere\nAlthoughthesedatasuggestthatpreinterventionaltheo-\nreceivingpravastatintreatmentforhypercholesterolemia.SCr\nphyllineadministrationmightbehelpfulinpatientsat\nlevelsweremeasuredatbaseline(preprocedure)andwithin48\nincreasedriskforCI-AKI,thepossibilityofcardiovascular\nhoursaftercontrast-mediumexposure(peakpostprocedure). side-effectsandtheinteractionswithnumerousdrugs\n510,511\nLogisticregressionanalysisrevealedthatpravastatintreatment,\nshouldberecognized\nassociatedwiththeophylline\npreprocedureSCr,andcontrastvolumewereindependently\n(SupplTables26and27).Ascanbenotedfromtheevidence\nrelatedtothedecreasedriskofCI-AKI.However,suchstudies\nproﬁletables,theevidenceislowandthebalanceofbeneﬁts\naresusceptibletotheso-called‘‘healthyusereffect’’where\nvs.harmisuncertain.Inviewofthelowevidenceandthe\ncertaingroupsmayhavereducedrisk,notbecauseofthe\nuncertainbalanceofbeneﬁtsvs.harm,theWorkGroup\ndrugbutbecauseofhealthierlifestyles,forwhichuseofthe\ndoesnotsupporttheuseoftheophyllineforpreventionof\nmedicationisamarker.Forexample,patientstakingstatins\nCI-AKI. mayalsobemorecompliantwithothermedical-careregimens\nthatmayreduceadverseevents. Fenoldopam\n4.4.5:Werecommendnotusingfenoldopamtoprevent\nSUPPLEMENTARYMATERIAL\nSupplementaryTable22:EvidenceprofileofRCTsexaminingeffectof\nCI-AKI.(1B)\ni.v.sodiumbicarbonatevs.controlforthepreventionofCI-AKI. SupplementaryTable23:SummarytableofRCTsexaminingtheeffect\nofi.v.sodiumbicarbonateonthepreventionofCI-AKI. RATIONALE\nSupplementaryTable24:EvidenceprofileofRCTsexaminingtheeffect\nFenoldopamisaselectivedopamineA1receptoragonist\nofNACvs.placeboonthepreventionofCI-AKI. thatmighttheoreticallyincreasebloodﬂow,especiallytothe\nSupplementaryTable25:SummarytableofRCTsexaminingtheeffect\nrenalmedulla.Severaluncontrolledstudies(historical\nofNACvs.placeboonthepreventionofCI-AKI. controls,retrospectivereview)suggestedthatitiseffective\nSupplementaryTable26:EvidenceprofileofRCTsexaminingtheeffect\noftheophyllinevs.placeboonthepreventionofCI-AKI. inreducingtheriskforcontrast-inducednephropathy,and\nSupplementaryTable27:SummarytableofRCTsexaminingtheeffect\ntheresultsofapilottrialwerepromising(forreview,see\noftheophyllinevs.placeboonthepreventionofCI-AKI.",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "ofCI-AKI (Part 12)",
    "content": "512\nStaculetal.).However,twoprospectiverandomizedtrials\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\n220,513513\nshowednegativeresults.Intheﬁrsttrial,patients\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n86\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.5\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 83,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter4.5:Effectsofhemodialysisorhemofiltration (Part 1)",
    "content": "521\n4.5.1:Wesuggestnotusingprophylacticintermittent\nBycontrast,Leeetal.presentedaprospectiveRCT\nhemodialysis(IHD)orhemoﬁltration(HF)for\nindicatingthatprophylacticIHDmightbeusefulinpatients\ncontrast-mediaremovalinpatientsatincreased\nscheduledforcoronaryangiographyorcoronaryintervention\nriskforCI-AKI.(2C)\nwithseverelyimpairedrenalfunction(baselineCrClof13ml/\nminper1.73m).Patientsweretreatedwithnormalsalineat\n1ml/kg/hfor6hoursbeforeand12hoursaftercontrast-\nmediaadministrationandrandomizedtoreceiveIHDfor\nRATIONALE\nContrastmediaareexcretedmainlybyglomerularﬁltration\n4hoursassoonaspossibleafterangiographyorcontrol\nandthereisasigniﬁcantcorrelationbetweenbothtotalbody\ntreatment.Fourdaysafterangiography,SCrconcentrations\nandrenalclearancesofcontrastmediaandGFR;therenal\nwerelowerintheIHDgroupcomparedtothecontrolgroup. excretionofcontrastmediawillthusbedelayedinpatients\nOutof42patients,onepatient(2%)intheIHDgroupbut14\n516\nContrastmedia\nwithrenalfailure(forreview,seeDeray). (35%)outof40patientsinthecontrolgrouprequired\ncanbeefﬁcientlyremovedfrombloodbyIHDandasingle\ntemporaryIHDaftercoronaryangiography.Furthermore,\n516,517\nsessioneffectivelyremoves60–90%ofcontrastmedia. noneofthe42patientsintheIHDgroup,butﬁve(13%)out\nOnthebasisoftheseobservations,severalstudieshave\nof40patientsinthecontrolgroup,requiredmaintenance\nexploredtheprophylacticvalueofIHDinpatientsathigh\nIHDafterdischargefromthehospital(P0.05). risk,butmostofthesestudieshavenotdemonstrateda\nArecentmeta-analysisofstudiesusingperiprocedural\n516,518\n517\nreducedincidenceofCI-AKI.Forexample,Vogt\nextracorporealbloodpuriﬁcationtechniquesconcluded\n518\netal.recordedrenalfunctionandotherparameters,IHD\nthatsuchtreatmentsdidnotdecreasetheincidenceof\nrequirements,andrelevantclinicaleventsbeforeandduring6\nCI-AKI.Itcouldtheoreticallybeanticipatedthathigh-ﬂux\ndaysafteradministrationofcontrastmediain113patients\nmembranesusedinHForhemodiaﬁltration(HDF)moda-\n44m\nwithabaselineSCr2.3mg/dl(203mol/l).Eightoutof\nlitiesshouldbeabletoremovecontrastmediamore\n55patientsintheprophylacticIHDgroupandthreeinthe\nefﬁcientlythanlow-ﬂuxmembranesusedinroutineIHD.",
    "page": 90,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter4.5:Effectsofhemodialysisorhemofiltration (Part 2)",
    "content": "non-IHDgroup(P¼0.12),requiredIHDaftercontrast-\nHowever,recentpublicationsonthistopichaveaddedtothe\n519\nmediaexamination.Reineckeetal.performedaprospec-\ncontroversyabouttheroleofIHDorHFtopreventCI-AKI\n522\ntivesingle-centertrialin424consecutivepatientswith\n(SupplTables28and29).Marenzietal.studied114\nSCrconcentrationsbetween1.3–3.5mg/dl(115–309mol/l)4\nconsecutivepatientswithCRF(SCrconcentration2mg/dl\nwhounderwentelectivecoronaryangiography.Patientswere\n4m\nor177mol/l)whowereundergoingcoronaryinterven-\nrandomizedtooneofthreetreatmentstrategieswithall\ntions.Fifty-eightpatientswereassignedtoeitherHFstarting\npatientsreceivingpre-andpostproceduralﬂuids:onegroup\nbeforethecontrast-mediumadministrationandcontinuing\nreceivednoadditionaltherapy,patientsinthesecondgroup\nforupto24hoursafter,while56patientsweretreatedwith\nwerehemodialyzedonce,andthethirdgroupreceivedoral\nisotonicsalineatarateof1mlperkilogramofbodyweight\nNAC.ThefrequencyofCI-AKI(deﬁnedasanincreaseinSCr\nperhour,giveninastep-downunitoverthesametime\nXX\n0.5mg/dlor44.2mol/l)from48to72hoursafter\ninterval.In-hospitalmortalitywas2%intheHFgroupand\ncatheterizationwas6.1%intheﬂuids-onlygroup,15.9%with\n14%inthecontrolgroup(P0.02),andthecumulative\nIHDtreatment,and5.3%intheNACgroup(intention-\n1-yearmortalitywas10%and30%,respectively(P0.01). to-treatanalysis;P¼0.008).Therewerenodifferences\nTemporaryRRTwasrequiredin25%ofthecontrolgroup\nbetweenthetreatmentgroupswithregardtoincreasedSCr\nandinonly3%ofthepatientsintheHFgroup.Anincrease\nXX\n0.5mg/dl(44.2mol/l)after30–60days(4.8%,5.1%,and\nintheSCrconcentrationof25%fromthebaselinevalue\n3.1%,respectively;P¼0.700).Analysesoflong-termfollow-\nafterthecoronaryinterventionoccurredlessfrequently\nup(range63–1316days)byCoxregressionsmodelsofthe\namongpatientsintheHFgroupthanamongthecontrol\nstudygroupsfoundquitesimilarsurvivalrates(P0.500). patients(5%vs.50%,P0.001).Theeffectiveremovalof\nThislargestudyconcludedthatIHD,inadditiontoﬂuids,for\ncreatinineduringHForIHDmakesitdifﬁculttobecertain\nthepreventionofCI-AKIprovidednoevidenceforany\nthatanobservedlowerincidenceofCI-AKIisnotrelatedto\noutcomebeneﬁtbutshowedevidenceforprobableharm. thetransportremovalofcreatinineduringtheprocedure. 523\nAretrospectivebutimportantcohortstudyof391patients\nrandomized\nInasubsequentstudy,thesameauthors\n(age698years,withchronicrenalinsufﬁciency[SCr\n92patientswithCKD(CrCl30ml/min)tothreedifferent\nXX\n1.3mg/dl;115mol/l])whounderwentcardiaccathe-\nprophylactictreatments:i.v.isotonicsaline(controlgroup);\n520\nterization,alsodidnotﬁndanybeneﬁcialpreventiveeffect.",
    "page": 90,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter4.5:Effectsofhemodialysisorhemofiltration (Part 3)",
    "content": "i.v.salinefor12hoursbeforecontrast-mediaexposure,\n87\nKidneyInternationalSupplements(2012)2,69–88\nchapter4.5\nfollowedbyHFfor18–24hoursaftercontrast-media\nNovartis,RobertandJaneCizikFoundation,Shire,\nexposure;andathirdgroupwhereHFwasperformedfor6TranswesternCommercialServices,andWyeth.KDIGOis\nhoursbeforeandfor18–24hoursaftercontrast-mediasupportedbyaconsortiumofsponsorsandnofundingis\nexposure.TheincidenceofCI-AKI(25%increaseinacceptedforthedevelopmentofspeciﬁcguidelines. SCr)andthein-hospitalclinicalcoursewerecomparedinthe\nDISCLAIMER\nthreegroups.In-hospitalmortalitywas20%,10%,and0%,\nWhileeveryeffortismadebythepublishers,editorial\nrespectively,inthethreegroups;IHDwasrequiredinnine\nboard,andISNtoseethatnoinaccurateormisleadingdata,\n(30%),3(10%),andzero(0%)patients,respectively\nopinionorstatementappearsinthisJournal,theywish\n(P0.002).Accordingtotheseresults,pre-HFisrequired\ntomakeitclearthatthedataandopinionsappearingin\ntoobtainthefullclinicalbeneﬁt,suggestingthatamong\nthearticlesandadvertisementshereinaretheresponsibility\ndifferentmechanismspossiblyinvolved,high-volumecon-\nofthecontributor,copyrightholder,oradvertiserconcerned. trolledvolumeexpansionbeforecontrast-mediaexposure\nAccordingly,thepublishersandtheISN,theeditorialboard\nplaysamajorroleinprevention.Thisstudyfurthersuggests\nandtheirrespectiveemployers,ofﬁceandagentsaccept\nthatbicarbonateexposurewithHFmayultimatelyhavebeen\nnoliabilitywhatsoeverfortheconsequencesofanysuch\nthemechanismforthelowerCI-AKIincidence(SupplTable\ninaccurateormisleadingdata,opinionorstatement.While\n29).Insummary,theevidenceproﬁleforIHDvs.HFshowed\neveryeffortismadetoensurethatdrugdosesandother\nlow-qualityevidenceandanuncertainbeneﬁtvs.harm\nquantitiesarepresentedaccurately,readersareadvisedthat\nbalanceofHF/IHDinpreventingCI-AKIinpatientswith\nnewmethodsandtechniquesinvolvingdrugusage,and\nsevereCKD.Giventhecostsandlogisticaldifﬁculties,theuse\ndescribedwithinthisJournal,shouldonlybefollowedin\nofHFmodalitiesforCI-AKIpreventioncanonlybe\nconjunctionwiththedrugmanufacturer’sownpublished\nadvocatediffuturestudieswillconvincinglyshowclear\nliterature. beneﬁt. SPONSORSHIP\nSUPPLEMENTARYMATERIAL\nKDIGOgratefullyacknowledgesthefollowingsponsorsthat\nSupplementaryTable28:EvidenceprofileofRCTsexaminingtheeffect\nofhemodialysisorhemofiltrationonthepreventionofCI-AKI. makeourinitiativespossible:Abbott,Amgen,BeloFounda-\nSupplementaryTable29:SummarytableofRCTsexaminingtheeffect\ntion,Coca-ColaCompany,DoleFoodCompany,Genzyme,\nofhemodialysisorhemofiltrationonthepreventionofCI-AKI. Hoffmann-LaRoche,JCPenney,NATCO—TheOrganization\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nforTransplantProfessionals,NKF—BoardofDirectors,\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n88\nKidneyInternationalSupplements(2012)2,69–88\nchapter5.1\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 90,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Section5:DialysisInterventionsforTreatmentofAKI",
    "content": "KidneyInternationalSupplements(2012)2,89–115;doi:10.1038/kisup.2011.35",
    "page": 92,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inAKI (Part 1)",
    "content": "WhetherornottoprovideRRT,andwhentostart,aretwoofinfusion,andbeta-2agonists)areexhausted,anexcessof\nthefundamentalquestionsfacingnephrologistsandinten-potassiumcanonlybeeliminatedwithRRT.Ontheother\nsive-carepractitionersinmostcasesofsevereAKI.Inrecenthand,whenintermittentdialysisisusedafterthese\npublications,thetimingofinitiationofRRTwaslistedasone\ntherapeuticinterventions,theextracorporealremovalof\n524\nofthetopprioritiesinresearchonAKI.However,thispotassiumwillbereducedandthepost-treatmentrebound\n526\ndimensionhasnotbeenincludedasafactorinanyoftheofserumpotassiumwillbemorepronounced. largeRCTsinthisarea.TheoptimaltimingofdialysisforMetabolicacidosisisafrequentclinicalproblemin\nAKIisnotdeﬁned.Incurrentpractice,thedecisiontostartpatientswithsevereAKI.Althoughthediscussionasto\nRRTisbasedmostoftenonclinicalfeaturesofvolumewhenmetabolicacidosisincriticallyillpatientsshouldbe\noverloadandbiochemicalfeaturesofsoluteimbalancecorrectedisoutsidethescopeofthisguideline,metabolic\n(azotemia,hyperkalemia,severeacidosis).However,intheacidosisassociatedwithAKIcanusuallybecorrectedwith\nabsenceofthesefactorsthereisgenerallyatendencytoavoidbicarbonateandshouldrarelyrequireurgentdialysisifnot\n527\nAsthepH\ndialysisaslongaspossible,athoughtprocessthatreﬂectstheaccompaniedbyvolumeoverloadoruremia. decisionsmadeforpatientswithCKDStage5.andbicarbonatevaluestoinitiatedialysisformetabolic\nClinicianstendtodelayRRTwhentheysuspectthatacidosisarenotsupportedbyevidence,nostandardcriteria\nforinitiatingdialysisforacidosisexist.Avarietyofpoisons,\npatientsmayrecoverontheirown,andbecauseofconcern\nforthewell-knownrisksassociatedwiththeRRTprocedure,drugoverdoses,andtoxiccompounds(e.g.,salicylates,\nincludinghypotension,arrhythmia,membranebioincom-ethyleneglycol,methanol,metformin)cancontributeto\npatibility,andcomplicationsofvascularaccessandanti-acid-baseproblemsandalsoleadtoAKI.Inthesecircum-\nstances,RRTmayalsofacilitateremovaloftheoffending\ncoagulantadministration.Thereisalsosomeconcernthat\n528–530\nRRTmaycompromiserecoveryofrenalfunction,anddrug. 525\nWhethertheserisksOnlyoneRCThasevaluatedtheeffectoftimingof\nincreasetheprogressionofCKD. 531\noutweighthepotentialbeneﬁtsofearlierinitiationofRRTisinitiationofRRTonoutcome.Boumanetal.randomized\nstillunclear.106criticallyillpatientswithAKItoearlyvs.lateinitiation\nofRRT.TheearlyinitiationgroupstartedRRTwithin\n5.1.1:InitiateRRTemergentlywhenlife-threatening12hoursofoliguria(30ml/hfor6hours,notrespond-\nchangesinﬂuid,electrolyte,andacid-basebalanceingtodiureticsorhemodynamicoptimization),orCrCl\nexist.(NotGraded)20ml/min.Thelate-initiationgroupstartedRRTwhen\n5.1.2:Considerthebroaderclinicalcontext,thepresenceclassicindicationsweremet.Thestudydidnotﬁnd\nofconditionsthatcanbemodiﬁedwithRRT,anddifferencesinICUorhospitalmortality,orinrenalrecovery\ntrendsoflaboratorytests—ratherthansingleBUNamongsurvivors,butwasclearlytoosmalltoallowfor\nandcreatininethresholdsalone—whenmakingthedeﬁnitiveconclusions(SupplTable30).",
    "page": 92,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inAKI (Part 2)",
    "content": "decisiontostartRRT.(NotGraded)Theremainingdatacomefromobservationalstudies.The\nassociationofearlyinitiationofdialysiswithsurvivalbeneﬁt\nwasﬁrstsuggestedbycaseserieswithhistoricalcontrols\n532–535\nconductedinthe1960sand1970s.Inthesestudies,\nRATIONALE\nWhilenoRCTsexistfordialysisforlife-threatening\nlevelsofbloodureaorBUNwereusedtodistinguishearlyvs. indications,itiswidelyacceptedthatpatientswithsevere\nlatestartofdialysis.However,thesestudiesmostlycombined\nhyperkalemia,severeacidosis,pulmonaryedema,anduremic\nearlystartwithmore-intensivedialysisandlatestartwith\ncomplicationsshouldbedialyzedemergently.Intheabsence\nless-intensivedialysis.Morerecentstudieshavecontinuedthe\nofkidneyfunction,andwhentherapeuticmeasuresthat\ntrendfocusingonBUNasabiomarkerforstartingRRT. promotetheintracellularshiftofpotassium(suchas\nSingle-centerobservationalstudiesthatwererestrictedto\n536537,538\ncorrectionofacidosiswithbicarbonate,glucoseandinsulin\nAKIaftertraumaandcoronaryarterybypasssurgery\n89\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.1\nsuggestedabeneﬁttoRRTinitiationatlowerBUNconcen-acausalrelationshipremainstobeproven,althougha\ntrations.Aprospectivemulticenterobservationalcohortrandomizedtrialinhemodynamicallystablepatientswith\nstudyperformedbytheProgramtoImproveCareinAcuteacuterespiratorydistresssyndromeseemstosuggestthat\n549\nRenalDisease(PICARD)analyzeddialysisinitiation—asitis.RandomizingpatientsaccordingtoRRTinitiationon\ninferredbyBUNconcentration—in243patientsfromﬁvethebasisofﬂuidstatuswouldallowthisquestiontobe\ngeographicallyandethnicallydiverseclinicalsites.Adjustinganswered.Asecondaryanalysisofarandomizedtrial\nforage,hepaticfailure,sepsis,thrombocytopenia,andSCr,comparingIHDtoCRRTshowedthatpatientsreceiving\nandstratiﬁedbysiteandinitialdialysismodality,initiationofRRTpredominantlyforsolutecontrolexperiencedbetter\n44\nRRTathigherBUN(76mg/dl[bloodurea27.1mmol/l])outcomesthanthosepredominantlytreatedforvolume\nwasassociatedwithanincreasedriskofdeath(RR1.85;95%overload.Patientsdialyzedforcontrolofbothazotemiaand\n539550\nCI1.16–2.96).Inaprospectivemulticenterobservationalvolumeoverloadexperiencedtheworstoutcome.Analysis\nstudyconductedat54ICUsin23countries,timingofRRTofamulticenterobservationalcohortshowedthatmean\nwasstratiﬁedinto‘‘early’’or‘‘late’’bymedianureaatthedailyﬂuidbalanceinAKIpatientswassigniﬁcantlymore\n84\ntimeRRTstarted(24.2mmol/l[BUN67.8mg/dl]),andalsopositiveamongnonsurvivorsthansurvivors.Datafrom\ncategorizedtemporallyfromICUadmissionintoearly(lessthePICARDgroupexamining396ICUpatientswithAKI\nthan2days),delayed(between2–5days),orlate(morethanrequiringRRTfurthersupportstheseﬁndings.Survivorshad\n5days).Timingbyserumureashowednosigniﬁcantlowerﬂuidaccumulationatdialysisinitiationcomparedto\ndifferenceinmortality.However,whentimingwasanalyzednonsurvivors(8.8%vs.14.2%ofbaselinebodyweight;\ninrelationtoICUadmission,lateRRTwasassociatedwithP¼0.01adjustedfordialysismodalityandseverityscore).",
    "page": 92,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inAKI (Part 3)",
    "content": "greatercrudemortality(72.8%latevs.62.3%delayedvs.59%TheadjustedORfordeathassociatedwithﬂuidoverloadat\n83\nearly,P0.001)andcovariate-adjustedmortality(OR1.95;dialysisinitiationwas2.07(95%CI1.27–3.37).Thesedata\nsuggestthatﬂuidoverloadshouldbefurtherevaluatedas\n95%CI1.30–2.92;P¼0.001).Overall,lateRRTwasasso-\nciatedwithalongerdurationofRRTandstayinhospital,andparametertoguidetheinitiationofRRT(seealsoPediatric\n540\ngreaterdialysisdependence.Itis,however,notclearConsiderations). whetherAKIoccurringlaterinthecourseofICUstayhastheOtherfactorsthatmightinﬂuencethedecisionofwhento\nsamepathophysiologyandprognosisthanAKIpresentonorstartRRTaretheseverityoftheunderlyingdisease(affecting\nearlyafteradmission.Themostrecentstudyonthissubjectisthelikelihoodofrecoveryofkidneyfunction),thedegreeof\ntheanalysisofsurgicalICUpatientswithAKI,showingthatdysfunctioninotherorgans(affectingthetolerancetoe.g.,\nlateinitiationofRRT(deﬁnedasRIFLE-Ior-F)wasaninde-ﬂuidoverload),theprevalentorexpectedsoluteburden(e.g.,\n541\npendentpredictorofmortality(HR1.846;CI1.07–3.18).intumorlysissyndrome),andtheneedforﬂuidinputrelated\nTraditionalindicationsforRRT,developedforpatients\ntonutritionordrugtherapy(Table17).Earlydetectionand\nwithadvancedCKD,arenotnecessarilyvalidinthecontextaccuratepredictionofpatientsthatultimatelywillrequire\nofAKI.Forinstance,massivevolumeoverloadresultingfromRRTmayallowearlierinitiationinthosewhoneeditand,at\nvolumeresuscitationmaybeanindicationforRRTeveninthesametime,preventharminthosewhodonot.Recent\ntheabsenceofsigniﬁcantelevationsinBUNorSCr.Inthis\nevidencesuggestsapotentialroleforbiomarkersinthisﬁeld. instance,itmaybemoreappropriatetoconsiderdialyticPlasmaneutrophilgelatinase-associatedlipocalinwasshown\ninterventionintheICUpatientasaformofrenalsupporttohaveanareaunderthereceiveroperatingcharacteristic\n551\nratherthanrenalreplacement.Indeed,someofthe\ncurveof0.82forthepredictionofRRTrequirement. traditionalindicationsfordialysis(e.g.,uremicpericarditis,\npleuritis,encephalopathy,coagulopathy)wouldbeconsid-\nPediatricconsiderations\nProvisionofacuteRRTtochildrenrequiresspecialconsi-\nered‘‘complications’’ofAKIratherthanindicationsforRRT. Additionally,thedecisiontostartRRTshouldrecognizethederations.Pediatricandadolescentpatientsrangeinagefrom\ngoalsoftherapy,keepinginmindthetherapeuticpotentialoftheprematureneonateto25yearsofage,withasizerangeof\n1.5–200kg.Inaddition,theepidemiologyofthepediatric\ndialysisingeneral,andeachdialysismodalityinparticular.",
    "page": 92,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "inAKI (Part 4)",
    "content": "ThetreatmentofAKIwithRRThasthefollowinggoals:i)toAKIhaschangedfromprimarykidneydiseaseinthe1980sto\nmaintainﬂuidandelectrolyte,acid-base,andsolutehomeo-injuryresultingfromanothersystemicillnessoritstreatment\n552,553\n(e.g.,sepsisandnephrotoxicmedications).Newborns\nstasis;ii)topreventfurtherinsultstothekidney;iii)to\npermitrenalrecovery;andiv)toallowothersupportivewithinbornerrorsofmetabolismwhodonotrespondto\nmeasures(e.g.,antibiotics,nutritionsupport)toproceeddietaryandpharmacologicmanagementrequireexpeditious\nwithoutlimitationorcomplication.Ideally,therapeuticinter-dialyticremovalofammoniatodecreasetheriskofdeathand\n554\nlong-termneurologicdysfunction,andinfantswhoreceive\nventionsshouldbedesignedtoachievetheabovegoalsanda\nsystematicassessmentofallthesefactorsiskeytodetermi-surgicalcorrectionofcongenitalheartdisease,oftenreceive\nPDearlyaftercardiopulmonarybypasstopreventﬂuid\nningtheoptimaltimingforinitiatingdialysis(Table17). overloadand/orminimizetheproinﬂammatoryresponse. Thereisincreasingevidencethatﬂuidoverloadincritical\nillnessandAKIisassociatedwithadverseoutcomes,Finally,childrendevelopmultiorgandysfunctionveryrapidly\n83,84,542–549\nWhetherthisisintheirICUcourse,withthemaximalorgandysfunction\nespeciallyinthepediatricsetting. 90\nKidneyInternationalSupplements(2012)2,89–115",
    "page": 92,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter5.1 (Part 1)",
    "content": "Table17|PotentialapplicationsforRRT\nApplicationsComments\nRenalreplacementThisisthetraditional,prevailingapproachbasedonutilizationofRRTwhenthereislittleornoresidualkidney\nfunction. Life-threateningindicationsNotrialstovalidatethesecriteria. HyperkalemiaDialysisforhyperkalemiaiseffectiveinremovingpotassium;however,itrequiresfrequentmonitoringofpotassium\nlevelsandadjustmentofconcurrentmedicalmanagementtopreventrelapses. AcidemiaMetabolicacidosisduetoAKIisoftenaggravatedbytheunderlyingcondition.Correctionofmetabolicacidosiswith\nRRTintheseconditionsdependsontheunderlyingdiseaseprocess. PulmonaryedemaRRTisoftenutilizedtopreventtheneedforventilatorysupport;however,itisequallyimportanttomanagepulmonary\nedemainventilatedpatients. UremiccomplicationsIncontemporarypracticeitisraretowaittoinitiateRRTinAKIpatientsuntilthereareuremiccomplications. (pericarditis,bleeding,etc.)\nNonemergentindications\nSolutecontrolBUNreflectsfactorsnotdirectlyassociatedwithkidneyfunction,suchascatabolicrateandvolumestatus. SCrisinfluencedbyage,race,musclemass,andcatabolicrate,andbychangesinitsvolumeofdistributiondueto\nfluidadministrationorwithdrawal. FluidremovalFluidoverloadisanimportantdeterminantofthetimingofRRTinitiation. Correctionofacid-baseNostandardcriteriaforinitiatingdialysisexist. abnormalities\nRenalsupportThisapproachisbasedontheutilizationofRRTtechniquesasanadjuncttoenhancekidneyfunction,modifyfluid\nbalance,andcontrolsolutelevels. VolumecontrolFluidoverloadisemergingasanimportantfactorassociatedwith,andpossiblycontributingto,adverseoutcomes\ninAKI. RecentstudieshaveshownpotentialbenefitsfromextracorporealfluidremovalinCHF. Intraoperativefluidremovalusingmodifiedultrafiltrationhasbeenshowntoimproveoutcomesinpediatriccardiac\nsurgerypatients. NutritionRestrictingvolumeadministrationinthesettingofoliguricAKImayresultinlimitednutritionalsupportandRRTallows\nbetternutritionalsupplementation. DrugdeliveryRRTsupportcanenhancestheabilitytoadministerdrugswithoutconcernsaboutconcurrentfluidaccumulation. Regulationofacid-basePermissivehypercapnicacidosisinpatientswithlunginjurycanbecorrectedwithRRT,withoutinducingfluidoverload\nandelectrolytestatusandhypernatremia. SolutemodulationChangesinsoluteburdenshouldbeanticipated(e.g.,tumorlysissyndrome).Althoughcurrentevidenceisunclear,\nstudiesareongoingtoassesstheefficacyofRRTforcytokinemanipulationinsepsis. AKI,acutekidneyinjury;BUN,bloodureanitrogen;CHF,congestiveheartfailure;SCr,serumcreatinine;RRT,renalreplacementtherapy.",
    "page": 94,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter5.1 (Part 2)",
    "content": "Table18|FluidoverloadandoutcomeincriticallyillchildrenwithAKI\nAuthorCohort(N)OutcomeP\n545\nGoldstein2001Single-center(22)Survivors16%FONonsurvivors34%FO0.03\n544\nGillespie2004Single-center(77)%FO410%withORdeath3.020.002\n543\nFoland2004Single-center(113)3organMODSpatients0.01\nSurvivors9%FONonsurvivors16%FO\n1.78ORdeathforeach10%FOincrease\n546\nGoldstein2005Multicenter(116)2+organMODSpatients0.002\nSurvivors14%FONonsurvivors25%FO\n20%FO:58%survival\n420%FO:40%survival\n547\nHayes2009Single-center(76)Survivors7%FONonsurvivors22%FO0.001\nORdeath6.1for420%FO\n548\nSutherland2010Multicenter(297)10%FO:70%survival0.001\n10–20%FO:57%survival\n420%FO:34%survival\nOR1.03(1.01–1.05)per%FO\nAKI,acutekidneyinjury;FO,fluidoverload;MODS,multiple-organdysfunctionsyndrome;OR,oddsratio. ReprintedfromGoldsteinSL.Advancesinpediatricrenalreplacementtherapyforacutekidneyinjury.SeminDial2011;24:\n560\n187–191withpermissionfromJohnWileyandSons;accessedhttp://onlinelibrary.wiley.com/doi/10.1111/j.1525-139X.2011.00834.x/full",
    "page": 94,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "timingofdialysisinitiationiscriticallyimportantinchildren.speciﬁcpediatricclinicalsituationsisbeyondthescopeof",
    "content": "91\nKidneyInternationalSupplements(2012)2,89–115\n[Table 1]\nVolumecontrol Fluidoverloadisemergingasanimportantfactorassociatedwith,andpossiblycontributingto,adverseoutcomes\ninAKI.\n------------------------------------------------------------\nRecentstudieshaveshownpotentialbenefitsfromextracorporealfluidremovalinCHF.\nIntraoperativefluidremovalusingmodifiedultrafiltrationhasbeenshowntoimproveoutcomesinpediatriccardiac\nsurgerypatients.\n\nchapter5.1\nthisguideline,andthereaderisreferredtoin-depthin297childrentreatedwithRRT:29.6%mortalitywithless\n557,558\nreviews.than10%ﬂuidoverload,43.1%with10–20%ﬂuidoverload,\n548\nImportantly,ﬂuidoverloadhasemergedasasigniﬁcantand65.6%with20%ﬂuidoverload.However,strong\nfactorassociatedwithmortalityinchildrenwithAKIevidencetosuggestthatpreventingthisﬂuidoverloadwith\nrequiringCRRT(Table18),althoughthephysiologicallinkearlierRRTwillimproveoutcomeremainsabsent.\nbetweenincreasingpercentvolumeoverloadandmortalityis\n543–548,559\nnotcompletelyclear.Thelargesttrialtoassessthis\nRESEARCHRECOMMENDATIONS\nrelationshipinchildrenisamulticenterprospectivestudy\nDeterminereproduciblecriteria(e.g.,fluidoverload,\nshowingthatthepercentageﬂuidaccumulationatCRRT\nbiomarkerlevel,severityscore)toinformthedecisionto\ninitiationissigniﬁcantlylowerinsurvivorsvs.non-survivors\nstartRRTinadultandpediatricAKIpatients.Such\n±±\n(14.215.9%vs.25.432.9%;P0.03)evenafter\ncriteriamayalsopermittheidentificationofpatientswho\nadjustmentforseverityofillness.Thisstudyalsofounda\nwillultimatelyrequireRRTandhencelimituncertainty\nsigniﬁcantlyhighermortalityinpatientwith20%ﬂuid\naroundwhethertobegintherapy.\noverload(58%)vs.20%ﬂuidoverload(40%)atCRRT\nDeterminewhetherearlyvs.latestartofRRT,basedon\n546\ninitiation.Oneretrospectivestudy,inpediatricpatients\ntheabove-mentionedcriteria,resultsinimprovedclinical\nwhoreceivedstem-celltransplantationanddevelopedAKI,\noutcomes(e.g.,mortality,evolutiontoCKDStage5)of\nsuggestedthatsurvivalmaybeimprovedbyanaggressiveuse\nAKIpatients.\nofdiureticsandearlyinitiationofRRT.Allsurvivors(n11)\nmaintainedorremainedwithpercentageﬂuidaccumulation\nSUPPLEMENTARYMATERIAL\n10%,withdiureticsandRRT.Amongthe15nonsurvivors,\nSupplementaryTable30:SummarytableofRCTsexaminingtheeffect\nonly6(40%)hadpercentageﬂuidaccumulation10%at\nofearlyvs.lateCVVHinthetreatmentofAKI.\n559\nthetimeofdeath.Thelatestanalysisonthisissue\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nconﬁrmedincreasedmortalitywithincreasingﬂuidoverload\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n92\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.2\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 94,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 1)",
    "content": "AlthoughmanypatientswithAKIrecoverkidneyfunction\nsolutelevelspreventachievingasteadystateandthusexclude\nsufﬁcientlytobeindependentofRRT,discontinuationoftheuseofclearancemeasurements.Nativekidneyfunction\nRRTinAKIhasreceivedlittleattentionintheliterature.Thecanonlybeassessedduringtheinterdialyticperiodby\ndecisionwhetherorwhentostopRRTinapatientwithAKIevaluatingurinevolume,urinaryexcretionofcreatinine,and\nneedstoconsideranimprovementinkidneyfunctionchangesinSCrand/orBUNvalues.However,onemust\nadequatetomeetdemand,animprovementinthedisorderrealizethatintermittenttreatmentwillbeassociatedwith\nthatpromptedkidneysupportorfutility.Itisevidentpost-treatmentreboundinsolutelevels,andthatchanges\nthateachoftheseeventsisinﬂuencedbytheinitialinBUNandcreatininelevelscanalsobemodiﬁedby\nindicationforstartingRRTandissubjecttoindividualnonrenalfactors,suchasvolumestatusandcatabolicrate. variation.ThestrategyforstoppingRRTrequiresconsidera-InCRRT,continuoussoluteclearanceof25–35ml/minwill\ntionofadditionalfactorsandofteninvolvesamodalitystabilizeserummarkersafter48hours.Thisallowsmore\ntransition.reliablemeasurementsofCrClbythenativekidneysduring\nCRRT. 5.2.1:DiscontinueRRTwhenitisnolongerrequired,VeryfewinvestigatorshavelookedaturineCrClvaluesas\neitherbecauseintrinsickidneyfunctionhasrecov-aguideforCRRTwithdrawal.Onesmallretrospectivestudy\neredtothepointthatitisadequatetomeetpatient(publishedasabstract)demonstratedthataCrCl(measured\nneeds,orbecauseRRTisnolongerconsistentwithover24hours)15ml/minwasassociatedwithsuccessful\nthegoalsofcare.(NotGraded)terminationofCRRT,deﬁnedastheabsenceofCRRT\n567\nrequirementforatleast14daysfollowingcessation.",
    "page": 96,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 2)",
    "content": "Furtherprospectivetrialswillbeneededtosupportthese\nﬁndings.Alargeprospectiveobservationalstudyshowed\nRATIONALE\nMany,butnotall,patientsrequiringRRTwillrecoverthat,in529patientswhosurvivedtheinitialperiodofCRRT,\n21,394,561\nenoughfunctionnottorequirelong-termRRT.313weresuccessfullyremovedfromRRT,whereas216\nThemeandurationofRRTintworecentlargeRCTspatientsneeded‘‘repeatCRRT’’within7daysofdiscontinua-\n562,563\nwas12–13days.Thus,dailyassessmentofbothtion.Multivariatelogisticregressionidentiﬁedurineoutput\nintrinsickidneyfunctionandtheongoingappropriate-asthemostsigniﬁcantpredictorofsuccessfultermination\nnessofRRTconsistentwiththegoalsoftherapyforthe(OR1.078per100ml/d).Notsurprisingly,thepredictive\npatientarerequired.Morethan50%ofpatientswithsevereabilityofurineoutputwasnegativelyaffectedbytheuse\n196\nAKIwillnotimprove,despiteappropriatetherapy.Theofdiuretics.Anotherretrospectiveobservationalanalysis\nincidenceofwithdrawaloflife-supporttreatmentsinshowedthat,ofatotalof304patientswithpostoperative\nAKIrequiringRRT(IHD),31%couldbeweanedformore\ncriticallyillpatientswithmultiorganfailurehasincreased\n564\nInadditiontovasoactivemedication,\noverthelastdecade.than5daysand21%weresuccessfullyweanedforatleast\nmechanicalventilation,andartiﬁcialnutrition,RRTisoneof30days.IndependentpredictorsforrestartingRRTwithin\nthetherapiesmostlikelytobediscontinuedduringwith-30dayswerelongerdurationofRRT,ahigherSequential\ndrawaloflifesupport.Ingeneral,decisionstowithdrawOrganFailureAssessmentscore,oliguria,andage65\n568\ntherapyoccurin10%ofallpatientsfromgeneralICUs,andyears.Inotherwords,urineoutputseemstobeavery\nareresponsibleforroughly40%ofalldeaths.AnalysisofaimportantpredictorofsuccessfuldiscontinuationofRRT. databaseof383AKIpatientsshowswithdrawaloflifeWhethertoo-earlydiscontinuationofRRT,requiring\n565\nsupportin72%ofdeaths.Inanothersingle-centerreinstitution,isbyitselfharmfulhasnotbeenproperly\nretrospectivestudyinvolving179AKIpatientsrequiringinvestigated.Theabove-mentionedobservationalstudies\n566\nRRT,therapywaswithheldorwithdrawnin21.2%.Afoundahighermortalityinpatientswhoneededtobe\n196\nposthocanalysisoftheBESTKIDNEYdatabaseshowedthatretreatedwithRRT(42.7%vs.28.5%and79.7%vs. 568\nCRRTwaswithdrawnin13%ofthepatients,representing40%).Itis,however,notclearwhetherfailuretoweanis\n29%ofthosewhodiedwhileonCRRTand21%ofallsimplyamarkerofillnessseverityorcontributedbyitselfto\n196\nnonsurvivors.theadverseoutcome.",
    "page": 96,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 3)",
    "content": "AssessmentofkidneyfunctionduringRRTisnoteasyandTheprocessofstoppingRRTmayconsistofsimple\nwilldependonthemodalityused.InIHD,theﬂuctuationsofdiscontinuationofRRT,ormayincludeachangeinthe\n93\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.2\nPediatricconsiderations\nmodality,frequency,ordurationofRRT.Forexample,\nThemedicalindicationsguidingdiscontinuationofRRTin\nswitchingfromCRRTtoIHD,ordecreasingthefrequencyof\nchildrendonotdifferfromadults,exceptinthoseinstances\nIHDfromdailytoeveryotherday,representsdifferent\nwhereRRTisinitiatedforpediatric-speciﬁcdisease,suchas\nmethodsoftestingtheabilityofthepatient’sownkidneyto\n557\ninbornerrorsofmetabolismtotreathyperammonemiaor\ntakeover.Nospeciﬁcguidancecanbeprovidedforhowto\nimmediatelyaftersurgicalcorrectionofcongenitalheart\nmanagethetransitionofRRTfromcontinuoustointer-\ndiseasetomaintaineuvolemia,and/orpossiblymitigatethe\nmittent.Evidencefromlargeobservationalstudiessuggests\n558\n196\npostbypassproinﬂammatoryresponse. thatlargevariationinpracticeexists. PrognosisinchildrenwhosurviveanAKIepisodeis\nsigniﬁcantlybetterthaninadults,andmanychildrenmayhave\n5.2.2:Wesuggestnotusingdiureticstoenhancekidney\nseveraldecadesoflifeexpectancy.Askenazidemonstratednearly\nfunctionrecovery,ortoreducethedurationor\n80%3-to5-yearsurvivalforchildrendischargedafteranAKI\nfrequencyofRRT.(2B)\n569\nepisodefromatertiarycenter,yettwo-thirdsofdeathsoccur-\nredintheﬁrst2yearsafterdischarge,suggestingahighprob-\nabilityofgreaterlifeexpectancyafterthatperiod.Inaddition,no\nRATIONALE\ndataexisttodeﬁneamaximalRRTduration;evendatafromthe\nTheroleofdiureticsinthepreventionandtreatmentofAKI\nProspectivePediatricCRRTRegistryshow35%survivalin\nhasalreadybeendiscussedinChapter3.4.OnlyoneRCThas\n570\nchildrenreceivingCRRTfor28days.Finally,sincepediatric\nevaluatedthepotentialroleofdiureticsinresolvingAKIin\nAKInowresultsmoreoftenasasecondaryphenomenonfrom\npatientsreceivingRRT.AftertheendoftheCVVHsession,\n552,553\nanothersystemicillnessoritstreatment,determinationof\ntheurineoftheﬁrst4hourswascollectedformeasuring\ntheoverallgoalsoftherapyforchildren,asinforadults,must\nCrCl.Seventyonepatientsweresubsequentlyrandomizedto\ntakeintoconsiderationlocalstandards,patientandfamily\nreceivefurosemide(0.5mg/kg/h)orplacebobycontinuous\nwishes,aswellastheprobabilityofrecoveryoftheunderlying\ninfusion,continueduntilCrClreached30ml/min.Urinary\nillnessleadingtoAKIandtheneedforRRT. ﬂuidlosseswerecompensatedbyi.v.infusion.Theprimary\nend-pointwasrenalrecovery(CrCl30ml/minorstable\nRESEARCHRECOMMENDATIONS\nSCrwithoutRRT)intheICUandinthehospital.CVVH\nDetermineclinicalparameters(e.g.,parametersofkidney\nwasrestartedbasedonpredeﬁnedcriteria.Patientstreated\nfunction,fluidoverload,hypercatabolism)thatpredict\nwithfurosemide(n¼36)hadasigniﬁcantlyincreased\nsuccessfuldiscontinuationofRRTinAKIpatients.",
    "page": 96,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 4)",
    "content": "urinaryvolumeandgreatersodiumexcretioncomparedto\nDeterminebiomarkersthatmayindicaterenalrecovery,\nplacebo-treatedpatients(n35).However,therewereno\nandwhethertheirlevelscanbeusedtoguidedisconti-\ndifferencesinneedforrepeatedCVVH,orrenalrecovery\n195\nnuationofRRT. duringICUorhospitalstay.Anobservationalstudyof\nDeterminemorereliablepredictorsoflong-termout-\ndiscontinuationofRRTalsofoundnodifferenceindiuretic\ncomes(e.g.,mortality,qualityoflife)inAKIpatients\nusebetweenpatentswithsuccessfulorunsuccessfuldis-\n568\n(includingclinicalseverityscores,biomarkers,machine\ncontinuationofIHD.Insummary,diureticsmayimprove\nlearningtechniques,orcombinationsofthese),that—\nurinevolumeafterRRT,butdonotappeartohaveany\naftervalidationinlargecohorts—couldbehelpful\nsigniﬁcantbeneﬁtinreducingtheneedforRRTorpromoting\nadjunctsinthedecisiontowithdrawtreatment. renalrecoveryfromAKI. 94\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.3\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 96,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 1)",
    "content": "InpatientswithAKIrequiringRRT,thecontactofbloodwithﬂowrates,diffusivetreatment,thereductionofblood-air\ntheforeignsurfaceoftheextracorporealcircuitresultsincontactinthebubbletrap,andassuringpromptreactionto\n577,578\nactivationofboththeintrinsicandtheextrinsicpathwayof\nalarms. 571\nplasmaticcoagulationandactivationofplatelets.Preven-ManypatientswithAKIrequiresystemicanticoagulation\ntionofdialyzer/hemoﬁlterclottingoftenrequiressomefortheirunderlyingdiseases(e.g.,artiﬁcialheartvalve,acute\nformofanticoagulation,whichmayrepresentaparticularcoronarysyndrome,atrialﬁbrillation).Itisevidentthat,in\nchallengeinpatientswithAKI.Theneedforcontinuousmostinstances,thesepatientswillnotrequireadditional\nanticoagulationrepresentsapotentialdrawbackofCRRT.anticoagulationforRRT;however,thisshouldbeassessedon\nacase-by-casebasis. 5.3.1:InapatientwithAKIrequiringRRT,basethe\n5.3.2:Forpatientswithoutanincreasedbleeding\ndecisiontouseanticoagulationforRRTonassess-\nriskorimpairedcoagulationandnotalready\nmentofthepatient’spotentialrisksandbeneﬁts\nreceivingeffectivesystemicanticoagulation,we\nfromanticoagulation(seeFigure17).(NotGraded)\nsuggestthefollowing:\n5.3.1.1:Werecommendusinganticoagulation\n5.3.2.1:ForanticoagulationinintermittentRRT,\nduringRRTinAKIifapatientdoes\nwerecommendusingeitherunfractio-\nnothaveanincreasedbleedingriskor\nnatedorlow-molecular-weightheparin,\nimpairedcoagulationandisnotalready\nratherthanotheranticoagulants.(1C)\nreceivingsystemicanticoagulation.(1B)\n5.3.2.2:ForanticoagulationinCRRT,wesug-\ngestusingregionalcitrateanticoagula-\ntionratherthanheparininpatients\nRATIONALE\nwhodonothavecontraindicationsfor\nThegoalofanticoagulationwithRRTistopreventclottingof\ncitrate.(2B)\ntheﬁlterand/orreductioninmembranepermeability,and\n5.3.2.3:ForanticoagulationduringCRRTin\nthustoachieveadequateRRTandtopreventbloodlossin\npatientswhohavecontraindicationsfor\ntheclottedﬁlter.Thesebeneﬁtshavetobeweighedagainst\ncitrate,wesuggestusingeitherunfractio-\ntheriskofbleeding,andeconomicissues,suchasworkload\nnatedorlow-molecular-weightheparin,\nandcosts. ratherthanotheranticoagulants.(2C)\nPatientswithimpairedcoagulation(e.g.,thrombocytopenia,\norprolongedprothrombintimeoractivatedpartialthrombo-\nplastintime[aPTT]),duetounderlyingdiseasessuchasliver\nRATIONALE\nfailureordilutioncoagulopathy,maynotbeneﬁtfrom\nWorldwide,unfractionatedheparinisstillthemostwidely\nadditionalanticoagulationforRRT.Intworecentlargetrials\nusedanticoagulant.ManyEuropeancenters,however,have\n50–60%ofAKIpatientsrequiringRRTweretreatedwithout\nswitchedfromunfractionatedtolow-molecular-weight\n562,563\n579\nWhileﬁlterperformancewasnotassessed,\nanticoagulant. heparinforroutineanticoagulationduringIHD.Advan-\nadequateCRRTﬁltersurvivalwithoutanticoagulationhas\ntagesanddisadvantagesofeachtypeofheparinare\n572–575\nmostlybeendescribedinpatientswithcoagulopathies. summarizedinTable19.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 2)",
    "content": "However,nospeciﬁccut-offpointshavebeendeterminedfor\nArecentmeta-analysisof11RCTscomparingunfractio-\nplateletcount,aPTT,InternationalNormalizedRatio,ﬁbrino-\nnatedtolow-molecular-weightheparininchronicIHD\ngen,orothercoagulationfactorsthatwouldindicatethe\nconcludedthatbothareequallysafeintermsofbleed-\npossibilitytoperformRRTwithoutanticoagulation.Onthe\ningcomplications(RR0.96;CI0.27–3.43)andaseffective\notherhand,prolongedclottingtimescanalsopointtoacon-\ninpreventingextracorporealthrombosis(RR1.15;CI\n586\nsumptivecoagulopathybasedonthepresenceofanactivated\n0.7–1.91).Mainlybecauseoftheconvenienceofusinga\ncoagulation.Inthesepatients,frequentﬁlterclottingwilloccur\nsinglebolusinjectionatthestartofIHD,thereducedriskof\n576\nandnecessitateaswitchtosomeformofanticoagulation. heparin-inducedthrombocytopenia(HIT),andoflong-term\nInpatientsthataretreatedwithoutanticoagulation,\nside-effectssuchasabnormalserumlipids,osteoporosis,and\nspecialattentionisrequiredtonon-anticoagulantstrategies\nhypoaldosteronism,theEuropeanpracticeguidelinefor\ntoprolongﬁltersurvival.Theseincludeagoodfunctioning\npreventionofdialyzerclottingsuggestsusinglow-molecu-\nvascularaccess,thereductionofbloodviscosityand\nlar-weightratherthanunfractionatedheparininchronic\n587\nhemoconcentrationbysalineﬂushes,predilution,highblood\ndialysispatients.ManyEuropeancentershaveextrapolated\n95\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.3\nYes\nImpaired Proceed without\ncoagulation? anticoagulation\nNo\nRec\n5.3.1.1\nUnderlying\nYes\nUse anticoagulation\ncondition requires\nadapted to this\nsystemic\ncondition\nanticoagulation? No\nChoose RRT\nCRRT Intermittent RRT\nModality\nRecs\nNo\n5.3.2.2\nRegional Citrate\nContraindication\nto Citrate? Anticoagulation\n5.3.3.1\nYes\nNo\nIncreased\nRec\nHeparin\nBleeding Risk? 5.3.2.3\nYes\nProceed without\nRec\nanticoagulation\n5.3.3.2\nNo\nIncreased\nBleeding Heparin\nRisk? Rec\n5.3.2.1\nYes\nProceed without\nanticoagulation\nFigure17|Flow-chartsummaryofrecommendations.Heparinincludeslow-molecular-weightorunfractionatedheparin. CRRT,continuousrenalreplacementtherapy;RRT,renalreplacementtherapy.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 3)",
    "content": "thistoIHDforAKI,althoughstudiesinthissettingareonthedegreeofkidneyinjury,andthedoseandtypeof\n590\nlacking.InpatientswithAKI,thedoseofheparinforIHDlow-molecular-weightheparin.TheAmericanCollegeof\nandthetargetaPTTshouldbeindividualizedaccordingtoChestPhysicians(ACCP)guidelinesforantithromboticand\nthepresenceorabsenceofcoagulationabnormalitiesand/orthrombolytictherapythereforesuggestusingunfractionated\n588,589\nriskofbleeding.Monitoringshouldalsoincludeinsteadoflow-molecular-weightheparininpatientswith\n581\nplateletcount,allowingtimelydetectionofHIT.Sincesevererenalinsufﬁciency(CrCl30ml/min)whorequire\nlow-molecular-weightheparinsrelyonthekidneyasprimarytherapeuticanticoagulation,ortoreducethedoseoflow-\n580\nrouteofelimination,patientswithkidneyinjuryareatriskmolecular-weightheparinby50%.Thedosesoflow-\nofaccumulationandbleedingcomplications,dependingmolecular-weightheparinthatarerequiredforIHDare\n96\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.3\nTable19|OverviewoftheadvantagesanddisadvantagesofdifferentanticoagulantsinAKIpatients\nAnticoagulantAdvantageDisadvantageReferences\nHeparin(unfractionated)WideavailabilityNarrowtherapeuticindex–riskofbleeding\nLargeexperienceUnpredictablekinetics–monitoringrequired\nShorthalf-lifeHIT\nAntagonistavailableHeparinresistance\n580,581\nMonitoringwithroutinetests\n(aPTTorACT)\nLowcosts\nLow-molecular-weightMorepredictablekineticsRiskofaccumulationinkidneyfailure\nheparin–Weight-baseddosingpossible\nMorereliableanticoagulantresponseMonitoringrequiresnonroutinetest(anti–FactorXa)\n580,582–584\n–Nomonitoringrequired\nSinglepredialysisdosemaybeDifferentdrugsnotinterchangeable\nsufficientinIHD\nReducedriskofHITIncompletereversalbyprotamine\nInmostcountriesmoreexpensivethanunfractionatedheparin\nCitrateStrictregionalanticoagulationRiskofaccidentaloverdosewithpotentiallyfatalconsequences\n–reducedbleedingrisk\nInsufficientcitratemetabolisminpatientswithreducedliver\nfunctionandshockstatesresultinginaccumulationwithmetabolic\nacidosisandhypocalcemia\n585\nOthermetaboliccomplication(acidosis,alkalosis,hypernatremia,\nhypocalcemia,hypercalcemia)\nIncreasedcomplexity\nRequiresstrictprotocol\naPTT,activatedpartialthromboplastintime;ACT,activatedclottingtime;HIT,heparin-inducedthrombocytopenia;IHD,intermittenthemodialysis\nlowerthanthoserequiredfortherapeuticanticoagulation.Theanticoagulanteffectofsodiumcitraterelieson\nThedosesoflow-molecular-weightheparin,asprovidedbyformingacomplexwithionizedcalcium,thusremovingan\nthemanufacturers,shouldbeadaptedtothebleedingriskofessentialcomponentofthecoagulationcascade.Partofthe\ntheindividualpatient.Dosereductionmayalsoberequiredcitrateisremovedintheextracorporealcircuit.Citrate\ninpatientsreceivingdailydialysis,whichincreasestheriskreachingthesystemiccirculationisrapidlymetabolizedin\nofaccumulation.SincemanypatientswithAKIrequire\ntheliver,muscle,andkidney,liberatingthecalciumand\nprophylaxisfordeep-veinthrombosis,schedulingthisproducingbicarbonate.Thebufferingeffectofsodiumcitrate\nprophylactic(oraslightlyhigher)doseatthebeginningofisproportionaltothesodiumionsitcontains:amoleof\nthedialysissessionmayservethetwopurposes.Periodictrisodiumcitrateproducesthesamebufferingeffectas\nmeasurementofanti–FactorXalevelsmaybeusefulwith3molesofsodiumbicarbonate;whereaspreparationsof\nprolongeduse.citrate,includinghydrogencitrate,haveproportionallyless\nAlternativeanticoagulantsforIHDincludeproteasebufferingeffect.Extracorporeallossesofcalciumhavetobe\ninhibitorssuchasnafamostateandplateletinhibitorssuch\ncompensatedbyanexogenousinfusion.Additionalcompli-\nasprostacyclinoritsanalogues.Randomizedtrialscompar-cationsofcitratearesummarizedinTable19.Regionalcitrate\ningtheseanticoagulants/antiaggregantswithheparinintheanticoagulationrequiresastrictprotocol,adaptedtothelocal\nsettingofIHDforAKIarenotavailable,andtheiruseintreatmentmodalityandﬂowsettings.Theprotocolshould\nclinicalpracticeislimited.Nafamostatisaproteaseinhibitor\nincludeinstructionsfortheinfusionofcitrateandcalcium,\nthatismainlyusedinJapanandnotavailableintheUSAorforthecompositionofthedialysate/replacementﬂuid,and\nEurope.Smallobservationaltrialsinchronicdialysispatientsforintensivemetabolicmonitoring,includingacid-base\nwithincreasedbleedingrisksuggestareducedbleeding\nstatus,sodium,andtotalandionizedcalciumlevels.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 4)",
    "content": "591–593\nincidence.ConcernswithnafamostatincludetheFiverandomizedtrialshavecomparedcitratetoheparins\nabsenceofanantidote,andside-effectssuchasanaphylaxis,\nduringCRRT(SupplTables31and32).Forethicalreasons,\n594–596\nhyperkalemia,andbonemarrowsuppression.Cross-thesetrialswereperformedinpatientswithoutincreased\novercomparisonsofprostacyclinwithlow-molecular-weight\nbleedingrisk.TheﬁrsttrialbyMonchietal.usedacrossover\nheparininchronicdialysispatientsshowreducedefﬁ-\ndesigntocompareanticoagulationwithunfractionated\n597\nciency.Asmalltrialshowedreducedbleedingcomplica-\nheparinorcitratein20patientstreatedwithpostdilution\ntionscomparedtolow-doseheparin;however,attheexpenseCVVH.Patientswithhighbleedingrisk,livercirrhosis,and\n598\nofslightlymoreprematureterminations.Additional\nsensitivitytoheparinwereexcluded.Forty-nineﬁlterswere\ndrawbacksaresystemichypotensionandthehighcosts. evaluated.Citratewastitratedtoachieveapostﬁlterionized\nTherefore,theroutineuseofalternativeanticoagulantscancalciumlevelbelow1.20mg/dl(0.3mmol/l).Thedosing\nnotberecommendedinpatientswithAKI.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 5)",
    "content": "regimenofheparinconsistedofabolusof2000to5000U,\n97\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.3\nfollowedbyacontinuousinfusionof500–2000U/h,aimingthelow-molecular-weightheparin,nadroparin.Again,patients\natanaPTTof60–80seconds.Despitethisratherhighheparinwithbleedingriskorlivercirrhosiswereexcluded.Nadroparin\ndose,thecitrategrouphadalongerﬁlterlifetimeandlesswasstartedwithabolusof2850Ufollowedby380U/hwithout\nspontaneousﬁlterfailure.Fewerpatientsinthecitrategroupfurthermonitoring.Citrate(500mmol/l)wasadministeredata\nrequiredtransfusion,andthenumberoftransfusedunitswasdoseof3mmolperliterbloodﬂow,withoutmonitoringof\nalsolower.Onepatientintheheparingroupexperiencedpostﬁlterionizedcalcium.Theprimaryoutcomesweresafety,\nbleedingandonepatientinthecitrategrouphadmetabolicdeﬁnedastheabsenceofadverseeventsnecessitatingdisconti-\n599\nalkalosis.nuationofthestudyanticoagulant,andefﬁcacy,deﬁnedascircuit\nThesecondtrialrandomized30patientswithAKIsurvival.Safetywassigniﬁcantlybetterinthecitrategroupwith\nundergoingpredilutioncontinuousvenovenoushemodiaﬁl-\nonlytwopatientsrequiringachangeinanticoagulationregimen\ntration(CVVHDF)toanticoagulationwithcitrateorvs.20patientsinthenadroparingroup(P0.001).Adverse\nunfractionatedheparin.Patientswithcontra-indicationstoeventswerecitrateaccumulation(n1)andearlyclottingdueto\noneofthetwoanticoagulants(mainlyhighbleedingrisk/\nprotocolviolation(n¼1)inthecitrategroup,andbleeding\nseverecoagulopathyormetabolicproblemsthatmightbe(n16)orseverethrombocytopenia(n4)inthenadroparin\n¼¼\naggravatedbycitrate)orwhorequiredsystemicantic-group.Circuitsurvivaldidnotsigniﬁcantlydiffer.Acomputer-\noagulationformedicalreasonswereexcluded.Heparinwas\ndrivencombinationofbufferedandnonbufferedreplacement\ntitratedtoachieveanaPTTof45–65seconds.Citratewas\nﬂuidswasusedinthecitrategroup,explainingwhymetabolic\ntitratedtoapostﬁlterionizedcalciumbetween1.0–1.40mg/dlalkalosisoccurredmorefrequentlyinthenadroparingroup. (0.25–0.35mmol/l).TwopatientsineachgroupcrossedoverRathersurprisingly,theauthorsalsofoundanimprovedrenal\ntotheotheranticoagulantandtheseﬁlterswerenotincluded\nrecoveryandanimprovedhospitalsurvivalinthecitrategroup. intheanalysis.Thetrialwasstoppedearlyafter79ﬁltersThiscouldnotbeattributedtodifferencesinseverityofillness,\nbecauseofanadvantageusingcitrate,whichresultedinanorinbleedingortransfusionrequirement,andrequiresfurther\n603\nsigniﬁcantlyimprovedﬁltersurvival(124.5hoursvs.38.3\ninvestigation.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 6)",
    "content": "hours;P0.001).Inaddition,signiﬁcantlylesscitrate-Metaboliccomplicationswereinfrequentintheserando-\nanticoagulatedﬁlterswereterminatedforclotting(16.7%mizedtrials.Inobservationaltrials,themostfrequent\nmetaboliccomplicationismetabolicalkalosis,occurringin\nvs.53.5%).Theincidenceofbleedingalsotendedtobelower\n604–606\nwithcitrate(RR0.17;CI0.03–1.04;P0.06),buttransfusionupto50%ofthepatients.Inrecentlypublishedsurveys\nrequirementwasnotsigniﬁcantlydifferent.Threepatientsinorlargeclinicaltrials,theuseofregionalcitrateantic-\noagulationisstilllimitedto0–20%ofthepatients/\nthecitrategrouphadmetabolicalkalosisandtwohad\n600562,563,607\nhypocalcemia.treatments. Thethirdtrialrandomized48patientswithAKI,treatedAmajorcontra-indicationfortheuseofcitrateantic-\nwithCVVH,tocitrateorunfractionatedheparin.Patientsoagulationisseverelyimpairedliverfunctionorshockwith\nrequiringsystemicanticoagulationformedicalreasonsandmusclehypoperfusion,bothrepresentingariskofcitrate\npatientswithhighbleedingrisk,severecoagulopathy,circulatoryaccumulation.Markedlyreducedcitrateclearancesandlower\nfailure,liverfailure,orhypocalcemiawereexcluded(n12).ionizedcalciumlevelshavebeenfoundinpatientswithacute\n608–610\nAtotalof142circuitswasanalyzed.Heparinwasadministeredliverfailureorwithseverelivercirrhosis.Thesepatients\nasabolusof3000–5000Ufollowedbyacontinuousinfusionofwereexcludedinalltherandomizedtrials.Inpatientsatrisk,\n1500U/hadjustedtoachieveanaPTTof50–70seconds.Citrateintensiﬁedmonitoringisrecommendable.Theratiooftotal\n(500mmol/l)wastitratedtoapostﬁlterionizedcalciumtoionizedcalciumappearstobethebestparametertodetect\n611,612613\nwithanoptimalcutoffat2.1. between1.0–1.20mg/dl(0.25–0.30mmol/l).Neithercircuitcitrateaccumulation\nAnotherimportantdrawbackofcitrateanticoagulation,that\nsurvivalnorthereasonsfordisconnectingtheCVVHcircuit\ndifferedsigniﬁcantlybetweenthetwogroups.However,themightinﬂuencethedecisiontoimplementitinroutine\nnumberofmajorbleedingsandtheneedfortransfusionwasclinicalpractice,istheincreasedcomplexityoftheprocedure,\nwithriskofmetaboliccomplicationsandtheneedforastrict\nsigniﬁcantlygreaterintheheparingroup.Twocasesof\nmetabolicalkalosiswerenotedintheheparingroupandtwoprotocoladaptedtothelocalRRTmodality.We,therefore,\n601\nepisodesofhypocalcemiainthecitrategroup.Findingsfromonlyrecommendtheuseofcitrateforanticoagulationduring\ntwostudiespublishedafterthecut-offdateforourliteratureCRRTinpatientsthatdonothaveshockorsevereliver\n601a,601b\nreviewareconsistentwithrecommendation5.3.2.2.failure,andincentersthathaveanestablishedprotocolfor\nAsmallrandomizedcrossoverstudycomparedcitratecitrateanticoagulation.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 7)",
    "content": "anticoagulationtoregionalheparinizationin10CVVHUnfractionatedheparinstillremainsthemostwidelyused\n562,563,607\npatients.BothtreatmentarmshadarelativelyshortﬁlterlifeanticoagulantduringCRRT,mostlyadministeredas\n(13hoursforregionalheparinizationand17hoursforapreﬁlterinfusion,withlargevariabilityintheadministered\ncitrate)thatdidnotdiffersigniﬁcantly.Nobleedingoccurreddoses.Whenchoosingadoseofheparin,theclinicianshould\n602\nineithergroup.realizethattherelationshipamongheparindose,aPTT,ﬁlter\nInthelargestandmostrecentrandomizedtrial,200patientssurvival,andbleedingcomplicationsisnotstraightfor-\n574,614–619\ntreatedwithpostdilutionCVVHwererandomizedtocitrateorward,butitiscommonpracticetomeasureaPTT\n98\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.3\nforsafetyreasonsandtoadaptthetargettothebleedingrisk5.3.3:Forpatientswithincreasedbleedingriskwhoare\nofthepatient.notreceivinganticoagulation,wesuggestthe\nOnlytwosmallprospectiveRCTshavecomparedun-followingforanticoagulationduringRRT:\nfractionatedtolow-molecular-weightheparinforanti-\n5.3.3.1:Wesuggestusingregionalcitrateanti-\ncoagulationduringCRRTinpatientswithAKIand,thus,\ncoagulation,ratherthannoanticoagula-\nnoﬁrmrecommendationscanbemade.Theﬁrsttrial\ntion,duringCRRTinapatientwithout\nrandomized47patientswithAKIorsystemicinﬂammatory\ncontraindicationsforcitrate.(2C)\nresponsesyndromeundergoingCVVHDFtoheparin,start-\n5.3.3.2:Wesuggestavoidingregionalheparini-\ningwithabolusof2000–5000Ufollowedbyaninfusionof\nzationduringCRRTinapatientwith\n10U/kg/htitratedtoanaPTTof70–80seconds,orto\nincreasedriskofbleeding.(2C)\ndalteparinadministeredasbolusof20U/kgfollowedbyan\ninfusionof10U/kg/h.ThemeanaPTTintheheparingroup\nwas79seconds.Themeananti–FactorXalevel,determinedin\nRATIONALE\nsixpatientsinthedalteparingroup,was0.49U/ml.Only37\nTheriskofbleedingisconsideredhighinpatientswithrecent\nofthe82testedﬁlterswerestoppedforcoagulation.There\n(within7days)oractivebleeding,withrecenttraumaor\nwasnodifferenceinﬁltersurvival(withelectivelydiscon-\nsurgery(especiallyinheadtraumaandneurosurgery),recent\ntinuedﬁltersbeingcensored).Themeantimetoﬁlterfailure\nstroke,intracranialarteriovenousmalformationoraneurysm,\nwas46.8hoursinthedalteparingroupand51.7hoursinthe\nretinalhemorrhage,uncontrolledhypertension,orpresence\nheparingroup(NS).Threepatientsineachgrouphad\nofanepiduralcatheter.Inthesepatients,thebeneﬁtof\nbleeding,withnodifferenceintransfusionrequirement\nanticoagulationmaynotoutweightheriskofbleeding,\nbetweenthetwogroups.Dailycosts,includingthecoagula-\nandtheyshould(atleastinitially)betreatedwithout\n620\ntionassays,were10%higherwithdalteparin. anticoagulation,orwithCRRTwithregionalcitrateanti-\nThesecondtrialusedacrossoverdesignin40patients\ncoagulation.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 8)",
    "content": "withnormalcoagulationparametersundergoingpredilution\nWesuggestperformingRRTwithoutanticoagulationin\nCVVH.Patientstreatedwithunfractionatedheparinreceived\npatientswithincreasedbleedingrisk.Apossibleexception\nabolusof30U/kgfollowedbyacontinuousinfusionof\ncanbemadeforpatientswhodonothavecontraindications\n7U/kg/htitratedtoachieveanaPTTof40–45seconds. forcitrate.Randomizedtrialscomparingcitratewith\nEnoxaparinwasgivenasaninitialbolusof0.15mg/kg\nheparinshavebeenperformedinpatientswithoutincreased\nfollowedbyacontinuousinfusionof0.05mg/kg/h,adjusted\nbleedingrisk.However,sincecitrateresultsinstrictlyregional\ntoananti–FactorXalevelof0.25–0.30U/ml.Inthe37\nanticoagulation,itseemsreasonabletoalsosuggestitsuse\npatientsthatcompletedbothtreatmentarms,meanﬁlterlife\nduringCRRTinAKIpatientswithincreasedbleedingrisk. was21.7hourswithheparinand30.6hourswithenoxaparin\nAnotherapproachtoachieveregionalanticoagulationis\n(P0.017).Asimilardifferencewasfoundintheper-\nregionalheparinizationcombiningapreﬁlterdoseofheparin,\nprotocolanalysis.Theincidenceofbleedingwaslowandnot\naimingataprolongationoftheextracorporealaPTT,with\ndifferentbetweenthetwoanticoagulants.Filterlifedidnot\npostﬁlterneutralizationwithprotamine,aimingatnormali-\ncorrelatewithaPTToranti–FactorXalevel.Costswere\nzingthesystemicaPTT.Thisprocedurehasbeendescribedin\n616\nsimilarinthetwogroups.Interestingly,theseclinical\n572,573,624,627,628\nbuthasnotbeen\nchronicdialysisandCRRT,\nstudiesdidnotﬁndacorrelationbetweenanti–FactorXa\nstudiedwithmuchscrutiny.Itiscumbersomeanddifﬁcultto\nlevelsandﬁlterlife,questioningthevalueofanti–FactorXa\ntitratebecauseheparinhasamuchlongerhalf-lifethan\n616,621\nmonitoringwithregardtoefﬁcacy.However,ifusedfor\nprotamine,inducingariskofrebound.Inaddition,itexposes\nmorethanafewdays,monitoringmightbeusefultodetect\nthepatienttotheside-effectsofbothheparin(mainlytherisk\naccumulation. ofHIT)andprotamine(mainlyanaphylaxis,plateletdysfunc-\nAlternativeanticoagulantsforuseduringCRRTinclude\ntion,hypotension,andpulmonaryvasoconstrictionwithright\ntheproteaseinhibitornafamostateandtheplateletinhibitors,\n629\nventricularfailure)andisthereforenotrecommended. prostacyclinandanalogues.Bothhaveashorthalf-lifeanda\nlowMW,withthetheoreticaladvantageofextracorporeal\n5.3.4:Inapatientwithheparin-inducedthrombocytopenia\neliminationandreducedsystemicanticoagulation.Nafamo-\n(HIT),allheparinmustbestoppedandwe\nstatisnotavailableintheUSAandEurope;thereisno\nrecommendusingdirectthrombininhibitors(such\nantidoteandseveralside-effects(agranulocytosis,hyperkale-\n594–596\nasargatroban)orFactorXainhibitors(suchas\nmia,anaphylactoidreactions)havebeendescribed.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 9)",
    "content": "danaparoidorfondaparinux)ratherthanotheror\nfewsmalltrialsshowedimprovedﬁltersurvivalduringCRRT\nnoanticoagulationduringRRT.(1A)\nwhenaddingprostaglandinstoheparincomparedtoheparin\n622–624\nalone.However,prostaglandinsappeartohavea\n5.3.4.1:InapatientwithHITwhodoesnothave\nlimitedefﬁcacywhenusedalone,inducesystemichypoten-severeliverfailure,wesuggestusing\n625,626\nsion,andareexpensive.TheiruseduringCRRTcanargatrobanratherthanotherthrombin\nthereforenotberecommended.orFactorXainhibitorsduringRRT.(2C)\n99\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.3\n636–638\nRATIONALE\nuses\nfrequentlystudiedpediatriccitrateprotocol\nImmune-mediatedHITresultsfromantibodiesdirected\nAnticoagulantDextrosesolutionA(ACD-A,BaxterHealth-\nagainstthecomplexofheparinandplateletfactor4,and\ncare,USA),prescribedbasedonthebloodﬂowrate:\noccursin1–3%ofheparin-exposedpatients.Itsmainclinical\n===:\nACDratemlhbloodpumpratemlminminh15\nðÞ¼ð(cid:2)Þ(cid:2)\ncomplicationisthedevelopmentofthrombocytopeniawith\n581\norwithoutthrombosis.InpatientswithAKIundergoing\nCRRT,thediagnosisshouldthereforealsobesuspectedin\nACD-Aisinfusedviaastopcockatthecatheter-CRRT\n630\npatientswithrepeatedprematureﬁlterclotting.The\ncircuitconnectionleadingtotheCRRTmachine.Sinceour\nlikelihoodofhavingHITcanbepredictedbytheso-called\nprescribedbloodpumpﬂowis200ml/min,theresulting\n4Tscore,thatincludesthedegreeofthrombocytopenia,the\nACD-Aratewouldbe300ml/h.Thesecondaspectofthe\ntimingofonsetofthefallinplateletcount,thepresence\ncitrateprotocolprovidespreventionofcitrate-induced\nofthrombosisoracutesystemicsymptoms,andthepresence\nsystemichypocalcemiabyprovidingacalciumchloride\n631\nofotheretiologiesofthrombocytopenia.IfHITislikely,all\ncontinuousinfusion(8gcalciumchlorideperliternormal\nheparinshavetobestopped,includingany‘‘heparinlock’’\nsaline)tothepatientviaacentralline.Thecalciumchloride\nsolutionsfordialysisorothercatheters. rateisalsobasedonthebloodpumprate:\nWithregardtothediagnosisandmanagementofHIT,\n581\n===:\nCalciumchlorideðmlhÞ¼bloodpumprateðmlmin(cid:2)minhÞ(cid:2)06\nwerefertotherecentguidelineoftheACCPandthe\n587\nEuropeanbestpracticeguidelineonchronicdialysis.These\nguidelinesrecommendtheuseoftherapeuticdosesofan\nThegoalsofregionalcitrateanticoagulationareto\nalternativenonheparinanticoagulantinpatientswithstrong\nmaintainthecircuitionizedcalciumbetween0.8and\nsuspicionofHIT.Candidatesarethedirectthrombin\n1.6mg/dl(0.2and0.4mmol/l),andthepatient’ssystemic\ninhibitorslepirudin,argatroban,orbivaluridin,ortheanti-\nionizedcalciuminthenormalphysiologicrange4.4–5.2mg/\nthrombin-dependentFactorXainhibitors,danaparoidor\ndl(1.1–1.3mmol/l).Thecircuitionizedcalciumconcentra-\nfondaparinix.Pharmacokineticdataanddosingguidelines\ntionismanagedbyadjustmentofthecitraterate,whilethe\nforthesealternativeanticoagulantshavebeenpublishedfor\npatient’ssystemicionizedcalciumconcentrationismanaged\n588,632633\nIHDandCRRT. byadjustmentofthecalciumchloriderate.",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.3:Anticoagulation (Part 10)",
    "content": "Argatrobanisadirectthrombininhibitor,iseliminated\nbytheliver,hasashorthalf-life,andcanbemonitored\nRESEARCHRECOMMENDATIONS\n634\nwithaPTT.Arecentobservationalstudyontheuseof\nRandomizedtrialsshouldcompareunfractionatedto\nargatrobanforanticoagulationduringcontinuousdialysisin\nlow-molecular-weightheparinduringIHDinpatients\n30patientswithAKIandHITderivedadosingequation,\nwithAKI. basedonillnessseverityscoresorbyuseofindocyaninegreen\nRandomizedtrialsshouldcompareunfractionatedto\n635\nplasmaclearance.Regionalcitrateanticoagulationhas\nlow-molecular-weightheparinduringCRRTinpatients\nbeenusedalongwithreduceddosesofargatrobanorother\nwithAKI. nonheparinanticoagulantsincaseswherebleedingoccurs. Randomizedtrialsshouldcomparecitratetounfractio-\nHowever,therearenopublishedreportsonthispractice. natedtolow-molecular-weightheparinduringCRRTin\npatientswithAKI. Pediatricconsiderations\nFuturetrialsshouldcompareastrategywithoutanti-\nStandardizedprotocolshavebeenwellestablishedforboth\ncoagulationagainstoneofanticoagulationduringCRRT. heparinandregionalcitrateanticoagulationinchildren\nOutcomesofinterestfortrialstestingdifferentanti-\nreceivingdialysis.TheppCRRTRegistryGrouphasshown\ncoagulationstrategieswithRRTinAKIareclinical\nthatheparin-andcitrate-basedanticoagulationprotocols\nend-points,includingbleeding,renalrecovery,mortality,\nhavebeenshowntoconferequitableﬁltersurvivalin\nincidenceofHIT,andsurrogatessuchascircuitsurvival\npediatricCRRT,andtheuseofeitherisclearlysupported\nandefficiencyofdialysis,metaboliccomplications,and\n636\novertheuseofnoanticoagulationschemes.Themain\neffectsonthecoagulationsystem. advantageofcitrateanticoagulationwasthepreventionof\nsystemicpharmacologicalanticoagulationofthepatient,\nSUPPLEMENTARYMATERIAL\nwhichcanbeanissueinpatientswithmultiorganfailureand\nSupplementaryTable31:EvidenceprofileofRCTsexaminingtheeffect\nofcitratevs.heparin/nadroparininCRRTforAKI. sepsis.Calciumisarequisitecofactorinboththeintrinsic\nSupplementaryTable32:SummarytableofRCTsexaminingtheeffect\nandextrinsiccoagulationcascades.Citratefunctionsby\nofcitratevs.heparin/nadroparininCRRTforAKI. bindingfreecalcium,therebyinhibitingcoagulationinboth\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\ntheintrinsicandextrinsiccoagulationpathways.Themost\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n100\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.4\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 98,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 1)",
    "content": "562,563\nFunctionalvascularaccessisessentialforadequateRRT.BasicdurationofRRTforAKIwas12–13days.Thisprobably\nrequirementsaretoensureadequateandregularﬂowwithdoesnotjustifytheburdenofaninitialtunneledcatheterinall\nlowmorbidity.MoststudiesonindwellingtunneleddialysispatientswithAKIreceivingRRT.Rather,selecteduseoftunneled\ncathetershavebeenperformedinchronicdialysispatients.cathetersinpatientswhorequireprolongedRRTiswarranted. Forindividualsrequiringacutedialysis,theevidenceonNorecommendationcanbegivenregardingtheoptimal\ndialysiscathetersismorelimited,butthereisabodyoftimingtochangethenontunneled-uncuffedcathetertoamore\nliteratureonnondialysiscentralvenouscatheters(CVC)inpermanentaccess.Itseemsreasonabletocreateamore\nintensive-carepatients.Manyoftherecommendationsforpermanentaccesswhenrecoveryofkidneyfunctionisunlikely. patientsrequiringacutedialysisare,therefore,basedonTheoptimaltimingshouldtakeintoaccounttheincreasedrisk\nextrapolationofevidencefromtunneleddialysiscathetersorofinfectionwithuntunneledcatheters,butalsothepractical\nfromnondialysisnontunneledCVC.issuesrelatedtotheinsertionofatunneledcatheter. Severalconﬁgurationsofdialysiscatheterlumenandtip\n5.4.1:WesuggestinitiatingRRTinpatientswithAKIviahaveemergedovertheyearswithnoprovenadvantageofone\nanuncuffednontunneleddialysiscatheter,ratherdesignoveranother.Theouterdiametervariesbetween11\nthanatunneledcatheter.(2D)and14Frenchanditisself-evidentthatlargersizesdecrease\ntheriskofinadequatebloodﬂow.Inordertoprovidean\nadequatebloodﬂowandreducetheriskofrecirculation,\nthetipofthecathetershouldbeinalargevein(see\nRATIONALE\nSincemostearlycatheter-relatedinfectionshaveacutaneousRecommendation5.4.2).Thismeansthattheoptimallength\norigin,tunnelingthecatheterundertheskintogetherwitha\nis12–15cmfortherightinternaljugularvein,15–20cmfor\nsubcutaneousanchoringsystem,mayreducetheriskoftheleftinternaljugularvein,and19–24cmforthefemoral\n642–644\ninfection.Tunnelingalsoincreasesmechanicalstabilityof\nvein. thecatheter.Ontheotherhand,theinsertionofatunneledInPD,theTenckhoffcatheter,asoft,siliconerubber\ncuffedcatheter(TCC)isacumbersomeprocedurethatcatheterwithapolyestercuff,reducedearlycomplicationssuch\nrequiresexpertise(mostlyperformedbysurgeonsorinter-asbowelperforation,massivebleeding,orleakage,andhas\nventionalradiologists),time,andeffort(mostlyperformedinbecomethestandardforPD.Furthermodiﬁcations,including\ntheoperatingroomorradiologydepartment),thuspoten-theuseofswan-neckcatheters,T-ﬂutedcatheters,curled\ntiallydelayinginitiationofRRT.TheremovalofTCCsisalsointraperitonealportions,dualcuffs,andinsertionthroughthe\ntechnicallymoredifﬁcult.rectusmuscleinsteadofthemidline,havebeenmadetoreduce\nArandomizedtrialcomparedtheinitialuseoftunneledremainingcomplicationssuchasperitonitis,exit/tunnel\n645,646\nvs.nontunneledfemoralcathetersin34patientswithAKI.infection,cuffextrusion,obstruction,anddialysateleaks.",
    "page": 104,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 2)",
    "content": "Blindplacementhasbeenlargelyreplacedbysurgical\nFailuretoinserttheTCCoccurredinfourpatients(12%)\nthatwereexcludedfromtheﬁnalanalysis.Intheremainingplacementorplacementguidedbyultrasound/ﬂuoroscopy,\n647–649\n30patients,thosewithtunneledcathetershadanincreasedlaparoscopy,orperitoneoscopy.Continuous-ﬂowPD\ndictatestheneedforanefﬁcientdual-lumencatheterortwo\ninsertiontimeandmorefemoralhematomas,butalsoless\n646\ndysfunction,fewerinfectiousandthromboticcomplications,separatecatheterswithportsseparatedmaximally.Outside\n639\nandasigniﬁcantlybettercathetersurvival.Thesmallsizethepediatricsetting,noinvestigationshavespeciﬁcallylooked\nofthisstudyandtheabsenceofanintention-to-treatanalysisatperitonealcathetersinthesettingofAKI. precludeﬁrmconclusions(SupplTable33).Inaddition,the\nuseoftunneledcathetersforstartingacutedialysisisnot5.4.2:Whenchoosingaveinforinsertionofadialysis\nwidespreadpractice.catheterinpatientswithAKI,considerthese\nBoththeCentersforDiseaseControl(CDC)guidelinesforpreferences(NotGraded):\npreventionofcatheter-relatedinfectionsandtheKDOQIFirstchoice:rightjugularvein;\nSecondchoice:femoralvein;\nguidelineforvascularaccessinchronicdialysispatients\nrecommendusingacuffedcatheterfordialysisifaprolongedThirdchoice:leftjugularvein;\n(e.g.,1–3weeks)periodoftemporaryaccessisantici-Lastchoice:subclavianveinwithpreferencefor\n640,641\npated.Intworecentlargerandomizedtrials,themeanthedominantside. 101\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.4\nRATIONALE\nforfemoral)butthestudywasnotpoweredforthisend-\nAlthoughgenerallyassociatedwiththelowestrateof\npoint.Thiswasalsothecaseforthromboticcomplications\n658\ninfectiouscomplications,theCDCguidelineaswellasthe\n(SupplTable34). KDOQIguidelinerecommendavoidingthesubclavianvein\nMalfunctionisanotherissuethatneedstobeconsidered\n640,641\nforRRTaccess,becausethismayleadtocentralvein\nwhenchoosingbetweenajugularandfemoralvascular\nstenosisandjeopardizesubsequentpermanentaccess.This\naccess.Observationaltrialsshowmoremalfunctioninganda\nrecommendationismainlyderivedfromobservationaldata\nshorteractuarialsurvivalforfemoralthanforjugulardialysis\n659–661\ninESRDpatientsshowingahigherincidenceofcentralvein\ncatheters],andmoremalfunctionwithleft-sided\n662\nstenosiswithsubclavianthanwithjugulardialysiscathe-\njugularcatheterscomparedtoright-sided.Recirculation\n650,651\nters.Ontheotherhand,centralveinstenosishasalso\nhasbeenshowntobemorefrequentinfemoralthan\n652,653\nbeendescribedafterjugularcatheterization.Contactof\nsubclavianorjugulardialysiscatheters,especiallywith\n642,643\nthecatheterwiththevesselwallisconsideredaprimary\nshorterfemoralcatheters.Asecondaryanalysisofthe\ninitiatingeventforcatheter-relatedthrombosisandstenosis.",
    "page": 104,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 3)",
    "content": "Frenchmulticentertrialdidnotﬁndadifferenceincatheter\nCathetersintherightinternaljugularveinhaveastraight\ndysfunctionbetweenjugularandfemoralcathetersinthe\ncourseintotherightbrachiocephalicveinandsuperiorvena\nintention-to-treatanalysis.However,aseparateanalysisof\ncava,and,therefore,theleastcontactwiththevesselwall.A\ntherightandleftjugularcathetersshowedatrendtoward\ncatheterinsertedthroughthesubclavianortheleftjugular\nmoredysfunctionwithfemoralthanwithrightjugular\nveinhasoneormoreangulations.explainingthehigherrisk\ncatheters,butsigniﬁcantlymoredysfunctionwithleftjugular\n663\nofvesselcontactandthrombosis/stenosiswithsubclavian\ncomparedtofemoralcatheters. 650,651\ncomparedtojugularcatheters,andwithleft-sided\nAnotherpointtoconsideristhatanypatientwhohasthe\n654–656\nThesub-\ncomparedtoright-sidedjugularcatheters. optionofundergoingakidneytransplantationshouldnot\nclavianveinshould,therefore,beconsideredthelastchoice\nhaveafemoralcatheterplacedtoavoidstenosisoftheiliac\nforinsertionofadialysiscatheterinpatientswithAKI,\nvein,towhichthetransplantedkidney’sveinisanato-\n640\nespeciallywhentheriskofnonrecoveryofkidneyfunctionis\nmized.Thepresenceofafemoralcatheteralsoreducesthe\nsubstantial.Whetherthisrecommendationshouldbeex-\npatient’smobilization,especiallywhentheRRTiscontin-\ntendedtotheleftjugularveinremainsunclear.Inpatients\nuous. wherethesubclavianveinremainstheonlyavailableoption,\nInsummary,therightjugularveinappearstobethebest\npreferenceshouldbegiventothedominantsideinorderto\noptionforinsertionofadialysiscatheter.Femoralcatheters\nsparethenondominantsideforeventualfuturepermanent\narepreferredoverleftjugularcathetersbecauseofreduced\naccess. malfunction,andthesubclavianveinshouldonlybe\nBecausethesubclavianveinshouldbeavoided,the\nconsideredarescueoption.Itisevidentthatindividual\nremainingoptionsarethejugularandfemoralveins.The\npatientcharacteristicsmayrequiredeviationsfromthisorder\nuseoffemoralcathetersisthoughttobeassociatedwiththe\nofpreferences.Catheterinsertionshouldbeperformedwith\nhighestriskofinfection,andavoidanceoffemorallinesis\nstrictadherencetoinfection-controlpolicies,including\npartofmany‘‘centrallinebundles’’thatintendtoreducethe\nmaximalsterilebarrierprecautions(mask,sterilegown,\n657\nincidenceofcatheter-relatedbloodstreaminfection. sterilegloves,largesteriledrapes)andchlorhexidine2%skin\n641,664,665\nThisdogmawasquestionedinaconcealed,randomized,\nantisepsis. multicenter,evaluator-blinded,parallel-grouptrialof750\nAKIpatients,comparingthefemoralwiththejugularsitefor\n5.4.3:Werecommendusingultrasoundguidancefor\nﬁrstcatheterinsertionforRRT.Ultrasoundwasseldomused,\ndialysiscatheterinsertion.(1A)\nprobablyexplainingthesomewhathigherrateoffailureon\nonesideandcrossoverinthejugulargroup.Therateof\nhematomaformationwasalsohigherinthejugulargroup.",
    "page": 104,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 4)",
    "content": "RATIONALE\nInbothgroups,20%ofthecatheterswereantiseptic-Forseveraldecades,techniquesinvolvingtheuseofanatomic\nimpregnated.Meandurationofcatheterizationwas6.2dayslandmarkshavebeenthetraditionalmainstayofaccessingthe\ncentralvenoussystem.Usingthe‘‘blind’’landmarktechnique\nforthefemoraland6.9daysforthejugulargroup.Themajor\nreasonsforcatheterremovalweredeathor‘‘nolongerisnotwithoutsigniﬁcantmorbidityandmortality.Compli-\nrequired’’.Theincidenceofcathetercolonizationatremovalcationsofcentralvenouscatheterizationincludearterial\npuncture(0.5–6%),hematoma(0.1–4.4%),hemothorax\n(theprimaryend-point)wasnotsigniﬁcantlydifferent\nbetweenthefemoralandjugulargroup.Whenstratiﬁed(0.4–0.6%),pneumothorax(0.1–3.1%),andupto10–20%\n666,667\nInviewoftheir\naccordingtobodymassindex(BMI),thosewithinthelowestofinsertionattemptsarenotsuccessful. BMItertilehadahigherincidenceofcolonizationwiththelargesize,theriskofcomplicationsofdialysiscathetersis\nexpectedtobeevenhigher.Twometa-analyseshave\njugularsite,whereasthosewithinthehighestBMItertilehad\nthehighestcolonizationratewithfemoralcatheters.Blood-addressedtheroleofreal-timetwo-dimensionalultrasound\nforcentralveincannulation,andconcludedthat,compared\nstreaminfectiondidnotdifferbetweenthegroups(2.3per\n1000catheter-daysforjugularand1.5per1000catheter-daystothelandmarkmethod,ultrasound-guidedvenousaccess\n102\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.4\nincreasestheprobabilityofsuccessfulcatheterplacementandinstructionsoncathetercare,thereaderisreferredtopub-\n640,641,664,665\nreducestheriskofcomplications,theneedformultiplelishedguidelines.Theseguidelinesalsorecom-\ncatheterplacementattempts,andthetimerequiredforthemendnotusingdialysiscathetersforapplicationsotherthan\n641\nprocedure.TheadvantageappearsmostpronouncedfortheRRT,exceptunderemergencycircumstances. jugularvein,whereastheevidenceisscarceforthesubclavianArecentmeta-analysisofﬁveRCTsconﬁrmedthattopical\n668,669\nandfemoralvein.Subsequentlargerandomizedtrialsantibiotics(mainlymupirocin)reducetheriskofbacteremia,\n670,671\nhaveconﬁrmedthesuperiorityofultrasoundguidance.exit-siteinfection,needforcatheterremoval,andhospitali-\n682\nTrialsevaluatingtheplacementofdialysiscathetersinESRDzationforinfectioninESRDpatients.Themajorityofthe\npatients,mostlywithobservationaldesign,yieldasimilarcathetersintheincludedstudiesweretunneled.However,the\n672–678\nconclusion.TheKDOQIguidelineforvascularaccessCDC,NationalHealthService,andInfectiousDiseases\n640\nalsorecommendsusingultrasound-assistedinsertion.SocietyofAmericaguidelinesstronglyrecommendagainst\ntopicalantibioticointmentforthecareofCVC,becauseof\n5.4.4:Werecommendobtainingachestradiographtheirpotentialtopromotefungalinfectionsandantimicro-\n641,664,665\npromptlyafterplacementandbeforeﬁrstuseofanbialresistance.ForpatientswithAKIthataretreated\ninternaljugularorsubclaviandialysiscatheter.(1B)inanICU,itseemsreasonabletofollowthislastrecommen-\ndation.NorecommendationscanbegivenforAKIpatients\nthataretreatedoutsideanICU.",
    "page": 104,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 5)",
    "content": "RATIONALE\nUncuffed,nontunneleddialysiscathetersaresemirigid.Their\n5.4.6:Wesuggestnotusingantibioticlocksforpreven-\ntipshouldnotbeintheheart,becauseoftheriskofatrial\ntionofcatheter-relatedinfectionsofnontunneled\nperforationandpericardialtamponade.Ontheotherhand,a\ndialysiscathetersinAKIrequiringRRT.(2C)\npositiontoohighinthebrachiocephalicvein,especiallywith\nsubclavianandleft-sidedcatheters,shouldalsobeavoided,\nbecauseitallowsanarrowcontactbetweenthecathetertip\nRATIONALE\nandthevesselwall,whichmayresultinimpropercatheterFourmeta-analyseshaveevaluatedtheefﬁcacyofvarious\n655,679,680\nfunctionandvesselthrombosis.Thecorrectpositionantibioticlocksolutionsinchronicdialysispatients,and\nofthetipofasemirigiddialysiscatheterisatthejunctionofconcludethattheysigniﬁcantlyreducecatheter-related\nthesuperiorvenacavaandtherightatrium,allowingthebloodstreaminfection.Drawbacksaretheoverallmoderate\ncathetertoruninparallelwiththelongaxisofthesuperiortrialqualityandtheshortfollow-upthatdoesnotallow\n679682–685\nvenacava.Tunneledcathetersareusuallysofterandcanbeexcludingthedevelopmentofresistance.However,the\npositionedintotherightatrium,thusallowingahigherCDC,NationalHealthService,andInfectiousDiseases\n680\nbloodﬂow.SocietyofAmericaguidelinesstronglyrecommendagainst\nToconﬁrmthecorrectpositionandtoassessforpotentialroutinelyusingantibioticlocksolutionsinCVC,becauseof\ncomplications,apostproceduralchestradiographisconven-theirpotentialtopromotefungalinfections,antimicrobial\n641,664,665\ntionallyperformed.Althoughthisprocedurehasbeendebatedresistance,andsystemictoxicity.Mentionedexcep-\nafteruneventfulplacementofaCVC,thehighbloodﬂowstionsarelong-termcuffedandtunneledcatheterswith\nusedduringRRTandtheadministrationofanticoagulantshistoryofmultiplecatheter-relatedbloodstreaminfections\n641,665\nnecessitateconﬁrmingthecorrectpositionbeforeinitiatingdespitemaximaladherencetoaseptictechnique,\n640\ndialysistherapy.Itshould,however,berememberedthatpatientswithlimitedvenousaccessandhistoryofrecurrent\nnoneoftheradiographiclandmarks(carina,righttracheo-catheter-relatedbloodstreaminfection,orpatientswith\nbronchialangle,etc)thatareusedtoexcludeintra-atrialtipheightenedriskofseveresequelaefromacatheter-related\n679,680664\nEchocardiographymightbe\npositionare100%reliable.bloodstreaminfection. 681\nanothertooltoconﬁrmthecorrectpositionofthecatheter. Pediatricconsiderations\nMostoftheguidelinesforadultsareapplicabletochildren.",
    "page": 104,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinAKI (Part 6)",
    "content": "5.4.5:Wesuggestnotusingtopicalantibioticsoverthe\nFunctionalCRRTcircuitsurvivalinchildrenisfavoredby\nskininsertionsiteofanontunneleddialysiscathe-\n686\nlargercathetersizethatshouldbeadaptedtopatientsize\nterinICUpatientswithAKIrequiringRRT.(2C)\n687\n(Table20).RecentdatafromtheProspectivePediatric\nCRRTRegistrygroupshowsthatinternaljugularcatheters\nmaybeassociatedwithlongerfunctionalCRRTcircuit\nRATIONALE\n686\nTheincidenceofcatheter-relatedbloodstreaminfectioncansurvival,comparedtofemoralandsubclavianaccess.In\nbereducedbyimplementingeducation-basedprogramsandaddition,theProspectivePediatricCRRTRegistrygroup\nso-calledcentral-linebundles,thatemphasizetheimportanceshowedextremelypoorcircuitsurvivalwithtwosingle-\nofhandhygiene,maximalbarrierprecautionsuponinser-lumen5Fcatheters;thesecathetersshouldthereforebe\ntion,chlorhexidineskinantisepsis,optimalcathetersiteavoided.Futurepermanentaccessintheformofanarterio-\n657\nselection,anddailyreviewoflinenecessity.FordetailedvenousgraftorﬁstulaforpatientswhodevelopCKDmaybe\n103\nKidneyInternationalSupplements(2012)2,89–115",
    "page": 104,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "chapter5.4",
    "content": "689\nTable20|Catheterandpatientsizes\ncatheters.Amorerecentretrospectiveanalysiswith\nhistoricalcontrolsreportsthat,comparedtothesurgically\nPatientsizeCathetersizeSiteofinsertion\nplacedTenckhoffcatheter,usingamoreﬂexiblecatheterfor\nNeonateDouble-lumen7FFemoralarteryor\npercutaneousinsertionmayachieveacomparablecatheter\nvein\n690\nsurvivalandcomplicationrate.\n3–6kgDouble-ortriple-lumen7FJugular,subclavian,\norfemoral\n6–30kgDouble-lumen8FJugular,subclavian,\nRESEARCHRECOMMENDATIONS\norfemoral\nDeterminewhethertheinitialuseofatunneledvs.\n415kgDouble-lumen9FJugular,subclavian,\nnontunneledcatheterforRRTinAKIpatientsresultsina\norfemoral\nbeneficialeffectoncatheterfunctionandcatheter-related\n430kgDouble-lumen10ForJugular,subclavian,\ntriple-lumen12Forfemoral\ncomplications,includinginfectionsandnumberof\nReprintedfromBunchmanTE,BrophyPD,GoldsteinSL.Technicalconsiderationsfor\nadditionalaccessprocedures.\n687\nrenalreplacementtherapyinchildren.SeminNephrol2008;28:488–492,copyright\nDevelopbettermeansofpredictingtheneedforlong-\n2008,withpermissionfromElsevier;accessedhttp://www.seminarsinnephrology.org/\ntermaccessandbettermethodstoselectaccesssitein\narticle/S0270-9295(08)00117-4/fulltext\nindividualpatientsbybalancingvariousrisksand\nbenefits.\ncompromisedifacuteaccessisplacedinasubclavianvein.\nCliniciansmustthereforeconsiderthepotentiallong-term\nSUPPLEMENTARYMATERIAL\nvascularneedsofpatientswhomaybeexpectedtodevelop\nSupplementaryTable33:SummarytableofRCTsexaminingtheeffect\nCKD,especiallychildrenwhohavedemonstratedexcellent\nofaccessplacementwithtunneledversusnon-tunneledcatheterson\n688\nAKI.\nlong-termsurvivalwithCKDandESRD.\nSupplementaryTable34:SummarytableofRCTsexaminingtheeffect\nAnalysisofapediatricdatabase(1989–1999)showed\nofjugularvs.femoralaccessplacementonAKI.\nthatsurgicallyplacedTenckhoffcathetersforPDinduce\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nlesscomplicationsthanmorestiffpercutaneouslyplaced\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n104\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.5\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 107,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "replacementtherapyinAKI (Part 1)",
    "content": "Semipermeablehollow-ﬁberdialyzersareusedasstandardthesyntheticmembranestocuprophane,therewasatrend\nofcareforbothsoluteclearanceandultraﬁltrationintowardsreducedmortalitywiththesyntheticmembranes. IHDandCRRTcircuits.MembranecompositionandThismeta-analysisalsodidnotassesstheside-effectsof\nclearancecharacteristicsvaryamongthecommerciallydifferentmembranecompositionsonmoreproximal,\navailabledialyzers.WhilenoRCTsexisttoprovidedeﬁnitivetemporalassociations,suchasacutehypotensionorfever. recommendationsforaparticulardialyzertype,thecharac-Asaresult,weagreewiththeauthors’conclusionthattheuse\nteristicsandpotentialside-effectsofeachdialyzertypeofeitherabiocompatibleormodiﬁedcelluloseacetate\nrequireconsideration.membraneappearstobeappropriate. Recentobservationsrevealspeciﬁcpotentialside-effects\n5.5.1:Wesuggesttousedialyzerswithabiocompatiblewhenusingcertaindialyzermembranes.Bradykininrelease\nmembraneforIHDandCRRTinpatientswithsyndromehasbeenobservedatthestartofCRRTwith\n703\nBradykininreleasesyn-\nAKI.(2C)uncoatedAN-69membranes. dromeischaracterizedbyacutehypotensionandpulmonary\nvascularcongestion.Thesyndromeisusuallyself-limitedand\nRATIONALE\nispH-dependent,andthereforemorepronouncedinpatients\nSemipermeablehollow-ﬁberdialyzerscurrentlyrepresentthe\nwithsevereacidosis.Also,primingofthecircuitwithbanked\nstandardofcareforIHDorCRRTforpatientswithAKI.All\nblood(thatisacidoticandcontainsalargeamountofcitrate,\ndialyzermembranesinducesomedegreeofactivationof\ninducinghypocalcemia)mayevokebradykininrelease\nbloodcomponents,aphenomenoncalledbioincompati-\nsyndrome.Numerousmeasureshavebeenpublishedto\n691\nbility.Earlier-generationdialyzermembranescomposedof\npreventormitigatethissyndrome,includingzero-balance\n704\ncuprophaneorunmodiﬁedcelluloseweremorebioincom-\nora\nHFtonormalizethebankedbloodpHandcalcium,\npatibleandhadthepotentialtocausea‘‘dialyzermembrane\nbypassmaneuverinwhichthebloodprimeisgiventothe\nreaction’’,mediatedbycomplementactivation,releaseof\npatientinsteadofthecircuit,whilethepatientisbledonto\n705\nproinﬂammatorymarkers,andoxidativestress,andmani-\nthecircuitwiththesalineprimediscarded.Finally,aform\nfestedclinicallybyacutehypotension,vasodilatation,leuco-\nofbradykininreleasesyndromehasbeenreportedinpatients\n692–697\n706–708\npenia,hypoxiaandfever.Morerecently,modiﬁed\nreceivingACE-IandIHDwithAN-69membranes,\ncellulosicmembranes(withsubstitutionofthehydroxyl\nsinceACE-Ipreventtheconversionofbradykininand\ngroups)andsyntheticmembranescomposedofpolyacyl-\ntherebyprolongthehypotensiveresponsewhenacidicblood\nnitrile,polysulfone,orpoly(methylmethacrylate)havebeen\ncomesincontactwiththeAN-69membrane.However,\n704,705\ndeveloped.These‘‘biocompatiblemembranes’’(orless\nNevertheless,\nothershavedisputedthisinteraction. bioincompatiblemembranes)producelesscomplementand\ncliniciansshouldbeawareofthepotentialforbradykinin\n697,698\ncytokineactivation,anddecreaseoxidativestress.",
    "page": 108,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "replacementtherapyinAKI (Part 2)",
    "content": "releasesyndromeifanuncoatedAN-69membraneis\nRecentstudiessuggestthatplateletactivationmightalso\nemployedforRRT,especiallyinacidoticpatientsorinthose\n698–701\nbeinvolvedinthebioincompatibilityphenomenon. receivingACE-I.Neutralizingtheelectronegativityofthe\nAnothermembranecharacteristicthatmighthaveclinical\nAN-69membranebycoatingwithpolyethyleneiminesig-\n709\nimportanceistheﬂuxproperty,withmembranesgenerally\nniﬁcantlyreducesbradykiningeneration. beingdividedinlow-ﬂuxandhigh-ﬂux,thelatterhaving\nWhetherconventionaldialysismembranesareableto\nlargerporesandthusthepotentialtoclearlargersolutes. affectclinicaloutcomesinsepsisbyremovalofinﬂammatory\nThequestionofwhethermembranebioincompatibilityor\nmediatorsremainshighlycontroversial.Untilfurtherevi-\nﬂuxhasclinicalrelevanceinthesettingofAKIhasbeenthe\ndencebecomesavailable,theuseofRRTtotreatsepsisshould\nsubjectofmanyclinicaltrials.Arecentmeta-analysisof10\nbeconsideredexperimental. randomizedorquasi-randomizedcontrolledtrialsin1100\npatientscouldnotestablishanyadvantageforbiocompatible\n702\nOfnote,theauthorschoseto\norhigh-ﬂuxmembranes. RESEARCHRECOMMENDATIONS\nincludemodiﬁedcellulosemembranesinthebioincompa-Futureresearchshouldassesstheimpactofmiddle-\ntiblegroup,althoughotherinvestigatorsconsidermodiﬁedmoleculeclearancebyhigh-fluxmembranesand/or\ncellulosicmembranestobebiocompatible.Whencomparingmembraneadsorptiononpatientoutcomeinsepsis. 105\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.5\nThecomparatorgroupshouldbepatientswithsepsisthatremainsunsettled,duetotherelativelysmallsizeoftrials. donotreceiveextracorporealtreatment(ifnoAKI)orItwouldbeusefultoconductlargertrialscomparing\nconventionalRRT(ifAKI).differentmembranesandexaminingpatient-centered\nThepotentialimpactofdialyzermembranecompositionoutcomesincludesurvival,renalrecovery,andresource\n(material,flux,etc.)onoutcomesinpatientswithAKIutilization. 106\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.6\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 108,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 1)",
    "content": "ControversyexistsastowhichistheoptimalRRTmodality\noftoxinsandtherestrictedtreatmentperiod,allowing\nforpatientswithAKI.Incurrentclinicalpractice,thedown-timefordiagnosticandtherapeuticinterventions. choiceoftheinitialmodalityforRRTisprimarilybasedIHDmay,therefore,bethepreferredtreatmentinpatients\nontheavailabilityof,andexperiencewith,aspeciﬁc\nwhereimmediateremovalofsmallsolutesisrequired,suchas\ntreatmentandonthepatient’shemodynamicstatus.Transi-severehyperkalemia,somecasesofpoisoning,andtumor\ntionsbetweenCRRTandIHDarealsofrequent,mostlylysissyndrome.Hybridtreatments,suchasSLED,mayshare\ndeterminedbythehemodynamicstatusofthepatientor\nsomeoftheadvantagesofbothIHDandCRRTwithout\ncoagulationproblems.ExperiencewithPDinAKIislimited,havingtheirdisadvantages(Table22). exceptinthepediatricsettingandinregionswithlimitedSeveralRCTshavecomparedCRRTtoIHDinAKI\nresources.patients.Themostinclusivemeta-analysiswasperformedby\ntheCochraneCollaboration,analyzing15RCTsin1550AKI\n5.6.1:UsecontinuousandintermittentRRTascomple-patients.Thisanalysisconcludedthatoutcomesweresimilar\nmentarytherapiesinAKIpatients.(NotGraded)\nincriticallyillAKIpatientstreatedwithCRRTandIHDfor\nhospitalmortality(RR1.01;95%CI0.92–1.12;n¼1245),\nICUmortality(RR1.06;95%CI0.90–1.26;n515),length\nofhospitalization(meandeviation6.1;95%CI26.45\n(cid:3)(cid:3)\nRATIONALE\nCurrentmodalitiesofRRTforAKIincludeIHD,CRRT,and\nto14.25;n25),andrenalrecovery(freeofdialysison\n(cid:3)¼\nPD.AnoverviewofthedifferentmodalitiesofRRTandtheir\ndischarge)insurvivors(RR0.99;95%CI0.92–1.07;\n713\ncommonlyusedsettingsisgiveninTable21.Comparableresultshavebeenreportedbyother\nn161).",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 2)",
    "content": "714,715\nSincetheintroductionofCRRTintoclinicalpracticeinmeta-analyses.Individualstudiesuseddifferentdeﬁni-\ntheearly1980s,itsuseincriticallyillpatientswithAKIhastionsofAKIandwereunderpowered.Mostofthetrials\n710–712\nincreasedsteadily.ThetheoreticaladvantagesofCRRTexcludedpatientswithhypotensionormaximizedeffortsto\noverIHDaretheslowerﬂuidremoval,resultinginmoreimprovethehemodynamictoleranceofIHD.Thehighrateof\nhemodynamicstabilityandbettercontrolofﬂuidbalance,crossoverbetweenthetreatmentmodalitiesalsocomplicates\ntheslowercontrolofsoluteconcentration,avoidinglargetheinterpretationoftheresults.Inaddition,insomeofthe\nﬂuctuationsandﬂuidshifts(includingareducedrisktrials,IHDpatientsweretreatedwithbioincompatible\n[worsening]ofcerebraledema),thegreatﬂexibility(allowingmembranesandstudieswerenotstandardizedfortreatment\nadaptationofthetreatmenttothepatient’sneedatanytime),dose.AsubsequentRCTnotincludedintheCochranemeta-\n716\nandtheabilitytoperformthetreatmentwithrelativelyanalysesreportedsimilaroutcomes.Tworecentstudies,\nsimpleanduser-friendlymachines(allowingICUnursestoconﬁnedtosinglegeographicregions,showedreducedcosts\n717,718\nmonitorthetreatment).DisadvantagesincludetheneedforwithIHDcomparedtoCRRT.However,ananalysisof\nimmobilization,theuseofcontinuousanticoagulation,thecostrangesfromamulticenter,multinationalobservational\nriskofhypothermiaand,insomesettings,highercosts.studyfoundconsiderableheterogeneityincostsrelatedto\nMajoradvantagesofIHDoverCRRTarethefastremovalIHDandCRRT,andconcludedthateithertherapymightbe\nTable21|TypicalsettingofdifferentRRTmodalitiesforAKI(for70-kgpatient)\nSCUFCVVHCVVHDCVVHDFPDSLEDIHD\nBloodflow(ml/min)100–200150–250150–250150–250N/A100–300200–300\nPredominantsolutetransportconvectionconvectiondiffusiondiffusionconvectiondiffusiondiffusiondiffusion\nprinciple\nUltrafiltrate(ml/h)100–3001500–2000variable1000–1500variablevariablevariable\nDialysateflow(ml/h)001500–20001000–15001–2lperexchange100–300ml/min300–500ml/min\nEffluentvolume(l/d)2–836–4836–4836–7224–48N/AN/A\nReplacementfluidforzero01500–200001000–1500000\nbalance(ml/h)\nUreaclearance(ml/min)1–525–3325–3325–33variable80–90variable\nCVVH,continuousvenovenoushemofiltration;CVVHD,continuousvenovenoushemodialysis,CVVHDF,continuousvenovenoushemodialfiltration;IHD,intermittent\nhemodialysis;N/A,notapplicable;PD,peritonealdialysis;SCUF,slowcontinuousultrafiltration;SLED,slowlow-efficiencydialysis.",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 3)",
    "content": "107\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.6\nTable22|TheoreticaladvantagesanddisadvantagesofCRRT,IHD,SLED,andPD\nModalityPotentialsettinginAKIAdvantagesDisadvantages\nIHDHemodynamicallystableRapidremovaloftoxinsandlow-molecular-weightHypotensionwithrapidfluidremoval\nsubstancesDialysisdisequilibriumwithriskofcerebral\nAllowsfor‘‘downtime’’fordiagnosticandedema\ntherapeuticproceduresTechnicallymorecomplexanddemanding\nReducedexposuretoanticoagulation\nLowercoststhanCRRT\nCRRTHemodynamicallyunstableContinuousremovaloftoxinsSlowerclearanceoftoxins\nPatientsatriskofincreasedHemodynamicstabilityNeedforprolongedanticoagulation\nintracranialpressureEasycontroloffluidbalancePatientimmobilization\nNotreatment-inducedincreaseofintracranialHypothermia\npressureIncreasedcosts\nUser-friendlymachines\nSLEDHemodynamicallyunstableSlowervolumeandsoluteremovalSlowerclearanceoftoxins\nHemodynamicstabilityTechnicallymorecomplexanddemanding\nAllowsfor‘‘downtime’’fordiagnosticand\ntherapeuticprocedures\nReducedexposuretoanticoagulation\nPDHemodynamicallyunstableTechnicallysimplePoorclearanceinhypercatabolicpatients\nCoagulopathyHemodynamicstabilityProteinloss\nDifficultaccessNoanticoagulationNocontrolofrateoffluidremoval\nPatientsatriskofincreasedNoneedforvascularaccessRiskofperitonitis\nintracranialpressureLowercostHyperglycemia\nUnder-resourcedregionGradualremovaloftoxinsRequiresintactperitonealcavity\nImpairsdiaphragmaticmovement,potential\nforrespiratoryproblems\nCRRT,continuousrenalreplacementtherapy;IHD,intermittenthemodialysis;PD,peritonealdialysis;SLED,sustainedlow-efficiencydialysis. moreorlesscostlydependingonlocalpractices,especially95%CI0.72–1.16;n514).Ontheotherhand,themean\n719\nstafﬁng.arterialpressureattheendofthetreatmentwassigniﬁcantly\nSomelargeobservationalstudies,includingallpatientshigherwithCRRTthanwithIHD(meandeviation5.35;95%\nreceivingRRT,suggestthatCRRTisanindependentpredic-CI1.41–9.29;n112)andthenumberofpatientsrequiring\n720–722\ntorofrenalrecoveryamongsurvivors.Thisevidence,\nescalationofvasopressortherapywassigniﬁcantlylower\nhowever,isinsufﬁcienttofullyelucidatetheimpactofchoicewithCRRTcomparedtoIHD(RR0.49;95%CI0.27–0.87;\n713\noftherapyonthisoutcome.Appropriatelyplannedprospec-n149).Ingeneral,thenumberofpatientsincludedin\ntivetrialswillberequiredtoaddressthisissue.theseanalysesofthehemodynamictoleranceofRRTremains\nInconclusion,noRRTisidealforallpatientswithAKI.limited,andnoneoftheRCTshasspeciﬁcallylookedatthe\nCliniciansshouldbeawareoftheprosandconsofdifferenteffectofdifferentmodalitiesofRRTinpatientswithshock.",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 4)",
    "content": "RRTs,andtailorRRTonthebasisoftheindividualandSLEDhasbeenproposedasanalternativetootherforms\npotentiallychangingneedsoftheirpatients.BesidestheofRRTandisusedinmanycentersworldwideforlogistical\n723\nindividualpatient’scharacteristics,theavailableexpertiseandreasons.Arecentreviewsummarizestheresultsobtained\nwithSLEDinseveralstudiesanddiscussesindetailthe\nresourcesmayalsobeanimportantdeterminantofthe\ntechnicalaspectsofthisdialysismethod.However,rando-\nultimatechoice. mizedtrialscomparingIHDwithSLEDhavenotbeen\n5.6.2:WesuggestusingCRRT,ratherthanstandardperformed.Also,clinicalexperienceisfarmorelimitedwith\nSLEDcomparedtoCRRT,andveryfewrandomizedstudies\nintermittentRRT,forhemodynamicallyunstable\npatients.(2B)havecomparedSLEDtoCRRT.Aﬁrstsmalltrialin39AKI\npatientsdidnotﬁndanydifferenceinhemodynamics,and\nlessneedforanticoagulationwithSLEDcomparedto\n724\nCRRT.An(evensmaller)Australianstudyshowedsimilar\nRATIONALE\nManyclinicianspreferCRRTincriticallyillAKIpatientswith\ncontrolofurea,creatinine,andelectrolytes,butabetter\nseverehemodynamicinstability,becauseofbetterhemo-\ncontrolofacidosisandlesshypotensionduringtheﬁrst\n725,726\ndynamictoleranceduetotheslowerﬂuidremovaland\nhoursofthetreatmentwithCRRT.Arecentretro-\ntheabsenceofﬂuidshiftsinducedbyrapidsoluteremoval. spectiveanalysisexaminedthemortalitydatafromthree\nTheCochranemeta-analysiscouldnotestablishadifference\ngeneralICUsindifferentcountriesthathaveswitchedtheir\ninthenumberofpatientswith(howeverpoorlydeﬁned)\npredominanttherapeuticdialysisapproachfromCRRTto\nhemodynamicinstability(RR0.48;95%CI0.10–2.28;\nSLED.Thischangewasnotassociatedwithachangein\n727728\nn205)norwith(variablydeﬁned)hypotension(RR0.92;\nmortality.Inaddition,Fieghenetal.examinedthe\n108\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.6\nrelativehemodynamictolerabilityofSLEDandCRRTin\nprotocols:ﬁxeddialysatesodium(140mEq)andﬁxedultra-\ncriticallyillpatientswithAKI.Thisstudyalsocomparedtheﬁltrationratevs.variabledialysatesodium(160to140mEq)\nfeasibilityofSLEDadministrationwiththatofCRRTandandvariableultraﬁltrationrate(50%inﬁrstthirdofthe\nIHD.RelativelysmallcohortsofcriticallyillAKIpatientsintreatmentand50%inthelasttwo-thirdsofthetreatment). fourcritical-careunitsincluded30patientstreatedwithThevariablesodiumandultraﬁltrationrateprotocol\nCRRT,13patientswithSLED,and34patientswithIHD.achievedbetterhemodynamicstability,neededfewerinter-\nHemodynamicinstabilityoccurredduring22(56.4%)SLEDventions,andinducedlesserrelativebloodvolumechanges,\nand43(50.0%)CRRTsessions(P0.51).Inamultivariabledespitehigherultraﬁltrationrates.",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 5)",
    "content": "734\nanalysisthataccountedforclusteringofmultiplesessionsSchortgenetal.evaluatedtheeffectsofimplementing\nspeciﬁcguidelinesaimingtoimproveIHDhemodynamic\nwithinthesamepatient,theORforhemodynamicinstability\nwithSLEDwas1.20(95%CI0.58–2.47)comparedtoCRRT.tolerance.Theclinicalpracticealgorithmincludedpriming\nSigniﬁcantsessioninterruptionsoccurredin16(16.3%),thedialysiscircuitwithisotonicsaline,settingdialysate\nsodiumconcentrationat145mEq/l,discontinuingvasodi-\n30(34.9%),and11(28.2%)ofIHD,CRRT,andSLED\ntherapies,respectively.Thisstudyconcludedthat,incriticallylatortherapy,andsettingdialysatetemperaturetobelow\nillpatientswithAKI,theadministrationofSLEDisfeasible37C.Atotalof289RRTsessionswereperformedin76\npatientsandcomparedtoahistoricalseriesof248sessionsin\nandprovideshemodynamiccontrolcomparabletoCRRT. 45patients.Hemodynamictolerancewasbetterinthe\nInconclusion,inthepresenceofhemodynamicinstability\ninpatientswithAKI,CRRTispreferabletostandardIHD.guidelinepatients.Theydevelopedlesssystolicdropatand\nSLEDmayalsobetoleratedinhemodynamicallyunstableduringRRT.Theyalsohadlesshypotensiveepisodesandthe\nneedfortherapeuticinterventionswaslessfrequent.The\npatientswithAKIinsettingswhereotherformsofCRRTare\nnotavailable,butdataoncomparativeefﬁcacyandharmareadoptionofguidelinesdidnotinﬂuenceICUmortality,but\nlimited.Oncehemodynamicstabilityisachieved,treatmentdeathratewassigniﬁcantlylowerthanpredictedfromillness\nseverityintheguidelinepatients,butnotinthehistorical\nmaybeswitchedtostandardIHD. seriessubjects.LengthofICUstaywasalsoreducedfor\n5.6.3:WesuggestusingCRRT,ratherthanintermittentsurvivorsintheprotocol-orientedgroup,ascomparedtothe\nRRT,forAKIpatientswithacutebraininjuryorhistoricalseriesofpatients.",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 6)",
    "content": "othercausesofincreasedintracranialpressureor\nPeritonealdialysis\ngeneralizedbrainedema.(2B)\nInthedevelopingworld,thedevelopmentofCRRT\ntechniqueshasresultedinasubstantialdeclineinthe\nexpertisewith,anduseof,PDfortreatmentofAKI.The\nRATIONALE\nInapatientwithacutebraininjury,IHDmayworsenuseofPDinAKIismainlyconﬁnedtopediatricsandin\nneurologicalstatusbycompromisingcerebralperfusion\nregionswithlimitedresources,becauseofitseaseofuse,low\npressure.Thismaybetheresultofadecreaseofmeancost,andminimalrequirementsoninfrastructure.Other\narterialpressure(dialysis-inducedhypotension)oranadvantagesincludethelackofaneedforvascularaccessand\nincreaseofcerebraledemaandintracranialpressure(dialysisanticoagulation,theabsenceofadisequilibriumsyndrome\ndisequilibrium),andmayjeopardizethepotentialfor\nandtherelativelygoodhemodynamictolerancecomparedto\nneurologicrecovery.DialysisdisequilibriumresultsfromIHD.Disadvantagesaretheoveralllowereffectiveness\ntherapidremovalofsolutes,resultinginintracellularﬂuid(especiallyinpatientswithsplanchnichypoperfusionor\nshifts.Bothhypotensionanddisequilibriumcanbeavoidedwhoareonvasopressors),theriskofproteinloss,the\nbytheslowprogressiveremovalofﬂuidsandsolutesthatunpredictabilityofsoluteandﬂuidremoval,theneedforan\n729\nSmallobservationaltrialsandcase\noccursduringCRRT.intactperitonealcavity,riskofperitonitis,diaphragmatic\nreportsinpatientswithintracranialpressuremonitoringsplintingleadingtoventilatorycompromiseandﬂuctuating\nindeedreportedincreasesinintracranialpressurewithbloodglucoselevels.Recentdevelopmentsinthetechniqueof\n730,731\nIHD.UsingCTscanstomeasurebraindensity,RoncoPD(useofﬂexibleandcuffedcatheters,automaticcycling,\n732\netal.showedanincreaseofbrainwatercontentafterIHD,\nandcontinuousﬂowPD)haveincreaseditspotentialto\nwhereasnosuchchangeswereobservedafterCRRT.becomeanacceptablealternativetootherformsofRRTin\n735–737\nAKI,butdirectcomparativeeffectivenesstrialsare\nextremelylimited.EarlierreportsonPDinAKIaremainly\nProtocolsfordecreasinghemodynamicinstabilitywith\nuncontrolledobservations.Onlytworelativelyrecentrando-\nintermittentRRT\nIntradialytichypotensionisamajorproblemduringRRTin\nmizedtrialshavecomparedPDtoothermodalitiesofRRTin\nAKIpatients,limitingitsefﬁcacyandcausingmorbidity.AKI.Phurandomized70patientswithsepticAKItoPDor\nSurprisingly,thereareonlyafewstudiesassessingthishighlycontinuousvenovenoushemoﬁltration(CVVH)andfound\n733\nrelevantclinicalproblem.Paganinietal.performedaabettersurvivalwithCVVH.However,thePDtreat-\nsmall-sample(10subjects)randomizedcrossovercontrolled\nmentappearednottobe‘‘uptodate’’withuseofarigid\ntrialinAKIpatients.TheyevaluatedtwodifferentRRTcatheter,manualexchangeswithopendrainageandacetate\n109\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.6\n738\nbuffering.ThesecondtrialcompareddailyIHDtohigh-useofadaptiveCRRTequipmenttoproductionofhigh-ﬂow\nvolumePD(withTenckhoffcatheterandautomatedcycler)machineswithvolumetriccontrolallowingforaccurate\nandshowednodifferenceinsurvivalorrecoveryofkidneyultraﬁltrationﬂowshaslikewiseleadtoachangeinpediatric\nfunction.ThedurationofRRTwassigniﬁcantlyshorterintheRRTmodalityprevalencepatternsintheUSA.Accurate\n739\nPDgroup(SupplTable35).However,thistrialhasnotultraﬁltrationandbloodﬂowratesarecrucialforpediatric\nbeenpublishedinapeer-reviewedjournalandtherandomi-RRT,sincetheextracorporealcircuitvolumecancomprise\nzationprocessisunclear.CurrentlyindicationsforPDinmorethan15%ofasmallpediatricpatient’stotalblood\npatientswithAKImayincludebleedingdiathesis,hemo-volume,andsmallultraﬁltrationinaccuraciesmayrepresenta\ndynamicinstabilityanddifﬁcultyinobtainingavascularlargepercentageofasmallpediatricpatient’stotalbody\naccess.Extremelyhighcatabolism,severerespiratoryfailure,water.PollsofUSApediatricnephrologistsdemonstrate\nsevereileus,intra-abdominalhypertension,recentabdominalincreasedCRRTuseoverPDasthepreferredmodalityfor\nsurgeryanddiaphragmaticperitoneum-pleuraconnectionstreatingpediatricARF.In1995,45%ofpediatriccenters\narecontraindicationstoPD.",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "forpatientswithAKI (Part 7)",
    "content": "rankedPDand18%rankedCRRTasthemostcommon\nmodalityusedforinitialARFtreatment.In1999,31%of\nPediatricconsiderations\ncenterschosePDvs.36%ofcentersreportedCRRTastheir\n745\nRRTmodalitychoiceforchildrenwithAKIisguidedbymany\nprimaryinitialmodalityforARFtreatment. ofthesameprinciplesusedforadultpatients.However,since\nInthe1990s,survivalratesstratiﬁedbyRRTmodalitywere\nsevereAKIisrelativelyrareinchildrencomparedtoadults,\nbetterforchildrenreceivingIHD(73–89%)thanthosereceiving\n740\n545,746\noccurringinlessthan1%ofhospitalizedchildrenandonly\nHowever,thisanalysis\nPD(49–64%)orCRRT(34–42%). 741\n4.5%ofchildrenadmittedtoanintensivecareunit,the\ndidnotcorrectforillnessseverity.Morerecentdatademon-\nimpactoflocalexpertiseandresourcerestrictionsmaybe\nstratemuchimprovedsurvivalinchildrenreceiving\n543,544,546,570\ngreaterforpediatricacuteRRTmodalitydecisions.Asnoted\nCRRT,withsurvivalratesrangingfrom50–70%\nbelow,eachmodalityofacuteRRTcanbesuccessfully\nforchildrenwithmultiple-organdysfunctionwhoreceive\nprovidedtopediatricpatientsofallsizes.Thus,withrare\nCRRT.WhilenoRCTexiststoassesstheimpactofCRRT\nexceptiondrivenbymedicalindicationorcontraindication,\nmodalityonsurvival,convectivemodalitieswereassociatedwith\nnoformofacuteRRTcanberecommendedaboveanotherat\nincreasedsurvivalinchildrenwithstem-celltransplantsina\n747\nthepresenttime.Eachprogramshouldevaluatewhich\nprospectivecohortstudy(59%vs.27%,P0.05). modalityisprovidedmostoptimallyandfeasiblyinits\nparticularsetting. RESEARCHRECOMMENDATIONS\nProvisionofRRTasIHD,PD,orCRRTisnowamainstayLargeRCTsshouldcompareSLEDagainstotherformsof\noftreatmentforthechildwithsevereAKI.ThewidelyRRTinpatientswithAKI.Thesetrialsshouldbe\nvaryingsizerangeofpediatricpatientsimpartstechnicalstandardizedfortreatmentdose,buffer,membrane,\nanticoagulant,andtimingoftreatment. considerationsinselectionofamodality.Giventheirsmall\nsizeandassociatedlowbloodvolume,PDmayprovidetheTheeffectsofdifferentmodalitiesofRRTonthelong-\nleasttechnicallychallengingoptionforinfantsandsmalltermneedforchronicdialysis,alongwithmortality,\nchildren.However,technologicaladvancesaimedatprovid-shouldbeevaluatedinprospectiverandomizedtrials. ingaccurateultraﬁltrationwithvolumetriccontrolincorpo-\nSUPPLEMENTARYMATERIAL\nratedintoIHDandCRRTequipment,anddisposablelines,\nSupplementaryTable35:SummarytableofRCTsexaminingtheeffect\ncircuits,anddialyzerssizedfortheentirepediatricweight\nofdialysismodality(continuousvs.intermittentRRT)inAKI. spectrumhavemadeIHDandCRRTsaferandfeasiblefor\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\n570,742–744\nchildrenofallagesandsizes.Transitionfromthe\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n110\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.7\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 110,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinpatientswithAKI (Part 1)",
    "content": "OnegoalofCRRTistomaintainnormalornear-normal\nthatlactatemaynotberapidlymetabolizedinthesettingof\n749\nacid-basebalance,thuspreventingdetrimentaleffectsofmultiple-organfailure.Sincelactateisastronganion,\nacidosisoncardiovascularperformanceandhormonalinsufﬁcientlactateconversionwillresultinworsening\nresponse.Optionsforcorrectionofmetabolicacidosisacidosis,especiallysincebicarbonatelossesareongoingin\nincludetheuseofacetate-,lactate-,andbicarbonate-theextracorporealcircuit.Hyperlactatemiahasalsobeen\ncontainingreplacementsolutionsordialysate.Somecenterslinkedtoimpairedcellularfunctionandcatabolismdueto\nusecitrateanticoagulation,andthecitrateloadprovidesanloweringofthecellularredoxstateandphosphorylation\n750\nadequatesupplyofanionicbasetocontrolmetabolicpotential.Inaddition,iatrogenicincreasesinlactatelevels\nacidosis.DialysatesolutionsforIHDareproducedon-linemayleadtomisinterpretationoftheclinicalsituation.The\nbythedialysismachine,bymixingspeciallytreatedriskof‘‘lactateintolerance’’ishighestinpatientswithliver\nmunicipalwaterwithelectrolytes.Dialysateorreplacementfailure(impairedlactateclearance)orcirculatoryshock\nsolutionsforCRRTareproducedcommerciallyorlocallyin(increasedendogenouslactateproduction). Fewadequatelydesignedtrialshavecompareddifferent\nhospitalpharmacies. buffersduringRRTinAKIpatients,andmostofthemhave\n751\n5.7.1:Wesuggestusingbicarbonate,ratherthanlactate,beenperformedduringCRRT.Barenbrocketal.rando-\nasabufferindialysateandreplacementﬂuidformized117AKIpatientstoCVVHwithlactateorbicarbonate\nreplacementﬂuid.Theuseofbicarbonateresultedinbetter\nRRTinpatientswithAKI.(2C)\n5.7.2:Werecommendusingbicarbonate,ratherthancorrectionofacidosisandlowerlactatelevels.Also,the\nlactate,asabufferindialysateandreplacementincidenceofhypotensionandothercardiovasculareventswas\nlowerwithbicarbonate.Inthesubgroupofpatientswith\nﬂuidforRRTinpatientswithAKIandcirculatory\nshock.(1B)cardiacfailure,mortalitytendedtobelowerwithbicarbo-\n5.7.3:Wesuggestusingbicarbonate,ratherthanlactate,nate,whereasinthesubgroupofsepticpatentsnodifference\nasabufferindialysateandreplacementﬂuidforinoutcomewasfound(SupplTable36).Anonrandomized\ncrossoverstudyin54patientswithmultiple-organdysfunc-\nRRTinpatientswithAKIandliverfailureand/or\nlacticacidemia.(2B)tionundergoingCVVHDFconﬁrmedthesuperiorcontrolof\nacidosisandbetterhemodynamictolerancewithbicarbo-\n752\nnate.However,anotherRCTin40patientstreatedwith\nCVVHcouldnotﬁndadifferenceinhemodynamic\nRATIONALE\nOptionsforcorrectionofmetabolicacidosisinpatientswithtolerance,despitethehigherlactatelevelsinthelactate-\n753\nAKIincludeacetate,lactate,bicarbonate,andcitrate.Theusebufferedgroup.Differencesinthecase-mixmayexplain\nofacetatehasbeenlargelyabandonedinviewofthethesedifferentresults.",
    "page": 114,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinpatientswithAKI (Part 2)",
    "content": "Twosmallprospectiverandomizedcrossovercomparisons\nassociatedhemodynamicinstabilityandweightloss,probably\nrelatedtoexcessivenitricoxideproductionandcytokineofbicarbonate-andlactate-bufferedsolutionsinAKIpatients\n748\nsynthesis.Citrate,usedforregionalanticoagulationofthetreatedwithCVVHorCVVHDFfoundelevatedserum\nextracorporealcircuit,isalkalinizing,andmostpatientslactatelevelswithlactate,aneffectthatwasmorepronounced\n754,755\nreceivingcitrateanticoagulationdonotneedanadditionalinpatientswithhepaticinsufﬁciency.Anobservational\nbufferinthedialysateorreplacementﬂuid.trialin27patientsfoundacompromisedlactatetolerancein\nOriginalHFsolutionscontainedlactateasabuffer.Underpatientswithcoincidentalliverdisease,thoseoninotropic\nnormalcircumstances,thislactateismetabolized,resultinginsupport,andinpatientswithinitialbloodlactatemeasure-\n44\nadequatecorrectionofacidosisinmostpatients.Asurveyinmentsof90.1mg/dl(10mmol/l)andlargebase\n756\n34AustralianICUsconcludedthat55%oftheICUpatientsdeﬁcits. 710\nwithAKIweretreatedwithlactate-basedsolutionsthat,inInconclusion,theuseofbicarbonateasabufferinthe\nmostcountries,arelessexpensivethanbicarbonatesolutions.dialysateorreplacementﬂuidofAKIpatientsresultsinbetter\nInaddition,bicarbonatesolutionshaveahigherriskofcorrectionofacidosis,lowerlactatelevels,andimproved\nbacterialcontaminationandthesolutionisunstableinthehemodynamictolerance.Thiseffectismostpronouncedin\npresenceofcalciumandmagnesium.However,inrecentpatientswithcirculatoryproblemsandinthosewithliver\nyears,bicarbonatehasgainedpopularitybecauseofconcernsdysfunction. 111\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.7\nTable23|Microbiologicalqualitystandardsofdifferentregulatoryagencies\n763–765765a\nANSI/AAMI/ISOERA-EDTAguidelines\nWaterfordialysis\nBacteria(CFU/ml)100(actionlevelat50)100\noo\nEndotoxin(EU/ml)0.50.25\noo\nDialysate\nBacteria(CFU/ml)100(actionlevelat50)100\noo\nEndotoxin(EU/ml)0.50.25\noo\nUltrapuredialysate\nBacteria(CFU/ml)0.10.1\noo\nEndotoxin(EU/ml)0.030.03\noo\nSubstitutionfluidforinfusion\n(cid:3)\nBacteria(CFU/ml)Sterile10\nEndotoxin(EU/ml)Undetectable0.03\nAAMI,AssociationfortheAdvancementofMedicalInstrumentation;ANSI,AmericanNationalStandardsInstitute;CFU,colony-formingunits;ERA-EDTA,EuropeanRenal\nAssociation—EuropeanDialysisandTransplantAsssociation;EU,endotoxinunits;ISO,InternationalOrganizationforStandardization. 760,761\n5.7.4:WerecommendthatdialysisﬂuidsandreplacementDialysate\ncommercial)ﬂuidsandcircuitryduringCRRT. ﬂuidsinpatientswithAKI,ataminimum,complyforCRRTshouldpreferablybeultrapure,andshouldatleast\nwithAmericanAssociationofMedicalInstrumen-complywithqualitystandardsfordialysiswateranddialysis\n762\ntation(AAMI)standardsregardingcontaminationﬂuidsthatmaydifferworldwide(Table23).",
    "page": 114,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "therapyinpatientswithAKI (Part 3)",
    "content": "withbacteriaandendotoxins.(1B)Finally,aninternationalqualitystandardfordialysisﬂuid\nisinpreparationbytheInternationalSocietyforStandardi-\nzation.Untilinternationalstandardsareinplace,we\nRATIONALE\nrecommendthatdialysisﬂuidsandreplacementﬂuidsin\nReplacementﬂuidsforHForHDFareinfuseddirectlyinto\npatientswithAKI,ataminimum,complywithAAMI\nthepatient’scirculationandshouldbesterile.Apotential\nstandardsforbacteriaandendotoxins.Whenlocalstandards\nmajorstepforwardinacuteRRT,reducingthecostsandthe\nexceedAAMIstandards,localstandardsshouldbefollowed\nneedforstorageofﬂuids,istheon-lineproductionof\n(Table23). replacementﬂuids,whichisachievedbypassingwaterand/or\ndialysatethroughtwoorthreeultraﬁltersbeforebeing\nRESEARCHRECOMMENDATION\n757,758\nOn-lineproductionofreplacementﬂuidshasFurtherstudiesarerequiredtoexploretheimpactofon-\ninfused. notyetbeenapprovedbytheFDAorbysomeregulatorylinepreparationofreplacementfluidforHDFonclinical\nauthoritiesinEurope.outcomes(incidenceofsepsis,renalrecovery,mortality)\nConventionalIHDusesnonsteriledialysate,asthereisnoinAKIpatientsrequiringRRT. directcontactbetweenbloodanddialysate.However,withthe\nuseofhigh-permeabilitymembranes,thelowerbloodsideSUPPLEMENTARYMATERIAL\nSupplementaryTable36:SummarytableofRCTsexaminingtheeffect\npressuresattheendofthedialyzerﬁltermayallowback-\nofbicarbonatevs.lactateasbufferforCVVHreplacementfluidon\n759\nﬁltrationofdialysatetotheblood,raisingthepossibilityof\nacidosisinAKI. endotoxinorothercontaminantexposure.Twostudies\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nconﬁrmedmicrobialcontaminationof(locallypreparedandhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n112\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.8\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 114,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.8:DoseofrenalreplacementtherapyinAKI (Part 1)",
    "content": "766\nTheﬁrstreportofRRTinAKIwaspublishedin1965. nutrition,presenceofliverdisease,sepsis,muscleinjury,\nDespitemorethansixdecadesofclinicalexperienceanddrugs,etc. research,controversyremainsaboutthebestwaytomeasureSeveralclinicalinvestigationshaveshownthattheactual\nandwhatconstitutesoptimaldoseofRRTforpatientswithdelivereddoseofRRTinAKIpatientsisfrequentlysmaller\nAKI.Indeed,threeofthetopﬁvequestionsconsideredmostthantheprescribeddose,andevensmallerthanthe\n771,773,776–778\nrelevantbyaninternationalexpert’spanelonRRTdeliveryinrecommendedminimumforCKDpatients. 767\nAKIwereaboutdose.Impedimentstoadequatedosedeliverywerehemodynamic\nThemethodsusedforRRTdosequantiﬁcationinAKIinstability,patientsize,accessproblems,technicalproblems,\nhaveseverallimitations,andhavenotbeenfullyvalidatedinneedforpatienttransportation,andearlyﬁlterclotting. thisspeciﬁcpopulation.Earliersingle-centertrialsassessingTrialsstudyingdoseinCRRThaveusedtheamount\ntheeffectsofRRTdoseinAKIprovidedconﬂictingofefﬂuentvolumenormalizedbythepatient’sweight\n531,768–772\nresults.ConsideringthecomplexityofAKIpatients,andproceduretimeasaparameterfordoseevaluation. RRTdose,byitself,mayhavelessimpactonmortalitybothHowever,theactualefﬂuentﬂowwillbeinﬂuencedby\ninpatientswithveryhighorverylowchanceofsurviving,\ninterruptionsofCRRT,andefﬂuentﬂowwillexceedactual\nbutmaybemostimportantinpatientswithintermediatedosewithuseofpredilutionorwithreductionsinmem-\n773\nscoresofdiseaseseverity.Inaddition,itispossiblethatbranepermeabilityduringthetreatment.Insummary,itis\ndoseandtimingarecloselylinkedfactors,i.e.,ahighRRTessentialtocheckverycarefullyiftheprescribedRRTdose\ndosemaynotworkadequatelyifprovidedlate,oranearlyisreallybeingdeliveredtoAKIpatients.Increasingﬁlter\nRRTstartingmaynotbeabletochangeoutcomesifthedosesize,dialysistime,bloodﬂowrate,dialysateﬂowrate,and/or\nisnotoptimized.Currently,onlyonesmallRCTconsideredefﬂuentﬂowrateshouldbeconsideredincaseofdose\n531\nbothvariablesatthesametime.inadequacy. IndeterminingaprescriptionofRRTitismandatoryto\n5.8.1:ThedoseofRRTtobedeliveredshouldbe\nconsiderparametersotherthansmall-soluteclearance,such\nprescribedbeforestartingeachsessionofRRT.aspatients’ﬂuidbalance,acid-baseandelectrolytehome-\n(NotGraded)Werecommendfrequentassessmentostasis,andnutrition,amongothers,aspossiblecomponents\noftheactualdelivereddoseinordertoadjustthe\nofanoptimalRRTdose.Infact,positiveﬂuidbalance\nprescription.(1B)appearstobeanindependentriskfactorformortalityinAKI\n83\n5.8.2:ProvideRRTtoachievethegoalsofelectrolyte,patients.",
    "page": 116,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.8:DoseofrenalreplacementtherapyinAKI (Part 2)",
    "content": "acid-base,solute,andﬂuidbalancethatwillmeet\nthepatient’sneeds.(NotGraded)5.8.3:WerecommenddeliveringaKt/Vof3.9perweek\nwhenusingintermittentorextendedRRTin\nAKI.(1A)\nRATIONALE\n5.8.4:Werecommenddeliveringanefﬂuentvolumeof\nThejudgmentandawarenessofhowmuchofaparticular\n20–25ml/kg/hforCRRTinAKI(1A).Thiswill\ntherapeuticprocedureshouldbe,andactuallyitis,delivered\nusuallyrequireahigherprescriptionofefﬂuent\nisessentialforagoodmedicalpractice.However,recent\nvolume.(NotGraded)\nsurveyshaveshownadisappointinglylownumberof\nphysiciansthatreportbeingawareof,orcalculating,RRT\n774\ndoseinAKI. RATIONALE\nAlthoughwidelyusedforevaluationofRRTinCKD,Kt/VThreeRCTsevaluatedthedoseofIHDinAKI(SupplTables\n771\nureahasimportantlimitationsasatoolforRRTdosingin37and38).Schifﬂetal.compareddailytoalternate-day\nAKI.AKIpatientsaremetabolicallyunstable,withvariationsIHDin146ICUpatientswithAKI.RRTwasstartedwith\ninureageneration.Inaddition,theirureavolumeofratherhighvaluesofSCr(over4.5mg/dl[398mol/l])and\ndistributionappearstoexceedthepatient’stotalbody-waterBUN(around90mg/dl[32.1mmol/lurea]).Thedailyarm\n775\nvolume.DifferentwaystomeasureKt/VobtainedreceivedaweeklyKt/Vapproximatelytwotimeshigherthan\n776\n±±\nsigniﬁcantlydifferentresultsinAKIpatients.Inthesamethealternate-dayarm(5.80.6vs.30.6,respectively). way,theselectionofatargetserumurealevelasanindicatorDailyIHDresultedinlowermortality(28%vs.46%,\nofdialysisdoseishighlyarbitrary,asserumureaisinﬂuencedP0.01)andfasterrecoveryofkidneyfunction(92vs. byseveralextrarenalfactors,suchasethnicity,age,gender,166days,P0.001).Majorlimitationsofthisstudywere\n113\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.8\n781\ninadequaterandomization,a‘‘verylowdose’’inthecontrolcomparedto1.16.IfweassumethatAKIpatientsshould\ngroup(actuallylessthanthatrecommendedforCKD).AlsoreceiveatleastthesamedoseasCKDpatients,itseems\noverallmortalityinthestudy(34%)waslowerthaninotherreasonabletorecommendathrice-weeklyKt/Vof1.3ora\nstudiesinthispopulation,suggestingthattheresultsmaynotweeklyKt/Vof3.9(assumingatleastthrice-weekly\ngeneralize.Moreover,alternate-dayIHDwasassociatedwithtreatment),whichalsorepresentsthelowestdoseinthe\nsigniﬁcantdifferencesinﬂuidremovalanddialysis-associatedlargestrandomizedtrialinAKI(ARFTNstudy).Whether\nhypotension,suggestingthataspectsotherthansolutespeciﬁcsubgroupsofAKIpatients,suchasthosewith\ncontrolmightmodifypatientoutcomes.hypercatabolism,maybeneﬁtfromhigherdoseswillrequire\nTheVeteransAffairs/NationalInstitutesofHealthAcutefurtherinvestigation.",
    "page": 116,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.8:DoseofrenalreplacementtherapyinAKI (Part 3)",
    "content": "563\nwasaRCT\nRenalFailureTrialNetwork(ARFTN)studyInconclusion,thereareonlytwoadequatelydesignedand\nassessingtheeffectsofintensivecomparedtoless-intensiveexecutedRCTstestingintermittentorextendedRRTdosein\nRRTin1124ICUpatientswithAKIin27VeteransAffairs–AKI.Neitherstudyshowedimprovementinmortalityorrenal\nanduniversity-afﬁliatedNorth-Americancenters.Within\nrecoverywhenthedialysisdosewasincreased,eitherby\neachrandomizationarmpatientswereswitchedbetweenincreasingKt/Vabove3.9weeklyorbyachievingaplasmaurea\nIHDandCRRTorSLED,basedontheirhemodynamictargetbelow90mg/dl(15mmol/l)inAKIpatients.However,\nstatus,reﬂectingaverageclinicalpracticeintheUSA. consistentwiththedataondoseofIHDinCKD,andconsistent\nIntermittenttreatmentswereprescribedataKt/Vof1.4,\nwiththelower-dosearmintheARFTNstudy,werecommend\nwithadeliveredKt/Vaveraging1.3,andwereperformedthrice-weeklyKt/Vof1.3oraweeklyKt/Vof3.9forIHDinAKI. three(less-intensivearm)orsix(more-intensivearm)timesSevenRCTshaveinvestigatedtheroleofCRRTdosein\n531,562,563,768–770,772\nperweek.Consequently,theweeklyKt/VwasapproximatelyWhile\nAKI(SupplTables37and38). 6.5intheintensiveand3.9intheless-intensivearm.earliersingle-centertrialsshowedmixedresults,twolarge\nmulticentertrialshavereachedremarkablyconsistentcon-\nMortalityat60dayswassimilarinbothgroups(53.6%and\n51.5%)aswasthepercentageofpatientsrecoveringkidneyclusionsconcerningthedoseofCRRTthatshouldbe\nfunction(15.4%and18.4%).LimitationsofthisstudyprovidedtocriticallyillpatientswithAKI. 563\nincludethepredominanceofmales,andthenonstandardizedTheARFTNstudycomparedstandard-intensity\npredilutionCVVHDFwithaprescribedefﬂuentﬂowof\ntimingforinitiatingRRT.Inaddition,asigniﬁcantlyhigher\nfrequencyofhypotensionandelectrolytedisturbanceswere20ml/kg/htohigh-intensityCVVHDFat35ml/kg/h.Asdis-\nseeninthemore-intensivearm.SimilartowhathasbeencussedinRecommendation5.8.3rationale,therewereno\ndifferencesinoutcomesbetweenthetwostudyarms. reportedinchronicdialysis,acuteIHDresultsinunder-\ndosingwhenKt/Visnotmeasured.IntheARFTNstudy,theImportantly,morethan95%oftheprescribeddoseofCRRT\nﬁrstsessionofIHDhadanaveragedeliveryof1.1Kt/V,whilewasdeliveredintheless-intensivegroup.Thisrepresentsa\nconsiderablygreaterintensityofdelivereddosethanis\ntheprescribeddosewas1.4. 768\nrandomizedtypicallyseeninclinicalpractice.Asinchronicdialysis,\nTheHannoverDialysisOutcomeStudy\n148ICUpatientswithAKItotwodifferentdosesofSLED:astudiesinCRRThaveshownthatdeliveryusuallyfalls\n782\nstandard-dialysisarmdosedtomaintainplasmaurealevelsThus,itwill\nsubstantiallyshortoftheprescribeddose. between120–150mg/dl(20–25mmol/l),oranintensiﬁed-usuallybenecessarytoprescribeahighdoseofCRRTin\ndialysisarmdosedtomaintainplasmaurealevels90mg/dlordertoachieveaspeciﬁctarget.Forexample,inorderto\n(15mmol/l).PatientswereincludedwithSCraroundachieveadelivereddoseof20–25ml/kg/h,itislikelythatthe\n3mg/dl(265mol/l)andplasmaureaaround60mg/dlprescriptionwillneedtobeintherangeof25–30ml/kg/h.",
    "page": 116,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.8:DoseofrenalreplacementtherapyinAKI (Part 4)",
    "content": "(10mmol/l).Themeanplasmaureawaskeptat68TheRandomizedEvaluationofNormalvs.AugmentedLevel\n±±\n24mg/dl(11.34mmol/l)intheintensiﬁedand114ofRRTstudywasconductedin35centersinAustraliaand\n562\n36mg/dl(196mmol/l)inthestandardgroup.MortalityNewZealand.Itcomparedtheeffectsofpostdilution\nat28dayswasnotstatisticallydifferentbetweengroupsCVVHDFatdosesof25and40ml/kg/hon28-and90-day\nmortalityratesin1464AKIpatients.Thedelivereddosewas\n(38.7%and44.4%)andthefrequencyofsurvivorsrecovering\nkidneyfunctionatday28wasverysimilar(63%and60%).88%and84%ofprescribedinthelow-andhigh-dose\n779\nInCKD,theanalysisbyGotchandSargentofthegroups,respectively.AsintheARFTNstudy,therewasno\nNationalCooperativeDialysisStudyshowedthatsurvivaldifferencein28-or90-daymortalitybetweenthetwogroups. couldbeincreasedbyincreasingKt/Vto1.0–1.2.AnalysisofaApartfromahigherincidenceofhypophosphatemiainthe\n562\nlargedatabaseof2311MedicareIHDpatientsalsoshowedahigh-dosegroup,thecomplicationratewassimilar. Inconclusion,therearenowconsistentdatafromtwo\nstrongassociationbetweenthedeliveredIHDdoseand\nmortality,withadecreasedmortalityriskof7%foreach0.1largemulticentertrialsshowingnobeneﬁtsofincrea-\nhigherlevelofdeliveredKt/VinCKDpatients.However,singCRRTdosesinAKIpatientsaboveefﬂuentﬂowsof\n20–25ml/kg/h.Inclinicalpractice,inordertoachievea\naboveaKt/Vof1.3,nofurtherdecreaseinmortalitywas\n780\nnoted.TheHEMOstudy,alargeRCTcomparingtwodelivereddoseof20–25ml/kg/h,itisgenerallynecessaryto\ndifferentdialysisdosesinCKD,alsocouldnotdemonstrateaprescribeintherangeof25–30ml/kg/h,andtominimize\nfurtherreductionofmortalitywithequilibratedKt/Vof1.43interruptionsinCRRT. 114\nKidneyInternationalSupplements(2012)2,89–115\nchapter5.8\nAdditionalconsiderations\nnecessarilymeanefficiency),assessingcontrolofBUN,\nInpatientswhodonotachievethetargetdoseofRRT,\ncreatinine,fluidbalance,andacid-baseandelectrolyte\ndespiteoptimizationoftheinitialmodality,aswitchto\nstatus.Thecomparatorsmightbedifferentefficiency\nanothermodalityorthecombinationofdifferentmodalities\ntargets.Thesuggestedoutcomesare60-to90-daymorta-\nshouldbeconsidered. lity,needforvasopressordrugs,timeonmechanical\nAlthoughthereareinsufﬁcientdatasupportinga\nventilation,ICUandhospitalstay,andrenalrecovery.",
    "page": 116,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.8:DoseofrenalreplacementtherapyinAKI (Part 5)",
    "content": "recommendationforelevatedRRTdosesinpatientswith\nAKIandsepticshock,limiteddatasuggestthatahigher\nSPONSORSHIP\ndosemightbebeneﬁcialinsomepatients.Asmallsingle-\nKDIGOgratefullyacknowledgesthefollowingsponsorsthat\ncenterRCTwasconductedin20patientswithsepticshock\nmakeourinitiativespossible:Abbott,Amgen,BeloFounda-\nandAKI.Patientswererandomizedtoeitherhigh-\ntion,Coca-ColaCompany,DoleFoodCompany,Genzyme,\nvolume(efﬂuentﬂowof65ml/kg/h)orlow-volumeCVVH\nHoffmann-LaRoche,JCPenney,NATCO—TheOrganization\n(efﬂuentﬂowof35ml/kg/h).Theprimaryend-pointwas\nforTransplantProfessionals,NKF—BoardofDirectors,\nvasopressordoserequiredtomaintainmeanarterialpressure\nNovartis,RobertandJaneCizikFoundation,Shire,\nat65mmHg.Meannorepinephrinedosedecreasedmore\nTranswesternCommercialServices,andWyeth.KDIGOis\nrapidlyafter24hoursofhigh-volumeascomparedto\nsupportedbyaconsortiumofsponsorsandnofundingis\nlow-volumeCVVHtreatment.Survivalonday28wasnot\nacceptedforthedevelopmentofspeciﬁcguidelines. 783\naffected. DISCLAIMER\nWhileeveryeffortismadebythepublishers,editorialboard,\nRESEARCHRECOMMENDATIONS\nandISNtoseethatnoinaccurateormisleadingdata,opinion\nDeterminetheoptimaldoseparameterthatshouldbe\norstatementappearsinthisJournal,theywishtomakeit\nusedinfuturetrialscomparingdifferentintensitiesof\nclearthatthedataandopinionsappearinginthearticlesand\ndialysisinAKIpatients.Somepossiblemethodsto\nadvertisementshereinaretheresponsibilityofthecontri-\nexploreareon-lineKt/Vurea,ureareductionratios,or\nbutor,copyrightholder,oradvertiserconcerned.Accord-\napplicationoftheconceptofcorrectedequivalentrenal\ningly,thepublishersandtheISN,theeditorialboardand\nureaclearanceforsoluteremovalmeasurementand\ntheirrespectiveemployers,ofﬁceandagentsacceptno\nultrafiltrationeffluentvolume,orsubstitutionfluid\nliabilitywhatsoeverfortheconsequencesofanysuch\nvolumenormalizedbybodyweightandtimeforCRRT. inaccurateormisleadingdata,opinionorstatement.While\nOtheraspectsofintensityshouldalsobestudied,e.g.,\neveryeffortismadetoensurethatdrugdosesandother\nfluidcontrolandacid-baseandelectrolytebalance.The\nquantitiesarepresentedaccurately,readersareadvisedthat\ncomparatorsmightbethestandardwaystomeasuredose\nnewmethodsandtechniquesinvolvingdrugusage,and\nasKt/Vorprescribedeffluentvolume.Suggestedoutcome\ndescribedwithinthisJournal,shouldonlybefollowedin\nparametersare60-to90-daymortality,ICUandhospital\nconjunctionwiththedrugmanufacturer’sownpublished\nLOS,andrecoveryofkidneyfunction. literature. DeterminetheoptimaldoseofRRTinAKIinhomo-\ngeneoussubpopulations,suchascardiacsurgeryorsepsis\npatients,andseparatelyinICUandnon-ICUpatients. SUPPLEMENTARYMATERIAL\nFutureRCTsshouldbecontrolledfortimingofRRT\nSupplementaryTable37:EvidenceprofileofRCTsexaminingtheeffect\nofdoseofcontinuousandintermittentRRTonAKI. initiationand,perhaps,forgeneralcareofpatients\nSupplementaryTable38:SummarytableofRCTsexaminingtheeffect\n(antibiotics,nutrition,kindandindicationforvasoactive\nofdoseofcontinuousandintermittentRRTonAKI.",
    "page": 116,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Chapter5.8:DoseofrenalreplacementtherapyinAKI (Part 6)",
    "content": "drugs,modeofmechanicalventilation).Studiesshould\nSupplementarymaterialislinkedtotheonlineversionofthepaperat\nalsoassesstheefficiencyofRRT(sincedosedoesnot\nhttp://www.kdigo.org/clinical_practice_guidelines/AKI.php\n115\nKidneyInternationalSupplements(2012)2,89–115\nbiographicanddisclosureinformation\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 116,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 1)",
    "content": "KidneyInternationalSupplements(2012)2,116–121;doi:10.1038/kisup.2011.36\nJohnAKellum,MD,FCCM,FACP(WorkGroupCo-Chair),\ncontributionstoimprovingandimplementingKDOQI\nisProfessorofCriticalCareMedicine,Medicine,Bio-\nGuidelines.HealsoservedastheKDIGOCo-Chairfrom\nengineeringandClinicalandTranslationalScience,andVice\n2004to2007. ChairforResearchwithintheDepartmentofCriticalCare\nDrLameirereportednorelevantﬁnancialrelationships. MedicineattheUniversityofPittsburgh.Inaddition,heis\ntheDirectoroftheProgramonBioengineeringandOrgan\nPeterAspelin,MD,PhD,receivedhisbasictrainingin\nSupportfortheCRISMA(ClinicalResearchInvestigation¨\nradiologyatMalmoUniversityHospital(LundUniversity)\nandSystemsModelingofAcuteIllness)Centeratthe\nandwasAssociateProfessortherefor13years.In1989he\nUniversityofPittsburgh. becameProfessorandChairmanoftheDepartmentof\nDrKellumisactivelyinvolvedineducation,research,and\nRadiologyatKarolinskaInstitutet,HuddingeUniversity\nadministration.Hisresearchinterestsspanvariousaspects\nHospital.ProfessorAspelinwasViceDeanoftheMedical\nofcritical-caremedicine,butcenterincritical-carenephro-\nSchoolatKarolinskaInstitutetfrom1993to1995andserved\nlogy,sepsis,multiorganfailure,andclinicalepidemiology,\nasVicePresidentattheinstitutionfrom1995to2001.Hewas\nincludingconsensusdevelopmentandresearchmethodology. alsoHeadofResearch&DevelopmentatHuddinge\nHehasauthoredmorethan300publicationsandservedas\nUniversityHospitalin2002andViceChairmanofResearch\neditorandcontributortorecenttextsincludingContinuous\n&DevelopmentattheKarolinskaUniversityHospital.Other\nRenalReplacementTherapy,CriticalCareNephrology,and\nnotableaccomplishmentsalsoincludehisrolesasPresident\nManagementofAcuteKidneyProblems.DrKellumhaswon\nfortheScientiﬁcBoardoftheSwedishCouncilofTechnology\nseveralawardsforteachingandhasgivenmorethan400\nAssessmentinHealthCare(1999–2005);Chairmanofthe\nseminarsandinvitedlecturesworldwiderelatedtohis\nSwedishSocietyofMedicalRadiology(2003–2005);andpast\nresearch. ViceChairmanandcurrentChairmanoftheSwedish\nAdvisor/Consultant:Abbott;Alere;AstuteMedical;Baxter;\nMedicalAssociation. CytoSorbents;EBI;EliLilly;Fresenius;Gambro;Siemens;\nProfessorAspelinhasconductedresearchoncontrast\nSpectralDiagnostics\nmediasince1972whenhestudiedunderthetutelageof\nSpeaker:Baxter;Fresenius;Gambro\nProfessorTorstenAlmen.Hehaswrittenmorethan170\nGrant/ResearchSupport:AstuteMedical;Baxter;CytoSorbents;\nscientiﬁcpublicationstodateandhisprimaryresearch\nGambro\ncentersonthedevelopmentofnonioniccontrastmediaand\ntheexaminationoftheireffectsonmedicalimagingand\nNorbertLameire,MD,PhD(WorkGroupCo-Chair),is\npatientsafety.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 2)",
    "content": "ProfessorofInternalMedicineandformerChiefofRenal\nSpeaker:GEHealthcare\nDivisionattheUniversityofGhentwherehealsoreceivedhis\nExpertwitness:GEHealthcare\nmedicaldegreeandPhD.DrLameire’sinterestsincludebasic\nresearchtopicssuchasrenalcirculationinexperimentalARF\nRashadSBarsoum,MD,FRCP,FRCPE,isEmeritus\nandperitonealcirculation,aswellasclinicaltopicsspanning\nProfessorofMedicineatCairoUniversityandcurrent\nclinicalARF,PD,andorganizationalandeconomicaspects\nChairmanofCairoKidneyCenterandMedicalSector\nofchronicRRTandtransplantation.Hecurrentlyoversees\nCommitteeforSupremeCouncilforEgyptianUniversities. theworldwidecontinuingmedicaleducationprogramsof\nHereceivedhismedicaldegreefromCairoUniversity,where\nCOMGANoftheInternationalSocietyofNephrology,and\nhealsocompletedhisfellowshipinnephrologyin1967. servesascurrentEditor-in-ChiefforActaClinicaBelgica\nDrBarsoumhasbeenaprimaryinvestigatorinclinicaltrials\nandisemeritusEditor-in-ChiefforNephrologyDialysis\ninvolvingthestudyofimmunosuppressionagentsinkidney\nTransplantation.ForhisactivitiesintheRenalSisterProgram\ntransplantationandtreatmentofHCVinfectionindialysis\noftheInternationalSocietyofNephrologyandhisleadership\npatients.Hehasalsoauthoredmorethan200journalarticles\noftheRenalDisasterReliefTaskForce,hewasawarded\nandbookchaptersandcurrentlyservesasAssociateEditor\nDoctorHonorisCausaattheKaunasMedicalAcademyin\nforNephronClinicalPracticeandeditorialboardmemberfor\nLithuaniaandanhonorarymembershipoftheInternational\nAmericanJournalofKidneyDiseases.DrBarsoumisalso\nSocietyofNephrology(ISN).DrLameirealsoreceivedthe\nactiveinnumerousmedicalsocieties,havingservedasPast\nGarabedEknoyanAwardfromtheNKF(USA)in2007forhis\nPresidentfortheArabSocietyofNephrologyandRenal\ncontinuingworktoimprovedialysistherapyandPD,andhis\nTransplantationandEgyptianSocietyofNephrology.Among\n116\nKidneyInternationalSupplements(2012)2,116–121\nbiographicanddisclosureinformation\nhisnotedachievementsincludetheInternationalAwardfrom\nCharlesAHerzog,MD,isDirectoroftheCardiovascular\ntheNKF(USA),theRoscoeRobinsonAwardfromthe\nSpecialStudiesCenter,UnitedStatesRenalDataSystem\nInternationalSocietyofNephrology,andtheDistinguished\n(USRDS).AninvestigatorattheUSRDSsince1999,\nResearcherAwardfromCairoUniversity.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 3)",
    "content": "DrHerzoghasbeenacardiologistatHennepinCounty\nAdvisor/Consultant:Wyeth\nMedicalCenter(HCMC)inMinneapolisandamemberofthe\nSpeaker:Amgen;B.Braun;Fresenius;JanssenCilag;\nUniversityofMinnesotafacultyfor27years.Hehasbeen\nNovartis;Roche;Wyeth\naprofessorofmedicineattheUniversityofMinnesotasince\n2004andthecardiologyconsultanttotheESRDprogram\nEmmanuelABurdmann,MD,PhD,isHeadofIntensiveCare\n(dialysisandrenaltransplant)atHCMCsince1985.He\nUnitandAssociateProfessor,DivisionofNephrologyat\nfoundedtheprogramininterventionalcardiologyandserved\nUniversityofSaoPauloMedicalSchool.Hereceivedhis\nasthedirectorofthecardiaccatheterizationlaboratoryat\nmedicaldegreefromtheUniversityofSaoPaulo,wherehealso\nHCMCfrom1985to1991.Since1997,DrHerzoghasbeen\ncompletedhisfellowship.HewasthePastPresidentofthe\nthedirectorofthecardiacultrasoundlaboratoryatHCMC. LatinAmericanSocietyofNephrologyandHypertensionand\nHeparticipatedinthedevelopmentoftheNationalKidney\ncurrentPresidentofBrazilianSocietyofNephrology.Dr\nFoundation’sK/DOQIClinicalPracticeGuidelinesforCardio-\nBurdmannhasauthoredover150journalarticlesandbook\nvascularDiseaseinDialysisPatients,andco-chairedthe2010\nchaptersandiscurrentlyontheeditorialboardsofClinical\nKDIGOControversiesConference,‘‘CardiovascularDiseasein\nJournaloftheAmericanSocietyofNephrology,Clinical\nCKD:WhatisitandWhatCanWeDoAboutIt?’’Theauthor\nNephrology,KidneyInternational,NephrologyDialysisTrans-\norco-authorofmorethan100publishedpapersandreviews,\nplantation,andNephronClinicalPractice.Heisalsoamember\nDrHerzoghasservedontheEditorialBoardfortheAmerican\nofnumerousprofessionalsocietiesandhasservedonthe\nHeartJournalsince2005andasliaisoneditor(cardiology)for\nCounciloftheInternationalSocietyofNephrologyand\nNephrologyDialysisTransplantationsince2007.Hisareasof\nKDIGOBoard.InadditiontohisresearchinterestinAKI,\nresearchandspecialinterestsincludecardiacdiseaseand\nDrBurdmannisalsoacoinvestigatorintheTREATstudy. chronickidneydisease,andechocardiography. DrBurdmannreportednorelevantﬁnancialrelationships.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 4)",
    "content": "Advisor/Consultant:Abbott;Affymax;Amgen;CorMedix;\nFibroGen;Fresenius\nStuartLGoldstein,MD,isProfessorofPediatricsandDirector,\nBoardofTrustees:RocheFoundationforAnemiaResearch\nCenterforAcuteCareNephrologyatCincinnatiChildren’s\nHonorarium:UpToDate\nHospitalMedicalCenter.Hereceivedhismedicaldegreefrom\nGrant/ResearchSupport:Johnson&Johnson;NationalInstitutes\nColumbiaUniversityandcompletedbothclinicalandresearch\nofHealth\nfellowshipsinpediatricnephrologyattheChildren’sHospital\nEquityInterest:BostonScientiﬁc;CambridgeHeart;Johnson\ninBoston,Massachusetts.DrGoldsteinisamemberofthe\n&Johnson;Merck\nAmericanAcademyofPediatrics,theAmericanSocietyof\nNephrology,theInternationalPediatricNephrologyAsso-\nMichaelJoannidis,MD,isAssociateProfessorinMedicine\nciation,theAmericanSocietyofPediatricNephrology,the\nandservesasDirectoroftheMedicalIntensiveCareUnit,\nInternationalSocietyofNephrology,andtheSocietyfor\nDept.InternalMedicineIatMedicalUniversityInnsbruckin\nPediatricResearch.Inaddition,heisChairmanoftheMedical\nAustria.Heisacertiﬁedspecialistincritical-caremedicine,\nAdvisoryCommitteetotheFORUMofESRDNetworksanda\nnephrology,andcardiology,andhisresearchinterestscover\nmemberoftheMedicalReviewBoardfortheESRDNetworks\nseveralaspectsofcritical-caremedicinewithamajorfocuson\n9and10,isthePediatricNephrologistRepresentativeforthe\nAKI,renaltubularepithelialpathophysiology,RRT,andsepsis. InternationalSocietyofNephrologyCommissionofAcute\nDrJoannidiscurrentlyservesaschairofthesectionAcute\nRenalFailure,andhasbeenelectedtotheCouncilofthe\nKidneyInjuryoftheEuropeanSocietyofIntensiveCare\nAmericanSocietyofPediatricNephrology.DrGoldsteinhas\nMedicine(ESICM),PresidentoftheAustrianSocietyof\ndevelopedandvalidatedthepediatricmodiﬁedRIFLE\nMedicalandGeneralIntensiveCareMedicine(OEGIAIM)\n(pRIFLE)AKIcriteria,isFounderandPrincipalInvestigator\nandassociateeditorofIntensiveCareMedicine. fortheProspectivePediatricContinuousRenalReplacement\nSpeaker:Baxter;Fresenius;Gambro\nTherapy(ppCRRT)RegistryGroup,andhasevaluatednovel\nurinaryAKIbiomarkersinthepediatriccriticalcaresetting.He\nAndreasKribben,MD,isProfessorofMedicineandHeadof\nhaswrittenover110journalarticlesandcontributedbook\ntheDepartmentofNephrologyattheUniversityHospital\nchapterstonumeroustextsincluding,CriticalCareNephrology,\nEssenattheUniversityofDuisburg-Essen.Hereceivedhis\nEvidence-BasedNephrology,HandbookofDialysisTherapy,\nmedicaldegreeattheJohann-WolfgangGoetheUniversity\nManagementofAcuteKidneyProblems,PediatricCriticalCare,\nFrankfurt,Germanyin1983.DrKribbenwastrainedin\nPediatricNephrology,andPediatricNephrologyintheICU.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 5)",
    "content": "InternalMedicineandNephrologyattheDepartmentof\nAdvisor/Consultant:Baxter;Gambro\nNephrologyoftheUniversityHospitalKlinikumSteglitz,\nSpeaker:Gambro\nFreeUniversityofBerlin,GermanyandattheUniversity\nGrant/ResearchSupport:Amgen;Baxter;Gambro\nHospitalEssen,UniversityDuisburg-Essen,Germany.From\n117\nKidneyInternationalSupplements(2012)2,116–121\nbiographicanddisclosureinformation\n1990to1993,hewasaresearchfellowattheRenalDivision\nsystematicliteraturereviewsandsheisamemberofthe\noftheUniversityofColoradoHealthSciencesCentrein\nEditorialBoardoftheCochraneReviewGroup.DrMacLeod\nDenver,Colorado,USA.Hismajorscientiﬁcinterestsinclude\nisacurrentcommitteememberoftheEuropeanRenal\nallaspectsofAKI,CRF,aswellastransplantationand\nRegistryExecutiveCommittee,AnemiaManagementin\nhypertension. ChronicKidneyDisease–NationalInstituteforHealthand\nDrKribbenismemberofnumerousprofessionalorgani-\nClinicalExcellence,ScientiﬁcCommittee,andEuropean\nzations,includingtheInternationalSocietyofNephrology,\nRenalAssociationCongress.Inaddition,sheisChairman\ntheAmericanSocietyofNephrology,theEuropeanDialysis\noftheScottishIntercollegiateGuidelinesNetwork,Diagnosis\nandTransplantationAssociation,andheisamemberofthe\nandManagementofChronicRenalFailureandwasa\nBoardofDirectorsoftheGermanSocietyofNephrology. memberoftheExecutiveCommitteeofKDIGO. HeisaneditorialmemberofClinicalNephrologyandserved\nDrMacLeodreportednorelevantﬁnancialrelationships. assubjecteditorofNephrologyDialysisTransplantation. DrKribbenisalsoamemberoftheWorldHealth\nRavindraLMehta,MD,FACP,FASN,FRCP,isProfessor\nOrganizationWorkGroupforthe11threvisionofICD. ofMedicineintheDivisionofNephrologyandAssociate\nAdvisor/Consultant:Roche;Shire;Teva\nChairforClinicalResearchintheDepartmentofMedicine\nSpeaker:Amgen;AphereseForschungsInstitut;Baxter;\nattheUniversityofCalifornia,SanDiego(UCSD)where\nBayer-Schering;Berlin-Chemie;Fresenius;GEHealthcare;\nhedirectstheAcuteDialysisProgramandtheUCSD\nGenzyme;Roche;Shire\nCRESTandMastersinClinicalResearchProgram.He\nGrant/ResearchSupport:B.Braun;Biosite;Fresenius;\nreceivedtheM.B.B.S.degree(1976)fromtheGovernment\nKoehler;Roche;Teva\nMedicalSchoolinAmritsar,India,andtheM.D.(1979)\nandD.M.(1981)degreesfromthePost-GraduateInstitute\nAndrewSLevey,MD,isDrGeraldJ.andDorothyR. ofMedicalEducationandResearchinChandigarh,India. FriedmanProfessorofMedicineatTuftsUniversitySchool\nHesubsequentlycompletedanephrologyfellowshipat\nofMedicine,ChiefoftheWilliamB.Schwartz,MDDivision\ntheUniversityofRochesterinRochester,NewYorkand\nofNephrologyatTuftsMedicalCenter,SeniorScientistat\nobtainedhisboardsininternalmedicine(1986)and\ntheUSDepartmentofAgricultureHumanNutrition\nNephrology(1988).HehasbeenonthefacultyatUCSD\nResearchCenteronAgingatTuftsUniversity,andProfessor,\nsince1988.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 6)",
    "content": "ClinicalResearchattheSacklerSchoolofGraduate\nDrMehtaisaninternationallyrecognizedexpertinthe\nBiomedicalSciencesatTuftsUniversity.Hisresearchis\nﬁeldofARFandhasdirectedseveralclinicalstudiesinthe\nmainlyintheareasofepidemiologyofCKDandcardio-\nmanagementofpatientswithkidneydiseaseincluding\nvasculardiseaseinCKD,controlledtrialstoslowthe\ncomparingdifferentdialyticmodalitiesinthetreatmentof\nprogressionofCKD,clinicalassessmentofkidneyfunction,\nAKI,conductinglargemulticenterobservationalstudiesof\nassessmentandimprovementofoutcomesindialysisand\nAKIwiththePICARDgroup,evaluatingdifferentpredictive\ntransplantation,andclinicalpracticeguidelinedevelop-\nmodelsforoutcomesinAKI,investigatingtheroleof\nmentandimplementation.DrLeveyiscurrentlyProgram\ncytokineremovalbydialysismembranesinsepsisandAKI,\nDirectorforanNIDDK-fundedclinicalresearchtraining\nandevaluatingtechniquesfordeterminingtheamountof\nprogram,‘‘ClinicalTrials,EpidemiologyandOutcomes\nexcessﬂuidindialysispatients.Inadditiontohisclinicaland\nResearchinNephrology’’.HeisalsotheDirectorofthe\nresearchactivities,hehasworkedwiththeAmericanSociety\nTuftsCenterforGuidelineDevelopmentandImplementation\nofNephrology,NKF,SocietyofCriticalCareMedicine,and\nandEditoroftheAmericanJournalofKidneyDisease. theInternationalSocietyofNephrologyindeveloping\nDrLeveyispastChairoftheNKF’sTaskForceon\ncoursesforfellowsandpracticingphysiciansinclinical\nCardiovascularDiseaseinChronicRenalDisease,KDOQI\nnephrologyanddialysistechniques.DrMehtachairsthe\nWorkGrouponChronicKidneyDisease:Evaluation,\nannualInternationalConferenceonCRRTthatisnowinits\nClassiﬁcationandStratiﬁcation,andKDOQIWorkGroup\n15thyearandheisalsotheChairoftheInternationalSociety\nonHypertensionandAntihypertensiveAgentsinChronic\nofNephrologyCommitteeonAKI,foundingmemberofthe\nKidneyDisease. ADQIandAKIN.Hehasauthoredover150scientiﬁcarticles,\nGrant/ResearchSupport:Amgen;NationalInstitutesof\npapersandbookchapters,andhasbeenactivelyinvolvedin\nHealth;NationalKidneyFoundation\nresidentandscholarteaching.Hewonthehousestaff\nteachingawardonfouroccasionsandwasawardedSchoolof\nAlisonMMacLeod,MBChB,MD,FRCPLondonand\nMedicineFacultyteachingawardin2003.Hehasbeen\nEdinburgh,isProfessorintheDepartmentofMedicine\nrecognizedasoneoftheBestDoctorsinSanDiegoandthe\nandTherapeuticsattheUniversityofAberdeenMedical\nUSA.In2008,hewasrecognizedbytheAmerican\nSchool,UK.ShecompletedherfellowshipattheRoyal\nNephrologistsofIndianOriginforhisachievementsin\nCollegesofPhysiciansofLondonandEdinburgh,andhas\nnephrology.InMarch2009,hewaselectedasaFellowofthe\ninterestsinepidemiologyofCKD,AKI,andevidencebased\nRoyalCollegeofPhysiciansintheUK.Overthecourseofhis\nmedicineinnephrology.Herresearchgroupalsoconducts\nacademiccareer,hehastrainedover50postdoctoralfellows\n118\nKidneyInternationalSupplements(2012)2,116–121\nbiographicanddisclosureinformation\ninnephrology,ofwhom15havecarriedouttheirresearch\nMedalofNKFoftheUSAin2005andwasawardedthe\nprojectswithhim.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 7)",
    "content": "prestigiousRoscoeRobinsonawardfornephrologyeducation\nAdvisor/Consultant:AstuteMedical;EliLilly;Takeda\nbytheISNatitsWorldCongressinMilaninMay2009.She\nSpeaker:Baxter;Gambro\nhashostedthenephrologytrainingofISNFellowsfrom\nGrant/ResearchSupport:EliLilly\nEthiopia,Nigeria,Botswana,Tanzania,Rwanda,Kenyaand\nZambiaaswellasISPDtraineesfromNigeriaandTanzania. PatrickTMurray,MD,FASN,FRCPI,FJFICMI,isa\nDuringherperiodasChairoftheAfricaCommitteeofISN\nnephrologistandclinicalpharmacologistattheMater\nCOMGANfrom2000to2007,shemadesitevisitsand\nMisericordiaeUniversityHospitalandUniversityCollege\nparticipatedincontinuingmedicaleducationprogramsin\nDublin,Ireland.DrMurrayreceivedhismedicaleducationat\nmanyAfricancountries.Herresearchinterestsincludeareas\nUniversityCollegeDublin,Irelandandfollowinghisintern-\nrelatedtoHIVandkidneydisease,preventionofCKD,CVD\nshipattheMaterMisericordiaeUniversityHospitalin\ninrenaldisease,andmedicaleducation. Dublin,hecompletedhisresidencyininternalmedicine\nAdvisor/Consultant:Amgen;Novartis;Roche\natHennepinCountyMedicalCenterinMinneapolis,Minnesota,\nUSAandfellowshiptrainingprogramsinnephrology,critical\nStevenMOpal,MD,isProfessorofMedicineatTheWarren\ncaremedicine,andclinicalpharmacologyattheUniversityof\nAlpertMedicalSchoolofBrownUniversityandChiefofthe\nChicagoHospitalsinChicago,Illinois,USA. InfectiousDiseaseDivision,MemorialHospitalofRhode\nDrMurrayisboard-certiﬁedininternalmedicine,\nIsland.HereceivedhismedicaldegreefromAlbanyMedical\nnephrology,criticalcaremedicine,andclinicalpharmacology\nSchool,Albany,NewYorkandcompletedhisfellowship\nandpracticedasanintensivist,nephrologist,andclinical\ntrainingininfectiousdiseasesatWalterReedArmyMedical\npharmacologistattheUniversityofChicagoHospitalsfrom\nCenterinWashington,DC.DrOpalisamemberof\n1996to2008,servingasthefellowshiptrainingprogram\nnumerousnationalandinternationalcommitteesincluding,\ndirectorinnephrologyandalsodirectingtheAcuteDialysis\nInternationalSteeringCommitteeforSepsisClinicalTrials;\nService.Since2008,hehasbeentheProfessorofClinical\nSteeringCommitteeFDAMeta-analysisCommitteeon\nPharmacologyatUniversityCollegeDublin,andaCon-\nSepsis;InternationalEndotoxinSociety;andInternational\nsultantinNephrology&ClinicalPharmacologyattheMater\nSepsisForum.Hehaswrittenextensivelywithover300\nMisericordiaeUniversityHospital.DrMurrayhaspublished\npublicationsandhasgivenmorethan100invitedpresenta-\nextensivelywithcontributionsinnumerousbooksinclu-\ntions.DrOpalcurrentlyservesontheeditorialboardsof\nding,CriticalCareNephrology,Evidence-BasedNephrology,\nAdvancesinSepsis,CriticalCareForum,CurrentOpinionin\nEvidence-BasedPracticeofCriticalCare,andIntensiveCarein\nCriticalCare,andShock.Inrecognitionforhiswork,hewas\nNephrology.Hehasalong-standinginterestinresearchand\nawardedtheBrownMedicalSchoolInfectiousDisease\neducationtoimprovetheprevention,diagnosis,andtherapy\nFellowshipTeacheroftheYearAwardin2008andwas\nofAKI. acknowledgedinBestDoctorsinAmericafrom2003to2009.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 8)",
    "content": "Advisor/Consultant:Abbott;Alere;AMPharma;Argutus\nDrOpalreportednorelevantﬁnancialrelationships. Medical;FASTDiagnostics;Reata;Sanoﬁ-Aventis\nGrant/ResearchSupport:Abbott;Alere;ArgutusMedical\nFranzSchaefer,MD,isProfessorofPediatricsandChiefof\nthePediatricNephrologyDivisionatHeidelbergUniversity\nSaraladeviNaicker,MBChB,MRCP,FRCP,FCP(SA),PhD,\nHospital.DrSchaeferreceivedhisM.D.atWurzburg\niscurrentlyAcademicHeadoftheDepartmentof\nUniversityMedicalSchoolandperformedresearchscholar-\nInternalMedicineandProfessorofRenalMedicineandhead\nshipsattheInstituteofChildHealth,London,Universityof\noftheDivisionofNephrologyattheUniversityofthe\nVirginia,andStanfordUniversity.Hisresearchinterests\nWitwatersrandinJohannesburg.Shecompletedherunder-\nincludetopicsonphysiopathologyofgrowthfailure,\ngraduateandpostgraduatemedicaltrainingprimarilyatthe\ncardiovascularandendocrinedisordersinCKDandtherole\nUniversityofNatalinDurban,SouthAfricaandspentshort\nofgeneticabnormalitiesincongenitalkidneydisorders.In\nperiodstraininginnephrologyattheUniversitiesofthe\nclinicalresearch,heconductednumerouscollaborative\nWitwatersrand,JohannesburgandNewcastleonTyneinthe\nclinicaltrialsandestablishedseveralinternationalconsortia\nUK.ShecurrentlychairsthePostgraduate(HigherDegrees)\nsuchasthetheEuropeanStudyGrouponProgressiveCKD\nCommitteeoftheFacultyofHealthSciencesattheUniversity\ninChildren,theInternationalPediatricPeritonealDialysis\noftheWitwatersrandandisamemberoftheCouncilofthe\nNetwork,andthePodoNetRegistryforSteroidResistant\nCollegeofPhysiciansoftheCollegesofMedicineofSouth\nNephroticSyndrome.DrSchaeferhaspublishedover280\nAfrica.SheisalsoaCouncilmemberoftheInternational\narticlesandbookchapters,andco-editedthestandard\nSocietyofNephrology(ISN)andchairsitsEducation\ntextbooksComprehensivePediatricNephrologyandPediatric\nCommittee. Dialysis.Hereceivedseveralprestigiousawardsforinnovative\nDrNaickerwastherecipientofthePhilipTobias/Convo-\nresearchincludingtheRecklinghausenPrizeandtheIBM\ncationDistinguishedTeachersAwardattheUniversityofthe\nFacultyAward.DrSchaeferisacurrentcouncilmemberof\nWitwatersrandin2006,theInternationalDistinguished\ntheInternationalPediatricNephrologyAssociationandthe\n119\nKidneyInternationalSupplements(2012)2,116–121\nbiographicanddisclosureinformation\nInternationalSocietyofPeritonealDialysis.Heisamember\nDisorders.DrEckardtisamemberoftheexecutivecommittee\nofseveraleditorialboardsandservesasSectionEditorfor\nofKDIGO. NephrologyDialysisTransplantationandPediatricNephrology.Advisor/Consultant:Affymax;Amgen;HexalSandoz;\nDrSchaeferreportednorelevantﬁnancialrelationships.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 9)",
    "content": "Johnson&Johnson;Roche\nSpeaker:Amgen;JanssenCilag;Johnson&Johnson;Roche\nMietSchetz,MD,PhD,graduatedfromthefacultyGrant/ResearchSupport:Roche\nofMedicineoftheCatholicUniversityofLeuven,Belgium,\nafterwhichshespecializedinanesthesiologyandlaterinBertramLKasiske,MD,isProfessorofMedicineatthe\nintensivecaremedicine.Since1981sheisstaffmemberofUniversityofMinnesota,USA.Hereceivedhismedical\nthedepartmentofIntensiveCareMedicineattheUniversitydegreefromtheUniversityofIowaandcompletedhis\nHospitalLeuven(Chair:GreetVandenBerghe)andhas\nInternalMedicineresidencyandfellowshiptrainingin\nbeenAssociateProfessorattheCatholicUniversityLeuvenNephrologyatHennepinCountyMedicalCenterwherehe\nsince2000.DrSchetzcompletedherPhDthesisontheiscurrentlyDirectorofNephrology. subject,‘‘TheHemostaticSystemandContinuousRenal\nDrKasiskeisformerDeputyDirectoroftheUnitedStates\nReplacementTherapy:MutualEffects’’.HermainﬁeldofRenalDataSystemandformerEditor-in-ChiefofThe\ninterestisAKIanditstreatment,onwhichshepublished\nAmericanJournalofKidneyDiseases.Hehasservedas\nseveralarticles.Secretary/TreasurerandontheBoardofDirectorsofthe\nGrant/ResearchSupport:Gambro\nAmericanSocietyofTransplantation,andontheOrgan\nProcurementandTransplantationNetwork/UnitedNetwork\nShigehikoUchino,MD,PhD,isAssociateProfessorandStaff\nofOrganSharingBoardofDirectors,andtheScientiﬁc\nIntensivistintheDepartmentofAnesthesiologyatJikei\nAdvisoryBoardoftheNationalKidneyFoundation.Heis\nUniversitySchoolofMedicineinTokyo,Japan.HereceivedcurrentlyservingontheBoardofCouncilorsofthe\nhismedicaldegreefromTokyoMedicalandDental\nInternationalSocietyofNephrology.HeisthePrincipal\nUniversityandhisPhDfromJikeiUniversitySchoolof\nInvestigatorforaNationalInstitutesofHealth-sponsored,\nMedicine.DrUchinoisamemberoftheJapaneseSocietyof\nmulti-centerstudyoflongtermoutcomesafterkidney\nIntensiveCareMedicine,JapaneseAssociationforAcutedonation.HeistheDirectoroftheScientiﬁcRegistryof\nMedicine,SocietyofCriticalCareMedicine,andthe\nTransplantRecipients.Hehasover160scientiﬁcpublications\nEuropeanSocietyofIntensiveCareMedicine.Inaddition\ninmajorpeerreviewedjournals,and230reviewarticles,\ntoservingasareviewerfornumerousjournals,hehaswritteneditorialsandtextbookchapters.DrKasiskeisalsoarecipient\nbookchaptersinrecenttextssuchasCriticalCareNephrology,\noftheNKF’sGarabedEknoyanAwardin2003. Evidence-BasedPracticeofCriticalCare,andIntensiveCare\nAdvisor/Consultant:Litholink\ninNephrology.DrUchinoisalsoacoinvestigatorintheGrant/ResearchSupport:Bristol-MyersSquibb;Merck-Schering\nBESTKidneystudy.Plough\nDrUchinoreportednorelevantﬁnancialrelationships.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 10)",
    "content": "EVIDENCEREVIEWTEAM\nKatrinUhlig,MD,MS,istheDirector,GuidelineDevelop-\nKDIGOCHAIRS\nKai-UweEckardt,MD,isProfessorofMedicineandChiefmentattheTuftsCenterforKidneyDiseaseGuideline\nofNephrologyandHypertensionattheUniversityofDevelopmentandImplementation,Boston,MA,Associate\nErlangen—Nuremberg,Germany.HereceivedhisMDfromProfessorofMedicineatTuftsUniversitySchoolofMedicine,\n¨¨¨\ntheWestfalischeWilhelms-UniversitatMunster,Germany.InandastaffnephrologistatTuftsMedicalCenter.DrUhlig\n1993,followingpostgraduatetrainingininternalmedicine,completedhertrainingininternalmedicine,nephrology,and\npathologyandphysiology,hewasappointedAssistantrheumatologyinGermany(AachenUniversityHospitaland\nProfessorofPhysiologyattheUniversityofRegensburg,MunichUniversityHospital)andtheUSA(Georgetown\nGermany.Subsequently,hecontinuedhistrainingininternalUniversityMedicalCenterandTuftsMedicalCenter).Since\nmedicineandnephrologyattheCharite,HumboldtUni-2001,shehasbeenparticipatinginordirectingtheevidence\nversityinBerlin,wherehewasappointedAssociateProfessorreviewforKDOQIandKDIGOguidelines.In2005,she\nofNephrologyin2000.Hismajorscientiﬁcinterestsareinco-chairedtheKDIGOEvidenceRatingGrouptodevelop\nthemolecularmechanismsandphysiological/pathophysio-aconsensusongradingofKDIGOguidelines.From2006\nlogicalrelevanceofoxygensensingandthemanagementofto2007,sheservedasCo-EditoroftheAmericanJournal\nanemia.Assuch,hehascontributedtothedevelopmentofofKidneyDiseases.Herfocusinteachingandresearchisin\ntheEuropeanBestPracticeGuidelinesforAnemiaManage-evidence-basedmedicine,systematicreview,clinicalpractice\nmentandparticipatedintheCREATEandTREATstudies.guidelinedevelopment,andcriticalliteratureappraisal. ProfessorEckardtissubjecteditorofNephrologyDialysisDrUhligreportednorelevantﬁnancialrelationships. Transplantationandservesontheeditorialboardofseveral\notherjournals.HehasalsoauthoredbookchaptersandmostJoseCalvo-Broce,MD,MS,servedasaresearchfellowatthe\nrecentlyservedasaCo-Editorofthetext,StudiesonRenalTuftsCenterforKidneyDiseaseGuidelineDevelopmentand\n120\nKidneyInternationalSupplements(2012)2,116–121\nbiographicanddisclosureinformation\nImplementationinBoston,MAandparticipatedinthe\nconductofsystematicreviewsandcriticalliteratureappraisals\nconductofsystematicreviewsandcriticalliteratureapprai-forthisguideline.DrDeowasawardedaMasterofScience\nsalsforthisguideline.DrCalvo-BrocewasrecentlyawardedinClinicalResearchforherthesison‘‘LosstoAnalysisin\naMasterofScienceinClinicalResearchforhisthesis\nRandomizedControlledTrialsofChronicKidneyDisease’’. on‘‘Hospital-AcquiredAKI:AnAnalysisofNadir-to-PeakDrDeoreportednorelevantﬁnancialrelationships.",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "BiographicandDisclosureInformation (Part 11)",
    "content": "SerumCreatinineIncrementsStratiﬁedbyBaselineEstimated\nGFR’’.AmyEarley,BS,isaprojectcoordinatorattheTuftsCenter\nDrCalvo-Brocereportednorelevantﬁnancialrelationships.forKidneyDiseaseGuidelineDevelopmentandImplementa-\ntioninBoston,MA.Sheassistsinthedevelopmentofclinical\nAneetDeo,MD,MS,servedasaresearchfellowatthepracticeguidelinesandconductssystematicreviewsand\nTuftsCenterforKidneyDiseaseGuidelineDevelopment\ncriticalliteratureappraisals. andImplementationinBoston,MA.SheparticipatedintheMsEarleyreportednorelevantﬁnancialrelationships. 121\nKidneyInternationalSupplements(2012)2,116–121\nacknowledgments\nhttp://www.kidney-international.org\n2012KDIGO",
    "page": 119,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Acknowledgments (Part 1)",
    "content": "KidneyInternationalSupplements(2012)2,122–123;doi:10.1038/kisup.2011.37\nAspecialdebtofgratitudeisowedtothecurrentKDIGO\nHemmelgarn(CanadianSocietyofNephrology),Hallvard\nCo-ChairsKai-UweEckardtandBertramKasiskeandthe\nHoldaas(NationalHospital-Norway),LaiSeongHooi\nKDIGOBoardfortheirinvaluableguidancethroughout\n(HospitalSultanahAminah),AtsukoIkemori(St.Marianna\nthedevelopmentofthisguideline.Inparticular,wethankthe\nUniversitySchoolofMedicine),EnyuImai(NagoyaUni-\nERTmembers:KatrinUhlig,JoseCalvo-Broce,AneetDeo,\nversitySchoolofMedicine),LesleyInker(Tufts-NewEngland\nandAmyEarley,fortheirsubstantialcontributiontothe\nMedicalCenter),SarwarIqbal(BIRDEMHospital),Kuni-\nrigorousassessmentoftheavailableevidence.Wearealso\ntoshiIseki(RyukynUniversity),SimonJenkins,Svend\nespeciallygratefultotheWorkGroupmembersfortheir\nLorentzJorgensen(PharmacosmosA/S),TakeiKake(Chugai\nexpertisethroughouttheentireprocessofliteraturereview,\nPharmaceutical),NadaKanaan(CliniquesUniversitaires\ndataextraction,meetingparticipation,thecriticalwriting\nSaintLuc),MarkusKetteler(KlinikumCoburgGGmbH),\nandeditingofthestatementsandrationale,whichmadethe\nMahmoudEl-Khatib(UniversityofCincinnati),Pradeep\npublicationofthisguidelinepossible.Thegenerousgiftof\nKumarRai(OpalHospital,Varanasi,India),HanifeKurtal\ntheirtimeanddedicationisgreatlyappreciated.Finally,and\n(Charite-Universitatsmedizin,Berlin),CraigBLangman\nonbehalfoftheWorkGroup,wegratefullyacknowledge\n(Children’sMemorialHospital,Chicago),IngridLedebo\nthecarefulassessmentofthedraftguidelinebyexternal\n(GambroAB),EdgarLerma(UniversityofIllinoisatChicago\nreviewers.TheWorkGroupconsideredallofthevaluable\nCollegeofMedicine),NathanWLevin(RenalResearch\ncommentsmadeandwhereappropriate,suggestedchanges\nInstitute),AndrewLewington(TheRenalAssociation,UK),\nwereincorporatedintotheﬁnalpublication.Thefollowing\nVisnjaLezaic(ClinicalCentreofSerbia),Zhi-HongLiu\nindividualsandorganizationsprovidedreviewofthedraft\n(NanjingUniversitySchoolofMedicine),RaulLombardi\nguideline:\n(LatinAmericanSocietyofNephrology&Hypertension),\n´´´\nOmarAbboud,MonaAl–Rukhaimi(DubaiHospital),\nGerardLondon(ERA/EDTA),JoseAntonioLopes(Hospital\nMustafaArici(HacettepeUniversityFacultyofMedicine),\ndeSantaMaria),RobertMactier(TheRenalAssociation,\nMarianoArriola(ClinicadeNefrologia,Urologiay\nUK),ConstantineManthous(AmericanThoracicSociety),\nEnfermedadesCardiovasculares,Argentina),AdanzeAsinobi\nOmarMaoujoud(MohammedVMilitaryHospital),PabloU\n(UniversityofIbadan,Nigeria),AlperAzak(AnkaraEduca-\nMassari,JohnMcIlwaine(AmericanCollegeofChest\ntionandResearchHospital),GavinBecker(RoyalMelbourne\nPhysicians),CeciliaMengarelli(FresenuisMansilla),Gong\nHospital),RudyBilous(TheJamesCookUniversityHospi-\nMengchun(PekingUnionMedicalCollegeHospital),Walid\ntal),YousefBoobes(TawamHospital,UAE),Catherine\nMohamed(AlexandriaUniversityHospital),RaﬁqueMoosa\nBouman(DutchSocietyofIntensiveCareMedicine),Carlo\n(UniversityofStellenbosch),JoseMMorales(Hospital12de\nBriguori(ClinicaMediterranea),EricSCantor(GEHealth-\nOctubre,Spain;EuropeanSocietyforOrganTransplanta-\ncare),MariaInesCarvallo,WilliamRClark(Gambro),\ntion),SamehKMorcos(NorthernGeneralHospital),\nAdrianCovic(HospitalCIParhon,Romania),DanielCoyne\nToshikiMoriyama(OsakaUniversityHealthCareCenter),\n(WashingtonUniversitySchoolofMedicine),JoeDasta\nAbdouNiang(CheikhAntaDiopUniversity),EiseiNoiri\n(SocietyofCriticalCareMedicine),JaneSDavis(University\n(JapaneseSocietyofNephrology),FernandoNolasco\nofAlabamaatBirmingham),AngeldeFrancisco(Spanish\n(PortugueseSocietyofNephrology),MaurizioNordio\nSocietyofNephrology),Jean-YvesDeVos(AZWerken\n(DirigenteMedico),MichałNowicki(MedicalUniversityof\nGlorieuxDialysisUnit),PierreDelanaye(Universityof\nLodz),ErcanOk(TurkishSocietyofNephrology),Suzanne\nLiege),SarahFaubel(AmericanSocietyofNephrology),\nOparil(UniversityofAlabamaatBirmingham),Heleen\nAnaElizabethFigueiredo(HospitalSaoLucas),Thorsten\nOudemans(DanishSocietyofIntensiveCare),Erling\n¨¨\nFeldkamp(UniversitatsklinikumEssen,Universitat\nPedersen(HolstebroHospitalandUniversityofAarhus),\nDuisburg-Essen),KevinFinkel(SocietyofCriticalCare\nMomirPolenakovic(BalkanCitiesAssociationofNephro-\nMedicine),LuiGForni(EuropeanSocietyofIntensiveCare\nlogy,Dialysis,TransplantationandArtiﬁcialOrgans),Manuel\nMedicine),HeidiFrankel(SocietyofCriticalCareMedicine),\nPraga(Hospital12deOctubre,Spain),WajehQunibi\nGerardFulda(SocietyofCriticalCareMedicine),\n(UniversityofTexasHealthScienceCenter),EnriqueAndres\nMohammedBenghanemGharbi(UniversityHospitalIbn\nRibes(FundacioPuigvert),EduardoRocha(RiodeJaneiro\nRochd),RichardJGlassock(UCLA),RobertSGold(DCBA),\nFederalUniversityMedicalSchool),CibeleRodrigues\nBasuGopal(ChristianMedicalCollege),JeffHarder\n(CatholicUniversityofSaoPaulo),GuillermoRosa-Diez\n(UniversityofWashingtonMedicalCenter),Brenda\n(HospitalItalianodeBuenosAires-Argentina),BradRovin\n122\nKidneyInternationalSupplements(2012)2,122–123\nacknowledgments\n(OhioStateUniversity),NestorSchor(UniversidadeFederal\nRaymondVanholder(UniversityHospitalGhent),Rowan\ndeSaoPaulo-UNIFESP),MehmetSukruSever(EuropeanWalker(RoyalMelbourneHospital),MichaelWalsh\nRenalBestPractice),AmmaSewaah-Bonsu(Nephrology(McMasterUniversity),HaiYanWang(BeijingUniversity),\nAssociatesofCentralFlorida),DeepakSharma(MilHospital\nJiandongWei(SUNYDownstateMedicalCenter),Colin\nJalandhar,India),JustinSilver(HadassahUniversityHospi-White(UniversityofBritishColumbia),HitoshiYokoyama\ntal),RichardSolomon(FletcherAllenHealthCare),Peter(KanazawaMedicalUniversity),LuisYu(Universityof\nSpiro(AmericanCollegeofChestPhysicians),Takeshi\nSaoPaulo),ElenaZakharova(MoscowCityHospital),\nSugaya(St.MariannaUniversitySchoolofMedicine),CemCarmineZoccali(CNR-IBIMClinResearchUnitOspedali\nSungur(AnadoluMedicalCenter),CharlesSwanepoelRiuniti,Italy),KimZuber(MetropolitanNephrology\n(UniversityofCapeTown),SengHoeTan(GleneaglesAssociates).",
    "page": 125,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "Acknowledgments (Part 2)",
    "content": "MedicalCentre,Singapore),SamuelATisherman(Society\nParticipationinthereviewdoesnotnecessarilyconstitute\nofCriticalCareMedicine),CharlesTomson(Southmeadendorsementofthecontentofthisreportbyaboveindivi-\n´ˆ´\nHospital),StephanTroyanov(HopitalduSacre-Coeur,dualsortheorganizationorinstitutiontheyrepresent. Montreal),Hung-BinTsai(BuddhistDalinTzuChiGeneral\nHospital),HirokazuTsukahara(OkayamaUniversityJohnAKellum,MD,FCCM,FACP,WorkGroupCo-Chair\nHospital),WimVanBiesen(UniversityHospitalGhent),NorbertLameire,MD,PhD,WorkGroupCo-Chair\n123\nKidneyInternationalSupplements(2012)2,122–123",
    "page": 125,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "References (Part 1)",
    "content": "KidneyInternationalSupplements(2012)2,124–138;doi:10.1038/kisup.2011.38\n1.ChertowGM,BurdickE,HonourM,etal.Acutekidneyinjury,mortality,\n26.KellumJA,BellomoR,RoncoC.Classiﬁcationofacutekidneyinjuryusing\nlengthofstay,andcostsinhospitalizedpatients.JAmSocNephrol2005;16:\nRIFLE:What’sthepurpose?CritCareMed2007;35:1983–1984. 3365–3370. 27.RicciZ,CruzD,RoncoC.TheRIFLEcriteriaandmortalityinacutekidney\n2.HosteEA,ClermontG,KerstenA,etal.RIFLEcriteriaforacutekidney\ninjury:Asystematicreview.KidneyInt2008;73:538–546. injuryareassociatedwithhospitalmortalityincriticallyillpatients:a\n28.ThakarCV,ChristiansonA,FreybergR,etal.Incidenceandoutcomesof\ncohortanalysis.CritCare2006;10:R73. acutekidneyinjuryinintensivecareunits:aVeteransAdministrationstudy. 3.LassniggA,SchmidlinD,MouhieddineM,etal.Minimalchangesofserum\nCritCareMed2009;37:2552–2558. creatininepredictprognosisinpatientsaftercardiothoracicsurgery:a\n29.JoannidisM,MetnitzB,BauerP,etal.Acutekidneyinjuryincriticallyill\nprospectivecohortstudy.JAmSocNephrol2004;15:1597–1605. patientsclassiﬁedbyAKINversusRIFLEusingtheSAPS3database. 4.LevyEM,ViscoliCM,HorwitzRI.Theeffectofacuterenalfailureon\n1702. IntensiveCareMed2009;35:1692–\nmortality.Acohortanalysis.JAMA1996;275:1489–1494. 30.OstermannM,ChangRW.Acutekidneyinjuryintheintensivecareunit\n5.UchinoS,BellomoR,GoldsmithD,etal.AnassessmentoftheRIFLE\naccordingtoRIFLE.CritCareMed2007;35:1837–1843. criteriaforacuterenalfailureinhospitalizedpatients.CritCareMed2006;\n31.AliT,KhanI,SimpsonW,etal.Incidenceandoutcomesinacutekidney\n34:1913–1917. injury:acomprehensivepopulation-basedstudy.JAmSocNephrol2007;\n6.HosteEA,KellumJA.Acuterenalfailureinthecriticallyill:impacton\n18:1292–1298. morbidityandmortality.ContribNephrol2004;144:1–11. 32.Akcan-ArikanA,ZappitelliM,LoftisLL,etal.ModiﬁedRIFLEcriteriain\n7.UchinoS,KellumJA,BellomoR,etal.Acuterenalfailureincriticallyill\ncriticallyillchildrenwithacutekidneyinjury.KidneyInt2007;71:\npatients:amultinational,multicenterstudy.JAMA2005;294:813–818. 1028–1035. 8.BagshawSM,LangenbergC,BellomoR.Urinarybiochemistryand\n33.HackworthLA,WenX,ClermontG,etal.Hospitalversuscommunity-\nmicroscopyinsepticacuterenalfailure:asystematicreview.AmJKidney\nacquiredacutekidneyinjuryinthecriticallyill:differencesinepidemiology\nDis2006;48:695–705. (abstr).JAmSocNephrol2009;20:115A. 9.BagshawSM,LangenbergC,WanL,etal.Asystematicreviewofurinary\n34.CerdaJ,BaggaA,KherV,etal.Thecontrastingcharacteristicsofacute\nﬁndingsinexperimentalsepticacuterenalfailure.CritCareMed2007;35:\nkidneyinjuryindevelopedanddevelopingcountries.NatClinPract\n1592–1598. Nephrol2008;4:138–153. 10.ShanleyPF,RosenMD,BrezisM,etal.Topographyoffocalproximal\n35.CerdaJ,LameireN,EggersP,etal.Epidemiologyofacutekidneyinjury. tubularnecrosisafterischemiawithreﬂowintheratkidney.AmJPathol\nClinJAmSocNephrol2008;3:881–886. 1986;122:462–468.",
    "page": 127,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "References (Part 2)",
    "content": "36.InstituteofMedicine.CrossingtheQualityChasm:aNewHealthSystemfor\n11.HeymanSN,BrezisM,EpsteinFH,etal.Effectofglycineandhypertrophy\nthe21stCentury.NationalAcademyPress:Washington,DC,2001. onrenaloutermedullaryhypoxicinjuryinischemiareﬂowandcontrast\n37.EknoyanG.Areglobalnephrologyguidelinesfeasible?NatClinPract\nnephropathy.AmJKidneyDis1992;19:578–586. Nephrol2008;4:521. 12.RosenS,HeymanSN.Difﬁcultiesinunderstandinghuman‘‘acutetubular\n38.EknoyanG,LameireN,BarsoumR,etal.Theburdenofkidneydisease:\nnecrosis’’:limiteddataandﬂawedanimalmodels.KidneyInt2001;60:\nimprovingglobaloutcomes.KidneyInt2004;66:1310–1314. 1220–1224. 39.LevinA,StevensLA.Executingchangeinthemanagementofchronic\n13.BrunC,MunckO.Lesionsofthekidneyinacuterenalfailurefollowing\nkidneydisease:perspectivesonguidelinesandpractice.MedClinNorthAm\nshock.Lancet1957;272:603–607. 2005;89:701–709. 14.KlenzakJ,HimmelfarbJ.Sepsisandthekidney.CritCareClin2005;21:\n40.AtkinsD,BestD,BrissPA,etal.Gradingqualityofevidenceandstrengthof\n211–222. recommendations.BMJ2004;328:1490. LameireN.Thepathophysiologyofacuterenalfailure.CritCareClin2005;\n15. 41.UhligK,MacleodA,CraigJ,etal.Gradingevidenceandrecommendations\n21:197–210. forclinicalpracticeguidelinesinnephrology.Apositionstatementfrom\n16.EknoyanG.Emergenceoftheconceptofacuterenalfailure.AmJNephrol\nKidneyDisease:ImprovingGlobalOutcomes(KDIGO).KidneyInt2006;\n2002;22:225–230. 70:2058–2065. 17.DaviesF,WeldonR.Acontributiontothestudyof‘‘warnephritis’’.Lancet\n42.NationalKidneyFoundation.K/DOQIclinicalpracticeguidelinesfor\n1917;ii:118–120. chronickidneydisease:evaluation,classiﬁcation,andstratiﬁcation.AmJ\n18.BywatersEGL,BeallD.Crushinjurieswithimpairmentofrenalfunction. KidneyDis2002;39(2Suppl1):S1–266. BMJ1947;1:427–432. 43.LeveyAS,EckardtKU,TsukamotoY,etal.Deﬁnitionandclassiﬁcationof\n19.KellumJA,LevinN,BoumanC,etal.Developingaconsensusclassiﬁcation\nchronickidneydisease:apositionstatementfromKidneyDisease:\nsystemforacuterenalfailure.CurrOpinCritCare2002;8:509–514. vingGlobalOutcomes(KDIGO).KidneyInt2005;67:2089–2100. Impro\n20.BrivetFG,KleinknechtDJ,LoiratP,etal.Acuterenalfailureinintensive\n44.LeveyAS,deJongPE,CoreshJ,etal.Thedeﬁnition,classiﬁcationand\ncareunits–causes,outcome,andprognosticfactorsofhospitalmortality;a\nprognosisofchronickidneydisease:aKDIGOControversiesConference\nprospective,multicenterstudy.FrenchStudyGrouponAcuteRenalFailure. report.KidneyInt2011;80:17–28. CritCareMed1996;24:192–198. 45.MurrayPT,DevarajanP,LeveyAS,etal.Aframeworkandkeyresearch\n21.LianoF,PascualJ.Epidemiologyofacuterenalfailure:aprospective,\nquestionsinAKIdiagnosisandstagingindifferentenvironments.ClinJAm\nmulticenter,community-basedstudy.MadridAcuteRenalFailureStudy\nSocNephrol2008;3:864–868. Group.KidneyInt1996;50:811–818. 46.EndreZH.Acutekidneyinjury:deﬁnitionsandnewparadigms.Adv\n22.BellomoR,RoncoC,KellumJA,etal.Acuterenalfailure-deﬁnition,\nChronicKidneyDis2008;15:213–221.",
    "page": 127,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "References (Part 3)",
    "content": "outcomemeasures,animalmodels,ﬂuidtherapyandinformation\n47.AmdurRL,ChawlaLS,AmodeoS,etal.Outcomesfollowingdiagnosisof\ntechnologyneeds:theSecondInternationalConsensusConferenceofthe\nacuterenalfailureinU.S.veterans:focusonacutetubularnecrosis.Kidney\nAcuteDialysisQualityInitiative(ADQI)Group.CritCare2004;8:\nInt2009;76:1089–1097. R204–212. 48.CocaSG,YusufB,ShlipakMG,etal.Long-termriskofmortalityandother\n23.MehtaRL,KellumJA,ShahSV,etal.AcuteKidneyInjuryNetwork:report\nadverseoutcomesafteracutekidneyinjury:asystematicreviewandmeta-\nofaninitiativetoimproveoutcomesinacutekidneyinjury.CritCare2007;\nanalysis.AmJKidneyDis2009;53:961–973. 11:R31. 49.WaldR,QuinnRR,LuoJ,etal.Chronicdialysisanddeathamongsurvivors\n24.LevyMM,MaciasWL,VincentJL,etal.Earlychangesinorganfunction\nofacutekidneyinjuryrequiringdialysis.JAMA2009;302:1179–1185. predicteventualsurvivalinseveresepsis.CritCareMed2005;33:2194–2201. 50.HarelZ,ChanCT.Predictingandpreventingacutekidneyinjuryafter\n25.BagshawSM,GeorgeC,DinuI,etal.Amulti-centreevaluationofthe\ncardiacsurgery.CurrOpinNephrolHypertens2008;17:624–628. RIFLEcriteriaforearlyacutekidneyinjuryincriticallyillpatients.Nephrol\n51.ReddyVG.Preventionofpostoperativeacuterenalfailure.JPostgradMed\nDialTransplant2008;23:1203–1210. 2002;48:64–70. 124\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 127,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "52.VenkataramanR.Canwepreventacutekidneyinjury?CritCareMed2008;\n77.PolancoPM,PinskyMR.Hemodynamicmonitoringintheintensivecare\n36:S166–171. unit.In:RoncoC,BellomoR,KellumJ(eds).CriticalCareNephrology,\n53.StewartJ,FindlayG,SmithN,etal.AddingInsulttoInjury:Areviewofthe\n2ndEdn.SaundersElsevier:Philadelphia,PA,2009,pp37–45. careofpatientswhodiedinhospitalwithaprimarydiagnosisofacute\n78.ProwleJR,BellomoR.Continuousrenalreplacementtherapy:recent\nkidneyinjury(acuterenalfailure).NationalConﬁdentialEnquiryinto\nadvancesandfutureresearch.NatRevNephrol2010;6:521–529. PatientOutcomeandDeath:London,UK,2009. 79.SchetzM.Assessmentofvolumestatus.In:RoncoC,BellomoR,KellumJ\n54.BellM,LiljestamE,GranathF,etal.Optimalfollow-uptimeaftercontinuous\n(eds).CriticalCareNephrology,2ndEdn.SaundersElsevier:Philadelphia,\nrenalreplacementtherapyinactualrenalfailurepatientsstratiﬁedwiththe\nPA,2009,pp499–504. RIFLEcriteria.NephrolDialTransplant2005;20:354–360. 80.VenkataramanR,KellumJA.Principlesofﬂuidtherapy.In:RoncoC,\n55.CruzDN,BolganI,PerazellaMA,etal.NorthEastItalianProspective\nBellomoR,KellumJ(eds).CriticalCareNephrology,2ndEdn.Saunders\nHospitalRenalOutcomeSurveyonAcuteKidneyInjury(NEiPHROS-\nElsevier:Philadelphia,PA,2009,pp568–571. AKI):targetingtheproblemwiththeRIFLECriteria.ClinJAmSocNephrol\n81.WajanaponsanN,PinskyMR.Monitoringandmanagementofsystemic\n2007;2:418–425. hemodyamics.In:JorresA,RoncoC,KellumJA(eds).Managementof\n1stEdn.Springer:NewYork,NY,2010,pp147–154. 56.Perez-ValdiviesoJR,Bes-RastrolloM,MonederoP,etal.Prognosisand\nAcuteKidneyProblems,\nserumcreatininelevelsinacuterenalfailureatthetimeofnephrology82.HimmelfarbJ,JoannidisM,MolitorisB,etal.Evaluationandinitial\nconsultation:anobservationalcohortstudy.BMCNephrol2007;8:14.managementofacutekidneyinjury.ClinJAmSocNephrol2008;3:\n962–967. 57.KuitunenA,VentoA,Suojaranta-YlinenR,etal.Acuterenalfailureafter\ncardiacsurgery:evaluationoftheRIFLEclassiﬁcation.AnnThoracSurg83.BouchardJ,SorokoSB,ChertowGM,etal.Fluidaccumulation,survival\nandrecoveryofkidneyfunctionincriticallyillpatientswithacutekidney\n2006;81:542–546. 58.CocaSG,BaulingP,SchifftnerT,etal.Contributionofacutekidneyinjuryinjury.KidneyInt2009;76:422–427. 84.PayenD,dePontAC,SakrY,etal.Apositiveﬂuidbalanceisassociated\ntowardmorbidityandmortalityinburns:acontemporaryanalysis. AmJKidneyDis2007;49:517–523.withaworseoutcomeinpatientswithacuterenalfailure.CritCare2008;\n12:R74. 59.ArnaoutakisGJ,BihoracA,MartinTD,etal.RIFLEcriteriaforacutekidney\ninjuryinaorticarchsurgery.JThoracCardiovascSurg2007;134:85.VincentJL.Relevanceofalbumininmoderncriticalcaremedicine.Best\n1554–1560;discussion1560–1551.PractResClinAnaesthesiol2009;23:183–191. 60.AbosaifNY,TolbaYA,HeapM,etal.Theoutcomeofacuterenalfailurein86.FinferS,BellomoR,BoyceN,etal.Acomparisonofalbuminandsalinefor\ntheintensivecareunitaccordingtoRIFLE:modelapplication,sensitivity,ﬂuidresuscitationintheintensivecareunit.NEnglJMed2004;350:\n2247–2256. andpredictability.AmJKidneyDis2005;46:1038–1048.",
    "page": 128,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "61.MaccarielloE,SoaresM,ValenteC,etal.RIFLEclassiﬁcationinpatients87.ErtmerC,RehbergS,VanAkenH,etal.Relevanceofnon-albumincolloids\ninintensivecaremedicine.BestPractResClinAnaesthesiol2009;23:\nwithacutekidneyinjuryinneedofrenalreplacementtherapy.Intensive\nCareMed2007;33:597–605.193–212. 88.McMahonBA,MurrayPT.Urinaryliverfattyacid-bindingprotein:another\n62.JenqCC,TsaiMH,TianYC,etal.RIFLEclassiﬁcationcanpredictshort-\nnovelbiomarkerofacutekidneyinjury.KidneyInt2010;77:657–659. termprognosisincriticallyillcirrhoticpatients.IntensiveCareMed2007;\n33:1921–1930.89.DickenmannM,OettlT,MihatschMJ.Osmoticnephrosis:acutekidney\n63.TallgrenM,NiemiT,PoyhiaR,etal.Acuterenalinjuryanddysfunctioninjurywithaccumulationofproximaltubularlysosomesduetoadminis-\nfollowingelectiveabdominalaorticsurgery.EurJVascEndovascSurg2007;trationofexogenoussolutes.AmJKidneyDis2008;51:491–503. 90.deSaint-AurinRG,KloecknerM,AnnaneD.Crystalloidsversuscolloidsfor\n33:550–555. 64.ZavadaJ,HosteE,Cartin-CebaR,etal.Acomparisonofthreemethodstoﬂuidresuscitationincritically-illpatients.ActaClinBelgSuppl2007:\n412–416. estimatebaselinecreatinineforRIFLEclassiﬁcation.NephrolDial\nTransplant2010;25:3911–3918.91.VincentJL.Fluidresuscitation:colloidsvscrystalloids.ActaClinBelgSuppl\nMacedoE,BouchardJ,SorokoSH,etal.Fluidaccumulation,recognition\n65.2007:408–411. andstagingofacutekidneyinjuryincritically-illpatients.CritCare2010;92.SchortgenF,LacheradeJC,BruneelF,etal.Effectsofhydroxyethylstarch\n14:R82. andgelatinonrenalfunctioninseveresepsis:amulticentrerandomised\n66.DoiK,YuenPS,EisnerC,etal.Reducedproductionofcreatininelimitsitsusestudy.Lancet2001;357:911–916. asmarkerofkidneyinjuryinsepsis.JAmSocNephrol2009;20:1217–1221. 93.BrunkhorstFM,EngelC,BloosF,etal.Intensiveinsulintherapyand\n67.LeveyAS,CoreshJ,GreeneT,etal.Usingstandardizedserumcreatinine\npentastarchresuscitationinseveresepsis.NEnglJMed2008;358:125–139. valuesinthemodiﬁcationofdietinrenaldiseasestudyequationfor\n94.EisenbachC,SchonfeldAH,VogtN,etal.Pharmacodynamicsandorgan\nestimatingglomerularﬁltrationrate.AnnInternMed2006;145:247–254. storageofhydroxyethylstarchinacutehemodilutioninpigs:inﬂuenceof\n68.StevensLA,CoreshJ,FeldmanHI,etal.Evaluationofthemodiﬁcationof\nmolecularweightanddegreeofsubstitution.IntensiveCareMed2007;33:\ndietinrenaldiseasestudyequationinalargediversepopulation.JAmSoc\n1637–1644. Nephrol2007;18:2749–2757. 95.ThomasG,BalkEM,JaberBL.Effectofintensiveinsulintherapyand\n69.EmamianSA,NielsenMB,PedersenJF,etal.Kidneydimensionsat\npentastarchresuscitationonacutekidneyinjuryinseveresepsis.AmJ\n17. sonography:correlationwithage,sex,andhabitusin665adultvolunteers.KidneyDis2008;52:13–\n96.WiedermannCJ.Systematicreviewofrandomizedclinicaltrialsontheuse\nAJRAmJRoentgenol1993;160:83–86. 70.BellomoR,WanL,MayCN.Vasoactivedrugsandacuterenalfailure.ofhydroxyethylstarchforﬂuidmanagementinsepsis.BMCEmergMed\nIn:RoncoC,BellomoR,KellumJ(eds).CriticalCareNephrology,2ndEdn.2008;8:1.",
    "page": 128,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "SaundersElsevier:Philadelphia,PA,2009,pp416–419.97.SakrY,PayenD,ReinhartK,etal.Effectsofhydroxyethylstarchadministration\nonrenalfunctionincriticallyillpatients.BrJAnaesth2007;98:216–224. 71.BouchardJ,MehtaRL.Fluidbalanceissuesinthecriticallyillpatient.In:\nRoncoC,CostanzoMR,BellomoR,MaiselA(eds).FluidOverload:98.PerelP,RobertsI,PearsonM.Colloidsversuscrystalloidsforﬂuid\nresuscitationincriticallyillpatients.CochraneDatabaseSystRev2007;4:\nDiagnosisandManagement.SKargerAG:Basel,Switzerland,2010,\npp69–78.CD000567. 72.FinferS,JonesDA.Crystalloidsandcolloids.In:RoncoC,BellomoR,99.SchortgenF,BrochardL.Colloid-inducedkidneyinjury:experimental\nevidencemayhelptounderstandmechanisms.CritCare2009;13:130. KellumJ(eds).CriticalCareNephrology,2ndEdn.SaundersElsevier:\n100.MagderS,PotterBJ,VarennesBD,etal.Fluidsaftercardiacsurgery:apilot\nPhiladelphia,PA,2009,pp571–575. 73.HolmesCL,WalleyKR.Shock.In:MurrayPT,BradyHR,HallJB(eds).studyoftheuseofcolloidsversuscrystalloids.CritCareMed2010;38:\nIntensiveCareinNephrology.Taylor&Francis:NewYork,NY,2006,2117–2124. 101.WiedermannCJ,DunzendorferS,GaioniLU,etal.Hyperoncoticcolloids\npp1–18. 74.LevineJS,IglesiasJI.Diureticuseandﬂuidmanagement.In:MurrayPT,andacutekidneyinjury:ameta-analysisofrandomizedtrials.CritCare\n2010;14:R191. BradyHR,HallJB(eds).IntensiveCareinNephrology.Taylor&Francis:\nNewYork,NY,2006,pp315–337.102.ProwleJR,BellomoR.Fluidadministrationandthekidney.CurrOpinCrit\n75.McDermottG,NeliganPJ.WhatvasopressoragentshouldbeusedintheCare2010;16:332–336. 103.KaplanLJ,KellumJA.Fluids,pH,ionsandelectrolytes.CurrOpinCritCare\nsepticpatient?In:DeutschmanCS,NeliganPJ(eds).Evidence-Based\nPracticeofCriticalCare.Saunders:Philadelphia,PA,2010,pp206–211.2010;16:323–331. 104.KarlssonS,VarpulaM,RuokonenE,etal.Incidence,treatment,and\n76.NeliganPJ,FanningN.Whatisthebestwaytoﬂuid-resuscitateapatient\nwithsepsis?In:DeutschmanCS,NeliganPJ(eds).Evidence-BasedPracticeoutcomeofseveresepsisinICU-treatedadultsinFinland:theFinnsepsis\nstudy.IntensiveCareMed2007;33:435–443. ofCriticalCare.Saunders:Philadelphia,PA,2010,pp198–205. 125\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 128,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "105.BellomoR,WanL,MayC.Vasoactivedrugsandacutekidneyinjury.Crit132.MuruganR,KellumJA.Acutekidneyinjury:what’stheprognosis?NatRev\nCareMed2008;36:S179–186.Nephrol2011;7:209–217. 106.Redl-WenzlEM,ArmbrusterC,EdelmannG,etal.Theeffectsof133.SiewED,HimmelfarbJ.Metabolicandnutritionalcomplicationsofacute\nnorepinephrineonhemodynamicsandrenalfunctioninsevereseptickidneyinjury.In:HimmelfarbJ,SayeghMH(eds).ChronicKidneyDisease,\nshockstates.IntensiveCareMed1993;19:151–154.Dialysis,andTransplantation.ACompaniontoBrennerandRector’sThe\n107.AlbaneseJ,LeoneM,DelmasA,etal.TerlipressinornorepinephrineinKidney,3rdEdn:London,UK,2011,pp654–667. hyperdynamicsepticshock:aprospective,randomizedstudy.CritCareMed\n134.VanCromphautSJ.Hyperglycaemiaaspartofthestressresponse:the\n2005;33:1897–1902.underlyingmechanisms.BestPractResClinAnaesthesiol2009;23:375–386. 108.LauzierF,LevyB,LamarreP,etal.Vasopressinornorepinephrineinearly135.KosiborodM,InzucchiSE,GoyalA,etal.Relationshipbetween\nhyperdynamicsepticshock:arandomizedclinicaltrial.IntensiveCareMedspontaneousandiatrogenichypoglycemiaandmortalityinpatients\n2006;32:1782–1789.hospitalizedwithacutemyocardialinfarction.JAMA2009;301:1556–1564. 109.DeBackerD,BistonP,DevriendtJ,etal.Comparisonofdopamineand136.KosiborodM,RathoreSS,InzucchiSE,etal.Admissionglucoseand\nnorepinephrineinthetreatmentofshock.NEnglJMed2010;362:779–789. mortalityinelderlypatientshospitalizedwithacutemyocardialinfarction:\n110.DelmasA,LeoneM,RousseauS,etal.Clinicalreview:Vasopressinandimplicationsforpatientswithandwithoutrecognizeddiabetes.Circulation\nterlipressininsepticshockpatients.CritCare2005;9:212–222.2005;111:3078–3086. 111.RussellJA,WalleyKR,SingerJ,etal.Vasopressinversusnorepinephrine\n137.InzucchiSE,SiegelMD.GlucosecontrolintheICU–howtightistootight? infusioninpatientswithsepticshock.NEnglJMed2008;358:877–887.NEnglJMed2009;360:1346–1349. 112.GordonAC,RussellJA,WalleyKR,etal.Theeffectsofvasopressinonacute\n138.vandenBergheG,WoutersP,WeekersF,etal.Intensiveinsulintherapyin\nkidneyinjuryinsepticshock.IntensiveCareMed2010;36:83–91.thecriticallyillpatients.NEnglJMed2001;345:1359–1367. 113.DellingerRP,LevyMM,CarletJM,etal.SurvivingSepsisCampaign:139.PalevskyPM,MurrayPT.Acutekidneyinjuryandcriticalcarenephrology. internationalguidelinesformanagementofseveresepsisandsepticshock:NephSAP2006;5(2):72–120. 2008.CritCareMed2008;36:296–327.140.VandenBergheG,WoutersPJ,KestelootK,etal.Analysisofhealthcare\n114.DellingerRP,CarletJM,MasurH,etal.SurvivingSepsisCampaignresourceutilizationwithintensiveinsulintherapyincriticallyillpatients. guidelinesformanagementofseveresepsisandsepticshock.CritCareMedCritCareMed2006;34:612–616. 2004;32:858–873.141.VandenBergheG,WilmerA,HermansG,etal.Intensiveinsulintherapyin\n115.RiversE,NguyenB,HavstadS,etal.Earlygoal-directedtherapyinthethemedicalICU.NEnglJMed2006;354:449–461. treatmentofseveresepsisandsepticshock.NEnglJMed2001;345:1368–1377.",
    "page": 129,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "142.SchetzM,VanhorebeekI,WoutersPJ,etal.Tightbloodglucosecontrolis\n116.MikkelsenME,MiltiadesAN,GaieskiDF,etal.Serumlactateisassociatedrenoprotectiveincriticallyillpatients.JAmSocNephrol2008;19:571–578. withmortalityinseveresepsisindependentoforganfailureandshock.143.GandhiGY,NuttallGA,AbelMD,etal.Intensiveintraoperativeinsulin\nCritCareMed2009;37:1670–1677.therapyversusconventionalglucosemanagementduringcardiacsurgery:a\n117.PhuaJ,KoayES,LeeKH.Lactate,procalcitonin,andamino-terminalpro-randomizedtrial.AnnInternMed2007;146:233–243. B-typenatriureticpeptideversuscytokinemeasurementsandclinical144.ManganoCM,DiamondstoneLS,RamsayJG,etal.Renaldysfunctionafter\nseverityscoresforprognosticationinsepticshock.Shock2008;29:328–333.myocardialrevascularization:riskfactors,adverseoutcomes,andhospital\nJonesAE,FochtA,HortonJM,etal.Prospectiveexternalvalidationofthe\n118.resourceutilization.TheMulticenterStudyofPerioperativeIschemia\nclinicaleffectivenessofanemergencydepartment-basedearlygoal-directed\nResearchGroup.AnnInternMed1998;128:194–203. therapyprotocolforseveresepsisandsepticshock.Chest2007;132:al.Insulintherapyandacutekidney\n145.ThomasG,RojasMC,EpsteinSK,et\n425–432.injuryincriticallyillpatientsasystematicreview.NephrolDialTransplant\n119.LinSM,HuangCD,LinHC,etal.Amodiﬁedgoal-directedprotocol2007;22:2849–2855. improvesclinicaloutcomesinintensivecareunitpatientswithsepticshock:146.WienerRS,WienerDC,LarsonRJ.Beneﬁtsandrisksoftightglucose\narandomizedcontrolledtrial.Shock2006;26:551–557.controlincriticallyilladults:ameta-analysis.JAMA2008;300:933–944. 120.NguyenHB,CorbettSW,MenesK,etal.Earlygoal-directedtherapy,147.BellomoR.Doesintensiveinsulintherapyprotectrenalfunctionin\ncorticosteroid,andrecombinanthumanactivatedproteinCforthecriticallyillpatients?NatClinPractNephrol2008;4:412–413. 148.FinferS,ChittockDR,SuSY,etal.Intensiveversusconventionalglucose\ntreatmentofseveresepsisandsepticshockintheemergencydepartment. AcadEmergMed2006;13:109–113.controlincriticallyillpatients.NEnglJMed2009;360:1283–1297. 121.RhodesA,BennettED.Earlygoal-directedtherapy:anevidence-based149.VandenBergheG,SchetzM,VlasselaersD,etal.Clinicalreview:Intensive\ninsulintherapyincriticallyillpatients:NICE-SUGARorLeuvenblood\nreview.CritCareMed2004;32:S448–450. 122.RiversEP,CobaV,WhitmillM.Earlygoal-directedtherapyinseveresepsisglucosetarget?JClinEndocrinolMetab2009;94:3163–3170. andsepticshock:acontemporaryreviewoftheliterature.CurrOpin150.GriesdaleDE,deSouzaRJ,vanDamRM,etal.Intensiveinsulintherapy\nAnaesthesiol2008;21:128–140.andmortalityamongcriticallyillpatients:ameta-analysisincluding\n123.HoBC,BellomoR,McGainF,etal.TheincidenceandoutcomeofsepticNICE-SUGARstudydata.CMAJ2009;180:821–827.",
    "page": 129,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "shockpatientsintheabsenceofearly-goaldirectedtherapy.CritCare2006;151.FiaccadoriE,LombardiM,LeonardiS,etal.Prevalenceandclinical\n10:R80.outcomeassociatedwithpreexistingmalnutritioninacuterenalfailure:a\n124.DonatiA,LoggiS,PreiserJC,etal.Goal-directedintraoperativetherapyprospectivecohortstudy.JAmSocNephrol1999;10:581–593. reducesmorbidityandlengthofhospitalstayinhigh-risksurgicalpatients.152.BtaicheIF,MohammadRA,AlanizC,etal.AminoAcidrequirementsin\nChest2007;132:1817–1824.criticallyillpatientswithacutekidneyinjurytreatedwithcontinuousrenal\n125.LoboSM,SalgadoPF,CastilloVG,etal.Effectsofmaximizingoxygenreplacementtherapy.Pharmacotherapy2008;28:600–613. 153.CanoN,FiaccadoriE,TesinskyP,etal.ESPENGuidelinesonEnteral\ndeliveryonmorbidityandmortalityinhigh-risksurgicalpatients.CritCare\nMed2000;28:3396–3404.Nutrition:Adultrenalfailure.ClinNutr2006;25:295–310. 126.ShoemakerWC,AppelPL,KramHB,etal.Prospectivetrialofsupranormal154.DrumlW.Nutritionalmanagementofacuterenalfailure.JRenNutr2005;\nvaluesofsurvivorsastherapeuticgoalsinhigh-risksurgicalpatients.Chest15:63–70. 1988;94:1176–1186.155.McClaveSA,HurtRT.Clinicalguidelinesandnutritiontherapy:better\n127.BrienzaN,GiglioMT,MarucciM,etal.Doesperioperativehemodynamicunderstandingandgreaterapplicationtopatientcare.CritCareClin2010;\noptimizationprotectrenalfunctioninsurgicalpatients?Ameta-analytic26:451–466,viii. study.CritCareMed2009;37:2079–2090.156.McClaveSA,MartindaleRG,VanekVW,etal.GuidelinesfortheProvision\n128.GattinoniL,BrazziL,PelosiP,etal.Atrialofgoal-orientedhemodynamicandAssessmentofNutritionSupportTherapyintheAdultCriticallyIll\ntherapyincriticallyillpatients.SvO2CollaborativeGroup.NEnglJMedPatient:SocietyofCriticalCareMedicine(SCCM)andAmericanSociety\n1995;333:1025–1032.forParenteralandEnteralNutrition(A.S.P.E.N.).JPENJParenterEnteral\n129.HayesMA,TimminsAC,YauEH,etal.ElevationofsystemicoxygenNutr2009;33:277–316. deliveryinthetreatmentofcriticallyillpatients.NEnglJMed1994;330:157.FiaccadoriE,RegolistiG,CabassiA.Speciﬁcnutritionalproblemsinacute\n1717–1722.kidneyinjury,treatedwithnon-dialysisanddialyticmodalities.NDTPlus\n130.SectionVII.Acuterenalfailure.In:SchrierRW(ed).DiseasesoftheKidney2010;3:1–7. andUrinaryTract,8thEdn,vol.2.LippincottWilliams&Wilkins:158.BasiS,PupimLB,SimmonsEM,etal.Insulinresistanceincriticallyill\nPA,2007,pp930–1207. Philadelphia,patientswithacuterenalfailure.AmJPhysiolRenalPhysiol2005;289:\n131.PartVI.Diagnosisandmanagementofspeciﬁcdisorders.In:JorresA,264. F259–\nRoncoC,KellumJA(eds).ManagementofAcuteKidneyProblems,1stEdn.159.MayRC,ClarkAS,GoheerMA,etal.Speciﬁcdefectsininsulin-mediated\nSpringer:NewYork,NY,2010,pp269–467.musclemetabolisminacuteuremia.KidneyInt1985;28:490–497. 126\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 129,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "160.CianciarusoB,BellizziV,NapoliR,etal.Hepaticuptakeandreleaseof188.CantarovichF,RangoonwalaB,LorenzH,etal.High-dosefurosemidefor\nglucose,lactate,andaminoacidsinacutelyuremicdogs.Metabolism1991;establishedARF:aprospective,randomized,double-blind,placebo-\n40:261–269.controlled,multicentertrial.AmJKidneyDis2004;44:402–409. 161.DrumlW,MitchWE.Metabolicabnormalitiesinacuterenalfailure.Semin189.LassniggA,DonnerE,GrubhoferG,etal.Lackofrenoprotectiveeffectsof\nDial1996;9:484–490.dopamineandfurosemideduringcardiacsurgery.JAmSocNephrol2000;\n162.SchneeweissB,GraningerW,StockenhuberF,etal.Energymetabolismin11:97–104. acuteandchronicrenalfailure.AmJClinNutr1990;52:596–601. 190.LombardiR,FerreiroA,ServettoC.Renalfunctionaftercardiacsurgery:\n163.MaciasWL,AlakaKJ,MurphyMH,etal.Impactofthenutritionalregimenadverseeffectoffurosemide.RenFail2003;25:775–786. onproteincatabolismandnitrogenbalanceinpatientswithacuterenal191.SolomonR,WernerC,MannD,etal.Effectsofsaline,mannitol,and\nfailure.JPENJParenterEnteralNutr1996;20:56–62.furosemidetopreventacutedecreasesinrenalfunctioninducedby\n164.FiaccadoriE,MaggioreU,RotelliC,etal.Effectsofdifferentenergyintakesradiocontrastagents.NEnglJMed1994;331:1416–1420. onnitrogenbalanceinpatientswithacuterenalfailure:apilotstudy.192.HoKM,SheridanDJ.Meta-analysisoffrusemidetopreventortreatacute\nNephrolDialTransplant2005;20:1976–1980.renalfailure.BMJ2006;333:420. 165.FiaccadoriE,CremaschiE.Nutritionalassessmentandsupportinacute193.HoKM,PowerBM.Beneﬁtsandrisksoffurosemideinacutekidneyinjury. kidneyinjury.CurrOpinCritCare2009;15:474–480.Anaesthesia2010;65:283–293. 166.Powell-TuckJ.Nutritionalinterventionsincriticalillness.ProcNutrSoc194.HagerB,BetschartM,KrapfR.Effectofpostoperativeintravenousloop\n2007;66:16–24.diureticonrenalfunctionaftermajorsurgery.SchweizMedWochenschr\n167.ScheinkestelCD,AdamsF,MahonyL,etal.Impactofincreasingparenteral\n1996;126:666–673. proteinloadsonaminoacidlevelsandbalanceincriticallyillanuric195.vanderVoortPH,BoermaEC,KoopmansM,etal.Furosemidedoesnot\npatientsoncontinuousrenalreplacementtherapy.Nutrition2003;19:improverenalrecoveryafterhemoﬁltrationforacuterenalfailurein\n733–740.criticallyillpatients:adoubleblindrandomizedcontrolledtrial.CritCare\n168.BellomoR,TanHK,BhonagiriS,etal.HighproteinintakeduringMed2009;37:533–538. continuoushemodiaﬁltration:impactonaminoacidsandnitrogenbalance.196.UchinoS,BellomoR,MorimatsuH,etal.Discontinuationofcontinuous\nIntJArtifOrgans2002;25:261–268.renalreplacementtherapy:aposthocanalysisofaprospectivemulticenter\n169.DrumlW.Metabolicaspectsofcontinuousrenalreplacementtherapies.observationalstudy.CritCareMed2009;37:2576–2582. KidneyIntSuppl1999:S56–61.197.WeisbergLS,KurnikPB,KurnikBR.Riskofradiocontrastnephropathyin\n170.ChimaCS,MeyerL,HummellAC,etal.Proteincatabolicrateinpatientspatientswithandwithoutdiabetesmellitus.KidneyInt1994;45:259–265.",
    "page": 130,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "withacuterenalfailureoncontinuousarteriovenoushemoﬁltrationand198.SchetzM.Shouldweusediureticsinacuterenalfailure?BestPractResClin\ntotalparenteralnutrition.JAmSocNephrol1993;3:1516–1521.Anaesthesiol2004;18:75–89. 171.LeblancM,GarredLJ,CardinalJ,etal.Catabolismincriticalillness:199.YallopKG,SheppardSV,SmithDC.Theeffectofmannitolonrenal\nestimationfromureanitrogenappearanceandcreatinineproductionfunctionfollowingcardio-pulmonarybypassinpatientswithnormal\nduringcontinuousrenalreplacementtherapy.AmJKidneyDis1998;32:pre-operativecreatinine.Anaesthesia2008;63:576–582. 444–453.200.SmithMN,BestD,SheppardSV,etal.Theeffectofmannitolonrenal\n172.MarshallMR,GolperTA,ShaverMJ,etal.Ureakineticsduringsustainedfunctionaftercardiopulmonarybypassinpatientswithestablishedrenal\nlow-efﬁciencydialysisincriticallyillpatientsrequiringrenalreplacementdysfunction.Anaesthesia2008;63:701–704. therapy.AmJKidneyDis2002;39:556–570.201.SchnuelleP,JohannesvanderWoudeF.Perioperativeﬂuidmanagementin\n173.SalahudeenAK,KumarV,MadanN,etal.Sustainedlowefﬁciencydialysisrenaltransplantation:anarrativereviewoftheliterature.TransplInt2006;\n959. inthecontinuousmode(C-SLED):dialysisefﬁcacy,clinicaloutcomes,and19:947–\n202.vanValenbergPL,HoitsmaAJ,TiggelerRG,etal.Mannitolasan\nsurvivalpredictorsincriticallyillcancerpatients.ClinJAmSocNephrol\n1346.indispensableconstituentofanintraoperativehydrationprotocolforthe\n2009;4:1338–\n174.BarnertJ,DumitrascuD,NeeserG,etal.Gastricemptyingofaliquidmealpreventionofacuterenalfailureafterrenalcadaverictransplantation. inintensivecareunitpatients(abstr).Gastroenterology1998;114:A865.Transplantation1987;44:784–788. 175.FiaccadoriE,MaggioreU,ClimaB,etal.Incidence,riskfactors,and203.WeimarW,GeerlingsW,BijnenAB,etal.Acontrolledstudyontheeffect\nprognosisofgastrointestinalhemorrhagecomplicatingacuterenalfailure.ofmannitolonimmediaterenalfunctionaftercadaverdonorkidney\nKidneyInt2001;59:1510–1519.transplantation.Transplantation1983;35:99–101. 176.MetnitzPG,KrennCG,SteltzerH,etal.Effectofacuterenalfailure204.BetterOS,RubinsteinI,WinaverJM,etal.Mannitoltherapyrevisited\nrequiringrenalreplacementtherapyonoutcomeincriticallyillpatients.(1940–1997).KidneyInt1997;52:886–894. CritCareMed2002;30:2051–2058.205.SeverMS,VanholderR,LameireN.Managementofcrush-relatedinjuries\n177.ScheinkestelCD,KarL,MarshallK,etal.Prospectiverandomizedtrialtoafterdisasters.NEnglJMed2006;354:1052–1063. assesscaloricandproteinneedsofcriticallyIll,anuric,ventilatedpatients206.VanholderR,SeverMS,ErekE,etal.Rhabdomyolysis.JAmSocNephrol\nrequiringcontinuousrenalreplacementtherapy.Nutrition2003;19:\n2000;11:1553–1561. 909–916.207.BellomoR,ChapmanM,FinferS,etal.Low-dosedopamineinpatients\n178.FiaccadoriE,MaggioreU,GiacosaR,etal.Enteralnutritioninpatientswithearlyrenaldysfunction:aplacebo-controlledrandomisedtrial.",
    "page": 130,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "withacuterenalfailure.KidneyInt2004;65:999–1008.AustralianandNewZealandIntensiveCareSociety(ANZICS)Clinical\n179.CaldwellMD,Kennedy-CaldwellC.Normalnutritionalrequirements.SurgTrialsGroup.Lancet2000;356:2139–2143. ClinNorthAm1981;61:489–507.208.MurrayPT.UseofdopaminergicagentsforrenoprotectionintheICU. 180.ZappitelliM,GoldsteinSL,SymonsJM,etal.ProteinandcalorieYearbookofIntensiveCareandEmergencyMedicine.Springer-Verlag:\nprescriptionforchildrenandyoungadultsreceivingcontinuousrenalBerlin,Germany,2003:637–648. replacementtherapy:areportfromtheProspectivePediatricContinuous209.LauschkeA,TeichgraberUK,FreiU,etal.‘Low-dose’dopamineworsens\nRenalReplacementTherapyRegistryGroup.CritCareMed2008;36:renalperfusioninpatientswithacuterenalfailure.KidneyInt2006;69:\n3239–3245.1669–1674. 181.MehtaRL,PascualMT,SorokoS,etal.Diuretics,mortality,and\n210.KellumJA,MDeckerJ.Useofdopamineinacuterenalfailure:ameta-\nnonrecoveryofrenalfunctioninacuterenalfailure.JAMA2002;288:analysis.CritCareMed2001;29:1526–1531. 2547–2553.211.MarikPE.Low-dosedopamine:asystematicreview.IntensiveCareMed\n182.UchinoS,DoigGS,BellomoR,etal.Diureticsandmortalityinacuterenal2002;28:877–883. failure.CritCareMed2004;32:1669–1677.212.FriedrichJO,AdhikariN,HerridgeMS,etal.Meta-analysis:low-dose\n183.KarajalaV,MansourW,KellumJA.Diureticsinacutekidneyinjury.dopamineincreasesurineoutputbutdoesnotpreventrenaldysfunctionor\nMinervaAnestesiol2009;75:251–257.death.AnnInternMed2005;142:510–524. 184.PontoLL,SchoenwaldRD.Furosemide(frusemide).Apharmacokinetic/213.MurrayPT.Fenoldopam:renal-dosedopamineredux?CritCareMed2006;\npharmacodynamicreview(PartII).ClinPharmacokinet1990;18:460–471.34:910–911. 185.PontoLL,SchoenwaldRD.Furosemide(frusemide).Apharmacokinetic/214.CogliatiAA,VellutiniR,NardiniA,etal.Fenoldopaminfusionforrenal\npharmacodynamicreview(PartI).ClinPharmacokinet1990;18:381–408.protectioninhigh-riskcardiacsurgerypatients:arandomizedclinical\n186.LudensJH,HookJB,BrodyMJ,etal.Enhancementofrenalbloodﬂowby\nstudy.JCardiothoracVascAnesth2007;21:847–850. furosemide.JPharmacolExpTher1968;163:456–460.215.LandoniG,Biondi-ZoccaiGG,MarinoG,etal.Fenoldopamreducesthe\n187.LudensJH,WilliamsonHE.Effectoffurosemideonrenalbloodﬂowintheneedforrenalreplacementtherapyandin-hospitaldeathincardiovascular\n515. consciousdog.ProcSocExpBiolMed1970;133:513–surgery:ameta-analysis.JCardiothoracVascAnesth2008;22:27–33. 127\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 130,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "216.MorelliA,RicciZ,BellomoR,etal.Prophylacticfenoldopamforrenalanalysisshowingapotentialadverseinteractionbetweennesiritideand\nprotectioninsepsis:arandomized,double-blind,placebo-controlledpilotacuterenaldysfunction.NephrolDialTransplant2008;23:144–153. trial.CritCareMed2005;33:2451–2456.243.MentzerRM,Jr.,OzMC,SladenRN,etal.Effectsofperioperativenesiritide\n217.AravindanN,NatarajanM,ShawAD.Fenoldopaminhibitsnuclearinpatientswithleftventriculardysfunctionundergoingcardiacsurgery:the\ntranslocationofnuclearfactorkappaBinaratmodelofsurgicalischemicNAPATrial.JAmCollCardiol2007;49:716–726. acuterenalfailure.JCardiothoracVascAnesth2006;20:179–186.244.EjazAA,MartinTD,JohnsonRJ,etal.Prophylacticnesiritidedoesnot\n218.AravindanN,SamuelsJ,RiedelB,etal.Fenoldopamimprovescortico-\npreventdialysisorall-causemortalityinpatientsundergoinghigh-risk\nmedullaryoxygendeliveryandattenuatesangiogenesisgeneexpressionincardiacsurgery.JThoracCardiovascSurg2009;138:959–964. acuteischemicrenalinjury.KidneyBloodPressRes2006;29:165–174.245.LingegowdaV,VanQC,ShimadaM,etal.Long-termoutcomeof\n219.KellumJA.Prophylacticfenoldopamforrenalprotection?No,thankyou,patientstreatedwithprophylacticnesiritideforthepreventionofacute\nnotforme–notyetatleast.CritCareMed2005;33:2681–2683.kidneyinjuryfollowingcardiovascularsurgery.ClinCardiol2010;33:\n220.StoneGW,McCulloughPA,TumlinJA,etal.Fenoldopammesylateforthe217–221. preventionofcontrast-inducednephropathy:arandomizedcontrolledtrial.246.HammermanMR.Potentialroleofgrowthfactorsintheprophylaxisand\nJAMA2003;290:2284–2291.treatmentofacuterenalfailure.KidneyIntSuppl1998;64:S19–22. 221.TumlinJA,FinkelKW,MurrayPT,etal.Fenoldopammesylateinearly247.BernhardtWM,EckardtKU.Physiologicalbasisfortheuseof\nacutetubularnecrosis:arandomized,double-blind,placebo-controllederythropoietinincriticallyillpatientsatriskforacutekidneyinjury. clinicaltrial.AmJKidneyDis2005;46:26–34.CurrOpinCritCare2008;14:621–626. 222.BrienzaN,MalcangiV,DalﬁnoL,etal.Acomparisonbetweenfenoldopam\n248.DingH,KoppleJD,CohenA,etal.Recombinanthumaninsulin-like\nandlow-dosedopamineinearlyrenaldysfunctionofcriticallyillpatients.growthfactor-Iacceleratesrecoveryandreducescatabolisminratswith\nCritCareMed2006;34:707–714.ischemicacuterenalfailure.JClinInvest1993;91:2281–2287. 223.LandoniG,Biondi-ZoccaiGG,TumlinJA,etal.Beneﬁcialimpactof249.FriedlaenderM,PopovtzerMM,WeissO,etal.Insulin-likegrowthfactor-1\nfenoldopamincriticallyillpatientswithoratriskforacuterenalfailure:(IGF-1)enhancesrecoveryfromHgCl2-inducedacuterenalfailure:the\nameta-analysisofrandomizedclinicaltrials.AmJKidneyDis2007;49:effectsonrenalIGF-1,IGF-1receptor,andIGF-bindingprotein-1mRNA. 56–68.JAmSocNephrol1995;5:1782–1791. 224.RickstenSE,SwardK.Atrialnatriureticpeptideinacuterenalfailure.250.MillerSB,MartinDR,KissaneJ,etal.Insulin-likegrowthfactorI\nIn:RoncoC,BellomoR,KellumJ(eds).CriticalCareNephrology,2ndEdn.acceleratesrecoveryfromischemicacutetubularnecrosisintherat.",
    "page": 131,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "SaundersElsevier:Philadelphia,PA,2009,pp429–433.ProcNatlAcadSciUSA1992;89:11876–11880. 225.VeselyDL.Natriureticpeptidesandacuterenalfailure.AmJPhysiolRenal251.PetrinecD,ReillyJM,SicardGA,etal.Insulin-likegrowthfactor-I\nPhysiol2003;285:F167–177.attenuatesdelayedgraftfunctioninacaninerenalautotransplantation\n226.Marin-GrezM,FlemingJT,SteinhausenM.Atrialnatriureticpeptidecausesmodel.Surgery1996;120:221–225;discussion225–226. pre-glomerularvasodilatationandpost-glomerularvasoconstrictioninrat252.FranklinSC,MoultonM,SicardGA,etal.Insulin-likegrowthfactorI\nkidney.Nature1986;324:473–476.preservesrenalfunctionpostoperatively.AmJPhysiol1997;272:F257–259. 227.ValssonF,RickstenSE,HednerT,etal.Effectsofatrialnatriureticpeptide253.HirschbergR,KoppleJ,LipsettP,etal.Multicenterclinicaltrialof\nonrenalfunctionaftercardiacsurgeryandincyclosporine-treatedheartrecombinanthumaninsulin-likegrowthfactorIinpatientswithacuterenal\ntransplantrecipients.JCardiothoracVascAnesth1994;8:425–430.failure.KidneyInt1999;55:2423–2432. 228.RatcliffePJ,RichardsonAJ,KirbyJE,etal.Effectofintravenousinfusionof254.HladunewichMA,CorriganG,DerbyGC,etal.Arandomized,placebo-\natriopeptin3onimmediaterenalallograftfunction.KidneyInt1991;39:controlledtrialofIGF-1fordelayedgraftfunction:ahumanmodeltostudy\n602. 164–168.postischemicARF.KidneyInt2003;64:593–\n255.SongYR,LeeT,YouSJ,etal.Preventionofacutekidneyinjuryby\n229.SandsJM,NeylanJF,OlsonRA,etal.Atrialnatriureticfactordoesnot\nerythropoietininpatientsundergoingcoronaryarterybypassgrafting:\nimprovetheoutcomeofcadavericrenaltransplantation.JAmSocNephrol\n1086.apilotstudy.AmJNephrol2009;30:253–260. 1991;1:1081–\n230.KurnikBR,AllgrenRL,GenterFC,etal.Prospectivestudyofatrial256.EndreZH,WalkerRJ,PickeringJW,etal.Earlyinterventionwith\nnatriureticpeptideforthepreventionofradiocontrast-inducednephro-erythropoietindoesnotaffecttheoutcomeofacutekidneyinjury\npathy.AmJKidneyDis1998;31:674–680.(theEARLYARFtrial).KidneyInt2010;77:1020–1030. 231.AllgrenRL,MarburyTC,RahmanSN,etal.Anaritideinacutetubular257.KarlowiczMG,AdelmanRD.Nonoliguricandoliguricacuterenalfailurein\nnecrosis.AuriculinAnaritideAcuteRenalFailureStudyGroup.NEnglJasphyxiatedtermneonates.PediatrNephrol1995;9:718–722. Med1997;336:828–834.258.GouyonJB,GuignardJP.Theophyllinepreventsthehypoxemia-induced\n232.LewisJ,SalemMM,ChertowGM,etal.Atrialnatriureticfactorinoliguricrenalhemodynamicchangesinrabbits.KidneyInt1988;33:1078–1083. acuterenalfailure.AnaritideAcuteRenalFailureStudyGroup.AmJKidney259.BakrAF.Prophylactictheophyllinetopreventrenaldysfunctionin\nDis2000;36:767–774.newbornsexposedtoperinatalasphyxia–astudyinadevelopingcountry. 233.SwardK,ValssonF,OdencrantsP,etal.Recombinanthumanatrial\nPediatrNephrol2005;20:1249–1252.",
    "page": 131,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "natriureticpeptideinischemicacuterenalfailure:arandomizedplacebo-260.BhatMA,ShahZA,MakhdoomiMS,etal.Theophyllineforrenalfunction\ncontrolledtrial.CritCareMed2004;32:1310–1315.intermneonateswithperinatalasphyxia:arandomized,placebo-controlled\n234.SwardK,ValssonF,SellgrenJ,etal.Differentialeffectsofhumanatrialtrial.JPediatr2006;149:180–184. natriureticpeptideandfurosemideonglomerularﬁltrationrateandrenal261.JenikAG,CerianiCernadasJM,GorensteinA,etal.Arandomized,double-\noxygenconsumptioninhumans.IntensiveCareMed2005;31:79–85.blind,placebo-controlledtrialoftheeffectsofprophylactictheophyllineon\n235.NigwekarSU,NavaneethanSD,ParikhCR,etal.Atrialnatriureticpeptiderenalfunctionintermneonateswithperinatalasphyxia.Pediatrics2000;\nformanagementofacutekidneyinjury:asystematicreviewandmeta-105:E45. analysis.ClinJAmSocNephrol2009;4:261–272.262.CattarelliD,SpandrioM,GasparoniA,etal.Arandomised,doubleblind,\n236.ForssmannW,MeyerM,ForssmannK.Therenalurodilatinsystem:clinicalplacebocontrolledtrialoftheeffectoftheophyllineinpreventionof\nimplications.CardiovascRes2001;51:450–462.vasomotornephropathyinverypretermneonateswithrespiratorydistress\n237.HummelM,KuhnM,BubA,etal.Urodilatin:anewpeptidewith\nsyndrome.ArchDisChildFetalNeonatalEd2006;91:F80–84. beneﬁcialeffectsinthepostoperativetherapyofcardiactransplant263.GottliebSS,BraterDC,ThomasI,etal.BG9719(CVT-124),anA1\nrecipients.ClinInvestig1992;70:674–682.adenosinereceptorantagonist,protectsagainstthedeclineinrenalfunction\n238.BrennerP,MeyerM,ReichenspurnerH,etal.Signiﬁcanceofprophylacticobservedwithdiuretictherapy.Circulation2002;105:1348–1353. urodilatin(INN:ularitide)infusionforthepreventionofacuterenalfailure264.GivertzMM,MassieBM,FieldsTK,etal.TheeffectsofKW-3902,an\ninpatientsafterhearttransplantation.EurJMedRes1995;1:137–143.adenosineA1-receptorantagonist,ondiuresisandrenalfunctioninpatients\n239.Sackner-BernsteinJD,KowalskiM,FoxM,etal.Short-termriskofdeathwithacutedecompensatedheartfailureandrenalimpairmentordiuretic\naftertreatmentwithnesiritidefordecompensatedheartfailure:apooledresistance.JAmCollCardiol2007;50:1551–1560. analysisofrandomizedcontrolledtrials.JAMA2005;293:1900–1905.265.CotterG,DittrichHC,WeatherleyBD,etal.ThePROTECTpilotstudy:\n240.Sackner-BernsteinJD,SkopickiHA,AaronsonKD.Riskofworseningrenalarandomized,placebo-controlled,dose-ﬁndingstudyoftheadenosineA1\nfunctionwithnesiritideinpatientswithacutelydecompensatedheartreceptorantagonistrolofyllineinpatientswithacuteheartfailureandrenal\nfailure.Circulation2005;111:1487–1491. impairment.JCardFail2008;14:631–640. 241.TopolEJ.Nesiritide-notveriﬁed.NEnglJMed2005;353:113–116.266.MassieBM,O’ConnorCM,MetraM,etal.Rolofylline,anadenosine\nredictorsofmortalityinadult\n242.IglesiasJI,DePalmaL,HomD,etal.PA1-receptorantagonist,inacuteheartfailure.NEnglJMed2010;363:\npatientswithcongestiveheartfailurereceivingnesiritide–retrospective\n1419–1428. 128\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 131,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "267.FalagasME,KopteridesP.Oldantibioticsforinfectionsincriticallyill\n294.WalkerPD,BarriY,ShahSV.Oxidantmechanismsingentamicin\npatients.CurrOpinCritCare2007;13:592–597.442. nephrotoxicity.RenFail1999;21:433–\n268.ReaRS,CapitanoB.Optimizinguseofaminoglycosidesinthecriticallyill.295.WatanabeA,NagaiJ,AdachiY,etal.Targetedpreventionofrenal\nSeminRespirCritCareMed2007;28:596–603.accumulationandtoxicityofgentamicinbyaminoglycosidebinding\n269.RobertsJA,LipmanJ.Pharmacokineticissuesforantibioticsinthecriticallyreceptorantagonists.JControlRelease2004;95:423–433. illpatient.CritCareMed2009;37:840–851.296.YanagidaC,ItoK,KomiyaI,etal.Protectiveeffectoffosfomycinon\n270.ZaharJR,RiouxC,GirouE,etal.Inappropriateprescribingofgentamicin-inducedlipidperoxidationofratrenaltissue.ChemBiol\naminoglycosides:riskfactorsandimpactofanantibioticcontrolteam.Interact2004;148:139–147. JAntimicrobChemother2006;58:651–656.297.BaciewiczAM,SokosDR,CowanRI.Aminoglycoside-associatednephro-\n271.BliziotisIA,MichalopoulosA,KasiakouSK,etal.Ciproﬂoxacinvsantoxicityintheelderly.AnnPharmacother2003;37:182–186. aminoglycosideincombinationwithabeta-lactamforthetreatmentof298.BarclayML,KirkpatrickCM,BeggEJ.Oncedailyaminoglycosidetherapy. febrileneutropenia:ameta-analysisofrandomizedcontrolledtrials.MayoIsitlesstoxicthanmultipledailydosesandhowshoulditbemonitored? ClinProc2005;80:1146–1156.ClinPharmacokinet1999;36:89–98. 272.FalagasME,MatthaiouDK,BliziotisIA.Theroleofaminoglycosidesin299.GrahamAC,MercierRC,AchusimLE,etal.Extended-intervalaminoglyco-\ncombinationwithabeta-lactamforthetreatmentofbacterialendocarditis:sidedosingfortreatmentofenterococcalandstaphylococcalosteomyelitis. ameta-analysisofcomparativetrials.JAntimicrobChemother2006;57:AnnPharmacother2004;38:936–941. 639–647.300.KielPJ,LoM,StockwellD,etal.Anevaluationofamikacinnephrotoxicity\n273.FalagasME,MatthaiouDK,KarveliEA,etal.Meta-analysis:randomizedinthehematology/oncologypopulation.AmJTher2008;15:131–136. controlledtrialsofclindamycin/aminoglycosidevs.beta-lactammono-301.KrausDM,PaiMP,RodvoldKA.Efﬁcacyandtolerabilityofextended-\ntherapyforthetreatmentofintra-abdominalinfections.AlimentPharmacolintervalaminoglycosideadministrationinpediatricpatients.PaediatrDrugs\n2002;4:469–484. Ther2007;25:537–556. 274.GlasmacherA,vonLilienfeld-ToalM,SchulteS,etal.Anevidence-based302.NestaasE,BangstadHJ,SandvikL,etal.Aminoglycosideextendedinterval\nevaluationofimportantaspectsofempiricalantibiotictherapyinfebriledosinginneonatesissafeandeffective:ameta-analysis.ArchDisChildFetal\nneutropenicpatients.ClinMicrobiolInfect2005;11(Suppl5):17–23.NeonatalEd2005;90:F294–300. 275.PaulM,Benuri-SilbigerI,Soares-WeiserK,etal.Betalactammonotherapy303.PeloquinCA,BerningSE,NittaAT,etal.Aminoglycosidetoxicity:daily\nversusbetalactam-aminoglycosidecombinationtherapyforsepsisinversusthrice-weeklydosingfortreatmentofmycobacterialdiseases. immunocompetentpatients:systematicreviewandmeta-analysisofClinInfectDis2004;38:1538–1544.",
    "page": 132,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "randomisedtrials.BMJ2004;328:668.304.Peters-VollebergGW,DortantPM,SpeijersGJ.Comparisonoftobramycin\n276.PaulM,SilbigerI,GrozinskyS,etal.Betalactamantibioticmonotherapynephrotoxicityinyoungadultandagedfemalerats.PharmacolToxicol\nversusbetalactam-aminoglycosideantibioticcombinationtherapyfor1999;84:147–153. sepsis.CochraneDatabaseSystRev2006:CD003344.305.RougierF,ClaudeD,MaurinM,etal.Aminoglycosidenephrotoxicity:\nmodeling,simulation,andcontrol.AntimicrobAgentsChemother2003;47:\n277.EnglishWP,WilliamsMD.Shouldaminoglycosideantibioticsbe\nabandoned?AmJSurg2000;180:512–515;discussion515–516.1010–1016. 278.CosgroveSE,ViglianiGA,FowlerVG,Jr.,etal.Initiallow-dosegentamicin306.RougierF,DucherM,MaurinM,etal.Aminoglycosidedosagesand\nforStaphylococcusaureusbacteremiaandendocarditisisnephrotoxic.Clinnephrotoxicity:quantitativerelationships.ClinPharmacokinet2003;42:\nInfectDis2009;48:713–721.493–500. 279.OlaisonL,SchadewitzK.EnterococcalendocarditisinSweden,1995–1999:307.RybakMJ,AbateBJ,KangSL,etal.Prospectiveevaluationoftheeffectof\ncanshortertherapywithaminoglycosidesbeused?ClinInfectDis2002;34:anaminoglycosidedosingregimenonratesofobservednephrotoxicityand\n1555. 159–166.ototoxicity.AntimicrobAgentsChemother1999;43:1549–\n308.SmythAR,TanKH.Once-dailyversusmultiple-dailydosingwithintra-\n280.AliBH.Agentsamelioratingoraugmentingexperimentalgentamicin\nvenousaminoglycosidesforcysticﬁbrosis.CochraneDatabaseSystRev\nnephrotoxicity:somerecentresearch.FoodChemToxicol2003;41:\n2006;3:CD002009. 1447–1452. BledsoeG,CrickmanS,MaoJ,etal.Kallikrein/kininprotectsagainst309.AliMZ,GoetzMB.Ameta-analysisoftherelativeefﬁcacyandtoxicity\n281. gentamicin-inducednephrotoxicitybyinhibitionofinﬂammationandofsingledailydosingversusmultipledailydosingofaminoglycosides. apoptosis.NephrolDialTransplant2006;21:624–633.ClinInfectDis1997;24:796–809. 282.BledsoeG,ShenB,YaoYY,etal.Roleoftissuekallikreininpreventionand310.BaileyTC,LittleJR,LittenbergB,etal.Ameta-analysisofextended-interval\nrecoveryofgentamicin-inducedrenalinjury.ToxicolSci2008;102:433–443.dosingversusmultipledailydosingofaminoglycosides.ClinInfectDis\n283.EkorM,FarombiEO,EmeroleGO.Modulationofgentamicin-induced1997;24:786–795. renaldysfunctionandinjurybythephenolicextractofsoybean(Glycine311.BarzaM,IoannidisJP,CappelleriJC,etal.Singleormultipledailydosesof\nmax).FundamClinPharmacol2006;20:263–271.aminoglycosides:ameta-analysis.BMJ1996;312:338–345. 284.FeldmanL,EfratiS,EviatarE,etal.Gentamicin-inducedototoxicityin\n312.Ferriols-LisartR,Alos-AlminanaM.Effectivenessandsafetyofonce-daily\nhemodialysispatientsisamelioratedbyN-acetylcysteine.KidneyInt2007;aminoglycosides:ameta-analysis.AmJHealthSystPharm1996;53:\n72:359–363. 1141–1150. 285.GirtonRA,SundinDP,RosenbergME.Clusterinprotectsrenaltubular313.HatalaR,DinhT,CookDJ.Once-dailyaminoglycosidedosinginimmuno-\nepithelialcellsfromgentamicin-mediatedcytotoxicity.AmJPhysiolRenalcompetentadults:ameta-analysis.AnnInternMed1996;124:717–725.",
    "page": 132,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "Physiol2002;282:F703–709.314.MunckhofWJ,GraysonML,TurnidgeJD.Ameta-analysisofstudiesonthe\n286.HoribeT,MatsuiH,TanakaM,etal.Gentamicinbindstothelectinsiteofsafetyandefﬁcacyofaminoglycosidesgiveneitheroncedailyorasdivided\ncalreticulinandinhibitsitschaperoneactivity.BiochemBiophysResdoses.JAntimicrobChemother1996;37:645–663. Commun2004;323:281–287.315.GavaldaJ,OnrubiaPL,GomezMT,etal.Efﬁcacyofampicillincombined\n287.KaynarK,GulS,ErsozS,etal.Amikacin-inducednephropathy:isthereanywithceftriaxoneandgentamicininthetreatmentofexperimental\nprotectiveway?RenFail2007;29:23–27.endocarditisduetoEnterococcusfaecaliswithnohigh-levelresistanceto\n288.Martinez-SalgadoC,Lopez-HernandezFJ,Lopez-NovoaJM.Glomerular\naminoglycosides.JAntimicrobChemother2003;52:514–517. nephrotoxicityofaminoglycosides.ToxicolApplPharmacol2007;223:86–98.316.LeT,BayerAS.Combinationantibiotictherapyforinfectiveendocarditis. 289.MontagutC,BoschF,VillelaL,etal.Aminoglycoside-associatedsevere\nClinInfectDis2003;36:615–621. renalfailureinpatientswithmultiplemyelomatreatedwiththalidomide.317.TamVH,McKinnonPS,LevineDP,etal.Once-dailyaminoglycosideinthe\nLeukLymphoma2004;45:1711–1712.treatmentofEnterococcusfaecalisendocarditis:casereportandreview. 290.MoralesAI,Rodriguez-BarberoA,Vicente-SanchezC,etal.ResveratrolPharmacotherapy2000;20:1116–1119. inhibitsgentamicin-inducedmesangialcellcontraction.LifeSci2006;78:318.BeauchampD,LabrecqueG.Aminoglycosidenephrotoxicity:dotimeand\n2373–2377.frequencyofadministrationmatter?CurrOpinCritCare2001;7:401–408. 291.ParlakpinarH,KocM,PolatA,etal.Protectiveeffectofaminoguanidine319.KimMJ,BertinoJS,Jr.,ErbTA,etal.ApplicationofBayestheorem\nagainstnephrotoxicityinducedbyamikacininrats.UrolRes2004;32:toaminoglycoside-associatednephrotoxicity:comparisonofextended-\n278–282.intervaldosing,individualizedpharmacokineticmonitoring,andmultiple-\n292.RougierF,ClaudeD,MaurinM,etal.Aminoglycosidenephrotoxicity. dailydosing.JClinPharmacol2004;44:696–707. CurrDrugTargetsInfectDisord2004;4:153–162.320.MurryKR,McKinnonPS,MitrzykB,etal.Pharmacodynamiccharacteri-\n293.SchmitzC,HilpertJ,JacobsenC,etal.Megalindeﬁciencyoffersprotectionzationofnephrotoxicityassociatedwithonce-dailyaminoglycoside. fromrenalaminoglycosideaccumulation.JBiolChem2002;277:618–622. Pharmacotherapy1999;19:1252–1260. 129\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 132,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "321.StreetmanDS,NafzigerAN,DestacheCJ,etal.Individualizedpharmaco-\ntherapyofhistoplasmosisinpatientswithAIDS.AnnInternMed2002;137:\nkineticmonitoringresultsinlessaminoglycoside-associatednephrotoxicity\n105–109. andfewerassociatedcosts.Pharmacotherapy2001;21:443–451.OlsonJA,Adler-MooreJP,SchwartzJ,etal.Comparativeefﬁcacies,\n348. 322.HeintzBH,MatzkeGR,DagerWE.Antimicrobialdosingconceptsandtoxicities,andtissueconcentrationsofamphotericinBlipidformulationsin\nrecommendationsforcriticallyilladultpatientsreceivingcontinuousrenalamurinepulmonaryaspergillosismodel.AntimicrobAgentsChemother\nreplacementtherapyorintermittenthemodialysis.Pharmacotherapy2009;2006;50:2122–2131. 29:562–577.349.VeerareddyPR,VobalaboinaV.Lipid-basedformulationsofamphotericinB. 323.DovasS,LiakopoulosV,PapatheodorouL,etal.AcuterenalfailureafterDrugsToday(Barc)2004;40:133–145. antibiotic-impregnatedbonecementtreatmentofaninfectedtotalknee350.WalshTJ,FinbergRW,ArndtC,etal.LiposomalamphotericinBfor\narthroplasty.ClinNephrol2008;69:207–212.empiricaltherapyinpatientswithpersistentfeverandneutropenia. 324.BoyleMP.Adultcysticﬁbrosis.JAMA2007;298:1787–1793.NationalInstituteofAllergyandInfectiousDiseasesMycosesStudyGroup. 325.RamseyBW,PepeMS,QuanJM,etal.IntermittentadministrationofNEnglJMed1999;340:764–771. inhaledtobramycininpatientswithcysticﬁbrosis.CysticFibrosisInhaled351.BoogaertsM,WinstonDJ,BowEJ,etal.Intravenousandoralitraconazole\nTobramycinStudyGroup.NEnglJMed1999;340:23–30.versusintravenousamphotericinBdeoxycholateasempiricalantifungal\n326.CannellaCA,WilkinsonST.Acuterenalfailureassociatedwithinhaledtherapyforpersistentfeverinneutropenicpatientswithcancerwhoare\ntobramycin.AmJHealthSystPharm2006;63:1858–1861.receivingbroad-spectrumantibacterialtherapy.Arandomized,controlled\n327.IzquierdoMJ,Gomez-AlamilloC,OrtizF,etal.Acuterenalfailuretrial.AnnInternMed2001;135:412–422. associatedwithuseofinhaledtobramycinfortreatmentofchronicairway352.JohansenHK,GotzschePC.AmphotericinBversusﬂuconazolefor\ncolonizationwithPseudomonasaeruginosa.ClinNephrol2006;66:controllingfungalinfectionsinneutropeniccancerpatients.Cochrane\n464–467.DatabaseSystRev2002;2:CD000239. 353.ParkSH,ChoiSM,LeeDG,etal.Intravenousitraconazolevs.amphotericin\n328.HarbarthS,BurkeJP,LloydJF,etal.Clinicalandeconomicoutcomesof\nconventionalamphotericinB-associatednephrotoxicity.ClinInfectDisBdeoxycholateforempiricalantifungaltherapyinpatientswithpersistent\n2002;35:e120–127.neutropenicfever.KoreanJInternMed2006;21:165–172. 329.UllmannAJ.Nephrotoxicityinthesettingofinvasivefungaldiseases.354.Raad,II,HannaHA,BoktourM,etal.Novelantifungalagentsassalvage\nMycoses2008;51(Suppl1):25–30.therapyforinvasiveaspergillosisinpatientswithhematologicmalignancies:\n330.WingardJR,KubilisP,LeeL,etal.Clinicalsigniﬁcanceofnephrotoxicityinposaconazolecomparedwithhigh-doselipidformulationsofamphotericin\npatientstreatedwithamphotericinBforsuspectedorprovenaspergillosis.Baloneorincombinationwithcaspofungin.Leukemia2008;22:496–503.",
    "page": 133,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "ClinInfectDis1999;29:1402–1407.355.WegnerB,BaerP,GauerS,etal.Caspofunginislessnephrotoxicthan\n331.PaiMP,NorenbergJP,TelepakRA,etal.AssessmentofeffectiverenalamphotericinBinvitroandpredominantlydamagesdistalrenaltubular\nplasmaﬂow,enzymuria,andcytokinereleaseinhealthyvolunteerscells.NephrolDialTransplant2005;20:2071–2079. receivingasingledoseofamphotericinBdesoxycholate.AntimicrobAgents356.SchwannNM,HorrowJC,StrongMD,3rd,etal.Doesoff-pumpcoronary\narterybypassreducetheincidenceofclinicallyevidentrenaldysfunction\nChemother2005;49:3784–3788. 332.VarlamDE,SiddiqMM,PartonLA,etal.Apoptosiscontributestoaftermultivesselmyocardialrevascularization?AnesthAnalg2004;99:\namphotericinB-inducednephrotoxicity.AntimicrobAgentsChemother959–964,tableofcontents. 2001;45:679–685.357.ShroyerAL,GroverFL,HattlerB,etal.On-pumpversusoff-pump\n333.FurrerK,SchaffnerA,VavrickaSR,etal.NephrotoxicityofcyclosporineAcoronary-arterybypasssurgery.NEnglJMed2009;361:1827–1837. andamphotericinB-deoxycholateascontinuousinfusioninallogenicstem358.SeabraVF,AlobaidiS,BalkEM,etal.Off-pumpcoronaryarterybypass\ncelltransplantation.SwissMedWkly2002;132:316–320.surgeryandacutekidneyinjury:ameta-analysisofrandomizedcontrolled\n334.deRosaFG,BargiacchiO,AudagnottoS,etal.Continuousinfusionoftrials.ClinJAmSocNephrol2010;5:1734–1744. Bdeoxycholate:doesdecreasednephrotoxicitycouplewith\namphotericin359.EfratiS,DishyV,AverbukhM,etal.TheeffectofN-acetylcysteineonrenal\ntime-dependentpharmacodynamics?LeukLymphoma2006;47:1964–1966. function,nitricoxide,andoxidativestressafterangiography.KidneyInt\n335.SundarS,ChakravartyJ,RaiVK,etal.AmphotericinBtreatmentfor\n2003;64:2182–2187. Indianvisceralleishmaniasis:responseto15dailyversusalternate-daytyl-L-cysteineimprovesrenal\n360.ConesaEL,ValeroF,NadalJC,etal.N-ace\ninfusions.ClinInfectDis2007;45:556–561.medullaryhypoperfusioninacuterenalfailure.AmJPhysiolRegulIntegr\n336.TechapornroongM,SuankratayC.Alternate-dayversusonce-dailyadminis-CompPhysiol2001;281:R730–737. trationofamphotericinBinthetreatmentofcryptococcalmeningitis:361.DiMariJ,MegyesiJ,UdvarhelyiN,etal.N-acetylcysteineameliorates\narandomizedcontrolledtrial.ScandJInfectDis2007;39:896–901.ischemicrenalfailure.AmJPhysiol1997;272:F292–298. 337.KleinbergM.Whatisthecurrentandfuturestatusofconventional362.JiangB,HavertyM,BrecherP.N-acetyl-L-cysteineenhancesinterleukin-\namphotericinB?IntJAntimicrobAgents2006;27(Suppl1):12–16.1beta-inducednitricoxidesynthaseexpression.Hypertension1999;34:\n338.SalibaF,DupontB.RenalimpairmentandamphotericinBformulationsin574–579. 363.NitescuN,RickstenSE,MarcussenN,etal.N-acetylcysteineattenuates\npatientswithinvasivefungalinfections.MedMycol2008;46:97–112. 339.UllmannAJ,SanzMA,TramarinA,etal.Prospectivestudyofamphotericinkidneyinjuryinratssubjectedtorenalischaemia-reperfusion.NephrolDial\nTransplant2006;21:1240–1247. Bformulationsinimmunocompromisedpatientsin4Europeancountries.",
    "page": 133,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "ClinInfectDis2006;43:e29–38.364.FishbaneS.N-acetylcysteineinthepreventionofcontrast-induced\n340.YooBK,JalilMiahMA,LeeES,etal.Reducedrenaltoxicityofnephropathy.ClinJAmSocNephrol2008;3:281–287. nanoparticularamphotericinBmicellespreparedwithpartiallybenzylated365.VanPraetJT,DeVrieseAS.Preventionofcontrast-inducednephropathy:\npoly-L-asparticacid.BiolPharmBull2006;29:1700–1705.acriticalreview.CurrOpinNephrolHypertens2007;16:336–347. 341.AlexanderBD,WingardJR.StudyofrenalsafetyinamphotericinBlipid366.HoffmannU,FischerederM,KrugerB,etal.ThevalueofN-acetylcysteine\ncomplex-treatedpatients.ClinInfectDis2005;40(Suppl6):S414–421.inthepreventionofradiocontrastagent-inducednephropathyseems\n342.CornelyOA,MaertensJ,BresnikM,etal.LiposomalamphotericinBasquestionable.JAmSocNephrol2004;15:407–410. initialtherapyforinvasivemoldinfection:arandomizedtrialcomparing367.IzzedineH,GuerinV,Launay-VacherV,etal.EffectofN-acetylcysteineon\nserumcreatininelevel.NephrolDialTransplant2001;16:1514–1151. ahigh-loadingdoseregimenwithstandarddosing(AmBiLoadtrial). ClinInfectDis2007;44:1289–1297.368.HaaseM,Haase-FielitzA,RatnaikeS,etal.N-Acetylcysteinedoesnot\nartifactuallylowerplasmacreatinineconcentration.NephrolDialTransplant\n343.GarbinoJ,AdamA.Useofhigh-doseliposomalamphotericinB:efﬁcacy\nandtolerance.ActaBiomed2006;77(Suppl4):19–22.2008;23:1581–1587. 344.GiroisSB,ChapuisF,DecullierE,etal.Adverseeffectsofantifungal369.MainraR,GalloK,MoistL.EffectofN-acetylcysteineonrenalfunctionin\ntherapiesininvasivefungalinfections:reviewandmeta-analysis.EurJClinpatientswithchronickidneydisease.Nephrology(Carlton)2007;12:510–513. MicrobiolInfectDis2005;24:119–130.370.RehmanT,FoughtJ,SolomonR.N-acetylcysteineeffectonserum\n345.HachemRY,BoktourMR,HannaHA,etal.AmphotericinBlipidcomplexcreatinineandcystatinClevelsinCKDpatients.ClinJAmSocNephrol\nversusliposomalamphotericinBmonotherapyforinvasiveaspergillosisin2008;3:1610–1614. patientswithhematologicmalignancy.Cancer2008;112:1282–1287.371.MolnarZ,SzakmanyT,KoszegiT.ProphylacticN-acetylcysteinedecreases\n346.JohansenHK,GotzschePC.AmphotericinBlipidsolubleformulationsvs.serumCRPbutnotPCTlevelsandmicroalbuminuriafollowingmajor\nabdominalsurgery.Aprospective,randomised,double-blinded,placebo-\namphotericinBincancerpatientswithneutropenia.CochraneDatabase\nSystRev2000;3:CD000969.controlledclinicaltrial.IntensiveCareMed2003;29:749–755. 347.JohnsonPC,WheatLJ,CloudGA,etal.Safetyandefﬁcacyofliposomal372.NiemiTT,MunsterhjelmE,PoyhiaR,etal.TheeffectofN-acetylcysteine\nonbloodcoagulationandplateletfunctioninpatientsundergoingopen\namphotericinBcomparedwithconventionalamphotericinBforinduction\n130\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 133,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "repairofabdominalaorticaneurysm.BloodCoagulFibrinolysis2006;17:nsofincreasesinserum\n399.WeisbordSD,ChenH,StoneRA,etal.Associatio\n29–34.creatininewithmortalityandlengthofhospitalstayaftercoronary\n373.PeakeSL,MoranJL,LeppardPI.N-acetyl-L-cysteinedepressescardiacangiography.JAmSocNephrol2006;17:2871–2877. performanceinpatientswithsepticshock.CritCareMed1996;24:400.McCulloughPA,WolynR,RocherLL,etal.Acuterenalfailureafter\n1302–1310.coronaryintervention:incidence,riskfactors,andrelationshiptomortality. 374.LynchRM,RobertsonR.AnaphylactoidreactionstointravenousAmJMed1997;103:368–375. N-acetylcysteine:aprospectivecasecontrolledstudy.AccidEmergNurs401.SolomonRJ,NatarajanMK,DoucetS,etal.CardiacAngiographyin\n2004;12:10–15.RenallyImpairedPatients(CARE)study:arandomizeddouble-blindtrial\n375.AppelboamAV,DarganPI,KnightonJ.Fatalanaphylactoidreactiontoofcontrast-inducednephropathyinpatientswithchronickidneydisease. N-acetylcysteine:cautioninpatientswithasthma.EmergMedJ2002;19:Circulation2007;115:3189–3196. 594–595.402.FreemanRV,O’DonnellM,ShareD,etal.Nephropathyrequiringdialysis\n376.HoKM,MorganDJ.Meta-analysisofN-acetylcysteinetopreventacuteafterpercutaneouscoronaryinterventionandthecriticalroleofanadjusted\nrenalfailureaftermajorsurgery.AmJKidneyDis2009;53:33–40.contrastdose.AmJCardiol2002;90:1068–1073. 377.AdabagAS,IshaniA,KoneswaranS,etal.UtilityofN-acetylcysteineto403.NikolskyE,MehranR,TurcotD,etal.Impactofchronickidneydiseaseon\npreventacutekidneyinjuryaftercardiacsurgery:arandomizedcontrolledprognosisofpatientswithdiabetesmellitustreatedwithpercutaneous\ntrial.AmHeartJ2008;155:1143–1149.coronaryintervention.AmJCardiol2004;94:300–305. 378.BurnsKE,ChuMW,NovickRJ,etal.PerioperativeN-acetylcysteineto404.VuurmansT,ByrneJ,FretzE,etal.Chronickidneyinjuryinpatientsafter\npreventrenaldysfunctioninhigh-riskpatientsundergoingCABGsurgery:cardiaccatheterisationorpercutaneouscoronaryintervention:acompa-\narandomizedcontrolledtrial.JAMA2005;294:342–350.risonofradialandfemoralapproaches(fromtheBritishColumbiaCardiac\n379.El-HamamsyI,StevensLM,CarrierM,etal.EffectofintravenousandRenalRegistries).Heart2010;96:1538–1542. N-acetylcysteineonoutcomesaftercoronaryarterybypasssurgery:405.DreyN,RoderickP,MulleeM,etal.Apopulation-basedstudyofthe\narandomized,double-blind,placebo-controlledclinicaltrial.JThoracincidenceandoutcomesofdiagnosedchronickidneydisease.AmJKidney\nCardiovascSurg2007;133:7–12.Dis2003;42:677–684. 380.SisilloE,CerianiR,BortoneF,etal.N-acetylcysteineforpreventionof406.KatzbergRW,HallerC.Contrast-inducednephrotoxicity:clinicalland-\nacuterenalfailureinpatientswithchronicrenalinsufﬁciencyundergoingscape.KidneyIntSuppl2006:S3–7. cardiacsurgery:aprospective,randomized,clinicaltrial.CritCareMed407.PerssonPB.Editorial:contrastmedium-inducednephropathy.NephrolDial\n2008;36:81–86.Transplant2005;20(Suppl1):i1.",
    "page": 134,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "381.WijeysunderaDN,BeattieWS,RaoV,etal.N-acetylcysteineforpreventing408.MehranR,NikolskyE.Contrast-inducednephropathy:deﬁnition,epide-\nacutekidneyinjuryincardiacsurgerypatientswithpre-existingmoderatemiology,andpatientsatrisk.KidneyIntSuppl2006:S11–15. renalinsufﬁciency.CanJAnaesth2007;54:872–881.409.StevensLA,CoreshJ,GreeneT,etal.Assessingkidneyfunction–measured\n382.HynninenMS,NiemiTT,PoyhiaR,etal.N-acetylcysteinefortheandestimatedglomerularﬁltrationrate.NEnglJMed2006;354:\npreventionofkidneyinjuryinabdominalaorticsurgery:arandomized,2473–2483. double-blind,placebo-controlledtrial.AnesthAnalg2006;102:1638–1645.410.LameireN,AdamA,BeckerCR,etal.Baselinerenalfunctionscreening. 383.MacedoE,AbdulkaderR,CastroI,etal.LackofprotectionofAmJCardiol2006;98:21K–26K. N-acetylcysteine(NAC)inacuterenalfailurerelatedtoelectiveaortic411.ChoykePL,CadyJ,DePollarSL,etal.Determinationofserumcreatinine\naneurysmrepair-arandomizedcontrolledtrial.NephrolDialTransplantpriortoiodinatedcontrastmedia:isitnecessaryinallpatients?TechUrol\n2006;21:1863–1869.1998;4:65–69. predictionofcontrast-\n384.KomisarofJA,GilkeyGM,PetersDM,etal.N-acetylcysteineforpatients412.McCulloughPA,AdamA,BeckerCR,etal.Risk\ninducednephropathy.AmJCardiol2006;98:27K–36K. withprolongedhypotensionasprophylaxisforacuterenalfailure\n413.ToprakO.Conﬂictingandnewriskfactorsforcontrastinduced\n(NEPHRON).CritCareMed2007;35:435–441. comparisonofcontemporarynephropathy.JUrol2007;178:2277–2283. 385.HarjaiKJ,RaizadaA,ShenoyC,etal.A\ndeﬁnitionsofcontrastnephropathyinpatientsundergoingpercutaneous414.GoldenbergI,MatetzkyS.Nephropathyinducedbycontrastmedia:\ncoronaryinterventionandaproposalforanovelnephropathygradingpathogenesis,riskfactorsandpreventivestrategies.CMAJ2005;172:\nsystem.AmJCardiol2008;101:812–819.1461–1471. 386.ThomsenHS,MorcosSK.Contrastmediaandthekidney:European415.MajumdarSR,KjellstrandCM,TymchakWJ,etal.Forcedeuvolemic\nSocietyofUrogenitalRadiology(ESUR)guidelines.BrJRadiol2003;76:diuresiswithmannitolandfurosemideforpreventionofcontrast-induced\n513–518.nephropathyinpatientswithCKDundergoingcoronaryangiography:\n387.RibichiniF,GrazianiM,GambaroG,etal.Earlycreatinineshiftspredictarandomizedcontrolledtrial.AmJKidneyDis2009;54:602–609. contrast-inducednephropathyandpersistentrenaldamageafterangio-416.BarrettBJ,ParfreyPS.Clinicalpractice.Preventingnephropathyinducedby\ngraphy.AmJMed2010;123:755–763.contrastmedium.NEnglJMed2006;354:379–386. 388.NewhouseJH,KhoD,RaoQA,etal.Frequencyofserumcreatininechanges\n417.BrownJR,DeVriesJT,PiperWD,etal.Seriousrenaldysfunctionafter\nintheabsenceofiodinatedcontrastmaterial:implicationsforstudiesofpercutaneouscoronaryinterventionscanbepredicted.AmHeartJ2008;\ncontrastnephrotoxicity.AJRAmJRoentgenol2008;191:376–382.155:260–266.",
    "page": 134,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "389.BaumgartenDA,EllisJH.Contrast-inducednephropathy:contrastmaterial418.MehranR,AymongED,NikolskyE,etal.Asimpleriskscoreforprediction\nnotrequired?AJRAmJRoentgenol2008;191:383–386.ofcontrast-inducednephropathyafterpercutaneouscoronaryintervention:\n390.BruceRJ,DjamaliA,ShinkiK,etal.Backgroundﬂuctuationofkidneydevelopmentandinitialvalidation.JAmCollCardiol2004;44:1393–1399. functionversuscontrast-inducednephrotoxicity.AJRAmJRoentgenol419.PerazellaMA.Gadolinium-contrasttoxicityinpatientswithkidneydisease:\n2009;192:711–718.nephrotoxicityandnephrogenicsystemicﬁbrosis.CurrDrugSaf2008;3:\n391.JabaraR,GadesamRR,PendyalaLK,etal.Impactofthedeﬁnitionutilized67–75. ontherateofcontrast-inducednephropathyinpercutaneouscoronary420.PerazellaMA.Currentstatusofgadoliniumtoxicityinpatientswithkidney\nintervention.AmJCardiol2009;103:1657–1662.disease.ClinJAmSocNephrol2009;4:461–469. 392.BernsAS.Nephrotoxicityofcontrastmedia.KidneyInt1989;36:730–740. 421.BriguoriC,ColomboA,AiroldiF,etal.Gadolinium-basedcontrastagents\n393.RudnickMR,GoldfarbS,TumlinJ.Contrast-inducednephropathy:istheandnephrotoxicityinpatientsundergoingcoronaryarteryprocedures. pictureanyclearer?ClinJAmSocNephrol2008;3:261–262.CatheterCardiovascInterv2006;67:175–180. 394.NashK,HafeezA,HouS.Hospital-acquiredrenalinsufﬁciency.AmJ422.ErgunI,KevenK,UrucI,etal.Thesafetyofgadoliniuminpatientswith\nKidneyDis2002;39:930–936.stage3and4renalfailure.NephrolDialTransplant2006;21:697–700. 395.PolenaS,YangS,AlamR,etal.NephropathyincriticallyIllpatients423.ErleyCM,BaderBD,BergerED,etal.Gadolinium-basedcontrastmedia\nwithoutpreexistingrenaldisease.ProcWestPharmacolSoc2005;48:comparedwithiodinatedmediafordigitalsubtractionangiographyin\n134–135.azotaemicpatients.NephrolDialTransplant2004;19:2526–2531. 396.BeckerCR,DavidsonC,LameireN,etal.High-risksituationsand424.KaneGC,StansonAW,KalnickaD,etal.Comparisonbetweengadolinium\nprocedures.AmJCardiol2006;98:37K–41K.andiodinecontrastforpercutaneousinterventioninatheroscleroticrenal\n397.LameireN.Contrast-inducednephropathyinthecritically-illpatient:focusarterystenosis:clinicaloutcomes.NephrolDialTransplant2008;23:\nonemergencyscreeningandprevention.ActaClinBelgSuppl2007:\n1233–1240. 346–352.425.SamAD,2nd,MoraschMD,CollinsJ,etal.Safetyofgadoliniumcontrast\n398.McCulloughPA.Radiocontrast-inducedacutekidneyinjury.Nephronangiographyinpatientswithchronicrenalinsufﬁciency.JVascSurg2003;\n318. Physiol2008;109:pp61–72. 38:313–\n131\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 134,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "426.SwanSK,LambrechtLJ,TownsendR,etal.Safetyandpharmacokinetic\n452.HardiekKJ,KatholiRE,RobbsRS,etal.Renaleffectsofcontrastmediain\nproﬁleofgadobenatedimeglumineinsubjectswithrenalimpairment. diabeticpatientsundergoingdiagnosticorinterventionalcoronary\nInvestRadiol1999;34:443–448. angiography.JDiabetesComplications2008;22:171–177. 427.KanalE,BroomeDR,MartinDR,etal.ResponsetotheFDA’sMay23,\n453.JuergensCP,WinterJP,Nguyen-DoP,etal.Nephrotoxiceffectsofiodixanol\n2007,nephrogenicsystemicﬁbrosisupdate.Radiology2008;246:11–14.iopromideinpatientswithabnormalrenalfunctionreceivingN-\nand\n428.KayJ.Nephrogenicsystemicﬁbrosis:agadolinium-associatedﬁbrosingacetylcysteineandhydrationbeforecoronaryangiographyandintervention:\ndisorderinpatientswithrenaldysfunction.AnnRheumDis2008;arandomizedtrial.InternMedJ2009;39:25–31. 67(Suppl3):iii66–69.454.LaskeyW,AspelinP,DavidsonC,etal.Nephrotoxicityofiodixanolversus\niopamidolinpatientswithchronickidneydiseaseanddiabetesmellitus\n429.WollankaH,WeidenmaierW,GiersigC.NSFafterGadovistexposure:a\ncasereportandhypothesisofNSFdevelopment.NephrolDialTransplantundergoingcoronaryangiographicprocedures.AmHeartJ2009;158:\n2009;24:3882–3884.822–828e823. 455.NieB,ChengWJ,LiYF,etal.Aprospective,double-blind,randomized,\n430.ElmholdtTR,JørgensenB,RamsingM,etal.Twocasesofnephrogenic\nsystemicﬁbrosisafterexposuretothemacrocycliccompoundgadobutrol.controlledtrialontheefﬁcacyandcardiorenalsafetyofiodixanolvs. NDTPlus2010;3:285–287.iopromideinpatientswithchronickidneydiseaseundergoingcoronary\n431.SterlingKA,TehraniT,RudnickMR.Clinicalsigniﬁcanceandpreventiveangiographywithorwithoutpercutaneouscoronaryintervention.Catheter\nstrategiesforcontrast-inducednephropathy.CurrOpinNephrolHypertensCardiovascInterv2008;72:958–965. 2008;17:616–623.456.RudnickMR,DavidsonC,LaskeyW,etal.Nephrotoxicityofiodixanol\n432.KellyAM,DwamenaB,CroninP,etal.Meta-analysis:effectivenessofdrugsversusioversolinpatientswithchronickidneydisease:theVisipaque\nforpreventingcontrast-inducednephropathy.AnnInternMed2008;148:Angiography/InterventionswithLaboratoryOutcomesinRenalInsufﬁ-\n284–294.ciency(VALOR)Trial.AmHeartJ2008;156:776–782. 457.HeinrichMC,HaberleL,MullerV,etal.Nephrotoxicityofiso-osmolar\n433.CigarroaRG,LangeRA,WilliamsRH,etal.Dosingofcontrastmaterialto\npreventcontrastnephropathyinpatientswithrenaldisease.AmJMediodixanolcomparedwithnonioniclow-osmolarcontrastmedia:meta-\nanalysisofrandomizedcontrolledtrials.Radiology2009;250:68–86. 1989;86:649–652. 434.ChenML,LeskoL,WilliamsRL.Measuresofexposureversusmeasuresof458.ReddanD,LavilleM,GarovicVD.Contrast-inducednephropathyandits\nrateandextentofabsorption.ClinPharmacokinet2001;40:565–572.prevention:Whatdowereallyknowfromevidence-basedﬁndings? 435.SherwinPF,CambronR,JohnsonJA,etal.Contrastdose-to-creatinineJNephrol2009;22:333–351.",
    "page": 135,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "clearanceratioasapotentialindicatorofriskforradiocontrast-induced459.JoSH,YounTJ,KooBK,etal.Renaltoxicityevaluationandcomparison\nnephropathy:correlationofD/CrCLwithareaunderthecontrastbetweenvisipaque(iodixanol)andhexabrix(ioxaglate)inpatientswith\nconcentration-timecurveusingiodixanol.InvestRadiol2005;40:598–603.renalinsufﬁciencyundergoingcoronaryangiography:theRECOVERstudy:\n436.NymanU,BjorkJ,AspelinP,etal.Contrastmediumdose-to-GFRratio:aarandomizedcontrolledtrial.JAmCollCardiol2006;48:924–930. measureofsystemicexposuretopredictcontrast-inducednephropathy460.MehranR,NikolskyE,KirtaneAJ,etal.Ioniclow-osmolarversusnonionic\niso-osmolarcontrastmediatoobviateworseningnephropathyafter\nafterpercutaneouscoronaryintervention.ActaRadiol2008;49:658–667. 437.LaskeyWK,JenkinsC,SelzerF,etal.Volume-to-creatinineclearanceratio:angioplastyinchronicrenalfailurepatients:theICON(Ionicversusnon-\napharmacokineticallybasedriskfactorforpredictionofearlycreatinineionicContrasttoObviateworseningNephropathyafterangioplastyin\nincreaseafterpercutaneouscoronaryintervention.JAmCollCardiol2007;chronicrenalfailurepatients)study.JACCCardiovascInterv2009;2:\n50:584–590.415–421. 438.NymanU,AlmenT,AspelinP,etal.Contrast-medium-inducednephro-461.KuhnMJ,ChenN,SahaniDV,etal.ThePREDICTstudy:arandomized\npathycorrelatedtotheratiobetweendoseingramiodineandestimateddouble-blindcomparisonofcontrast-inducednephropathyafterlow-or\nGFRinml/min.ActaRadiol2005;46:830–842.isoosmolarcontrastagentexposure.AJRAmJRoentgenol2008;191:\n439.MarenziG,AssanelliE,CampodonicoJ,etal.Contrastvolumeduring151–157. primarypercutaneouscoronaryinterventionandsubsequentcontrast-462.ThomsenHS,MorcosSK,ErleyCM,etal.TheACTIVETrial:comparison\nnnInternMed2009;150:170–177. inducednephropathyandmortality.Aoftheeffectsonrenalfunctionofiomeprol-400andiodixanol-320in\n440.CramerBC,ParfreyPS,HutchinsonTA,etal.Renalfunctionfollowing\npatientswithchronickidneydiseaseundergoingabdominalcomputed\ninfusionofradiologiccontrastmaterial.Aprospectivecontrolledstudy. tomography.InvestRadiol2008;43:170–178. ArchInternMed1985;145:87–89. 463.NguyenSA,SuranyiP,RavenelJG,etal.Iso-osmolalityversuslow-\n441.HellerCA,KnappJ,HallidayJ,etal.Failuretodemonstratecontrast\nosmolalityiodinatedcontrastmediumatintravenouscontrast-enhanced\nnephrotoxicity.MedJAust1991;155:329–332. CT:effectonkidneyfunction.Radiology2008;248:97–105. 442.RaoQA,NewhouseJH.Riskofnephropathyafterintravenousadminis-\n464.WeisbordSD,PalevskyPM.Preventionofcontrast-inducednephropathy\ntrationofcontrastmaterial:acriticalliteratureanalysis.Radiology2006;\nwithvolumeexpansion.ClinJAmSocNephrol2008;3:273–280. 239:392–397.PerssonPB,HansellP,LissP.Pathophysiologyofcontrastmedium-induced\n465. 443.BarrettBJ,KatzbergRW,ThomsenHS,etal.Contrast-inducednephro-nephropathy.KidneyInt2005;68:14–22.",
    "page": 135,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "pathyinpatientswithchronickidneydiseaseundergoingcomputed466.BetterOS,RubinsteinI.Managementofshockandacuterenalfailurein\ntomography:adouble-blindcomparisonofiodixanolandiopamidol.Investcasualtiessufferingfromthecrushsyndrome.RenFail1997;19:647–653. Radiol2006;41:815–821.467.WeisbordSD,MorMK,ResnickAL,etal.Prevention,incidence,and\n444.KatzbergRW,LambaR.Contrast-inducednephropathyafterintravenousoutcomesofcontrast-inducedacutekidneyinjury.ArchInternMed2008;\nadministration:factorﬁction?RadiolClinNorthAm2009;47:789–800.168:1325–1332. 445.KatzbergRW,BarrettBJ.Riskofiodinatedcontrastmaterial–induced468.StevensMA,McCulloughPA,TobinKJ,etal.Aprospectiverandomizedtrial\nofpreventionmeasuresinpatientsathighriskforcontrastnephropathy:\nnephropathywithintravenousadministration.Radiology2007;243:\n622–628.resultsoftheP.R.I.N.C.E.Study.PreventionofRadiocontrastInduced\nNephropathyClinicalEvaluation.JAmCollCardiol1999;33:403–411. 446.ThomsenHS,MorcosSK.Riskofcontrast-medium-inducednephropathy\ninhigh-riskpatientsundergoingMDCT–apooledanalysisoftwo469.MuellerC,BuerkleG,BuettnerHJ,etal.Preventionofcontrastmedia-\nrandomizedtrials.EurRadiol2009;19:891–897.associatednephropathy:randomizedcomparisonof2hydrationregimens\n447.EllisJH,CohanRH.Reducingtheriskofcontrast-inducednephropathy:in1620patientsundergoingcoronaryangioplasty.ArchInternMed2002;\naperspectiveonthecontroversies.AJRAmJRoentgenol2009;192:162:329–336. 1544–1549.470.MertenGJ,BurgessWP,GrayLV,etal.Preventionofcontrast-induced\n448.GoldfarbS,SpinlerS,BernsJS,etal.Low-osmolalitycontrastmedianephropathywithsodiumbicarbonate:arandomizedcontrolledtrial. JAMA2004;291:2328–2334. andtheriskofcontrast-associatednephrotoxicity.InvestRadiol1993;\n28(Suppl5):S7–10;discussionS11–12.471.CaulﬁeldJL,SinghSP,WishnokJS,etal.BicarbonateinhibitsN-nitrosation\ninoxygenatednitricoxidesolutions.JBiolChem1996;271:25859–25863. 449.BarrettBJ,CarlisleEJ.Metaanalysisoftherelativenephrotoxicityof\nhigh-andlow-osmolalityiodinatedcontrastmedia.Radiology1993;188:472.BakrisGL,LassN,GaberAO,etal.Radiocontrastmedium-induced\n171–178.declinesinrenalfunction:aroleforoxygenfreeradicals.AmJPhysiol1990;\n258:F115–120. 450.AspelinP,AubryP,FranssonSG,etal.Nephrotoxiceffectsinhigh-risk\npatientsundergoingangiography.NEnglJMed2003;348:491–499.473.HalliwellB,GutteridgeJM.Roleoffreeradicalsandcatalyticmetalionsin\n451.FeldkampT,BaumgartD,ElsnerM,etal.Nephrotoxicityofiso-osmolarhumandisease:anoverview.MethodsEnzymol1990;186:1–85. versuslow-osmolarcontrastmediaisequalinlowriskpatients.Clin474.AssadiF.Acetazolamideforpreventionofcontrast-inducednephropathy:\nNephrol2006;66:322–330.anewuseforanolddrug.PediatrCardiol2006;27:238–242. 132\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 135,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "475.BrarSS,HiremathS,DangasG,etal.Sodiumbicarbonateforthe\nControlled,RandomizedLeipzigImmediatePercutaneouSCoronary\npreventionofcontrastinduced-acutekidneyinjury:asystematicreviewand\nInterventionAcuteMyocardialInfarctionN-ACC)Trial.JAmCollCardiol\nmeta-analysis.ClinJAmSocNephrol2009;4:1584–1592. 2010;55:2201–2209. 476.HoganSE,L’AllierP,ChetcutiS,etal.Currentroleofsodiumbicarbonate-\n497.TrivediH,DaramS,SzaboA,etal.High-doseN-acetylcysteineforthe\nbasedpreproceduralhydrationforthepreventionofcontrast-inducedacute\npreventionofcontrast-inducednephropathy.AmJMed2009;122:\nkidneyinjury:ameta-analysis.AmHeartJ2008;156:414–421. 874.e9–874.15. 477.HosteEA,DeWaeleJJ,GevaertSA,etal.Sodiumbicarbonatefor\n498.MarenziG,AssanelliE,MaranaI,etal.N-acetylcysteineandcontrast-\npreventionofcontrast-inducedacutekidneyinjury:asystematicreviewand\ninducednephropathyinprimaryangioplasty.NEnglJMed2006;354:\nmeta-analysis.NephrolDialTransplant2010;25:747–758. 2773–2782. 478.JoannidisM,SchmidM,WiedermannCJ.Preventionofcontrastmedia-\n499.WebbJG,PateGE,HumphriesKH,etal.Arandomizedcontrolledtrialof\ninducednephropathybyisotonicsodiumbicarbonate:ameta-analysis. intravenousN-acetylcysteineforthepreventionofcontrast-induced\nWienKlinWochenschr2008;120:742–748. nephropathyaftercardiaccatheterization:lackofeffect.AmHeartJ2004;\n479.KanbayM,CovicA,CocaSG,etal.Sodiumbicarbonatefortheprevention\n148:422–429. BagshawSM,McAlisterFA,MannsBJ,etal.Acetylcysteineinthe\nofcontrast-inducednephropathy:ameta-analysisof17randomizedtrials. 500. IntUrolNephrol2009;41:617–627.preventionofcontrast-inducednephropathy:acasestudyofthepitfalls\n480.NavaneethanSD,SinghS,AppasamyS,etal.Sodiumbicarbonatetherapyintheevolutionofevidence.ArchInternMed2006;166:161–166. 501.VaitkusPT,BrarC.N-acetylcysteineinthepreventionofcontrast-induced\nforpreventionofcontrast-inducednephropathy:asystematicreviewand\nmeta-analysis.AmJKidneyDis2009;53:617–627.nephropathy:publicationbiasperpetuatedbymeta-analyses.AmHeartJ\n2007;153:275–280. 481.ZoungasS,NinomiyaT,HuxleyR,etal.Systematicreview:sodium\nbicarbonatetreatmentregimensforthepreventionofcontrast-induced502.JoSH,KooBK,ParkJS,etal.N-acetylcysteineversusAScorbicacidfor\npreventingcontrast-Inducednephropathyinpatientswithrenalinsufﬁ-\nnephropathy.AnnInternMed2009;151:631–638. 482.AdolphE,Holdt-LehmannB,ChatterjeeT,etal.RenalInsufﬁciencyciencyundergoingcoronaryangiographyNASPIstudy-aprospective\nrandomizedcontrolledtrial.AmHeartJ2009;157:576–583. FollowingRadiocontrastExposureTrial(REINFORCE):arandomized\ncomparisonofsodiumbicarbonateversussodiumchloridehydrationfor503.BrownJR,BlockCA,MalenkaDJ,etal.Sodiumbicarbonateplus\nthepreventionofcontrast-inducednephropathy.CoronArteryDis2008;19:N-acetylcysteineprophylaxis:ameta-analysis.JACCCardiovascInterv\n413–419.2009;2:1116–1124.",
    "page": 136,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "483.OzcanEE,GuneriS,AkdenizB,etal.Sodiumbicarbonate,N-acetyl-504.KocF,OzdemirK,KayaMG,etal.IntravenousN-acetylcysteineplus\nhigh-dosehydrationversushigh-dosehydrationandstandardhydrationfor\ncysteine,andsalineforpreventionofradiocontrast-inducednephropathy. Acomparisonof3regimensforprotectingcontrast-inducednephropathythepreventionofcontrast-inducednephropathy:CASIS-Amulticenter\nprospectivecontrolledtrial.IntJCardiol2010:doi:10.1016/j.ijcard. inpatientsundergoingcoronaryprocedures.Asingle-centerprospective\ncontrolledtrial.AmHeartJ2007;154:539–544.2010.1010.1041. 505.ArendLJ,BakrisGL,BurnettJC,Jr.,etal.Roleforintrarenaladenosinein\n484.BrarSS,ShenAY,JorgensenMB,etal.Sodiumbicarbonatevssodium\ntherenalhemodynamicresponsetocontrastmedia.JLabClinMed1987;\nchlorideforthepreventionofcontrastmedium-inducednephropathyin\npatientsundergoingcoronaryangiography:arandomizedtrial.JAMA2008;110:406–411. 300:1038–1046.506.BagshawSM,GhaliWA.Theophyllineforpreventionofcontrast-induced\n485.BudhirajaP,ChenZ,PopovtzerM.Sodiumbicarbonateversusnormalnephropathy:asystematicreviewandmeta-analysis.ArchInternMed2005;\n165:1087–1093. salineforprotectionagainstcontrastnephropathy.RenFail2009;31:\n118–123.507.HuberW,EckelF,HennigM,etal.Prophylaxisofcontrastmaterial-\ninducednephropathyinpatientsinintensivecare:acetylcysteine,theophyl-\n486.BriguoriC,AiroldiF,D’AndreaD,etal.RenalInsufﬁciencyFollowing\nContrastMediaAdministrationTrial(REMEDIAL):arandomizedline,orboth?Arandomizedstudy.Radiology2006;239:793–804. comparisonof3preventivestrategies.Circulation2007;115:1211–1217.508.BaskurtM,OkcunB,AbaciO,etal.N-acetylcysteineversusN-acetyl-\ncysteinetheophyllineforthepreventionofcontrastnephropathy.EurJ\n487.MaioliM,TosoA,LeonciniM,etal.Sodiumbicarbonateversussalineforþ\nClinInvest2009;39:793–799. thepreventionofcontrast-inducednephropathyinpatientswithrenal\n509.MalhisM,Al-BitarS,Al-DeenZaiatK.Theroleoftheophyllinein\ndysfunctionundergoingcoronaryangiographyorintervention.JAmColl\n604. Cardiol2008;52:599–preventionofradiocontrastmedia-inducednephropathy.SaudiJKidney\n488.Recio-MayoralA,ChaparroM,PradoB,etal.Thereno-protectiveeffectof\nDisTranspl2010;21:276–283. hydrationwithsodiumbicarbonateplusN-acetylcysteineinpatients\n510.UptonRA.Pharmacokineticinteractionsbetweentheophyllineandother\nundergoingemergencypercutaneouscoronaryintervention:theRENO\nmedication(PartII).ClinPharmacokinet1991;20:135–150. Study.JAmCollCardiol2007;49:1283–1288. 511.UptonRA.Pharmacokineticinteractionsbetweentheophyllineandother\n489.FromAM,BartholmaiBJ,WilliamsAW,etal.Sodiumbicarbonateis\nmedication(PartI).ClinPharmacokinet1991;20:66–80. associatedwithanincreasedincidenceofcontrastnephropathy:a\n512.StaculF,AdamA,BeckerCR,etal.Strategiestoreducetheriskofcontrast-\nretrospectivecohortstudyof7977patientsatmayoclinic.ClinJAmSoc77K.",
    "page": 136,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "inducednephropathy.AmJCardiol2006;98:59K–\nNephrol2008;3:10–18.513.AllaqabandS,TumuluriR,MalikAM,etal.Prospectiverandomizedstudy\n490.TaylorAJ,HotchkissD,MorseRW,etal.PREPARED:PreparationforofN-acetylcysteine,fenoldopam,andsalineforpreventionofradiocontrast-\nAngiographyinRenalDysfunction:arandomizedtrialofinpatientvsinducednephropathy.CatheterCardiovascInterv2002;57:279–283. outpatienthydrationprotocolsforcardiaccatheterizationinmild-514.TosoA,MaioliM,LeonciniM,etal.Usefulnessofatorvastatin(80mg)in\nto-moderaterenaldysfunction.Chest1998;114:1570–1574.preventionofcontrast-inducednephropathyinpatientswithchronicrenal\ndisease.AmJCardiol2010;105:288–292. 491.TrivediHS,MooreH,NasrS,etal.Arandomizedprospectivetrialtoassess\ntheroleofsalinehydrationonthedevelopmentofcontrastnephrotoxicity.515.YoshidaS,KamihataH,NakamuraS,etal.Preventionofcontrast-induced\nnephropathybychronicpravastatintreatmentinpatientswithcardio-\nNephronClinPract2003;93:C29–34. 492.YoshikawaD,IsobeS,SatoK,etal.Importanceoforalﬂuidintakeaftervasculardiseaseandrenalinsufﬁciency.JCardiol2009;54:192–198. coronarycomputedtomographyangiography:Anobservationalstudy.516.DerayG.Dialysisandiodinatedcontrastmedia.KidneyIntSuppl2006:\nS25–29. EurJRadiol2011;77:118–122. 493.ChoR,JavedN,TraubD,etal.Oralhydrationandalkalinizationis517.CruzDN,PerazellaMA,RoncoC.Theroleofextracorporealblood\nnoninferiortointravenoustherapyforpreventionofcontrast-inducedpuriﬁcationtherapiesinthepreventionofradiocontrast-inducednephro-\nnephropathyinpatientswithchronickidneydisease.JIntervCardiol2010;pathy.IntJArtifOrgans2008;31:515–524. 23:460–466.518.VogtB,FerrariP,SchonholzerC,etal.Prophylactichemodialysisafter\n494.McCulloughPA.Contrast-inducedacutekidneyinjury.JAmCollCardiolradiocontrastmediainpatientswithrenalinsufﬁciencyispotentially\nharmful.AmJMed2001;111:692–698. 2008;51:1419–1428. 495.Klein-SchwartzW,DoyonS.Intravenousacetylcysteineforthetreatmentof519.ReineckeH,FobkerM,WellmannJ,etal.Arandomizedcontrolledtrial\nacetaminophenoverdose.ExpertOpinPharmacother2011;12:119–130.comparinghydrationtherapytoadditionalhemodialysisorN-acetyl-\ncysteineforthepreventionofcontrastmedium-inducednephropathy:the\n496.ThieleH,HildebrandL,SchirdewahnC,etal.Impactofhigh-dose\nN-acetylcysteineversusplacebooncontrast-inducednephropathyandDialysis-versus-Diuresis(DVD)Trial.ClinResCardiol2007;96:130–139. 520.KawashimaS,TakanoH,IinoY,etal.Prophylactichemodialysisdoes\nmyocardialreperfusioninjuryinunselectedpatientswithST-segment\nelevationmyocardialinfarctionundergoingprimarypercutaneouscoronarynotpreventcontrast-inducednephropathyaftercardiaccatheterizationin\nintervention.TheLIPSIA-N-ACC(Prospective,Single-Blind,Placebo-patientswithchronicrenalinsufﬁciency.CircJ2006;70:553–558. 133\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 136,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "521.LeePT,ChouKJ,LiuCP,etal.Renalprotectionforcoronaryangiographytheprospectivepediatriccontinuousrenalreplacementtherapyregistry. inadvancedrenalfailurepatientsbyprophylactichemodialysis.AAmJKidneyDis2010;55:316–325. randomizedcontrolledtrial.JAmCollCardiol2007;50:1015–1020.549.WiedemannHP,WheelerAP,BernardGR,etal.Comparisonoftwoﬂuid-\n522.MarenziG,MaranaI,LauriG,etal.Thepreventionofradiocontrast-managementstrategiesinacutelunginjury.NEnglJMed2006;354:\nagent-inducednephropathybyhemoﬁltration.NEnglJMed2003;349:2564–2575. 1333–1340.550.MehtaRL,McDonaldB,PahlM,etal.Continuousvs.intermittentdialysis\n523.MarenziG,LauriG,CampodonicoJ,etal.Comparisonoftwo\nforacuterenalfailureintheICU:Resultsfromarandomizedmulticenter\nhemoﬁltrationprotocolsforpreventionofcontrast-inducednephropathytrial(abstract).JAmSocNephrol1996;7:1456. inhigh-riskpatients.AmJMed2006;119:155–162.551.CruzDN,deCalM,GarzottoF,etal.Plasmaneutrophilgelatinase-\n524.KellumJA,MehtaRL,LevinA,etal.Developmentofaclinicalresearchassociatedlipocalinisanearlybiomarkerforacutekidneyinjuryinanadult\nagendaforacutekidneyinjuryusinganinternational,interdisciplinary,ICUpopulation.IntensiveCareMed2010;36:444–451. three-stepmodiﬁedDelphiprocess.ClinJAmSocNephrol2008;3:887–894.552.Hui-StickleS,BrewerED,GoldsteinSL.PediatricARFepidemiologyata\n525.PalevskyPM,BaldwinI,DavenportA,etal.Renalreplacementtherapyandtertiarycarecenterfrom1999to2001.AmJKidneyDis2005;45:96–101. thekidney:minimizingtheimpactofrenalreplacementtherapyon553.WilliamsDM,SreedharSS,MickellJJ,etal.Acutekidneyfailure:apediatric\nrecoveryofacuterenalfailure.CurrOpinCritCare2005;11:548–554.experienceover20years.ArchPediatrAdolescMed2002;156:893–900. 526.AllonM,ShanklinN.Effectofalbuteroltreatmentonsubsequentdialytic\n554.PiccaS,Dionisi-ViciC,AbeniD,etal.Extracorporealdialysisinneonatal\npotassiumremoval.AmJKidneyDis1995;26:607–613.hyperammonemia:modalitiesandprognosticindicators.PediatrNephrol\n527.GauthierPM,SzerlipHM.Metabolicacidosisintheintensivecareunit. 2001;16:862–867. CritCareClin2002;18:289–308.555.ProulxF,FayonM,FarrellCA,etal.Epidemiologyofsepsisandmultiple\n528.KrautJA,KurtzI.Toxicalcoholingestions:clinicalfeatures,diagnosis,andorgandysfunctionsyndromeinchildren.Chest1996;109:1033–1037. management.ClinJAmSocNephrol2008;3:208–225.556.ProulxF,GauthierM,NadeauD,etal.Timingandpredictorsofdeathin\n529.PearlmanBL,GambhirR.Salicylateintoxication:aclinicalreview.Postgradpediatricpatientswithmultipleorgansystemfailure.CritCareMed1994;\nMed2009;121:162–168.22:1025–1031. 530.TyagiPK,WinchesterJF,FeinfeldDA.Extracorporealremovaloftoxins.557.PiccaS,BartuliA,Dionisi-ViciC.Medicalmanagementanddialysis\nKidneyInt2008;74:1231–1233.therapyfortheinfantwithaninbornerrorofmetabolism.SeminNephrol\n531.BoumanCS,Oudemans-VanStraatenHM,TijssenJG,etal.Effectsof2008;28:477–480.",
    "page": 137,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "earlyhigh-volumecontinuousvenovenoushemoﬁltrationonsurvivaland\n558.PiccaS,RicciZ,PicardoS.Acutekidneyinjuryinaninfantafter\nrecoveryofrenalfunctioninintensivecarepatientswithacuterenalfailure:cardiopulmonarybypass.SeminNephrol2008;28:470–476. aprospective,randomizedtrial.CritCareMed2002;30:2205–2211.559.MichaelM,KuehnleI,GoldsteinSL.Fluidoverloadandacuterenalfailure\n532.CongerJD.Acontrolledevaluationofprophylacticdialysisinpost-inpediatricstemcelltransplantpatients.PediatrNephrol2004;19:91–95. traumaticacuterenalfailure.JTrauma1975;15:1056–1063.560.GoldsteinSL.Advancesinpediatricrenalreplacementtherapyforacute\n533.FischerRP,GriffenWO,Jr.,ReiserM,etal.Earlydialysisinthetreatmentofkidneyinjury.SeminDial2011;24:187–191. acuterenalfailure.SurgGynecolObstet1966;123:1019–1023.561.BagshawSM,MortisG,Godinez-LunaT,etal.Renalrecoveryaftersevere\nJArtifOrgans2006;29:1023–1030. 534.KleinknechtD,JungersP,ChanardJ,etal.Uremicandnon-uremicacuterenalfailure.Int\n562.BellomoR,CassA,ColeL,etal.Intensityofcontinuousrenal-replacement\ncomplicationsinacuterenalfailure:Evaluationofearlyandfrequent\ntherapyincriticallyillpatients.NEnglJMed2009;361:1627–1638. dialysisonprognosis.KidneyInt1972;1:190–196. timefordialysisin563.PalevskyPM,ZhangJH,O’ConnorTZ,etal.Intensityofrenalsupportin\n535.ParsonsFM,HobsonSM,BlaggCR,etal.Optimum\nacutereversiblerenalfailure.Descriptionandvalueofanimproveddialysercriticallyillpatientswithacutekidneyinjury.NEnglJMed2008;359:7–20. withlargesurfacearea.Lancet1961;1:129–134.564.PrendergastTJ,LuceJM.Increasingincidenceofwithholdingand\n536.GettingsLG,ReynoldsHN,ScaleaT.Outcomeinpost-traumaticacutewithdrawaloflifesupportfromthecriticallyill.AmJRespirCritCare\nrenalfailurewhencontinuousrenalreplacementtherapyisappliedearlyvs.Med1997;155:15–20. late.IntensiveCareMed1999;25:805–813.565.SwartzR,PerryE,DaleyJ.Thefrequencyofwithdrawalfromacutecareis\n537.DemirkilicU,KuralayE,YenicesuM,etal.Timingofreplacementtherapyimpactedbysevereacuterenalfailure.JPalliatMed2004;7:676–682. foracuterenalfailureaftercardiacsurgery.JCardSurg2004;19:17–20.566.HoKM,LiangJ,HughesT,etal.Withholdingandwithdrawaloftherapyin\n538.ElahiMM,LimMY,JosephRN,etal.Earlyhemoﬁltrationimprovespatientswithacuterenalinjury:aretrospectivecohortstudy.Anaesth\nsurvivalinpost-cardiotomypatientswithacuterenalfailure.EurJ\nIntensiveCare2003;31:509–513. CardiothoracSurg2004;26:1027–1031.567.ShealyCB,CampbellRC,HeyJC,etal.24-hrcreatinineclearanceasaguide\n539.LiuKD,HimmelfarbJ,PaganiniE,etal.TimingofinitiationofdialysisinforCRRTwithdrawal:aretrospectivestudy(abstr).BloodPurif2003;\ncriticallyillpatientswithacutekidneyinjury.ClinJAmSocNephrol2006;1:21:192. 915–919.568.WuVC,KoWJ,ChangHW,etal.Riskfactorsofearlyredialysisafter\n540.BagshawSM,UchinoS,BellomoR,etal.Timingofrenalreplacementweaningfrompostoperativeacuterenalreplacementtherapy.IntensiveCare\ntherapyandclinicaloutcomesincriticallyillpatientswithsevereacuteMed2008;34:101–108.",
    "page": 137,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "kidneyinjury.JCritCare2009;24:129–140.569.AskenaziDJ,FeigDI,GrahamNM,etal.3–5yearlongitudinalfollow-upof\n541.ShiaoCC,WuVC,LiWY,etal.Lateinitiationofrenalreplacementtherapypediatricpatientsafteracuterenalfailure.KidneyInt2006;69:184–189. isassociatedwithworseoutcomesinacutekidneyinjuryaftermajor570.SymonsJM,ChuaAN,SomersMJ,etal.Demographiccharacteristicsof\nabdominalsurgery.CritCare2009;13:R171.pediatriccontinuousrenalreplacementtherapy:areportoftheprospective\n542.BrandstrupB,TonnesenH,Beier-HolgersenR,etal.Effectsofintravenous\npediatriccontinuousrenalreplacementtherapyregistry.ClinJAmSoc\nﬂuidrestrictiononpostoperativecomplications:comparisonoftwoNephrol2007;2:732–738. perioperativeﬂuidregimens:arandomizedassessor-blindedmulticenter571.SchetzM.Anticoagulationincontinuousrenalreplacementtherapy. trial.AnnSurg2003;238:641–648.ContribNephrol2001;132:283–303. 543.FolandJA,FortenberryJD,WarshawBL,etal.Fluidoverloadbefore572.BellomoR,ParkinG,LoveJ,etal.Useofcontinuoushaemodiaﬁltration:\ncontinuoushemoﬁltrationandsurvivalincriticallyillchildren:aanapproachtothemanagementofacuterenalfailureinthecriticallyill. retrospectiveanalysis.CritCareMed2004;32:1771–1776.AmJNephrol1992;12:240–245. 544.GillespieRS,SeidelK,SymonsJM.Effectofﬂuidoverloadanddoseof573.MorabitoS,GuzzoI,SolazzoA,etal.Continuousrenalreplacement\nreplacementﬂuidonsurvivalinhemoﬁltration.PediatrNephrol2004;19:therapies:anticoagulationinthecriticallyillathighriskofbleeding. 1394–1399.JNephrol2003;16:566–571. 545.GoldsteinSL,CurrierH,GrafC,etal.Outcomeinchildrenreceiving574.TanHK,BaldwinI,BellomoR.Continuousveno-venoushemoﬁltration\ncontinuousvenovenoushemoﬁltration.Pediatrics2001;107:1309–1312.withoutanticoagulationinhigh-riskpatients.IntensiveCareMed2000;26:\n1657. 546.GoldsteinSL,SomersMJ,BaumMA,etal.Pediatricpatientswithmulti-1652–\n575.UchinoS,FealyN,BaldwinI,etal.Continuousvenovenoushemoﬁltration\norgandysfunctionsyndromereceivingcontinuousrenalreplacement\nwithoutanticoagulation.ASAIOJ2004;50:76–80. therapy.KidneyInt2005;67:653–658. 576.AgarwalB,ShawS,HariMS,etal.Continuousrenalreplacementtherapy\n547.HayesLW,OsterRA,ToﬁlNM,etal.Outcomesofcriticallyillchildren\n(CRRT)inpatientswithliverdisease:iscircuitlifedifferent?JHepatol2009;\nrequiringcontinuousrenalreplacementtherapy.JCritCare2009;24:\n400.51:504–509. 394–\n548.SutherlandSM,ZappitelliM,AlexanderSR,etal.Fluidoverloadand577.DaviesH,LeslieG.MaintainingtheCRRTcircuit:non-anticoagulant\nmortalityinchildrenreceivingcontinuousrenalreplacementtherapy:\nalternatives.AustCritCare2006;19:133–138. 134\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 137,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "578.JoannidisM,Oudemans-vanStraatenHM.Clinicalreview:Patencyofthe\n602.FealyN,BaldwinI,JohnstoneM,etal.Apilotrandomizedcontrolled\ncircuitincontinuousrenalreplacementtherapy.CritCare2007;11:218. crossoverstudycomparingregionalheparinizationtoregionalcitrate\n579.DavenportA.Reviewarticle:Low-molecular-weightheparinasan\nanticoagulationforcontinuousvenovenoushemoﬁltration.IntJArtif\nalternativeanticoagulanttounfractionatedheparinforroutineoutpatient\nOrgans2007;30:301–307. haemodialysistreatments.Nephrology(Carlton)2009;14:455–461. 603.Oudemans-vanStraatenHM,BosmanRJ,KoopmansM,etal.Citrate\n580.HirshJ,BauerKA,DonatiMB,etal.Parenteralanticoagulants:Americanforcontinuousvenovenoushemoﬁltration.CritCareMed\nanticoagulation\nCollegeofChestPhysiciansEvidence-BasedClinicalPracticeGuidelines2009;37:545–552. (8thEdition).Chest2008;133:141S–159S.604.MehtaRL,McDonaldBR,AguilarMM,etal.Regionalcitrateanti-\ncoagulationforcontinuousarteriovenoushemodialysisincriticallyill\n581.WarkentinTE,GreinacherA,KosterA,etal.Treatmentandpreventionof\nheparin-inducedthrombocytopenia:AmericanCollegeofChestPhysicianspatients.KidneyInt1990;38:976–981. Evidence-BasedClinicalPracticeGuidelines(8thEdition).Chest2008;133:605.MorgeraS,ScholleC,VossG,etal.Metaboliccomplicationsduring\nregionalcitrateanticoagulationincontinuousvenovenoushemodialysis:\n340S–380S. 582.BaglinT,BarrowcliffeTW,CohenA,etal.Guidelinesontheuseandsingle-centerexperience.NephronClinPract2004;97:c131–136. monitoringofheparin.BrJHaematol2006;133:19–34.606.ThoenenM,SchmidER,BinswangerU,etal.Regionalcitrateanti-\n583.GrayE,MulloyB,BarrowcliffeTW.Heparinandlow-molecular-weightcoagulationusingacitrate-basedsubstitutionsolutionforcontinuous\nheparin.ThrombHaemost2008;99:807–818.venovenoushemoﬁltrationincardiacsurgerypatients.WienKlin\n584.MartelN,LeeJ,WellsPS.Riskforheparin-inducedthrombocytopeniawithWochenschr2002;114:108–114. unfractionatedandlow-molecular-weightheparinthromboprophylaxis:607.UchinoS,BellomoR,MorimatsuH,etal.Continuousrenalreplacement\nameta-analysis.Blood2005;106:2710–2715.therapy:aworldwidepracticesurvey.Thebeginningandendingsupportive\n585.DavenportA,TolwaniA.Citrateanticoagulationforcontinuousrenaltherapyforthekidney(B.E.S.T.kidney)investigators.IntensiveCareMed\n2007;33:1563–1570. replacementtherapy(CRRT)inpatientswithacutekidneyinjuryadmitted\ntotheintensivecareunit.NDTPlus2009;2:439–447.608.ApsnerR,SchwarzenhoferM,DerﬂerK,etal.Impairmentofcitratemeta-\nbolisminacutehepaticfailure.WienKlinWochenschr1997;109:123–127. 586.LimW,CookDJ,CrowtherMA.Safetyandefﬁcacyoflowmolecular\nweightheparinsforhemodialysisinpatientswithend-stagerenalfailure:609.DuraoMS,MonteJC,BatistaMC,etal.Theuseofregionalcitrate\nameta-analysisofrandomizedtrials.JAmSocNephrol2004;15:anticoagulationforcontinuousvenovenoushemodiaﬁltrationinacute\n3192–3206.kidneyinjury.CritCareMed2008;36:3024–3029.",
    "page": 138,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "587.EuropeanBestPracticeGuidelinesforHaemodialysis(Part1).V.Chronic610.KramerL,BauerE,JoukhadarC,etal.Citratepharmacokineticsand\nintermittenthaemodialysisandpreventionofclottingintheextracorporalmetabolismincirrhoticandnoncirrhoticcriticallyillpatients.CritCare\nsystem.NephrolDialTransplant2002;17(Suppl7):63–71.Med2003;31:2450–2455. 588.FischerKG.Essentialsofanticoagulationinhemodialysis.HemodialInt611.HetzelGR,TaskayaG,SuckerC,etal.Citrateplasmalevelsinpatients\n2007;11:178–189.underregionalanticoagulationincontinuousvenovenoushemoﬁltration. AmJKidneyDis2006;48:806–811. 589.OusephR,WardRA.Anticoagulationforintermittenthemodialysis.Semin\nDial2000;13:181–187.612.Meier-KriescheHU,GitomerJ,FinkelK,etal.Increasedtotaltoionized\n590.LimW,DentaliF,EikelboomJW,etal.Meta-analysis:low-molecular-calciumratioduringcontinuousvenovenoushemodialysiswithregional\nweightheparinandbleedinginpatientswithsevererenalinsufﬁciency.citrateanticoagulation.CritCareMed2001;29:748–752. AnnInternMed2006;144:673–684.613.BakkerAJ,BoermaEC,KeidelH,etal.Detectionofcitrateoverdosein\n591.AkizawaT,KoshikawaS,OtaK,etal.Nafamostatmesilate:aregionalcriticallyillpatientsoncitrate-anticoagulatedvenovenoushaemoﬁltration:\nanticoagulantforhemodialysisinpatientsathighriskforbleeding.useofionisedandtotal/ionisedcalcium.ClinChemLabMed2006;44:\nNephron1993;64:376–381.962–966. 592.MatsuoT,KarioK,NakaoK,etal.Anticoagulationwithnafamostat614.DaviesHT,LeslieG,PereiraSM,etal.Arandomizedcomparativecrossover\nmesilate,asyntheticproteaseinhibitor,inhemodialysispatientswithastudytoassesstheaffectoncircuitlifeofvaryingpre-dilutionvolume\n141. bleedingrisk.Haemostasis1993;23:135–associatedwithCVVHandCVVHDF.IntJArtifOrgans2008;31:221–227. 593.YangJW,HanBG,KimBR,etal.Superioroutcomeofnafamostatmesilateusrenalreplacementtherapy\n615.HoltAW,BiererP,BerstenAD,etal.Continuo\nasananticoagulantinpatientsundergoingmaintenancehemodialysiswithincriticallyillpatients:monitoringcircuitfunction.AnaesthIntensiveCare\nintracerebralhemorrhage.RenFail2009;31:668–675.1996;24:423–429. 594.MaruyamaH,MiyakawaY,GejyoF,etal.Anaphylactoidreactioninducedby616.JoannidisM,KountchevJ,RauchenzaunerM,etal.Enoxaparinvs. nafamostatmesilateinahemodialysispatient.Nephron1996;74:468–469.unfractionatedheparinforanticoagulationduringcontinuousveno-venous\n595.MutoS,ImaiM,AsanoY.Mechanismsofhyperkalemiacausedbyhemoﬁltration:arandomizedcontrolledcrossoverstudy.IntensiveCare\nnafamostatmesilate.GenPharmacol1995;26:1627–1632.Med2007;33:1571–1579. 596.OkadaH,SuzukiH,DeguchiN,etal.Agranulocytosisinahaemodialysed617.StefanidisI,HagelJ,FrankD,etal.Hemostaticalterationsduring\npatientinducedbyaproteinaseinhibitor,nafamostatemesilate.Nephrolcontinuousvenovenoushemoﬁltrationinacuterenalfailure.ClinNephrol\nDialTransplant1992;7:980.1996;46:199–205.",
    "page": 138,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "597.NovacekG,KapiotisS,JilmaB,etal.Enhancedbloodcoagulationand618.vandeWeteringJ,WestendorpRG,vanderHoevenJG,etal.Heparinuse\nenhancedﬁbrinolysisduringhemodialysiswithprostacyclin.ThrombResincontinuousrenalreplacementprocedures:thestrugglebetweenﬁlter\n1997;88:283–290.coagulationandpatienthemorrhage.JAmSocNephrol1996;7:145–150. 598.SwartzRD,FlamenbaumW,DubrowA,etal.Epoprostenol(PGI2,619.YangRL,LiuDW.[Clinicalevaluationofhemoﬁltrationwithoutanti-\nprostacyclin)duringhigh-riskhemodialysis:preventingfurtherbleedingcoagulationincriticallyillpatientsathighriskofbleeding].ZhongguoYi\ncomplications.JClinPharmacol1988;28:818–825.XueKeXueYuanXueBao2007;29:651–655. 599.MonchiM,BerghmansD,LedouxD,etal.Citratevs.heparinfor620.ReevesJH,CummingAR,GallagherL,etal.Acontrolledtrialof\nanticoagulationincontinuousvenovenoushemoﬁltration:aprospectivelow-molecular-weightheparin(dalteparin)versusunfractionatedheparin\nrandomizedstudy.IntensiveCareMed2004;30:260–265.asanticoagulantduringcontinuousvenovenoushemodialysiswith\n600.KutsogiannisDJ,GibneyRT,StolleryD,etal.Regionalcitrateversusﬁltration.CritCareMed1999;27:2224–2228. systemicheparinanticoagulationforcontinuousrenalreplacementin621.dePontAC,Oudemans-vanStraatenHM,RoozendaalKJ,etal.Nadroparin\ncriticallyillpatients.KidneyInt2005;67:2361–2367.versusdalteparinanticoagulationinhigh-volume,continuousvenovenous\n601.BetjesMG,vanOosteromD,vanAgterenM,etal.Regionalcitrateversushemoﬁltration:adouble-blind,randomized,crossoverstudy.CritCareMed\nheparinanticoagulationduringvenovenoushemoﬁltrationinpatientsat2000;28:421–425. lowriskforbleeding:similarhemoﬁltersurvivalbutsigniﬁcantlyless622.BirnbaumJ,SpiesCD,KlotzE,etal.Iloprostforadditionalanticoagulation\nbleeding.JNephrol2007;20:602–608.incontinuousrenalreplacementtherapy–apilotstudy.RenFail2007;29:\n601a.HetzelGR,Schmitz,WissingH,etal.Regionalcitrateversussystemic271–277. heparinforanticoagulationincriticallyillpatientsoncontinuous623.Kozek-LangeneckerSA,SpissCK,GamsjagerT,etal.Anticoagulationwith\nvenovenoushaemoﬁltration:aprospectiverandomizedmulticentretrial.prostaglandinsandunfractionatedheparinduringcontinuousvenovenous\nNephrolDialTransplant2011;26:232–239.haemoﬁltration:arandomizedcontrolledtrial.WienKlinWochenschr2002;\n601b.ParkJS,KimGH,KangCM,etal.Regionalanticoagulationwithcitrateis114:96–101. superiortosystemicanticoagulationwithheparinincriticallyillpatients624.FabbriLP,NuceraM,AlMalyanM,etal.Regionalanticoagulation\nundergoingcontinuousvenovenoushemodiaﬁltration.KoreanJInternMedandantiaggregationforCVVHincriticallyillpatients:aprospective,\n2011;26:68–75.randomized,controlledpilotstudy.ActaAnaesthesiolScand2010;54:92–97. 135\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 138,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "625.FiaccadoriE,MaggioreU,RotelliC,etal.Continuoushaemoﬁltrationin\n653.TaalMW,ChestertonLJ,McIntyreCW.Venographyatinsertionof\nacuterenalfailurewithprostacyclinasthesoleanti-haemostaticagent. tunnelledinternaljugularveindialysiscathetersrevealssigniﬁcantoccult\nIntensiveCareMed2002;28:586–593.1545. stenosis.NephrolDialTransplant2004;19:1542–\n626.LangeneckerSA,FelfernigM,WerbaA,etal.Anticoagulationwith654.AgarwalAK,PatelBM,HaddadNJ.Centralveinstenosis:anephrologist’s\nprostacyclinandheparinduringcontinuousvenovenoushemoﬁltration.perspective.SeminDial2007;20:53–62. CritCareMed1994;22:1774–1781.655.PuelV,CaudryM,LeMetayerP,etal.Superiorvenacavathrombosis\n627.BiancoﬁoreG,EspositoM,BindiL,etal.Regionalﬁlterheparinizationforrelatedtocathetermalpositionincancerchemotherapygiventhrough\ncontinuousveno-venoushemoﬁltrationinlivertransplantrecipients.implantedports.Cancer1993;72:2248–2252. 656.YevzlinAS.Hemodialysiscatheter-associatedcentralvenousstenosis.Semin\nMinervaAnestesiol2003;69:527–534;534–528. 628.KaplanAA,PetrilloR.Regionalheparinizationforcontinuousarterio-Dial2008;21:522–527. venoushemoﬁltration(CAVH).ASAIOTrans1987;33:312–315.657.PronovostP.Interventionstodecreasecatheter-relatedbloodstream\n629.CarrJA,SilvermanN.Theheparin-protamineinteraction.Areview.infectionsintheICU:theKeystoneIntensiveCareUnitProject.AmJ\nJCardiovascSurg(Torino)1999;40:659–666.InfectControl2008;36:S171e171–175. 630.LasockiS,PiednoirP,AjzenbergN,etal.Anti-PF4/heparinantibodies658.ParientiJJ,ThirionM,MegarbaneB,etal.Femoralvsjugularvenous\nassociatedwithrepeatedhemoﬁltration-ﬁlterclotting:aretrospectivestudy.catheterizationandriskofnosocomialeventsinadultsrequiringacuterenal\nCritCare2008;12:R84.replacementtherapy:arandomizedcontrolledtrial.JAMA2008;299:2413–2422. 631.LoGK,JuhlD,WarkentinTE,etal.Evaluationofpretestclinicalscore659.HryszkoT,BrzoskoS,MazerskaM,etal.Riskfactorsofnontunneled\n(4T’s)forthediagnosisofheparin-inducedthrombocytopeniaintwononcuffedhemodialysiscathetermalfunction.Aprospectivestudy. clinicalsettings.JThrombHaemost2006;4:759–765.NephronClinPract2004;96:c43–47. 632.O’SheaSI,OrtelTL,KovalikEC.Alternativemethodsofanticoagulationfor660.LiangosO,RaoM,RuthazerR,etal.Factorsassociatedwithureareduction\nratioinacuterenalfailure.ArtifOrgans2004;28:1076–1081. dialysis-dependentpatientswithheparin-inducedthrombocytopenia. SeminDial2003;16:61–67.661.NaumovicRT,JovanovicDB,DjukanovicLJ.Temporaryvascularcatheters\n633.DavenportA.Anticoagulationoptionsforpatientswithheparin-inducedforhemodialysis:a3-yearprospectivestudy.IntJArtifOrgans2004;27:\nthrombocytopeniarequiringrenalsupportintheintensivecareunit.848–854. ContribNephrol2007;156:259–266.662.OliverMJ,EdwardsLJ,TreleavenDJ,etal.Randomizedstudyoftemporary\n634.HurstingMJ,MurrayPT.Argatrobananticoagulationinrenaldysfunction:hemodialysiscatheters.IntJArtifOrgans2002;25:40–44.",
    "page": 139,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "aliteratureanalysis.NephronClinPract2008;109:c80–94.663.ParientiJJ,MegarbaneB,FischerMO,etal.Catheterdysfunctionand\n635.LinkA,GirndtM,SelejanS,etal.Argatrobanforanticoagulationindialysisperformanceaccordingtovascularaccessamong736criticallyill\ncontinuousrenalreplacementtherapy.CritCareMed2009;37:105–110.adultsrequiringrenalreplacementtherapy:arandomizedcontrolledstudy. 636.BrophyPD,SomersMJ,BaumMA,etal.Multi-centreevaluationofCritCareMed2010;38:1118–1125. anticoagulationinpatientsreceivingcontinuousrenalreplacementtherapy664.MarschallJ,MermelLA,ClassenD,etal.Strategiestopreventcentralline-\nassociatedbloodstreaminfectionsinacutecarehospitals.InfectControl\n(CRRT).NephrolDialTransplant2005;20:1416–1421. 637.BunchmanTE,MaxvoldNJ,BarnettJ,etal.Pediatrichemoﬁltration:HospEpidemiol2008;29(Suppl1):S22–30. Normocarbdialysatesolutionwithcitrateanticoagulation.PediatrNephrol665.PrattRJ,PelloweCM,WilsonJA,etal.epic2:Nationalevidence-based\n2002;17:150–154.guidelinesforpreventinghealthcare-associatedinfectionsinNHShospitals\n638.BunchmanTE,MaxvoldNJ,BrophyPD.Pediatricconvectivehemoﬁltra-inEngland.JHospInfect2007;65(Suppl1):S1–64. tion:Normocarbreplacementﬂuidandcitrateanticoagulation.AmJ666.KusminskyRE.Complicationsofcentralvenouscatheterization.JAmColl\nKidneyDis2003;42:1248–1252.Surg2007;204:681–696. 639.KloucheK,AmiguesL,DeleuzeS,etal.Complications,effectsondialysis667.McGeeDC,GouldMK.Preventingcomplicationsofcentralvenous\nerization.NEnglJMed2003;348:1123–1133. dose,andsurvivaloftunneledfemoraldialysiscathetersinacuterenalcathet\nmJKidneyDis2007;49:99–108.668.HindD,CalvertN,McWilliamsR,etal.Ultrasoniclocatingdevicesfor\nfailure.A\n640.NationalKidneyFoundation.KDOQIclinicalpracticeguidelinesandcentralvenouscannulation:meta-analysis.BMJ2003;327:361. clinicalpracticerecommendationsfor2006updates:vascularaccess.AmJ669.RandolphAG,CookDJ,GonzalesCA,etal.Ultrasoundguidancefor\nKidneyDis2006;48:S176–S307.placementofcentralvenouscatheters:ameta-analysisoftheliterature. 641.O’GradyNP,AlexanderM,DellingerEP,etal.GuidelinesforthepreventionCritCareMed1996;24:2053–2058. ofintravascularcatheter-relatedinfections.InfectControlHospEpidemiol670.KarakitsosD,LabropoulosN,DeGrootE,etal.Real-timeultrasound-guided\n2002;23:759–769.catheterisationoftheinternaljugularvein:aprospectivecomparisonwith\n642.LeblancM,FedakS,MokrisG,etal.Bloodrecirculationintemporarythelandmarktechniqueincriticalcarepatients.CritCare2006;10:R162. centralcathetersforacutehemodialysis.ClinNephrol1996;45:315–319.671.LeungJ,DuffyM,FinckhA.Real-timeultrasonographically-guidedinternal\n643.LittleMA,ConlonPJ,WalsheJJ.Accessrecirculationintemporaryjugularveincatheterizationintheemergencydepartmentincreases\nhemodialysiscathetersasmeasuredbythesalinedilutiontechnique.AmJ\nsuccessratesandreducescomplications:arandomized,prospectivestudy. KidneyDis2000;36:1135–1139.AnnEmergMed2006;48:540–547.",
    "page": 139,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "644.OliverMJ.Acutedialysiscatheters.SeminDial2001;14:432–435.672.BansalR,AgarwalSK,TiwariSC,etal.Aprospectiverandomizedstudyto\n645.TwardowskiZJ.Historyofperitonealaccessdevelopment.IntJArtifOrganscompareultrasound-guidedwithnonultrasound-guideddoublelumen\n2006;29:2–40.internaljugularcatheterinsertionasatemporaryhemodialysisaccess. 646.RoncoC,Dell’AquilaR.Peritonealaccessforacuteperitonealdialysis.RenFail2005;27:561–564. In:RoncoC,BellomoR,KellumJ(eds).CriticalCareNephrology,2ndEdn.673.FarrellJ,GellensM.Ultrasound-guidedcannulationversusthelandmark-\nSaundersElsevier:Philadelphia,PA,2009,pp1467–1471.guidedtechniqueforacutehaemodialysisaccess.NephrolDialTransplant\n647.AsifA,ByersP,VieiraCF,etal.Peritoneoscopicplacementofperitoneal1997;12:1234–1237. dialysiscatheterandbowelperforation:experienceofaninterventional674.GallieniM.Centralveincatheterizationofdialysispatientswithrealtime\nnephrologyprogram.AmJKidneyDis2003;42:1270–1274.ultrasoundguidance.JVascAccess2000;1:10–14. 648.MayaID.Ultrasound/ﬂuoroscopy-assistedplacementofperitonealdialysis\n675.KwonTH,KimYL,ChoDK.Ultrasound-guidedcannulationofthefemoral\ncatheters.SeminDial2007;20:611–615.veinforacutehaemodialysisaccess.NephrolDialTransplant1997;12:1009–1012. 649.SchmidtSC,PohleC,LangrehrJM,etal.Laparoscopic-assistedplacement676.LinBS,HuangTP,TangGJ,etal.Ultrasound-guidedcannulationofthe\nofperitonealdialysiscatheters:implantationtechniqueandresults.internaljugularveinfordialysisvascularaccessinuremicpatients.Nephron\nJLaparoendoscAdvSurgTechA2007;17:596–599.1998;78:423–428. 650.CimochowskiGE,WorleyE,RutherfordWE,etal.Superiorityofthe677.NadigC,LeidigM,SchmiedekeT,etal.Theuseofultrasoundforthe\ninternaljugularoverthesubclavianaccessfortemporarydialysis.Nephronplacementofdialysiscatheters.NephrolDialTransplant1998;13:978–981. 1990;54:154–161.678.ZolloA,CavatortaF,GalliS.Ultrasound-guidedcannulationofthefemoral\n651.SchillingerF,SchillingerD,MontagnacR,etal.Postcatheterisationveinveinforacutehemodialysisaccesswithsiliconecatheters.JVascAccess2001;\nstenosisinhaemodialysis:comparativeangiographicstudyof50subclavian2:56–59. and50internaljugularaccesses.NephrolDialTransplant1991;6:679.SchummerW,SakrY,SchummerC.Towardsoptimalcentralvenous\n722–724. cathetertipposition.In:VincentJ-L(ed).IntensiveCareMedicine.Springer\n652.OguzkurtL,TercanF,TorunD,etal.Impactofshort-termhemodialysisVerlag:Berlin,Germany,2008,pp581–590. cathetersonthecentralveins:acathetervenographicstudy.EurJRadiol680.VeselyTM.Centralvenouscathetertipposition:acontinuingcontroversy. 2004;52:293–299.JVascIntervRadiol2003;14:527–534. 136\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 139,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "681.HsuJH,WangCK,ChuKS,etal.Comparisonofradiographiclandmarks\n707.PetrieJJ,CampbellY,HawleyCM,etal.Anaphylactoidreactionsinpatients\nandtheechocardiographicSVC/RAjunctioninthepositioningoflong-\nonhemodiaﬁltrationwithAN69membraneswhilstreceivingACE\ntermcentralvenouscatheters.ActaAnaesthesiolScand2006;50:731–735. inhibitors.ClinNephrol1991;36:264–265. 682.JamesMT,ConleyJ,TonelliM,etal.Meta-analysis:antibioticsforylactoidreactionsduring\n708.TielemansC,MadhounP,LenaersM,etal.Anaph\nprophylaxisagainsthemodialysiscatheter-relatedinfections.AnnInternhemodialysisonAN69membranesinpatientsreceivingACEinhibitors. Med2008;148:596–605.KidneyInt1990;38:982–984. 683.JafferY,SelbyNM,TaalMW,etal.Ameta-analysisofhemodialysiscatheter709.DesormeauxA,MoreauME,LepageY,etal.Theeffectofelectronegativity\nlockingsolutionsinthepreventionofcatheter-relatedinfection.AmJandangiotensin-convertingenzymeinhibitiononthekinin-formingcapacity\nofpolyacrylonitriledialysismembranes.Biomaterials2008;29:1139–1146. KidneyDis2008;51:233–241. 684.LabriolaL,CrottR,JadoulM.Preventinghaemodialysiscatheter-related710.RENALStudyInvestigators.Renalreplacementtherapyforacutekidney\nbacteraemiawithanantimicrobiallocksolution:ameta-analysisofinjuryinAustralianandNewZealandintensivecareunits:apracticesurvey. CritCareResusc2008;10:225–230. prospectiverandomizedtrials.NephrolDialTransplant2008;23:1666–1672. 685.YahavD,Rozen-ZviB,Gafter-GviliA,etal.Antimicrobiallocksolutionsfor711.GatwardJJ,GibbonGJ,WrathallG,etal.Renalreplacementtherapyfor\nthepreventionofinfectionsassociatedwithintravascularcathetersinacuterenalfailure:asurveyofpracticeinadultintensivecareunitsinthe\npatientsundergoinghemodialysis:systematicreviewandmeta-analysisofUnitedKingdom.Anaesthesia2008;63:959–966. randomized,controlledtrials.ClinInfectDis2008;47:83–93.712.LangfordS,SlivarS,TuckerSM,etal.ExploringCRRTpracticesinICU:\n686.HackbarthR,BunchmanTE,ChuaAN,etal.TheeffectofvascularaccessasurveyofCanadianhospitals.Dynamics2008;19:18–23. locationandsizeoncircuitsurvivalinpediatriccontinuousrenal713.RabindranathK,AdamsJ,MacleodAM,etal.Intermittentversus\nreplacementtherapy:areportfromthePPCRRTregistry.IntJArtifOrganscontinuousrenalreplacementtherapyforacuterenalfailureinadults. 2007;30:1116–1121.CochraneDatabaseSystRev2007:CD003773. 714.BagshawSM,BerthiaumeLR,DelaneyA,etal.Continuousversus\n687.BunchmanTE,BrophyPD,GoldsteinSL.Technicalconsiderationsforrenal\nreplacementtherapyinchildren.SeminNephrol2008;28:488–492.intermittentrenalreplacementtherapyforcriticallyillpatientswithacute\nkidneyinjury:ameta-analysis.CritCareMed2008;36:610–617. 688.McDonaldSP,CraigJC.Long-termsurvivalofchildrenwithend-stage\nrenaldisease.NEnglJMed2004;350:2654–2662.715.PannuN,KlarenbachS,WiebeN,etal.Renalreplacementtherapyinpatients\n689.ChadhaV,WaradyBA,BloweyDL,etal.Tenckhoffcathetersprovesuperiorwithacuterenalfailure:asystematicreview.JAMA2008;299:793–805.",
    "page": 140,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "tocookcathetersinpediatricacuteperitonealdialysis.AmJKidneyDis716.LinsRL,ElseviersMM,VanderNiepenP,etal.Intermittentversus\n2000;35:1111–1116.continuousrenalreplacementtherapyforacutekidneyinjurypatients\n690.AuronA,WaradyBA,SimonS,etal.Useofthemultipurposedrainageadmittedtotheintensivecareunit:resultsofarandomizedclinicaltrial. catheterfortheprovisionofacuteperitonealdialysisininfantsandNephrolDialTransplant2009;24:512–518. children.AmJKidneyDis2007;49:650–655.717.FareseS,JakobSM,KalickiR,etal.Treatmentofacuterenalfailureinthe\n691.ModiGK,PereiraBJ,JaberBL.Hemodialysisinacuterenalfailure:doestheintensivecareunit:lowercostsbyintermittentdialysisthancontinuous\nvenovenoushemodiaﬁltration.ArtifOrgans2009;33:634–640. membranematter?SeminDial2001;14:318–321. 692.CanivetE,LavaudS,WongT,etal.Cuprophanebutnotsynthetic718.KlarenbachS,MannsB,PannuN,etal.Economicevaluationofcontinuous\nmembraneinducesincreasesinserumtumornecrosisfactor-alphalevelsrenalreplacementtherapyinacuterenalfailure.IntJTechnolAssessHealth\nduringhemodialysis.AmJKidneyDis1994;23:41–46.Care2009;25:331–338. 693.MarchantA,TielemansC,HussonC,etal.Cuprophanehaemodialysis719.SrisawatN,LawsinL,UchinoS,etal.Costofacuterenalreplacementtherapy\ninducesupregulationofLPSreceptor(CD14)onmonocytes:roleofintheintensivecareunit:resultsfromTheBeginningandEndingSupportive\ncomplementactivation.NephrolDialTransplant1996;11:657–662.TherapyfortheKidney(BESTKidney)study.CritCare2010;14:R46. al.Comprehensiveevaluationof\n694.PatarcaR,PerezG,GonzalezA,et720.BellM,GranathF,SchonS,etal.Continuousrenalreplacementtherapyis\nacuteimmunologicalchangesinducedbycuprophaneandpolysulfone\nassociatedwithlesschronicrenalfailurethanintermittenthaemodialysis\nmembranesinapatientonchronichemodialysis.AmJNephrol1992;12:\nafteracuterenalfailure.IntensiveCareMed2007;33:773–780. 274–278.JackaMJ,IvancinovaX,GibneyRT.Continuousrenalreplacementtherapy\n721. 695.PuentesF,PonsH,Rodriguez-IturbeB.Hemodialysiswithcuprophaneimprovesrenalrecoveryfromacuterenalfailure.CanJAnaesth2005;52:\nmembranesisassociatedwithareductioninperipheralbloodmononuclear327–332. cellsexpressingVLA-4celladhesionmolecule.ClinNephrol1994;42:722.UchinoS,BellomoR,KellumJA,etal.Patientandkidneysurvivalby\n278–279.dialysismodalityincriticallyillpatientswithacutekidneyinjury.IntJArtif\n696.SchaeferRM,HuberL,GilgeU,etal.Clinicalevaluationofanewhigh-ﬂuxOrgans2007;30:281–292. celluloseacetatemembrane.IntJArtifOrgans1989;12:85–90.723.KielsteinJT,SchifferM,HaferC.Backtothefuture:extendeddialysisfor\n697.WalkerRJ,SutherlandWH,DeJongSA.Effectofchangingfromacellulosetreatmentofacutekidneyinjuryintheintensivecareunit.JNephrol2010;\nacetatetoapolysulphonedialysismembraneonproteinoxidationand23:494–501. 724.KielsteinJT,KretschmerU,ErnstT,etal.Efﬁcacyandcardiovascular\ninﬂammationmarkers.ClinNephrol2004;61:198–206.",
    "page": 140,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "698.ItohS,SusukiC,TsujiT.Plateletactivationthroughinteractionwithtolerabilityofextendeddialysisincriticallyillpatients:arandomized\nhemodialysismembranesinducesneutrophilstoproducereactiveoxygencontrolledstudy.AmJKidneyDis2004;43:342–349. species.JBiomedMaterResA2006;77:294–303.725.BaldwinI,BellomoR,NakaT,etal.Apilotrandomizedcontrolled\n699.HakimRM,SchaferAI.Hemodialysis-associatedplateletactivationandcomparisonofextendeddailydialysiswithﬁltrationandcontinuousveno-\nthrombocytopenia.AmJMed1985;78:575–580.venoushemoﬁltration:ﬂuidremovalandhemodynamics.IntJArtifOrgans\n700.SirolliV,StrizziL,DiStanteS,etal.Plateletactivationandplatelet-2007;30:1083–1089. erythrocyteaggregatesinend-stagerenaldiseasepatientsonhemodialysis.726.BaldwinI,NakaT,KochB,etal.Apilotrandomisedcontrolledcomparison\nThrombHaemost2001;86:834–839.ofcontinuousveno-venoushaemoﬁltrationandextendeddailydialysis\n701.TakeshitaK,SusukiC,ItohS,etal.Preventiveeffectofalpha-tocopherolwithﬁltration:effectonsmallsolutesandacid-basebalance.IntensiveCare\nandglycyrrhizinagainstplatelet-neutrophilcomplexformationinducedbyMed2007;33:830–835. 727.MarshallMR,CreamerJM,FosterM,etal.Mortalityratecomparisonafter\nhemodialysismembranes.IntJArtifOrgans2009;32:282–290. 702.AlonsoA,LauJ,JaberBL.Biocompatiblehemodialysismembranesforswitchingfromcontinuoustoprolongedintermittentrenalreplacementfor\nacuterenalfailure.CochraneDatabaseSystRev2008:CD005283.acutekidneyinjuryinthreeintensivecareunitsfromdifferentcountries. 703.BrophyPD,MottesTA,KudelkaTL,etal.AN-69membranereactionsareNephrolDialTransplant2011;26:2169–2175. pH-dependentandpreventable.AmJKidneyDis2001;38:173–178.728.FieghenHE,FriedrichJO,BurnsKE,etal.Thehemodynamictolerability\n704.HackbarthRM,EdingD,GianoliSmithC,etal.Zerobalanceultraﬁltrationandfeasibilityofsustainedlowefﬁciencydialysisinthemanagementof\n(Z-BUF)inblood-primedCRRTcircuitsachieveselectrolyteandacid-basecriticallyillpatientswithacutekidneyinjury.BMCNephrol2010;11:32. homeostasispriortopatientconnection.PediatrNephrol2005;20:729.DavenportA.Continuousrenalreplacementtherapiesinpatientswith\n1328–1333.acuteneurologicalinjury.SeminDial2009;22:165–168. 705.PaskoDA,MottesTA,MuellerBA.Predialysisofbloodprimein730.BagshawSM,PeetsAD,HameedM,etal.DialysisDisequilibrium\ncontinuoushemodialysisnormalizespHandelectrolytes.PediatrNephrolSyndrome:braindeathfollowinghemodialysisformetabolicacidosisand\nacuterenalfailure–acasereport.BMCNephrol2004;5:9. 2003;18:1177–1183. 706.Perez-GarciaR,GalanA,GarciaVinuesaM,etal.Anaphylactoidreactions731.LinCM,LinJW,TsaiJT,etal.Intracranialpressureﬂuctuationduring\nduringhemodialysisonAN69membranes:roleofACEinhibitorsandhemodialysisinrenalfailurepatientswithintracranialhemorrhage. ActaNeurochirSuppl2008;101:141–144. back-ﬁltration.Nephron1992;61:123. 137\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 140,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "732.RoncoC,BellomoR,BrendolanA,etal.Braindensitychangesduringrenal\n758.MarshallMR,MaT,GallerD,etal.Sustainedlow-efﬁciencydaily\nreplacementincriticallyillpatientswithacuterenalfailure.Continuous\ndiaﬁltration(SLEDD-f)forcriticallyillpatientsrequiringrenalreplacement\nhemoﬁltrationversusintermittenthemodialysis.JNephrol1999;12:\ntherapy:towardsanadequatetherapy.NephrolDialTransplant2004;19:\n173–178. 877–884. 733.PaganiniEP,SandyD,MorenoL,etal.Theeffectofsodiumand\n759.RoncoC.Backﬁltrationinclinicaldialysis:natureofthephenomenon,\nultraﬁltrationmodellingonplasmavolumechangesandhaemodynamicJArtifOrgans1990;13:11–21. mechanismsandpossiblesolutions.Int\nstabilityinintensivecarepatientsreceivinghaemodialysisforacuterenal760.KanagasundaramNS,LariveAB,PaganiniEP.Apreliminarysurveyof\nfailure:aprospective,stratiﬁed,randomized,cross-overstudy.NephrolDialbacterialcontaminationofthedialysatecircuitincontinuousveno-venous\nhemodialysis.ClinNephrol2003;59:47–55. Transplant1996;11(Suppl8):32–37. 734.SchortgenF,SoubrierN,DelclauxC,etal.Hemodynamictoleranceof761.MooreI,BhatR,HoenichNA,etal.Amicrobiologicalsurveyof\nintermittenthemodialysisincriticallyillpatients:usefulnessofpracticebicarbonate-basedreplacementcircuitsincontinuousveno-venoushemo-\nﬁltration.CritCareMed2009;37:496–500. guidelines.AmJRespirCritCareMed2000;162:197–202. 735.BargmanJM.Newtechnologiesinperitonealdialysis.ClinJAmSocNephrol762.WardRA.Worldwideguidelinesforthepreparationandqualitymanage-\n2007;2:576–580.mentofdialysisﬂuidandtheirimplementation.BloodPurif2009;\n736.ChionhCY,SoniS,CruzDN,etal.Peritonealdialysisforacutekidney27(Suppl1):2–4. injury:techniquesanddose.ContribNephrol2009;163:278–284.763.AssociationfortheAdvancementofMedicalInstrumentation.Waterfor\n737.RoncoC,AmerlingR.Continuousﬂowperitonealdialysis:currentstate-of-HemodialysisandRelatedTherapies.ANSI/AAMI/ISO13959:2009.AAMI:\nthe-artandobstaclestofurtherdevelopment.ContribNephrol2006;150:Arlington,VA,2010. 310–320.764.AssociationfortheAdvancementofMedicalInstrumentation.Concentrates\n738.PhuNH,HienTT,MaiNT,etal.HemoﬁltrationandperitonealdialysisinforHemodialysisandRelatedTherapies.ANSI/AAMI/ISO13958:2009. AAMI:Arlington,VA,2011. infection-associatedacuterenalfailureinVietnam.NEnglJMed2002;347:\n895–902.765.AssociationfortheAdvancementofMedicalInstrumentation.Qualityof\nDialysisFluidforHemodialysisandRelatedTherapies.ANSI/AAMI/ISO\n739.GabrielDP,CaramoriJT,MartimLC,etal.Highvolumeperitonealdialysis\nvsdailyhemodialysis:arandomized,controlledtrialinpatientswithacute11663:2009.AAMI:Arlington,VA,2010. kidneyinjury.KidneyIntSuppl2008:S87–93.765a.Europeanbestpracticeguidelinesforhaemodialysis(Part1).SectionIV:\n740.VachvanichsanongP,DissaneewateP,LimA,etal.ChildhoodacuterenalDialysisﬂuidpurity.NephrolDialTransplant2002;17(Suppl):45–62. failure:22-yearexperienceinauniversityhospitalinsouthernThailand.766.KolffWJ.Firstclinicalexperiencewiththeartiﬁcialkidney.AnnInternMed\nPediatrics2006;118:e786–791.1965;62:608–619.",
    "page": 141,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "741.BaileyD,PhanV,LitalienC,etal.Riskfactorsofacuterenalfailurein767.DavenportA,BoumanC,KirpalaniA,etal.Deliveryofrenalreplacement\ncriticallyillchildren:Aprospectivedescriptiveepidemiologicalstudy.therapyinacutekidneyinjury:whatarethekeyissues?ClinJAmSoc\nPediatrCritCareMed2007;8:29–35.Nephrol2008;3:869–875. 768.Faulhaber-WalterR,HaferC,JahrN,etal.TheHannoverDialysisOutcome\n742.BunchmanTE,MaxvoldNJ,KershawDB,etal.Continuousvenovenous\nhemodiaﬁltrationininfantsandchildren.AmJKidneyDis1995;25:study:comparisonofstandardversusintensiﬁedextendeddialysisfor\n17–21.treatmentofpatientswithacutekidneyinjuryintheintensivecareunit. 743.SadowskiRH,HarmonWE,JabsK.AcutehemodialysisofinfantsweighingNephrolDialTransplant2009;24:2179–2186. lessthanﬁvekilograms.KidneyInt1994;45:903–906.769.RoncoC,BellomoR,HomelP,etal.Effectsofdifferentdosesincontinuous\nveno-venoushaemoﬁltrationonoutcomesofacuterenalfailure:\n744.SymonsJM,BrophyPD,GregoryMJ,etal.Continuousrenalreplacement\ntherapyinchildrenupto10kg.AmJKidneyDis2003;41:984–989.aprospectiverandomisedtrial.Lancet2000;356:26–30. 745.WaradyBA,BunchmanT.Dialysistherapyforchildrenwithacuterenal770.SaudanP,NiederbergerM,DeSeigneuxS,etal.Addingadialysisdose\n13. failure:surveyresults.PediatrNephrol2000;15:11–tocontinuoushemoﬁltrationincreasessurvivalinpatientswithacuterenal\n746.BunchmanTE,McBrydeKD,MottesTE,etal.Pediatricacuterenalfailure:\nfailure.KidneyInt2006;70:1312–1317. outcomebymodalityanddisease.PediatrNephrol2001;16:1067–1071. 771.SchifﬂH,LangSM,FischerR.Dailyhemodialysisandtheoutcomeofacute\n747.FloresFX,BrophyPD,SymonsJM,etal.Continuousrenalreplacement\nrenalfailure.NEnglJMed2002;346:305–310. therapy(CRRT)afterstemcelltransplantation.Areportfromthe\n772.TolwaniAJ,CampbellRC,StofanBS,etal.Standardversushigh-dose\nprospectivepediatricCRRTRegistryGroup.PediatrNephrol2008;23:\nCVVHDFforICU-relatedacuterenalfailure.JAmSocNephrol2008;19:\n625–630. 1233–1238. 748.NorisM,TodeschiniM,CasiraghiF,etal.Effectofacetate,bicarbonate\n773.PaganiniEP,TapolyaiM,GoormasticM,etal.Establishingadialysis\ndialysis,andacetate-freebioﬁltrationonnitricoxidesynthesis:implicationsy/patientoutcomelinkinintensivecareunitacutedialysisfor\ntherap\nfordialysishypotension.AmJKidneyDis1998;32:115–124.patientswithacuterenalfailure.AmJKidneyDis1996;28(Suppl3):\n749.LevrautJ,IchaiC,PetitI,etal.LowexogenouslactateclearanceasanearlyS81–S89. predictorofmortalityinnormolactatemiccriticallyillsepticpatients.774.RicciZ,RoncoC,D’AmicoG,etal.Practicepatternsinthemanagementof\nCritCareMed2003;31:705–710.acuterenalfailureinthecriticallyillpatient:aninternationalsurvey. NephrolDialTransplant2006;21:690–696. 750.VeechRL.Theuntowardeffectsoftheanionsofdialysisﬂuids.KidneyInt\n1988;34:587–597.775.IkizlerTA,SezerMT,FlakollPJ,etal.Ureaspaceandtotalbodywater\n751.BarenbrockM,HausbergM,MatzkiesF,etal.Effectsofbicarbonate-andmeasurementsbystableisotopesinpatientswithacuterenalfailure. lactate-bufferedreplacementﬂuidsoncardiovascularoutcomeinCVVHKidneyInt2004;65:725–732.",
    "page": 141,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "patients.KidneyInt2000;58:1751–1757.776.EvansonJA,IkizlerTA,WingardR,etal.Measurementofthedeliveryof\ndialysisinacuterenalfailure.KidneyInt1999;55:1501–1508. 752.McLeanAG,DavenportA,CoxD,etal.Effectsoflactate-bufferedand\nlactate-freedialysateinCAVHDpatientswithandwithoutliverdysfunc-777.EvansonJA,HimmelfarbJ,WingardR,etal.Prescribedversusdelivered\ntion.KidneyInt2000;58:1765–1772.dialysisinacuterenalfailurepatients.AmJKidneyDis1998;32:731–738. 753.ThomasAN,GuyJM,KishenR,etal.Comparisonoflactateand778.SchifﬂH.Diseaseseverityadverselyaffectsdeliveryofdialysisinacuterenal\nbicarbonatebufferedhaemoﬁltrationﬂuids:useincriticallyillpatients.failure.NephronClinPract2007;107:c163–169. NephrolDialTransplant1997;12:1212–1217.779.GotchFA,SargentJA.AmechanisticanalysisoftheNationalCooperative\nDialysisStudy(NCDS).KidneyInt1985;28:526–534. 754.TanHK,UchinoS,BellomoR.Theacid-baseeffectsofcontinuous\nhemoﬁltrationwithlactateorbicarbonatebufferedreplacementﬂuids.780.HeldPJ,PortFK,WolfeRA,etal.Thedoseofhemodialysisandpatient\nIntJArtifOrgans2003;26:477–483.mortality.KidneyInt1996;50:550–556. 781.EknoyanG,BeckGJ,CheungAK,etal.Effectofdialysisdoseand\n755.ZimmermanD,CotmanP,TingR,etal.Continuousveno-venous\nhaemodialysiswithanovelbicarbonatedialysissolution:prospectivemembraneﬂuxinmaintenancehemodialysis.NEnglJMed2002;347:\n2010–2019. cross-overcomparisonwithalactatebufferedsolution.NephrolDial\nTransplant1999;14:2387–2391.782.VenkataramanR,KellumJA,PalevskyP.Dosingpatternsforcontinuous\n756.HollowayP,BenhamS,StJohnA.ThevalueofbloodlactatemeasurementsrenalreplacementtherapyatalargeacademicmedicalcenterintheUnited\ninICU:anevaluationoftheroleinthemanagementofpatientsonStates.JCritCare2002;17:246–250. haemoﬁltration.ClinChimActa2001;307:9–13.783.BoussekeyN,ChicheA,FaureK,etal.Apilotrandomizedstudycomparing\n757.LedeboI.On-linepreparationofsolutionsfordialysis:practicalaspectshighandlowvolumehemoﬁltrationonvasopressoruseinsepticshock. versussafetyandregulations.JAmSocNephrol2002;13(Suppl1):S78–83.IntensiveCareMed2008;34:1646–1653. 138\nKidneyInternationalSupplements(2012)2,124–138",
    "page": 141,
    "source": "KDIGO-2012-AKI-Guideline-English.pdf"
  }
]